Conditions: Niemann-Pick Disease, Type C
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 33
Healthy volunteers: no

Brief summary:
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Niemann-Pick type C disease (NPC).

There are two phases to this study: the Parent Study, and the Extension Phase.

The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the symptomatic treatment of NPC.

The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of NPC.

Detailed description:
In the Parent Study, Patients will be assessed during three study phases: a baseline period, a 6-week treatment period, and a 6-week post-treatment washout period. If within 6 weeks prior to the initial screening visit, a patient has received any of the prohibited medications defined in the eligibility criteria (irrespective of the preceding treatment duration) a wash-out study-run in of 6 weeks is required prior to the first baseline assessment. All patients will receive the study drug during the treatment period. For each individual patient, the Parent Study lasts for approximately 3.5 - 4 months during which there are 6 visits to the study site.

This Extension Phase allows patients who have completed the Parent Study to, at the discretion of the Principal Investigator (PI), continue treatment with N-Acetyl-L-Leucine (IB1001). Patients will receive treatment with IB1001 for two one-year treatment periods, separated by a 6-week washout. All patients will receive the study drug during the two one-year treatment periods. For each individual patient, the Extension Phase lasts for approximately 25.5 months, during which there are 6 visits to the study site.

Arms:
arm 1: Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.

Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).

Patients 6-12 years old will receive weight-tiered doses:

* Patients aged 6-12 years weighing 15 to \<25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.
* Patients aged 6-12 years weighing 25 to \<35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.
* Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults) arm 2: After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.

Interventions: intervention 1: IB1001
Intervention descriptions: intervention 1: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.

Protocol document:
Prot_000.pdf: 
 
 
 
Page 1 of 161 
CLINICAL TRIAL PROTOCOL 
Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C: A multinational, 
multicenter, open-label, rater-blinded Phase II study. 
 
Protocol Number: 
IB1001-201 
Investigational Medicinal Product: 
N-Acetyl-L-Leucine (IB1001) 
Indication: 
Niemann-Pick disease type C (NPC) 
Phase: 
II 
 
SPONSOR: 
 
 
 
 
US LEGAL REPRESENTATIVE: 
 
 
 
 
EU LEGAL REPRESENTATIVE: 
 
IntraBio Ltd. 
Begbroke Science Park, Begbroke Hill 
Woodstock Road, Begbroke, Oxfordshire 
OX5 1PF, United Kingdom 
 
IntraBio Inc 
270 Devon Road 
Tenafly NJ 07670 
United States 
 
IntraBio Ireland Ltd 
10 Earlsfort Terrace, 
Dublin 2, 
D02 T380, Ireland 
 
 
EUDRACT Number: 
IND Number: 
 
 
2018-004331-71 
134369 
 
Protocol Version and Date: 
Version 7.0, 10-Oct-2022  
 
 
 
 
 
 
The study will be conducted according to the protocol and in compliance with Good 
Clinical Practice (GCP), with the Declaration of Helsinki, and with other applicable 
regulatory requirements. 
This 
document 
contains 
confidential 
information 
of 
IntraBio 
Ltd. 
Do 
not 
copy 
or 
distribute 
without 
written 
permission 
from 
the 
IntraBio 
Ltd. 
CONFIDENTIAL 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 2 of 161 
Version 7.0, 10 Oct 2022 
Protocol Approval 
 
Sponsor: 
IntraBio Ltd. 
Begbroke Science Park, Begbroke Hill 
Yarnton, Oxford OX5 1PF, UK 
Tel: +44 (0) 1865 271858 
Fax: +44 (0) 1865 271853 
E-mail: mfactor@intrabio.com 
 
 
 
__________________________________                      ________________________ 
Signature 
Date 
 
 
Medical Monitor: 
Dr Glyn Belcher, MA, MB, BChir, PhD, FFPM 
Begbroke Science Park, Begbroke Hill 
Yarnton, Oxford OX5 1PF, UK 
Tel: +44 (0) 7484 546479 
E-mail: glynbelcher@pvconsult.co.uk 
 
 
__________________________________                      ________________________ 
Signature 
Date 
 
Biostatistician: 
Dr Richard Kay, PhD 
RK Statistics 
Brook House, Mesne Lane 
Bakewell, DE45 1AL, UK 
Tel: +44 (0)1629 810093 
E-mail: richard.kay@rkstatistics.com 
 
 
 
__________________________________                      ________________________ 
Signature 
Date 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 3 of 161 
Version 7.0, 10 Oct 2022 
Principal Investigator Agreement 
I, _______________________________________________, (Investigator’s Name) have read 
this protocol and agree that it contains all necessary details for carrying out this trial. I will 
conduct the trial as outlined herein and will complete the trial within the time designated. 
 
The information contained in this protocol is provided to me in confidence, for review only by 
myself, the ethics committee authorized to review and approve the trial at this trial site, and 
designated trial staff participating in this clinical study.  
 
I agree to the conditions as set out in this protocol and fully accept that any change requires 
prior approval by the trial Sponsor. 
 
I will provide copies of the protocol and all pertinent information to all individuals responsible 
to me who assist in the conduct of this trial. I will discuss this material with them to ensure 
they are fully informed regarding the investigational medicinal product (IMP), N-Acetyl-L-
Leucine, and the conduct of the trial. 
 
I will use only the informed consent form approved by the Sponsor or its representative and 
will fulfil all responsibilities for submitting pertinent information to the Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) responsible for this trial. 
 
I agree to carry out all terms of this protocol in accordance with the ICH GCP (Good Clinical 
Practice) Guidelines, the Declaration of Helsinki and local regulations. I will ensure that the 
Investigational Medicinal Product is used only as described in the protocol or any subsequent 
amendment. 
 
I understand that the information/technology contained in this protocol is proprietary and may 
not be disclosed to any other party, in any form, without prior authorisation from the trial 
Sponsor except to the extent necessary to obtain informed consent from potential trial patients.  
 
_________________________________________  
__________________ 
Investigator’s Signature 
 
 
 
 
 
Date 
 
_________________________________________ 
Clinical Trial Site Name 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 4 of 161 
Version 7.0, 10 Oct 2022 
Protocol Amendment Summary of Changes Table 
 
DOCUMENT HISTORY 
Document 
Protocol Version 
Date 
Amendment 5  
Version 7.0 
10-Oct-2022 
Amendment 4 – Slovakia Version 
Slovakia Version 6.2 
07-Dec-2020 
Amendment 4 – US Version 
US Version 6.1 
26-Aug-2020 
Amendment 4 
Version 6.0 
25-Aug-2020 
Amendment 3 – US Version 
US Version 5.1 
14-Dec-2019 
Amendment 3 
Version 5.0 
14-Nov-2019 
UK Amendment 1 
Version 2.1 
07-Oct-2019 
Amendment 2 
Version 4.0 
28-Aug-2019 
US Specific Amendment 1  
Version 3.0 
27-Jan-2019 
Global Protocol Version 2 
(Original Protocol Submitted) 
Version 2.0 
11-Dec-2018 
Global Protocol Version 1 
Version 1.0 
4-Dec-2018 
 
The Summary of Changes is located in the supplementary document, “IB1001-201 Protocol Summary of 
Changes Version 2.0, 10-Oct-2022”.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 5 of 161 
Version 7.0, 10 Oct 2022 
PROTOCOL SYNOPSIS 
Included as Appendix 1.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 6 of 161 
Version 7.0, 10 Oct 2022 
TABLE OF CONTENTS 
Protocol Amendment Summary of Changes Table .................................................... 4 
PROTOCOL SYNOPSIS .................................................................................................. 5 
TABLE OF CONTENTS .................................................................................................. 6 
LIST OF TABLES AND FIGURES ............................................................................... 12 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .............................. 13 
1 
INTRODUCTION ............................................................................................... 16 
1.1 
Risk/Benefit Considerations ........................................................................... 17 
1.2 
COVID-19 ........................................................................................................ 20 
2 
STUDY OBJECTIVES ........................................................................................ 22 
2.1 
Primary Objective ........................................................................................... 22 
2.2 
Secondary Objective(s) ................................................................................... 22 
2.3 
Exploratory Objective .................................................................................... 22 
3 
OVERALL DESIGN AND PLAN OF THE STUDY ....................................... 23 
3.1 
Overview .......................................................................................................... 23 
3.1.1 
Trial Design/Patient Population ........................................................... 23 
3.1.2 
Study Design ........................................................................................ 23 
3.1.2.1 
Baseline Period ............................................................................. 23 
3.1.2.2 
Treatment Period ........................................................................... 25 
3.1.2.3 
Washout Period ............................................................................. 25 
3.1.2.4 
Extension Phase ............................................................................ 25 
3.1.2.5 
COVID-19 Modifications to the Original Study Schema ............ 25 
3.1.2.6 
Interim Analyses ........................................................................... 27 
3.1.3 
Target Number of Patients ................................................................... 27 
3.1.4 
Number of Centers ............................................................................... 28 
3.1.5 
Study Duration ..................................................................................... 28 
3.2 
Discussion of Study Design ............................................................................. 28 
3.2.1 
Study Design ........................................................................................ 28 
3.2.2 
Development of the Primary Endpoint: Clinical Impression of Change 
in Severity (CI-CS) .............................................................................. 29 
3.2.2.1 
Anchor Tests: 9-hole Peg Test Dominant Hand (9HPT-D) or 8-
meter Walk Test (8MWT) ............................................................... 29 
3.2.2.2 
Blinded Raters & Video Assessments ............................................ 30 
3.2.2.3 
Serial Endpoint Evaluation ............................................................ 31 
3.2.3 
Choice of the Secondary and Exploratory Endpoints .......................... 31 
3.2.4 
Separate Trial Protocols by Indication ................................................. 32 
3.3 
End of Study Definition .................................................................................. 32 
4 
STUDY POPULATION ...................................................................................... 33 
4.1 
Inclusion Criteria ............................................................................................ 33 
4.2 
Exclusion Criteria ........................................................................................... 35 
4.3 
Patient Withdrawal ......................................................................................... 36 
4.4 
Patient Identification ...................................................................................... 37 
5 
STUDY DRUG ..................................................................................................... 38 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 7 of 161 
Version 7.0, 10 Oct 2022 
5.1 
Identity ............................................................................................................. 38 
5.2 
Administration ................................................................................................. 39 
5.3 
Modification of Dose Schedule ....................................................................... 39 
5.4 
Packaging, Labeling and Storage .................................................................. 40 
5.5 
Blinding and Breaking the Blind ................................................................... 40 
5.6 
Drug Accountability ........................................................................................ 40 
5.7 
Investigational Medicinal Product (IMP; ‘study drug’) Compliance ........ 41 
5.8 
Concomitant Medications and Therapies ..................................................... 41 
5.9 
Treatment of Overdose ................................................................................... 42 
6 
PARAMETERS AND METHODS OF ASSESSMENT .................................. 43 
6.1 
Efficacy Parameters ........................................................................................ 43 
6.1.1 
Measurement of Clinical Impression of Change in Severity ............... 43 
6.1.1.1 
Secondary Efficacy Endpoints That Directly Supplement the 
Analysis of the Primary Endpoint .................................................. 43 
6.1.2 
Spinocerebellar Ataxia Functional Index (SCAFI) .................... 44 
6.1.2.1 
Scale for the Assessment and Rating of Ataxia (SARA) ................. 44 
6.1.3 
Measurement of Health-related Quality of Life ................................... 45 
6.1.4 
Measurement of Overall Neurological Status ...................................... 45 
6.1.5 
Measurement of Global Impression ..................................................... 45 
6.1.6 
NPC Clinical Severity Scale (NPC-CSS) ............................................ 46 
6.1.7 
Remote Assessments ............................................................................ 47 
6.2 
Safety Parameters ........................................................................................... 47 
6.2.1 
Adverse Events .................................................................................... 48 
6.2.1.1 
Adverse Event Intensity ................................................................ 49 
6.2.1.2 
Adverse Event Relatedness ........................................................... 49 
6.2.2 
Serious Adverse Events ....................................................................... 49 
6.2.2.1 
Reporting Serious Adverse Events ............................................... 50 
6.2.2.2 
Responsibilities of the Sponsor ..................................................... 51 
6.2.3 
Pregnancy ............................................................................................. 51 
6.2.4 
Vital Signs ............................................................................................ 51 
6.2.5 
Electrocardiograms (ECGs) ................................................................. 52 
6.2.6 
Physical Examinations ......................................................................... 52 
6.2.7 
Additional Safety Assessments ............................................................ 52 
6.3 
Laboratory Parameters .................................................................................... 53 
6.3.1 
Safety Laboratory Assessments ........................................................... 53 
6.3.2 
Measurement of N-Acetyl-L-Leucine Concentration in Blood ........... 54 
6.3.3 
Measurement of N-Acetyl-D-Leucine Concentrations in Urine .......... 54 
6.3.4 
Additional Laboratory Samples for Research Purposes ...................... 54 
6.3.5 
Sample Processing ............................................................................... 55 
7 
STUDY CONDUCT ............................................................................................. 56 
7.1 
Observations by Visit ...................................................................................... 56 
7.1.1 
Screening (Visit 0 or Visit 1) ............................................................... 56 
7.1.1.1 
“Naïve” Patients Screening ........................................................... 56 
7.1.1.2 
“Non-naïve” Patients: Baseline Period ........................................ 57 
7.1.2 
Baseline Visit (Visit 2) ......................................................................... 59 
7.1.3 
Treatment 1 (Visit 3) ............................................................................ 59 
7.1.4 
Treatment 2 (Visit 4) ............................................................................ 60 
7.1.5 
Washout 1 (Visit 5) .............................................................................. 60 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 8 of 161 
Version 7.0, 10 Oct 2022 
7.1.6 
Washout Visit 2 (Visit 6) ..................................................................... 61 
7.1.7 
Early Termination Visit ....................................................................... 62 
8 
STATISTICAL METHODS ............................................................................... 63 
8.1 
General Analysis Plan ..................................................................................... 63 
8.1.1 
Disposition of Patients ......................................................................... 63 
8.1.2 
Analysis Populations ............................................................................ 63 
8.2 
General Considerations .................................................................................. 63 
8.3 
Demographics, Baseline Characteristics and Concomitant Medications .. 63 
8.4 
Treatment Compliance ................................................................................... 64 
8.5 
Efficacy Analyses ............................................................................................. 64 
8.5.1 
Primary Efficacy Endpoint .................................................................. 64 
8.5.2 
Secondary Efficacy Endpoints ............................................................. 65 
8.5.3 
Exploratory Efficacy Endpoints ........................................................... 67 
8.6 
Missing Data .................................................................................................... 67 
8.7 
Blinding ............................................................................................................ 68 
8.8 
Safety Analyses ................................................................................................ 68 
8.9 
Interim Analyses .............................................................................................. 68 
8.10 
Determination of Sample Size ........................................................................ 68 
8.11 
COVID-19 Details ........................................................................................... 68 
9 
DATA HANDLING AND RECORD KEEPING .............................................. 70 
9.1 
Data Collection ................................................................................................ 70 
9.2 
Data Correction ............................................................................................... 70 
9.2.1 
Deviations from the Protocol ............................................................... 70 
9.3 
Data Quality Assurance .................................................................................. 70 
9.3.1 
Retention of Records ............................................................................ 70 
9.4 
Protection of personal data ............................................................................ 70 
9.5 
COVID-19 Protocol Deviations and Missing Data ....................................... 71 
10 
QUALITY CONTROL AND QUALITY ASSURANCE ................................. 72 
10.1 
Study Initiation Activities ............................................................................... 72 
10.2 
Training of Site Staff ....................................................................................... 72 
10.3 
Documentation and Filing .............................................................................. 72 
10.3.1 
List of Patients (patient identification log) .......................................... 72 
10.3.2 
Source Data .......................................................................................... 72 
10.3.3 
Investigator Site File / Regulatory Binder ........................................... 72 
10.4 
Alternative Site due to COVID-19 ................................................................. 73 
10.5 
Monitoring ....................................................................................................... 73 
10.6 
Audits and Inspections .................................................................................... 74 
11 
ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS ........................... 75 
11.1 
Good Clinical Practice .................................................................................... 75 
11.2 
Informed Consent ............................................................................................ 75 
11.3 
Protocol Approval and Amendment .............................................................. 76 
11.4 
Archiving Study Records ................................................................................ 76 
11.5 
Data Safety Monitoring Board ....................................................................... 77 
11.6 
Premature Termination of the Study ............................................................ 77 
11.7 
Confidentiality ................................................................................................. 78 
11.8 
Liability and Insurance ................................................................................... 78 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 9 of 161 
Version 7.0, 10 Oct 2022 
11.9 
Publication Policy ............................................................................................ 78 
12 
REFERENCE LIST ............................................................................................. 79 
13 
APPENDICES ...................................................................................................... 82 
13.1 
Appendix 1: Synopsis ...................................................................................... 82 
13.2 
Appendix 2: List of Institutions Involved in the Study .............................. 108 
13.3 
Appendix 3: Schedule of Events ................................................................... 111 
13.4 
Appendix 4: Rationale for the Clinical Impression of Change in Severity 
(CI-CS) ........................................................................................................... 119 
13.5 
Appendix 5: Protocol Amendment History ................................................ 120 
13.6 
Appendix 6: Extension Phase ....................................................................... 121 
1 
INTRODUCTION – EXTENSION PHASE .................................................... 122 
1.1 
Risk/Benefit Considerations ......................................................................... 122 
2 
STUDY OBJECTIVES – EXTENSION PHASE ............................................ 125 
2.1 
Primary Objective ......................................................................................... 125 
2.2 
Secondary Objectives .................................................................................... 125 
2.3 
Exploratory Objectives ................................................................................. 125 
3 
OVERALL DESIGN AND PLAN OF THE EXTENSION PHASE ............. 126 
3.1 
Overview ........................................................................................................ 126 
3.1.1 
Trial Design/Patient Population ......................................................... 126 
3.1.2 
Study Design ...................................................................................... 126 
3.1.2.1 
Baseline Visit of the Extension Phase .......................................... 126 
3.1.2.2 
Extension Phase Treatment Period I ........................................... 126 
3.1.2.3 
Extension Phase Washout Period .............................................. 127 
3.1.2.4 
Extension Phase Treatment Period II .......................................... 127 
3.1.3 
Centers ............................................................................................... 127 
3.1.4 
Study Duration ................................................................................... 127 
3.2 
Discussion of Study Design ........................................................................... 127 
3.2.1 
Choice of the Primary Endpoint ........................................................ 127 
3.2.2 
Choice of the Secondary Endpoints ................................................... 127 
3.2.3 
Choice of the Exploratory Endpoints ................................................. 127 
3.2.4 
Dose/ Duration of Treatment ............................................................. 128 
3.3 
End of Study Definition ................................................................................ 128 
4 
STUDY POPULATION – EXTENSION PHASE .......................................... 129 
4.1 
Inclusion Criteria .......................................................................................... 129 
4.2 
Patient Withdrawal ....................................................................................... 129 
4.3 
Patient Identification .................................................................................... 129 
5 
STUDY DRUG – EXTENSION STUDY ......................................................... 130 
5.1 
Identity ........................................................................................................... 130 
5.1.1 
N-Acetyl-L-Leucine, 1000 mg powder for oral suspension in 60 mL 
glass bottles (without further excipients) ........................................... 130 
5.1.2 
N-Acetyl-L-Leucine, 1000 mg Granules for oral suspension in sachet131 
5.2 
Administration ............................................................................................... 131 
5.3 
Modification of Dose Schedule and Transition to Sachet Formulation ... 132 
5.3.1 
Modification of Dose ......................................................................... 132 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 10 of 161 
Version 7.0, 10 Oct 2022 
5.3.2 
Transition from IB1001 in Bottles to Sachet Formulation ................ 133 
5.4 
Packaging, Labeling and Storage ................................................................ 133 
5.4.1 
N-Acetyl-L-Leucine, 1000 mg powder for oral suspension in 60 mL 
glass bottles (without further excipients) ........................................... 133 
5.4.2 
N-Acetyl-L-Leucine, 1000 mg granules for oral suspension in sachet134 
5.5 
Blinding and Breaking the Blind ................................................................. 134 
5.6 
Drug Accountability ...................................................................................... 134 
5.7 
Investigational Medicinal Product (IMP; ‘study drug’) Compliance ...... 134 
5.8 
Concomitant Medications and Therapies ................................................... 134 
5.9 
Treatment of Overdose ................................................................................. 135 
6 
PARAMETERS AND METHODS OF ASSESSMENT – EXTENSION 
PHASE ................................................................................................................ 136 
6.1 
Updated Efficacy Parameters ...................................................................... 136 
6.1.1 
Measurement of Global Impression ................................................... 136 
6.1.2 
Clinical Impression of Change in Severity ........................................ 137 
6.2 
New Efficacy Parameters Introduced for the Extension Phase ................ 138 
6.2.1 
NPC Clinical Severity Scale (NPC-CSS) .......................................... 138 
6.2.2 
Annual Severity Increment Score (ASIS) .......................................... 139 
6.3 
Exploratory Endpoints for the Washout Phase .......................................... 139 
6.4 
Safety Parameters ......................................................................................... 139 
6.4.1 
Adverse Events .................................................................................. 139 
6.4.2 
Serious Adverse Events ..................................................................... 139 
6.4.3 
Pregnancy ........................................................................................... 139 
6.4.4 
Vital Signs .......................................................................................... 140 
6.4.5 
Electrocardiograms (ECGs) ............................................................... 140 
6.4.6 
Physical Examinations ....................................................................... 140 
6.4.7 
Medical History ................................................................................. 140 
6.5 
Laboratory Parameters ................................................................................ 140 
6.5.1 
Safety Laboratory Assessments ......................................................... 140 
6.5.2 
Measurement of N-Acetyl-L-Leucine Concentration in Blood on 
FULL PK days ................................................................................... 140 
6.5.3 
Measurement of N-Acetyl-D-Leucine Concentration in Urine ......... 141 
6.5.4 
Additional Laboratory Samples for Research Purposes .................... 141 
6.5.5 
Total Blood Volume .......................................................................... 141 
7 
STUDY CONDUCT – EXTENSION PHASE ................................................. 143 
7.1 
Observations by Visit .................................................................................... 143 
7.1.1 
Visit 7: Extension Phase Baseline Visit ............................................. 143 
7.1.2 
Visit 8: Day 180 (+/- 14 days): First assessment of the Extension 
Phase treatment period I with N-Acetyl-L-Leucine ........................... 144 
7.1.3 
Visit 9:  Day 365 (+/- 14 days): Final assessments of the Extension 
Phase treatment period I with N-Acetyl-L-Leucine ........................... 144 
7.1.3.1 
Visit 9, Part A:  Day 365 (+/- 14 days) of the treatment period .. 145 
7.1.3.2 
Visit 9, Part B ............................................................................... 145 
7.1.4 
Visit 10: Extension Phase Washout Visit .......................................... 145 
7.1.5 
Visit 11: Day 587 (+/- 14 days): Interim Extension Phase visit 
treatment period II .............................................................................. 146 
7.1.6 
Visit 12 Day 767: Final assessments of the Extension Phase treatment 
period II with N-Acetyl-L-Leucine .................................................... 146 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 11 of 161 
Version 7.0, 10 Oct 2022 
7.1.7 
Extension Phase Early Termination (ET) .......................................... 147 
8 
STATISTICAL METHODS – EXTENSION PHASE ................................... 149 
8.1 
General Analysis Plan ................................................................................... 149 
8.1.1 
Disposition of Patients ....................................................................... 149 
8.1.2 
Analysis Populations .......................................................................... 149 
8.2 
General Considerations ................................................................................ 149 
8.3 
Demographics, Baseline Characteristics and Concomitant Medications 149 
8.4 
Treatment Compliance ................................................................................. 150 
8.5 
Efficacy Analyses ........................................................................................... 150 
8.5.1 
Primary Efficacy Endpoint ................................................................ 150 
8.5.2 
Exploratory Efficacy Endpoints ......................................................... 151 
8.5.2.1 
Exploratory Efficacy Endpoints related to the Washout Phase ... 151 
8.6 
Missing Data .................................................................................................. 152 
8.7 
Blinding .......................................................................................................... 152 
8.8 
Safety Analyses .............................................................................................. 152 
8.9 
Interim Analyses ............................................................................................ 152 
8.10 
Determination of Sample Size ...................................................................... 153 
9 
DATA HANDLING AND RECORD KEEPING – EXTENSION PHASE .. 154 
10 
QUALITY CONTROL AND QUALITY ASSURANCE – EXTENSION 
PHASE ................................................................................................................ 155 
11 
ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS – EXTENSION 
PHASE ................................................................................................................ 156 
12 
LIST OF REFERENCES – EXTENSION PHASE ........................................ 157 
 
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 12 of 161 
Version 7.0, 10 Oct 2022 
LIST OF TABLES AND FIGURES 
Tables in Text 
Table 5.1: Prohibited Medications ............................................................................................................ 41 
 
Figures in Text 
Figure 3-1: Study Schema for “Naïve” Patients ........................................................................................... 23 
Figure 3-2: Study Schema for Non-naïve Patients ....................................................................................... 25 
Figure 4-1: Sample ID Format for a IB1001-201 Subject ............................................................................ 37 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 13 of 161 
Version 7.0, 10 Oct 2022 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
 
Abbreviation 
Definition 
8MWT 
8-meter walk test 
9HPT-D 
9-hole peg test of the dominant hand 
9HPT-ND 
9-hole peg test of the non-dominant hand 
AE 
Adverse event 
AEMPS 
Spanish Agency of Medicines and Medical Devices  
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase 
AST 
Aspartate aminotransferase 
ATC 
Anatomic Therapeutic Chemical 
CFR 
Code of Federal Regulations 
CGI 
Clinical global impression  
CGI-C 
Clinical global impression of change 
CGI-S 
Clinical global impression of severity 
CHMP 
Committee for Medicinal Products for Human use 
CHO 
Chinese hamster ovary 
CI-CS 
Clinical impression of change in severity 
CPMP 
Committee for Proprietary Medicinal Products 
CRF 
Case report form 
CS 
Clinically significant 
CI-S 
Clinical impression of severity 
DSMB 
Data Safety Monitoring Board 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
EQ 
EuroQol 
ET 
Early termination 
FAS 
Full analysis set 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 14 of 161 
Version 7.0, 10 Oct 2022 
FDA 
Food and Drug Administration 
FSH 
Follicle stimulating hormone 
GCP 
Good Clinical Practice 
GGT 
Gamma-glutamyl transpeptidase 
GMP 
Good manufacturing practice 
ICF 
Informed consent form 
ICH 
International Council on Harmonization 
IEC 
Independent Ethics Committee 
IMP 
Investigational medicinal product 
IRB 
Institutional Review Board 
ISF 
Investigator Site File 
ISPOR 
International Society for Pharmacoeconomics and Outcomes Research 
ITT 
Intention-to-treat 
IUD 
Intrauterine device 
IUS 
Intrauterine hormone releasing system 
LAM 
Lactational amenorrhoea method 
LOCF 
Last observation carried forward 
MASAP 
Meta-analysis statistical analysis plan 
mDRS 
Modified disability rating scale 
MEB 
Dutch Medicines Evaluation Board 
MedDRA 
Medical Dictionary for Regulatory Activities 
MHRA 
United Kingdom Medicines and Healthcare Products Regulatory 
Agency 
mITT 
Modified intention to treat 
MoCA 
Montreal Cognitive Assessment 
NCS 
Not clinically significant 
NPC  
Niemann-Pick disease type C 
NPC-CSS 
NPC clinical severity scale 
PI 
Principal investigator 
PK 
Pharmacokinetic(s) 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 15 of 161 
Version 7.0, 10 Oct 2022 
PPS 
Per protocol set 
SAE 
Serious adverse event 
SAF 
Safety analysis set 
SAP 
Statistical Analysis Plan 
SARA 
Scale for the assessment and rating of ataxia  
SCAFI 
Spinocerebellar ataxia functional index 
SD 
Standard deviation 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual analogue scale 
WHO 
World Health Organization 
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 16 of 161 
Version 7.0, 10 Oct 2022 
1 
INTRODUCTION 
The goal of this study is to demonstrate that N-Acetyl-L-Leucine is efficacious in improving 
symptoms, functioning, and quality of life against the defined endpoints in patients with 
Niemann-Pick Type C disease (NPC) for the purpose of establishing the benefit/risk balance 
of investigational medicinal product in the proposed clinical setting.  
NPC is a rare, devastating, neurovisceral autosomal-recessive inherited metabolic, lysosomal 
storage disorder (LSD) that predominantly affects pediatric patients [Vanier, 2010; Utz et al, 
2017]. In general, patients with neurological onset early in life have more severe symptoms, 
deteriorate faster, and die sooner [Wraith et al, 2009]. NPC is estimated to affect 1:100,000 
live births [Vanier, 2010].  
There are limited and no curative treatments approved for NPC worldwide, and no approved 
treatments in the United States. Therefore, there is a strong need for the development of novel 
and more effective therapies to treat these intractable diseases.  
N-Acetyl-L-Leucine is the L-enantiomer of N-Acetyl-DL-Leucine, a modified amino acid that 
has been available in France since 1957 under the trade name Tanganil® (Pierre Fabre 
Laboratories) as a treatment for acute vertigo and is available as a solution for injection and as 
a tablet. N-Acetyl-L-Leucine is not currently authorized anywhere in the world for the 
treatment of any condition.   
The Sponsor’s (IntraBio Ltd.) development of Acetyl-Leucine for NPC began with the 
investigation of the commercially available racemic mixture, N-Acetyl-DL-Leucine 
(Tanganil®). IntraBio’s collaborators reported in a case series on 12 patients with NPC that the 
modified amino-acid Acetyl-DL-Leucine (3 g/day for one week followed by 5 g per day for 
three weeks) significantly improved the symptoms of NPC, measured by the Scale for the 
Assessment and Rating of Ataxia (SARA), the Spinocerebellar Ataxia Functional Index 
(SCAFI) and EuroQol-5D-5L. N-Acetyl-DL-Leucine was very well tolerated, and no side 
effects except intermittent dizziness were reported [Bremova et al, 2015]. An additional case 
series is available in the literature describing the disease modifying effect of long-term 
treatment with N-Acetyl-DL-Leucine in 10 patients with NPC treated for a median length of 
7.7 months (maximum 21.2, minimum 2.7 months) [Cortina-Borja et al, 2018]. In all studies, 
the compound was well-tolerated with no discernible serious side effects.  
Recent in vitro and in vivo studies have demonstrated that the L-enantiomer mediates the 
therapeutic effect and has potential clinical benefits over the racemic mixture [Platt, 2018; 
Mann, 2018]. IntraBio therefore intends to focus further development on N-Acetyl-L-Leucine 
without the presence of D-enantiomer. The safety profiles of both N-Acetyl-DL-Leucine and 
N-Acetyl-L-Leucine have been characterized in both preclinical and clinical studies. In 
addition, the safety profile of N-Acetyl-DL-Leucine has been characterized on the basis of 
compassionate use experience in NPC (as well as in patients with other lysosomal storage 
disorders, neurodegenerative and genetic diseases, and further indications).  
Based on these findings, IntraBio is conducting this Phase II study investigating the efficacy 
and safety of N-Acetyl-L-Leucine for the treatment of NPC.  
The study drug used in the Parent Study is formulated as 1000 mg Powder for suspension in 
40 mL Ora-Blend® and oral administration. Patients aged ≥18 years in the United States and 
patients aged ≥13 years in Europe will receive a total daily dose of 4 g/day (administered as 
3 doses per day). Patients 6 to 12 years of age will receive weight-tiered doses.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 17 of 161 
Version 7.0, 10 Oct 2022 
Patients will only be included in the study if they meet the inclusion and exclusion criteria 
described in the study protocol approved by the relevant ethics committees and the regulatory 
authorities and informed consent is obtained. To further minimize risks, patients will receive 
the best available clinical care to manage the underlying conditions with careful monitoring of 
adverse events that may arise during the course of the clinical study. 
The overall design of the study is presented and discussed in Section 3.  
1.1 
Risk/Benefit Considerations 
NPC is a rare, serious, and life-threatening indication that predominantly affects the pediatric 
population. Treatment of NPC is so-far limited to symptomatic management and miglustat 
(Zavesca™) (not approved in the United States). Therefore, there is a strong need for the 
development of novel and more effective therapies to treat this disease.  
 
The active ingredient in IB1001 is N-Acetyl-L-Leucine, an acetylated derivate of a 
ubiquitously present amino acid occurring in human food. N-Acetyl-L-Leucine is also an 
endogenously generated metabolite of L-Leucine.  
 
The non-clinical (safety pharmacology, PK, and toxicology) profile supports the development 
of IB1001 as a potential treatment for NPC. No mortality and no noteworthy findings were 
observed in rats at the maximum feasible dose level, i.e. 1000 and 2000 mg/kg/day after 
repeated (28 days) intravenous (i.v.) and per oral (p.o.) administration, respectively. The L-
enantiomer and the racemate exhibited the same toxicity profile in rats and Beagle dogs, 
without any adverse systemic effects at the maximum feasible dose levels: i.e., up to 
2500 mg/kg/day after p.o. and up to 1000 mg/kg/day after i.v./intraperitoneal (i.p.) 
administration. The only findings observed in rats after i.v. bolus injections of the racemate at 
2000 mg/kg/day for 7 days were slight to moderate hypomotricity lasting from 30 seconds to 
5 minutes post-dosing as well as cyanosis of the caudal extremity from Day 2 up to the end of 
the study in some rats. In dogs dosed at 750 and 2500 mg/kg/day for 6 weeks, signs of 
gastrointestinal intolerance in form of emesis, increased salivation, and defecation (diarrhea, 
partly greenish discolored) were noted, which resolved within two hours after administration.  
 
The no-observed-adverse-effect-level (NOAEL) of 2000 mg/kg/day derived from a 28-day, 
p.o., repeat-dose toxicity study in rats corresponds to an area under the concentration-time 
curve (AUC) of 59 and 79 µg*h/mL in male and female rats, respectively. The NOAEL of 
2500 mg/kg/day derived from a 6-week, p.o., repeat-dose toxicity study in dogs corresponds to 
an AUC of 590 and 694 µg*h/mL in male and female dogs, respectively. These plasma 
exposures are 3-fold (rats) and 30-fold (dogs) higher than the human mean area under the 
concentration-time curve to the last quantifiable timepoint (AUClast) observed after a p.o. dose 
level of 4 g (21 µg*h/mL). Moreover, in a 4-week repeat-dose toxicity study in dogs, the 
highest dose level of 1000 mg/kg/administration given via 15-minute i.v. administrations 
repeated three times a day (total daily dose = 3000 mg/kg), was the NOAEL. This dose level 
corresponded to maximum observed plasma drug concentration (Cmax)/ AUClast levels in Week 
4 of 2844 µg/mL/1937 µg/mL*h in males and 2936 µg/mL/ 1819 µg/mL*h in females. These 
systemic exposure levels were more than 60-fold higher than the human exposure values after 
daily p.o. administration of 4 g (administered as one dose per day). 
 
N-Acetyl-L-Leucine induced no genotoxic effect in two in vitro cell systems and one in vivo 
mammalian erythrocytes micronucleus test performed in rat bone marrow up to high dose 
levels. No relevant modification was observed neither in vitro on the N-Acetyl-L-Leucine 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 18 of 161 
Version 7.0, 10 Oct 2022 
profile on hERG current, nor in vivo to the central nervous system, the cardiovascular and the 
respiratory function after a single i.v. administration in rats or dogs. 
 
The racemate, N-Acetyl-DL-Leucine, has been available in France since 1957 under the trade 
name Tanganil® (Pierre Fabre Laboratories) as an oral treatment for acute vertigo. It has 
demonstrated very good tolerability. Contraindications are restricted to hypersensitivity to 
N-Acetyl-DL-Leucine and other ingredients in the Tanganil® formulation. Known side effects 
are rare cases of skin rash (sometimes associated with pruritus) and urticaria. 
 
A broad set of clinical studies with N-Acetyl-L-Leucine in patients with balance disorders have 
been conducted, demonstrating the clinical safety of the compound. For N-Acetyl-L-Leucine, 
two PK studies in 24 (i.v.) and 19 (oral) healthy subjects ([Study No. V00251 IV 101] and 
[Study No. V00251 ST 101], respectively) have been conducted. Further, the safety of N-
Acetyl-L-Leucine was assessed in a multicenter placebo-controlled clinical study conducted in 
107 patients (80 patients randomized to N-Acetyl-L-Leucine) with vestibular neuritis [Study 
No. V00251 IV 201], in which subjects received doses up to 4 g/day i.v. (2 g twice-daily) for 
4 days and in a second multicenter placebo-controlled clinical study in 76 patients (50 
randomized to N-Acetyl-L-Leucine) with vestibular neuritis [Study No. V00251 ST 201], in 
which subjects received 8 g/day p.o. for 14 days. The results showed that N-Acetyl-L-Leucine 
has a good safety profile. It has been further demonstrated that there no interconversion from 
the L to the D-enantiomers.  
 
Publications on the racemate show N-Acetyl-DL-Leucine to be well tolerated in patients with 
NPC [Bremova et al, 2015; Cortina-Borja et al, 2018]. In Bremova et al. (2015) patients 
received N-Acetyl-DL-Leucine for 4 weeks before undergoing a 4-week washout period and 
in Cortina-Borja et al. (2018) patients were treated with N-Acetyl-DL-Leucine for a median 
length of 7.7 months (maximum 21.16, minimum 2.7 months). Further information on long-
term dosing is provided by an ongoing case series, in which 25 patients with NPC have been 
dosed with 5 g/day N-Acetyl-DL-Leucine (administered over 3 daily doses) for a minimum of 
one year and up to over two years, in which N-Acetyl-DL-Leucine was found to be well-
tolerated [Dr Michael Strupp, MD, Professor of Neurology LMU Munich, Personal 
Communication].  
 
From an efficacy point of view, encouraging first data is available from the above studies. 
Bremova et al. (2015), which compared ataxia symptoms at baseline, after 4 weeks treatment, 
and after 4 weeks washout, concluded that N-Acetyl-DL-Leucine improved ataxic symptoms 
and quality of life in patients with NPC. The two case series following individuals receiving 
N-Acetyl-DL-Leucine ([Cortina-Borja et al, 2018] and [Kaya et al, 2020a]) additionally 
suggest that N-Acetyl-DL-Leucine slows the rate of disease progression. Pre-clinical studies 
have also further demonstrated that N-Acetyl-L-Leucine is the active ingredient that 
medications the long-term, neuroprotective, diseases modifying effect of the racemate, while 
the D-enantiomer is inactive or potentially antagonistic [Kaya et al, 2020a]. 
 
Appropriate patient selection is one factor in considering the balance of risks of adverse events 
(AEs) against potential clinical benefit. The protocol inclusion and exclusion criteria 
appropriately consider the patient’s overall health and medical history.  
 
Based upon the very good safety profile of N-Acetyl-L-Leucine (and N-Acetyl-DL-Leucine) 
observed in animals at dose levels up to the limit dose (p.o. 2000 mg/kg/day) as well as 
Commented [FP1]: @Taylor: as discussed with 
Katharine, this one paragraph is public knowledge and, 
as such, would not qualify for redaction. 
Commented [TF2R1]: I disagree - the last 2 
paragraphs are but the first are PF data which we 
explictly cannot share and it has not ever been 
published, or it is IB’s non clinical studies conducted. I 
left the text in yellow which should be redacted 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 19 of 161 
Version 7.0, 10 Oct 2022 
knowledge of safe use of N-Acetyl-DL-Leucine in children as young as 9 months of age 
[Picone, 2018], inclusion of children aged 6 years and over is judged to be safe. Women of 
childbearing potential and partners of women of childbearing potential will be required to 
adhere to strict precautions to prevent pregnancy. Women who are pregnant, breast-feeding, or 
planning to become pregnant will be excluded from the study. In addition, a negative pregnancy 
test will be a prerequisite for the inclusion of women of child bearing potential and urine 
pregnancy tests will be carried out at approximately 6-weekly intervals throughout the trial.  
 
Levels of risk and burden on participants 
 
N-Acetyl-L-Leucine is being developed for the treatment of adults and children with NPC, a 
rare and ultimately fatal disorder that predominantly affects pediatric patients [Vanier, 2010; 
Utz et al, 2017]. As described above, published case series and long-term use of N-Acetyl-DL-
Leucine in patients with NPC suggest the prospect of a direct benefit to the participating 
patients over standard of care.  
 
To ensure the feasibility of this trial, NPC clinical experts [Dr Marc Patterson, MD, Mayo 
Clinic, Professor Pediatric Neurology] and the heads of multinational NPC patient 
organizations [Dr William Evans, Chairman Nieman-Pick UK; Joslyn Crowe, Executive 
Director, National Niemann-Pick Disease Foundation, Inc.] were consulted and involved in 
its design.  
 
The degree of burden to participants in the study is defined by the description of assessments 
in Section 7.  
 
The behavioral tests for evidence of efficacy are routinely used in the evaluation of NPC and 
are relatively fast to perform, with the individual subtests of the SCAFI rarely taking more than 
2 minutes for patients with NPC to complete [Bremova et al, 2015]. With regard to the 
secondary endpoint assessments, the Scale for Assessment and Rating of Ataxia (SARA) takes 
about 15 minutes and the Niemann-Pick type C Clinical Severity Scale (NPC-CSS) takes about 
45 minutes to complete [Dr Marc Patterson, MD, Mayo Clinic, Professor Pediatric Neurology]. 
The use of these tests was determined together with representatives of the patient community 
and parents of patients with NPC and Tay-Sachs disease, as being clinically meaningful for the 
patients and families and reflective of the ability to perform acts of everyday life safety and 
securely, while at the same time not being exhausting [Dr William Evans, Chairman Nieman-
Pick UK, Personal Communication; Daniel Lewi, President, Cure Action for Tay-Sachs 
Foundation, Personal Communication]. 
 
To minimize blood draws sparse PK sampling will be carried out at the same times that blood 
is drawn for the safety blood laboratory tests in the Parent Study. Topical anesthesia may be 
applied before blood sampling. The total amount of blood taken per subject during Parent Study 
will be approximately 66 mL (42 mL blood for the safety analyses, 24 mL blood for the PK 
analyses) evenly distributed over the 6 scheduled visits that will take place over a study 
duration of 14 to 20 weeks. Patients will be ≥15 kg and the total blood volume taken in 
accordance with the maximum allowable research-related blood sample volumes provided in 
the incoming EU ethical considerations for clinical trials on medicinal products conducted with 
minors [EudraLex Volume 10, 2017].  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 20 of 161 
Version 7.0, 10 Oct 2022 
The impact of the interventions will be assessed by patient-reported outcomes (measurement 
of global impression, see Section 6.1.5, where feasible, and quality of life assessments (EQ-
5D-5L and EQ-5D-Y, see Section 6.1.3.  
 
The investigator will monitor the degree of stress to patients and the risk threshold throughout 
the trial. Patients will be instructed to report any AEs that they experience to the Investigator 
and the Investigator will ask about the occurrence of AEs at each visit. As described in Section 
11.6, if the Investigator (or the Sponsor or Medical Monitor) becomes aware of conditions or 
events that suggest a possible hazard to patients if the study continues, the clinical study may 
be terminated after appropriate consultation between the involved parties. 
 
In addition, as described in Section 11.5, the Data Safety Monitoring Board (DSMB), in 
conjunction with the study Medical Monitor and/or Sponsor, will monitor the level of risk on 
a regular basis throughout the study. The DSMB is a multidisciplinary group consisting of 
clinicians with pediatric experience and a biostatistician. The DSMB has been set up to 
safeguard the interests of study participants by providing an independent review of patient 
safety data to monitor that no undue harm is occurring to patients due to their participation. 
The DSMB may recommend changes in the conduct of the studies to IntraBio, if needed, to 
ensure the safety of patients in the study and the proper conduct of the studies. The DSMB may 
also recommend suspending recruitment or terminate the study early because of undue safety 
risks to patients or any issues concerning the rights of patients. For this purpose, the DSMB 
will receive regular updates of safety and review all safety data on a regular basis.  
 
Based upon the nature of the drug, the available non-clinical and clinical data for N-Acetyl-L-
Leucine and N-Acetyl-DL-Leucine, the current lack of effective treatments NPC, and in the 
context of a marketed racemate, this clinical trial is concluded to pose acceptable levels of risk 
and burden on participants.  
 
1.2 
COVID-19 
This study is ongoing during the COVID-19 epidemic. Coronavirus (COVID-19) outbreaks 
have been recorded in all countries with study sites and subjects participating in IntraBio’s 
clinical trials and have significantly impacted the IB1001-201 clinical trial. 
 
Protocol Version 5.0 (EU)/ 5.1 (US) was active in countries prior to the widespread outbreak 
of COVID-19 in the US and Europe. Protocol deviations, urgent safety measures, and 
modifications to this protocol have been necessary to prioritize and ensure the safety of trial 
participants, their families, and study site teams, and maintain the integrity of the study.  
 
New or modified processes / contingency measures enacted due to the outbreak of COVID-
19 are described throughout the Parent Study Protocol, including a risk/benefit assessment 
when applicable. All measures and actions that have been implemented due to COVID-19 
were first reviewed and agreed by the Data Safety Monitoring Committee (DSMB), the 
Medical Monitor, and applicable Principal Investigators.  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 21 of 161 
Version 7.0, 10 Oct 2022 
These new or modified processes enacted due to the outbreak of COVID-19 are consistent 
and permitted per the guidance’s issued from applicable regulatory bodies1 regarding the 
management of clinical trials in relation to COVID-19. In addition, applicable competent 
authorities (CA), research ethic committees (REC), and institutional review boards (IRBs) 
were notified and provided with copies of the applicable guidance’s issued by the Sponsor to 
participating Study Sites regarding the management of the COVID-19 pandemic (including 
IntraBio 2020a).  
 
Note: This protocol amendment (Version 6.0 25-Aug-2020) has been made to include 
changes to protocol procedures which have been enacted due to COVID-19 at this time. 
However, because COVID-19 is an evolving situation, the ultimate impact of COVID-19 on 
the IB1001-201 clinical trial remains unknown. Therefore, the protocol and related study 
documents may be updated as applicable. Any measures implemented in relation to COVID-
19 will be in accordance with Guidance’s issued from applicable National Competent 
Authorities. The Data Safety Monitoring Board (DSMB) will also be consulted as applicable 
to ensure the safety of trial participants and clinical trial site study teams, as well as 
maintain the integrity of the clinical study.  All protocol deviations related to COVID-19 will 
be well-documented to enable appropriate evaluation of the IB1001-201 clinical trial.   
 
 
 
 
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 22 of 161 
Version 7.0, 10 Oct 2022 
2 
STUDY OBJECTIVES 
2.1 
Primary Objective 
The primary objective is to evaluate the efficacy of N-Acetyl-L-Leucine based on blinded 
raters’ clinical impression of change in severity (CI-CS) in the treatment of NPC. 
2.2 
Secondary Objective(s) 
The secondary objectives are: 
o To assess the clinical efficacy of N-Acetyl-L-Leucine on symptoms of ataxia, 
functioning, and quality of life for patients with NPC; 
o To evaluate the safety and tolerability of N-Acetyl-L-Leucine at 4 g/day in patients 
with NPC, including patients aged ≥18 years in the United States and patients aged 
≥13 years in Europe, and weight-tiered doses in patients 6 to 12 years of age in 
Europe 
2.3 
Exploratory Objective 
The exploratory objective is: 
• To characterize the pharmacokinetics (PK) of N-Acetyl-L-Leucine in patients with 
NPC 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 23 of 161 
Version 7.0, 10 Oct 2022 
3 
OVERALL DESIGN AND PLAN OF THE STUDY 
3.1 
Overview 
This study is ongoing during the COVID-19 outbreak. The impact of the global pandemic on 
the overall design and plan of the study is described in section 3.1.2.5. 
3.1.1 Trial Design/Patient Population 
This is a multinational, multicenter, open-label, rater-blinded Phase II study that will enroll 
male or female patients aged ≥6 years in Europe AND ≥18 years in the United States with a 
confirmed diagnosis of NPC at the time of signing informed consent.  
3.1.2 Study Design 
Patients will be assessed during three study phases: a baseline period (with or without a study 
run-in), a treatment period, and a washout period. It is not uncommon for symptoms and 
functioning to fluctuate over a week, so to help account for intra-patient variability, patients 
will be assessed twice during each period. Section 7 contains more detailed information on 
which study assessments and procedures will be conducted for each study phase and visit.  
At the initial screening visit, patients will be classified as either “naïve” or “non-naïve” patients 
depending on their use of prohibited medications within the past 42 days. The schedule of 
events during the initial screening visit and throughout the baseline period (through Visit 1) 
will vary depending on the patient’s classification as either “naïve” or “non-naïve”. 
3.1.2.1  Baseline Period 
Baseline: “Naïve” Patients (Figure 3-1). 
(See Appendix 3A for “naïve” patients schedule of events) 
“Naïve” patients are defined as patients who, at the initial screening visit, confirm (or whose 
legal representatives confirm on behalf of the patient) that they have not used any prohibited 
medications within the past 42 days. For these patients, the initial screening visit will be treated 
as Visit 1 (Baseline 1). 
A urine sample will be taken at Visit 1 to detect N-Acetyl-D-Leucine. Provided the patient’s 
levels of N-Acetyl-D-Leucine are below the permitted threshold, the initial screening visit will 
be confirmed as Visit 1 (Baseline 1). Visit 2 (Baseline 2/ Start of treatment period) will take 
place 14 days (+7 days) after Visit 1. 
 
Figure 3-1: 
Study Schema for “Naïve” Patients 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 24 of 161 
Version 7.0, 10 Oct 2022 
 
 
Reclassifying “Naïve” Patients to “Non-naïve” Patients 
Visit 1 will not be confirmed for “naïve” patients whose urine sample test unexpectedly detects 
levels of N-Acetyl-D-Leucine above the permitted threshold. Provided the treating physician 
believes the patient will indeed comply with the pre-treatment washout and complete study the 
protocol2, these patients will be given the option to undergo a minimum of 42 days washout 
before returning for Visit 1 (Baseline 1). Provided the patient (or legal representative on behalf 
of the patient) consents, the patient will be reclassified as “non-naïve” and will return for a 
repeat Visit 1 after the study run-in washout period.   
Baseline: “Non-Naïve” Patients (Figure 3-2). 
(See Appendix 3B for “non-naïve” patients schedule of events) 
“Non-naïve” patients are defined as patients who confirm (or whose legal representatives on 
behalf of the patient confirm) they have used, or are unable to confirm or deny if they have 
used, any prohibited medication within the past 42 days3.  
Provided the treating physician believes the patient will comply with the pre-treatment 
washout and complete the study protocol, the “non-naïve” patient will be given the 
opportunity to undergo a minimum of 42 days washout before returning for Baseline 1. 
Provided the patient (or their legal representatives on behalf of the patient) consent, the initial 
screening visit will be treated and confirmed as Visit 0 (Figure 3-2). 
Visit 0 will commence study the run-in period where patients undergo a washout from 
prohibited medications. Patients are eligible to return for Baseline 1 after a minimum of 42 
days washout. For patients (or their legal representatives on behalf of the patient) who confirm 
they have not used any prohibited medications for a minimum of 42 days, the second visit will 
be treated as Visit 1 (Baseline 1)4.  
A urine sample will be taken at Visit 1 to assess the level of N-Acetyl-D-Leucine. Provided 
the level of N-Acetyl-D-Leucine is below the permitted threshold, the second visit will be 
confirmed as Visit 1 (Baseline 1). Visit 2 (Baseline 2/ Start of treatment period) will take place 
14 days (+7 days) after Visit 1.  
 
 
2 If the treating physician has reason to believe the patient will not comply with the study run-in washout or the complete 
study protocol, the patient will be notified they are ineligible for the study.  
3 As described, “non-naïve” patients can also be defined as patients who were initially classified as “naïve,” but whose initial 
urine sample unexpectedly detected levels of N-Acetyl-D-Leucine above the permitted threshold. Provided they are eligible, 
patients will be reclassified as “non-naïve” and return for a second screening visit after a minimum of 42 days washout.  
4 At Visit 1, patients who confirm (or whose legal representatives confirm) they have used, or are unable to confirm or deny 
if they have used, any prohibited medication within the past 42 days are ineligible to continue in the study.   
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 25 of 161 
Version 7.0, 10 Oct 2022 
 
Figure 3-2: 
Study Schema for Non-naïve Patients  
 
3.1.2.2 Treatment Period 
From Visit 2 onward, all visits will be the same for all patients regardless of whether they were 
considered to be “naïve” or “non-naïve” at the time of screening. 
During the treatment period, all patients will receive N-Acetyl-L-Leucine for 42 days 
(+7 days). Visit 3 (Treatment 1) will occur at Day 28 (+7 days) of the treatment period and 
Visit 4 (Treatment 2) will occur after the full 42 days (+7 days) of treatment. 
3.1.2.3 Washout Period 
A 42-day (+7 days) washout period will be performed following treatment with N-Acetyl-L-
Leucine. Visit 5 (Washout 1) will occur on Day 28 (+7 days) of the washout period and Visit 6 
(Washout 2) will occur after the full 42 days (+7 days) of washout. 
3.1.2.4 Extension Phase 
Patients who have participated in the study will be offered the opportunity to participate in a 
planned Extension Phase if the safety and tolerability during the 42-day (+7 days) treatment 
are considered to be acceptable by the Investigator for each specific patient, and the 
Investigator determines further treatment with IB1001 to be in the patient’s interest. Provided 
the patient (or their legal representative on their behalf) subsequently consent to participate, 
the Extension Phase is planned to allow patients to have further access to IB1001 for one year. 
Following a 6-week post Extension Phase treatment washout (Visit 10 of the Extension Phase), 
patients will have access to IB1001 for an additional one-year in the Extension Phase Treatment 
Period II. 
See Appendix 6 for the Protocol for Extension Phase.  
3.1.2.5 COVID-19 Modifications to the Original Study Schema 
COVID-19 has significantly impacted study subjects’ ability to attend study visits due to 
government-ordered lockdowns or the closure of state (domestic) and/or national borders. In 
addition, the issuance of site-specific policies limiting or halting the conduct of non-essential 
study visits, the conversion of study-sites into COVID-19 wards, and site staff not on duty or 
reassigned to other priorities at the hospitals have affected the feasibility of conducting study 
visits. Finally, considering NPC patients are already classified as a vulnerable patient 
population, patients may be self-isolating. 
 
If, per the reasons above, in-person visits cannot be carried out in accordance with the 
schedule of events, the following departures from the original study schema are allowed:  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 26 of 161 
Version 7.0, 10 Oct 2022 
3.1.2.5.1 Non-Essential In-Person Visits: Treatment Visit 3/ Washout Visit 5 
- 
Visit 3 and Visit 5 are “interim” visits of the treatment and washout phases, 
respectively.  
- 
The Sponsor’s Medical Expert, Medical Monitor, the DSMB, Biostatistician and 
Principal Investigators consider that missing the in-person Visit 3 and / or Visit 5 
would not compromise the safety of the patient or the integrity of the study, and that 
the patient could continue with medication (Visit 3) or the post-treatment washout 
phase (Visit 5) without attending the in-person Visit 3 and / or Visit 5. This risk 
assessment was based on the previously established safety profile of IB1001 (see 
Section 1), the observed very good tolerability shown to date in this ongoing, open-
label study, including that no related serious adverse reactions had been reported with 
IB1001 (in any ongoing trial ), that these visits are not critical to the primary outcome 
assessment, and that the integrity of the clinical trial could be maintained if these 
visits were not performed due to COVID-19 restrictions. 
- 
Therefore, in-person Visit 3 and Visit 5 have been classified as non-essential visits 
and may be skipped if they are not feasible to conduct in-person due to national, local, 
or site-specific restrictions, or necessary to safeguard the site staff, patients, and their 
families. If the in-person Visit 3 and / or Visit 5 is skipped, a remote visit should be 
conducted in lieu of the in-person visit (see Section 3.1.2.5.3 below).  
 
3.1.2.5.2 Essential In-Person Visits: End of Treatment Visit 4/ Washout Visit 6 
- 
Visit 4 and Visit 6 are the final visits of the treatment/washout phase (respectively) 
- 
The Sponsor’s Medical Expert, Medical Monitor, the DSMB, and each Principal 
Investigator determined that the in-person Visit 4 and Visit 6 are necessary visits 
needed to fully assess the safety of trial participants, the primary endpoint, and 
maintain the integrity of the clinical trial.  
- 
However, it was determined (if they are not feasible to conduct in-person due to 
national, local, or site-specific restrictions, or necessary to safeguard the site staff, 
patients, and their families) postponing the in-person Visit 4 and/or Visit 6 would not 
compromise the safety of the patient, and that the patient could continue with 
medication / be dosed longer than the planned 42 days (+7 days) treatment period 
(Visit 4).  This risk assessment was based on the previously established safety profile 
of IB1001 (see Section 1), the observed good tolerability shown to date in this 
ongoing, open-label study, including that no related serious adverse reactions had 
been reported with IB1001 (in any ongoing clinical trial), that the Extension Phase 
(including one-year treatment period with IB1001) had been approved in all countries, 
and that data collected from these postponed in-person Visit 4 and/or Visit 6 was 
acceptable for the purpose of assessing a true treatment-related effect. 
- 
Therefore, Visit 4 and Visit 6 have been classified as essential study visits which may 
be postponed (if they are not feasible to conduct in-person due to national, local, or 
site-specific restrictions, or necessary to safeguard the site staff, patients, and their 
families) but cannot be skipped. If Visit 4 and / or Visit 6 is postponed, a remote visit 
should be conducted at the time of the original the in-person visit (see 
Section 3.1.2.5.3 below) 
 
3.1.2.5.3 Remote Visits 
For any (i) skipped in-person Visit 3/5; (ii) postponed in-person Visit 4/6: based on the 
availability of the patient/ the study team, within approximately  +/- 3 days of the originally 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 27 of 161 
Version 7.0, 10 Oct 2022 
scheduled visit, the study team/ principal investigator (PI) should contact the patient (and as 
applicable, their parents/caregiver/legal representative) via phone/Skype5 to collect 
information in order to monitor adverse or serious adverse events, and provide study 
oversight (hereafter referred to as “remote visits”).  
 
Assessments which may be able to be performed remotely (as feasible) may include: 
• 
Documentation of (changes in) frequency of therapy (hours per week) 
• 
Documentation of (changes in) concomitant medication 
• 
Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• 
Clinical Global Impression of Severity (CGI-S)  
• 
Clinical Global Impression of Change (CGI-C)  
• 
Documentation of changes in or new adverse events / serious adverse events 
• 
Discuss if additional study drug is needed (V3 only) 
• 
PATA Speech Test 
• 
Modified Disability Rating Scale  
• 
Scale for the Assessment and Rating of Ataxia  
• 
Additional Protocol Assessments which the Investigator/ Patient mutually agree to 
perform/assess  
 
Assessments collected at a remote Visits 3 and/or Visit 5 should be entered into the electronic 
case report form (eCRF) under Visit 3 and/or Visit 5. 
 
Assessments collected from remote Visit 4 and/or Visit 6 should be entered into eCRF as an 
Unscheduled Visit. When the postponed, in-person Visit 4 and/or Visit 6 is performed, all 
assessments collected at this visit should be entered into the eCRF as Visit 4 and/or Visit 6.  
 
See Section 9.5 for additional information on how contingency measures/protocol deviations 
related to COVID-19 will be captured in the electronic case report form (eCRF)/ documented 
in the Parent Study Clinical Study Report (CSR). 
 
3.1.2.6 Interim Analyses  
No interim analyses are planned throughout the Parent Study.  
At the end of the Parent Study (defined as the date of the last visit of the last patient in the 
Parent Study globally; see Section 3.3) an interim clinical study report will be written which 
will include the results of the Parent Study. 
3.1.3 Target Number of Patients 
• To be enrolled: Approximately 39 patients  
 
• To be analyzed according to the modified Intention to Treat (mITT) analysis: 
Approximately 36 patients 
 
• To be analyzed according to the Per Protocol Analysis: Approximately 30 patients 
 
 
5 As feasible; Skype is used as a generic term for videoconferencing, telemedicine but other software’s may be used. No video recordings 
should be made of these remote visits.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 28 of 161 
Version 7.0, 10 Oct 2022 
3.1.4  Number of Centers 
The trial will be conducted in a total of approximately 9 centers in the United States, the United 
Kingdom, Germany, Slovakia, or Spain, which must meet the structural and personnel 
requirements for performing the planned regular trial-related investigations.  
If necessary, additional countries may be included in the trial. 
3.1.5 Study Duration 
The treatment and washout duration for all patients, from the first day of dosing with the study 
drug (Visit 2) to the final follow-up visit after washout (Visit 6), is expected to be 
approximately 84 days.  
For “naïve” patients, there is a 14-day (+7 days) baseline period between Visit 1 and Visit 2. 
For “non-naïve” patients, there is a 42-day (+7 days) run-in period before Visit 1, and a 14-day 
(+7 days) baseline period between Visit 1 and Visit 2.  
COVID-19 will impact the duration of the study for patients whose Visit 4 and/or Visit 6 are 
postponed. 
3.2 
Discussion of Study Design 
3.2.1 Study Design 
Open-label rater-blinded study 
IntraBio initially proposed to investigate the safety and efficacy of N-Acetyl-L-Leucine for 
NPC, Tay-Sachs disease, and inherited Cerebellar Ataxias in a randomized, double-blind, 
placebo-controlled, crossover study. This design was discussed with regulators in the United 
States and Europe, including the United States Food and Drug Administration (US FDA; July 
2018), the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA), 
the Dutch Medicines Evaluation Board (MEB), and the Spanish Agency of Medicines and 
Medical Devices (AEMPS).  
Following these meetings, a formal feasibility study was initiated by IntraBio that demonstrated 
that a randomized, double-blind, placebo-controlled, crossover study would be difficult to 
recruit and commence without changes to the study design for the following reasons: 
- 
 IntraBio discussed these findings with NPC clinical experts and the heads of 
multinational NPC patient organizations, who believe that given the relentless and often 
rapid progression, invariably fatal outcome, and –the common use of unlicensed 
treatments/therapies by patients, families/caregivers would be reluctant to enroll 
patients in the planned placebo-controlled study where patients would be on treatment 
for 6-weeks, but without study drug for 18 to 24 weeks (depending on whether they are 
considered as “naïve” or “non-naïve” patients).  
- 
Moreover, both NPC clinical experts and the heads of multinational NPC patient 
organizations have questioned the appropriateness of initiating randomized, double-
blind, controlled studies for ultra-orphan indications like NPC, and strongly 
recommended the trial design be amended so that it is (a) feasible to enroll and retain 
the trial subjects and (b) appropriate in view of the size of the patient population with 
NPC and their need to have the rapidly progressing and fatal condition properly 
managed. This feedback was similar to a concern raised by the US FDA, who 
recommended that a crossover design should not be used in a study intended to 
demonstrate the effectiveness and controlled safety data because of the potential for 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 29 of 161 
Version 7.0, 10 Oct 2022 
missing data caused by dropouts [United States Department of Health and Human 
Services, 2018b]. 
Therefore, the current proposed multinational, multicenter, open-label, rater-blinded Phase II 
study was designed with regard to an informed assessment based on input from the clinical 
experts and patient representatives. The proposed study now reduces the time patients are asked 
to go without study drug. During the trial, naïve patients will be without study drug for 6 out 
of 12 weeks (compared previously to 18 out of 24 weeks) and non-naïve patients will be 
without study drug for 14 of 20 weeks (compared previously to 24 out of 30 weeks). 
To reduce bias in an open-label clinical study, and especially in the clinical assessment of the 
trial subjects against the pre-defined variables, the primary analysis will be based on two 
independent raters’ blinded assessment of videos documenting the patients’ performance on 
the 9-Hole Peg Test of the Dominant Hand (9HPT-D) or 8-meter Walk Test (8MWT) (for 
details see Section 8.5.1). 
Two Study Schemas during Baseline Period 
As NPC is has an ultra-small patient population, and the number of eligible patients is already 
restricted, the study will permit patients who have used prohibited medications over the past 
42 days to enroll provided they meet the inclusion/exclusion criteria and agree to perform a 
minimum 42-day washout from the prohibited medication prior to Visit 1. 
3.2.2 Development of the Primary Endpoint: Clinical Impression of Change in 
Severity (CI-CS) 
The development of the CI-CS follows the recommendation of the US FDA and was designed 
in accordance with the FDA PRO Guidance and International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) Task Force papers [ISPOR, 2018] to assist in establishing a 
well-defined and reliable blinded-clinician reported outcome assessment for use in the planned 
clinical studies [United States Department of Health and Human Services, 2018a].  
The conceptual framework and description of the CI-CS methodology is provided in Fields, 
2020. 
3.2.2.1 Anchor Tests: 9-hole Peg Test Dominant Hand (9HPT-D) or 8-meter Walk Test 
(8MWT) 
To account for the clinical heterogeneity of NPC and to better ensure that the primary 
assessment is clinically meaningful for each individual patient, the proposed CI-CS asks the 
treating physician to select, based on the patient’s unique clinical symptoms, either the 9HPT-D 
or the 8MWT as an anchor test for the CI-CS. This decision will be made based on the treating 
physician’s assessment of the patient at Visit 1 (Baseline 1), before the start of treatment with 
N-Acetyl-L-Leucine. At the recommendation of the US FDA, a cognitive assessment should 
be performed at Visit 1 according to the standard procedures of the clinical site to assist with 
the selection of the anchoring functional test appropriate for each patient from both a cognitive 
and a motor perspective [United States Department of Health and Human Services, 2018a]. 
The anchor test will also be selected based on interactions with the patient, their family, and 
caregivers, to ensure the selected scale is considerate of their quality of life.  
As recommended by the US FDA, the 9HPT-D and 8MWT were selected as the anchor tests 
based on concept elicitation interviews with NPC clinical experts and representatives of NPC 
patient organizations worldwide [United States Department of Health and Human Services, 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 30 of 161 
Version 7.0, 10 Oct 2022 
2018a], as well as questionnaire completed by parents caring for a child with NPC and NPC 
clinical experts [Cortina-Borja et al, 2018]. 
Based on these findings, it is proposed that physicians will be able to select either the 9HPT-D 
or the 8MWT as the anchor by which the CI-CS is assessed. The United Kingdom Medicines 
and Healthcare Products Regulatory Agency [MHRA, 2018], the Dutch Medicines Evaluation 
Board [MEB, 2018], and the Spanish Agency of Medicines and Medical Devices [AEMPS, 
2018] all considered the 9HPT and 8MWT to be relevant, acceptable measures. 
The US FDA initially suggested the 6-Minute Walk Test be used in lieu of the 8MWT. This 
was discussed extensively with the agency, who confirmed in the meeting notes that IntraBio 
provided additional rationale for the 8MWT over the 6-Minute Walk Test [United States 
Department of Health and Human Services, 2018a], including the consideration that from a 
clinical perspective, the 6-minute walk test is a crude measure of gait functionality, as the 
distance a patient can walk in 6 minutes does not equate to how stable their gait is or how 
secure their movement is. Although readily measurable, the 6-minute walk test is 
predominately a measure of strength and endurance, and therefore an appropriate for muscular 
dystrophy disorders but not muscular atrophy disorders [Dr Marc Patterson, MD, Mayo Clinic, 
Professor Pediatric Neurology, Personal Communication].  
Moreover, as discussed by representatives of the patient community and parents of patients 
with NPC and Tay-Sachs disease, the 6-minute walk test is described as being a poor 
measurement that is not clinically meaningful for patients or their families, as their interest is 
for patients’ (many of whom are severely impaired) ability to perform acts of everyday life 
safely and securely rather than more exhaustive tasks [Dr William Evans, Chairman Nieman-
Pick UK, Personal Communication; Daniel Lewi, President, Cure Action for Tay-Sachs 
Foundation, Personal Communication]. 
3.2.2.2 Blinded Raters & Video Assessments  
Because a double-blind, placebo-controlled, crossover study is not believed to be feasible, 
having the primary evaluation of the CI-CS performed by two blinded, independent raters 
based on videos of the anchor test is intended to reduce detection and performance bias.  
This decision was based on MHRA recommendation, which suggested and strongly endorsed 
the plan for blinded evaluation of video recordings of both the 9HPT-D and 8MWT [MHRA, 
2018]. 
Based on the US FDA recommendation, the assessments and recordings will be made in the 
clinic rather than in the patient’s home to standardize assessments across the diversity of 
patients’ home environments [United States Department of Health and Human Services, 
2018a]. 
In addition to adding blinded control to the primary assessment, at the recommendation of the 
US FDA, videos will be used to increase reliability and minimize testing burden on patients. 
Video recordings allow repeated viewings without the necessity for repetition and patient 
fatigue, and permit the blinded rater to control the pace of the movement analysis [Lord et al, 
1998]. Finally, at the recommendation of the US FDA, basing the primary assessment on videos 
minimizes the recall bias that can be associated with the traditional Clinical Global Impression 
of Change (CGI-C) scale [United States Department of Health and Human Services, 2018a]. 
Each site will have the same video-recording devices and receive the same standardized 
training and instructions to create homogeneity in the video recordings. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 31 of 161 
Version 7.0, 10 Oct 2022 
The CI-CS will also be performed for the anchor test (9HPT-D or 8MWT) that was not selected 
as the patient’s primary anchor test (i.e., the non-primary anchor test). This will enable the 
evaluation of both of the possible anchor tests, and to assess the appropriateness of the chosen 
primary anchor test with regard to its ability to function as a clinically meaningful outcome 
measure for the patient. 
The blinded raters will be independent senior raters, who have ideally performed the 9HPT, 
8MWT, and Clinical Global Impression (CGI) in a clinical setting. At the recommendation of 
the US FDA, definitions of disease severity and components for blinded raters to assess and 
rate the patients’ change in severity will be provided [United States Department of Health and 
Human Services, 2018a]. The blinded raters will receive the same standardized training and 
instructions to create homogeneity in the assessments of patient’s clinical change in severity 
while performing the 9HPT-D/8MWT. 
3.2.2.3 Serial Endpoint Evaluation 
Three additional visits have been added to the study so that patients will be assessed twice 
during each period (baseline, treatment, washout) based on the US FDA recommendation to 
have more frequent primary endpoint evaluations given the high degree of variability within 
these patient populations and in small sample sizes generally. These additional visits are 
intended to allow serial endpoint evaluations to mitigate against within-patient heterogeneity 
and missing data [United States Department of Health and Human Services, 2018a]. 
3.2.3 Choice of the Secondary and Exploratory Endpoints 
The proposed secondary endpoints for ataxia, described in Section 8.5.2, were selected on the 
recommendation of the US FDA to narrow the selection of secondary endpoints to minimize 
testing burden [United States Department of Health and Human Services, 2018a]. 
Ultimately, it was decided not to include the Niemann-Pick type C Clinical Severity Scale 
(NPC-CSS) or a modified version of NPC-CSS as a secondary endpoint for the Phase II Parent 
Study investigating the efficacy of 6-weeks of treatment with N-Acetyl-L-Leucine. This is 
because the NPC-CSS was designed to be a measure to characterize and quantify disease 
progression and is not a sensitive measure of short-term symptomatic treatment [Yanjanin et 
al, 2010]. The major domains of the NPC-CSS scale are each a 5-point scale recording the 
trajectory between normal functionality and negligible function. For a short-term study of 42 
days (+7 days), the assessments are too crude to detect clinically meaningful effects.  
Therefore, for the Phase II Parent Study, the NPC-CSS is too burdensome an endpoint, 
considering its graduation of changes is not fine enough to detect minor but clinically relevant 
changes in functioning / benefit after 42 days (+7 days) of treatment. However, a single NPC-
CSS assessment will be performed at baseline Visit 1 to generate an additional measurement 
of disease severity at the start of the Parent Study. 
Similarly, although IntraBio has demonstrated in in vitro studies that treatment with N-Acetyl-
L-Leucine and N-Acetyl-DL-Leucine corrects a number of phenotypes, including expanded 
lysosomal volume and the accumulation of sphingosines and glycosphingolipids in fibroblasts 
from patients with NPC and expanded lysosomal volume in NPC1-null CHO (Chinese hamster 
ovary) cells [Mann, 2018], for a short-term study of 6 weeks, no major changes in lysosomal 
volume/accumulation of sphingosines and glycosphingolipids can be expected to be detected 
by analyzing biomarkers.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 32 of 161 
Version 7.0, 10 Oct 2022 
3.2.4 Separate Trial Protocols by Indication 
Initially it was proposed to include patients with NPC, Tay-Sachs disease, and cerebellar ataxia 
patients in a single, basket trial. Based on the recommendation of the US FDA [United States 
Department of Health and Human Services, 2018a] and the Dutch MEB [MEB, 2018], separate 
trials will be conducted for NPC, as well as for GM2-Gangliosidosis (Tay-Sachs and Sandhoff 
Disease) and ataxia-telangiectasia (an inherited cerebellar ataxia subtype), to investigate the 
safety and efficacy of N-Acetyl-L-Leucine for the treatment of each indication. At the 
recommendation of the UK MHRA [MHRA, 2018] there will be a series of meta-analyses that 
will bring together the data from the three studies for the primary and secondary endpoints. 
Further details will be provided in a meta-analysis statistical analysis plan (MASAP).  
In addition, the Phase II study for Tay-Sachs disease (separate to this protocol) has been 
extended to include all GM2 gangliosidosis patients (Tay-Sachs and Sandhoff Disease). This 
is based on the fact that Tay-Sachs and Sandhoff disease are clinically indistinguishable, as 
well as recent compassionate use reports in patients with Sandhoff disease where significant 
benefit was observed [Kaya et al, 2020b], in vitro findings in Sandhoff patient cells where N-
Acetyl-D-Leucine normalized lysosomal volume [Mann, 2018], and in vivo studies in a 
Sandhoff mouse model (Hexb-/-) where the efficacy of N-Acetyl-D-Leucine for symptomatic 
and neuroprotective treatment was observed [Platt, 2018; Kaya et al, 2020b]. 
 
3.3 
End of Study Definition 
A patient is considered to have completed the Parent Study if he/she has completed all phases 
of the Parent Study including the last visit (Visit 6). 
The end of the Parent Study is defined as the date of the last visit of the last patient in the Parent 
Study globally. At this time, an interim report will be written which will include the results of 
the Parent Study. 
A complete Clinical Study Report (CSR) will be written when the last visit of the last patient 
in the Extension Phase has been completed (see Section 3.3 of the Extension Phase in 
Appendix 6).   
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 33 of 161 
Version 7.0, 10 Oct 2022 
4 
STUDY POPULATION 
The study population comprises patients with NPC. To be eligible, patients must satisfy the 
following entry criteria:   
4.1 
Inclusion Criteria 
Individuals who meet all of the following criteria are eligible to participate in the study: 
1. Written informed consent signed by the patient and/or their legal representative/ parent/ 
impartial witness 
2. Male or female aged ≥6 years in Europe OR ≥18 years in the United States with a 
confirmed diagnosis of NPC at the time of signing informed consent. Confirmed 
diagnosis includes [Patterson et al, 2017]: 
a) Clinical features and positive biomarker screen and/or filipin test without genetic 
tests results (has not been performed) 
b) Clinical features and positive genetic test 
c) Clinical features and positive biomarker screen and/or filipin test but only one NPC 
mutation identified on genetic test  
d) Clinical features with positive biomarker screen and/or filipin test and positive 
genetic test 
3. Females of childbearing potential, defined as a premenopausal female capable of 
becoming pregnant, will be included if they are either sexually inactive (sexually 
abstinent6 for 14 days prior to the first dose and confirm to continue through 28 days 
after the last dose) or using one of the following highly effective contraceptives (i.e. 
results in <1% failure rate when used consistently and correctly) 14 days prior to the 
first dose continuing through 28 days after the last dose: 
a) intrauterine device (IUD); 
b) surgical sterilization of the partner (vasectomy for 6 months minimum); 
c) combined (estrogen or progestogen containing) hormonal contraception associated 
with the inhibition of ovulation (either oral, intravaginal, or transdermal); 
d) progestogen only hormonal contraception associated with the inhibition of 
ovulation (either oral, injectable, or implantable); 
e) intrauterine hormone releasing system (IUS);  
f) bilateral tubal occlusion. 
4. Females of non-childbearing potential must have undergone one of the following 
sterilization procedures at least 6 months prior to the first dose: 
 
 
6 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatments. In this trial abstinence is only 
acceptable if in line with the patient’s preferred and usual lifestyle. 
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. As well, female 
condom and male condom should not be used together. 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 34 of 161 
Version 7.0, 10 Oct 2022 
a) hysteroscopic sterilization; 
b) bilateral tubal ligation or bilateral salpingectomy; 
c) hysterectomy; 
d) bilateral oophorectomy; 
OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and 
follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. 
FSH analysis for postmenopausal women will be done at screening. FSH levels should 
be in the postmenopausal range as determined by the central laboratory. 
5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from 
sexual intercourse during the study until 90 days beyond the last dose of study 
medication and the female partner agrees to comply with inclusion criteria 3 or 4. For 
a vasectomized male who has had his vasectomy 6 months or more prior to study start, 
it is required that they use a condom during sexual intercourse. A male who has been 
vasectomized less than 6 months prior to study start must follow the same restrictions 
as a non-vasectomized male. 
6. If male, patient agrees not to donate sperm from the first dose until 90 days after their 
last dose. 
7. Patients must fall within: 
a) A SARA score of 5 ≤ X ≤ 33 points (out of 40)  
AND 
b) Either: 
i. 
Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale   
OR  
ii. 
Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI 
subtest) in 20 ≤ X ≤150 seconds. 
8. Weight ≥15 kg at screening. 
9. Patients are willing to disclose their existing medications/therapies for (the symptoms) 
of NPC, including those on the prohibited medication list. Non-prohibited 
medications/therapies (e.g. miglustat, concomitant speech therapy, and physiotherapy) 
are permitted provided: 
a) The Investigator does not believe the medication/therapy will interfere with the 
study protocol/results 
b) Patients have been on a stable dose/duration and type of therapy for at least 42 days 
before Visit 1 (Baseline 1)  
c) Patients are willing to maintain a stable dose/do not change their therapy throughout 
the duration of the study. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 35 of 161 
Version 7.0, 10 Oct 2022 
10. An understanding of the implications of study participation, provided in the written 
patient 
information 
and 
informed 
consent 
by 
patients 
or 
their 
legal 
representative/parent, and demonstrates a willingness to comply with instructions and 
attend required study visits (for children this criterion will also be assessed in parents 
or appointed guardians).  
4.2 
Exclusion Criteria 
Individuals who meet any of the following criteria are not eligible to participate in the study: 
1. Asymptomatic patients 
2. Patient has clinical features of NPC and a positive biomarker screen and/or filipin test, 
but a completely negative result on a previous genetic test for NPC 
3. Patients who have any of the following: 
a) Chronic diarrhea; 
b) Unexplained visual loss; 
c) Malignancies; 
d) Insulin-dependent diabetes mellitus. 
e) Known history of hypersensitivity to the Acetyl-Leucine (DL-, L-, D-) or 
derivatives. 
f) History of known hypersensitivity to excipients of Ora-Blend® (namely sucrose, 
sorbitol, cellulose, carboxymethylcellulose, xanthan gum, carrageenan, 
dimethicone, methylparaben, and potassium sorbate). 
4. Simultaneous participation in another clinical study or participation in any clinical 
study involving administration of an investigational medicinal product (IMP; ‘study 
drug’) within 6 weeks prior to Visit 1. 
5. Patients with a physical or psychiatric condition which, at the investigator’s discretion, 
may put the patient at risk, may confound the study results, or may interfere with the 
patient’s participation in the clinical study.  
6. Known clinically-significant (at the discretion of the investigator) laboratories in 
hematology, coagulation, clinical chemistry, or urinalysis, including, but not limited to: 
a. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x 
upper limit of normal (ULN); 
b. Total bilirubin >1.5x ULN, unless Gilbert’s syndrome is present in which case 
total bilirubin >2x ULN. 
7. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol. 
8. Current or planned pregnancy or women who are breastfeeding. 
9. Patients with severe vision or hearing impairment (that is not corrected by glasses or 
hearing aids) that, at the investigator’s discretion, interferes with their ability to perform 
study assessments. 
10. Patients who have been diagnosed with arthritis or other musculoskeletal disorders 
affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient’s 
mobility and, at the investigator’s discretion, interferes with their ability to perform 
study assessments. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 36 of 161 
Version 7.0, 10 Oct 2022 
11. Patients unwilling and/or not able to undergo a 42-day washout period from any of the 
following prohibited medication prior to Visit 1 (Baseline 1) and remain without 
prohibited medication through Visit 6. 
a) Aminopyridines (including sustained-release form); 
b) N-Acetyl-DL-Leucine (e.g. Tanganil®); 
c) N-Acetyl-L-Leucine (prohibited if not provided as IMP); 
d) Riluzole; 
e) Gabapentin; 
f) Varenicline; 
g) Chlorzoxazone; 
h) Sulfasalazine; 
i) Rosuvastatin. 
4.3 
Patient Withdrawal  
Patients may withdraw from the study at any time at their own request without stating the 
reason(s) for withdrawal. If a patient withdraws early from the study after start of treatment an 
early termination (ET) visit should be arranged, preferably 7-14 days after the last dose of study 
drug. 
“Non-naïve” patients (including “naïve” patients reclassified as “non-naïve”) will be 
withdrawn from the study if their urine sample from Visit 1 (Baseline 1) detects levels of N-
Acetyl-D-Leucine above the permitted threshold.  
The treating physician may decide that a patient should be withdrawn from the study or from 
the study drug. Reasons for withdrawal from the study or the study drug may include, but are 
not limited to, the following: 
• Development of any adverse event (AE), serious AE (SAE), laboratory abnormality, 
condition, intercurrent illness, injury, medical condition, or use of a medication that is 
likely to interfere with patient safety, the overall assessment, or the study procedures, 
such that continued participation in the study would not be in the best interest of the 
patient. 
• Consent withdrawal. 
• The patient becomes pregnant or plans to become pregnant. 
• Significant patient noncompliance, defined as an unwillingness to complete the 
procedures defined in the schedule of events. 
• Patient lost to follow-up (i.e., staff unable to contact patient after several attempts). 
• Investigator, Medical Monitor, and/or Sponsor decision for any other reason not listed 
above that may invalidate the results of the study or jeopardizes the health and/or safety 
of a patient 
• Complications related to pandemics such as COVID-19. 
Patients who discontinue study drug prior to completing the full treatment period, should be 
asked to complete the remaining study visits as far as possible and complete safety assessments 
at a minimum. If unwilling to complete the remaining study visits, regardless of the reason for 
withdrawal, best efforts should be made to have the patient take part in early termination (ET) 
procedures, preferably 7-14 days weeks following the last dose of the study drug, unless the 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 37 of 161 
Version 7.0, 10 Oct 2022 
patient is lost to follow-up or has withdrawn his/her consent to further study participation.  Due 
to COVID-19, the ET visit may need to be postponed or conducted remotely, after discussion 
with the PI and the Sponsor. 
The reason for withdrawal will be recorded in the electronic case report form (eCRF). Adverse 
event follow-up procedures will be required if the patient is withdrawn from the study as a 
result of an AE/SAE. Data collected before withdrawal will be evaluated for safety and efficacy 
(if possible).  
If the Investigator, Sponsor, or Medical Monitor becomes aware of conditions or events that 
suggest a possible hazard to patients if the study continues, the clinical study may be terminated 
after appropriate consultation between the involved parties. The clinical study may also be 
terminated at the Sponsor’s discretion in absence of such a finding. The reasons will be 
explained should the situation arise. 
Conditions that may warrant termination of the study include (but are not limited to): 
• The discovery of an unexpected, relevant, or unacceptable risk to patients; 
• Failure to enroll patients at the required rate; 
• A decision of the Sponsor to suspend or discontinue development of the study drug. 
Recruitment will continue until approximately 30 patients complete dosing and Visit 6 or 
approximately 39 patients are enrolled.  
 
4.4 
Patient Identification  
All patients (also referred to as “subject”) will be assigned a unique, seven-digit identification 
number at screening, the “patient number”. The first 4 digits will refer to the site: the first 2 
numbers refer to the country (e.g. 49 for Germany, 34 for Spain, etc.) and the second 2 digits 
refer to the site number (e.g. 01 for the first site in German, 02 for the second site in Germany, 
etc.) (Figure 4-1). 
The next 3 digits will refer to the indication/patient: the first digit will refer to the study (1 for 
the NPC study). The final two digits refer to the patient number. 
The site and patient digits will be separated by a dash, e.g.  4901-101, 4301-105. 
This unique patient number will not be replaced by an enrollment number if the patient is 
eligible and will start treatment. 
 
Figure 4-1: 
Sample ID Format for a IB1001-201 Subject 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 38 of 161 
Version 7.0, 10 Oct 2022 
5 
STUDY DRUG 
5.1 
Identity 
Product: N-Acetyl-L-Leucine (internal development name: IB1001) 
Chemical name: 2(S)-(acetylamino)-4-methylpentanoic acid 
Generic name: N-Acetyl-L-Leucine 
Trade name: to be determined 
Dosage form: N-Acetyl-L-Leucine, 1000 mg powder for oral suspension in 60 mL glass 
bottles (without further excipients) 
Strength: 1000 mg per 60 mL glass bottle 
Manufacturer:  
Manufacture of dosage form, QC testing, Stability studies: 
Patheon UK Limited,  
151 Milton Park, Abingdon, Oxfordshire OX14 4SD, United Kingdom  
 
Secondary packaging, Labelling, IMP release, Clinical distribution 7 
Fisher Clinical Services UK Ltd,  
Langhurstwood Road, Horsham, West Sussex, RH12 4QD, United Kingdom 
 
Description: 
All patients are to receive N-Acetyl-L-Leucine (IB1001) in this single-arm study; there will be 
no comparator or placebo.  
The product is formulated as 1000 mg powder for oral suspension, to be suspended in 40 mL 
Ora-Blend®.  
The suspension vehicle Ora-Blend® contains the following excipients: 
- 
purified water 
- 
sucrose 
- 
glycerin  
- 
sorbitol  
- 
flavoring 
- 
microcrystalline cellulose 
- 
carboxymethylcellulose sodium 
- 
xanthan gum 
 
 
7 It is currently planned that in the event of Brexit without further (transitional) rules or in the event Fisher Clinical Services in the United 
Kingdom is no longer able to carry out the importation and the final approval of the investigational drugs within the EU, Fisher Clinical 
Services Germany, with offices at Im Wörth 3, 79576 Weil am Rhein, Germany will assume responsibility for Fisher Clinical Services Ltd. 
UK.  
 
Commented [FP3]: @Taylor: Ora-Blend at the moment 
is redacted in some sections of the protocol and not in 
others.  
Is it the general fact that you use Ora-Blend as the 
suspension vehicle that you regard as commercially 
confidential? If so, then you would need to do a search 
for “Ora-Blend” in the document and redact everywhere.  
 
Or is it just the details of the use (i.e. how many ml)? In 
this case it would be sufficient to just redact the 
respective information specifically. 
E.g you would not need to redact the excipients, 
because once the reader knows that you are using Ora-
Blend, the list of excipients is available in the public 
domain.  
 
Commented [TF4R3]: got it, will not remove and will 
not remove the 1000 mg 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 39 of 161 
Version 7.0, 10 Oct 2022 
- 
carrageenan 
- 
calcium sulfate 
- 
trisodium phosphate 
- 
citric acid and sodium phosphate as buffers 
- 
dimethicone antifoam emulsion 
- 
preserved with methylparaben and potassium sorbate 
5.2 
Administration 
All patients are to receive N-Acetyl-L-Leucine (IB1001) in this single-arm study; there will be 
no comparator or placebo.  
The 40mL of Ora-Blend® will be combined into the powder and must be shaken vigorously 
for 2 minutes so that it fully mixes before being administered.  
The study drug should be taken 30 minutes before, or at least two hours after a meal. 
During the treatment period of this study, the dosing of the study drug is as follows: 
• Patients aged ≥13 years in Europe and aged ≥18 years in the United States will take 4 g 
per day: 2 g in the morning, 1 g in the afternoon, and 1 g in the evening. 
• Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning 
and 1 g in the evening. 
• Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 
1 g in the afternoon, and 1 g in the evening. 
• Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g 
in the afternoon and 1 g in the evening (as per patients aged ≥13). 
The planned maximum dosage for patients ≥13 years, or aged 6-12 weighing ≥35 kg is 4 g per 
day for 42 days (+7 days). 
Patients aged 6 to 12 years and <35 kg will receive 2 g or 3 g per day for 42 days (+7 days), in 
accordance with their body weight (see above).  
5.3 
Modification of Dose Schedule 
On visit days, patients should keep to their usual dosing schedule.  
If a patient misses a dose of study drug, the patient should wait and take the next dose according 
to the treatment schedule.  
Compliance will be assessed upon a review of the inventory of IB1001 bottles returned from 
patients.   
The patient’s total daily dose may be reduced by up to one-half of their assigned dose at the 
discretion of the investigator. 
In the event a patient turns 13 years old, or a patient aged 6-12 years old changes weight 
category over the course of the study, their daily dose will not change from the initial dosing 
regimen prescribed at Visit 2, the start of IMP.  
Study drug will be taken during the 42-day (+7 day) treatment period. After the 42-day (+7 
day) treatment period, patients will enter a 42-day (+7 day) washout period, which includes 
efficacy and safety assessments.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 40 of 161 
Version 7.0, 10 Oct 2022 
If Visit 4 is postponed due to COVID-19, patients who remain in the study must be dosed 
through the postponed Visit 4. The study drug will therefore be taken longer than the planned 
42 days (+7 days). Based on the known risk/benefit profile of IB1001, the Sponsor’s Medical 
Expert, Medical Monitor, the DSMB, and each Principal Investigator have determined that 
postponing Visit 4 will not compromise the safety of the patient, nor would continuing the 
patient on IMP until the postponed Visit 4. 
 
Note: at the time of the initial COVID-19 outbreak, the Extension Phase (providing patients 
with further access to treatment for one-year) had been accepted by all applicable Competent 
Authorities (CA)/ Institutional Review Boards (IRB)/ Research Ethics Committees (REC) 
where the trial is being conducted, supporting the continued dosing of patients until the 
postponed in person Visit 4. 
 
See Section 5.9 for information on the treatment of overdose.  
5.4 
Packaging, Labeling and Storage 
IB1001 and Ora-Blend® will be supplied in kits. Each kit contains 28 bottles of N-Acetyl-L-
Leucine (each bottle containing 1000 mg N-Acetyl-L-Leucine for a total of 28,000 mg per kit), 
packed with 3 bottles of Ora-Blend® (each bottle contains 473 mL, for a total of 1,419 mL per 
kit). 
 
Study drug will be packaged by Fisher Clinical Services UK Ltd (Langhurstwood Road, 
Horsham, West Sussex, RH12 4QD, United Kingdom) according to all local legal 
requirements. Study drug will be labelled in accordance with applicable regulatory 
requirements. 
All study drug supplies must be stored in accordance with the manufacturer’s instructions. 
Until dispensed to the patients, the study drug will be stored in a securely locked area, 
accessible to authorized personnel only. 
Packaging and labelling of IMP will comply with Good Manufacturing Practice (GMP), Good 
Clinical Practice (GCP) rules, Annex 13, and country-specific regulatory requirements. 
Packaging and labeling of the IMP will be available in the local language. 
 
5.5 
Blinding and Breaking the Blind 
This study is not blinded.  
5.6 
Drug Accountability 
The Investigator is responsible for maintaining accurate study drug accountability records 
throughout the study. Study drug accountability will be performed at Visit 3 (only if feasible), 
Visit 4 (or after Visit 4, if IMP is returned via courier), and, if applicable, at the ET (or after 
ET, if the IMP is returned via courier). Unused or returned drug will be destroyed at the site. 
Alternatively, the study drug may be returned to Fisher Clinical Services UK Ltd 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 41 of 161 
Version 7.0, 10 Oct 2022 
(Langhurstwood Road, Horsham, West Sussex, RH12 4QD, United Kingdom) 8or Fisher 
Clinical Services US (7554 Schantz Rd, Allentown, PA 18106, USA) if sites are unable to 
dispose of the study drug and it cannot be destroyed at the site. The Investigator, institution, or 
the head of the medical institution (where applicable) is responsible for maintaining up to date 
inventory and site accountability logs. Each dispensing of study drug to a patient will be 
documented in the medical records and patient-level accountability logs. 
5.7 
Investigational Medicinal Product (IMP; ‘study drug’) Compliance 
Compliance will be assessed upon a review of the inventory of IB1001 bottles returned from 
patients.  
Urine tests for N-Acetyl-D-Leucine will be done at Visit 1, Visit 2 (baseline period), Visits 5, 
and Visit 6 (washout period) (see Section 6.3.3 for more details). 
If a patient initially classified as “naïve” has a urine sample after the initial screening visit 
which unexpectedly detects levels of N-Acetyl-D-Leucine above the permitted threshold, they 
will (provided eligible) be reclassified as “non-naïve”. These patients are eligible to return for 
Visit 1 (Baseline 1) after a minimum 42-day wash-out.  
“Non-naïve” patients (including “naïve” patients reclassified as “non-naïve”) who test above 
the permitted threshold for N-Acetyl-D-Leucine in their urine at Visit 1 (Baseline 1) will be 
classified as non-compliant and withdrawn from the study.  
5.8 
Concomitant Medications and Therapies 
At Visit 0/Visit 1, all medication taken in the last 60 days prior to the date of informed consent 
must be recorded. The current amount (in hours per week) of therapy (e.g., physiotherapy, 
speech therapy) needs to be recorded at the time of informed consent.  
Table 5.1 lists medications that are prohibited and must not have been used by the patient for 
at least 42 days before Visit 1 (for both “naïve” and “non-naïve” patients). Medication not 
listed in this table may be permitted, at the discretion of the investigator, as long as there is no 
interference with the study objectives or patient safety. Doses of medications and therapies 
used for (the symptoms of) NPC should remain as constant as possible (at the investigator’s 
discretion) throughout the trial.  
 
Table 5.1: 
Prohibited Medications 
Prohibited medication 
Washout prior to treatment 
(minimum time period) 
Aminopyridines (including sustained-release form) 42 days 
N-Acetyl-DL-Leucine (e.g. Tanganil®) or N-
Acetyl-L-Leucine (if not provided as study drug 
during the study) 
42 days 
 
 
8  It is currently planned that in the event of Brexit without further (transitional) rules or in the event Fisher Clinical Services in the United 
Kingdom is no longer able to accept unused or returned study drug from European trial sites for destruction. Fisher Clinical Services 
Germany, with offices at Im Wörth 3, 79576 Weil am Rhein, Germany will assume responsibility for Fisher Clinical Services Ltd. UK.  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 42 of 161 
Version 7.0, 10 Oct 2022 
Table 5.1: 
Prohibited Medications 
Riluzole 
42 days 
Gabapentin 
42 days 
Varenicline 
42 days 
Chlorzoxazone  
42 days 
Sulfasalazine 
42 days 
Rosuvastatin 
42 days 
 
From Visit 0 (non-naïve) or Visit 1 onward, any ongoing or new medication the patient takes 
other than the study drug is considered a concomitant medication. All concomitant medications 
must be recorded in the eCRF. The following information must be recorded in the eCRF for 
each concomitant medication: generic name, route of administration, start date, stop date, 
dosage, and indication. Any changes in the dosage or regimen of a concomitant medication 
must be recorded in the eCRF.  
A patient who changes their previous regimen/dose, is permitted to continue with the 
study/study drug if the Investigator does not believe the medication/therapy will interfere with 
the patient’s safety.  
Note: Drug interactions with substrates of transporters MDR1, BCRP, or BSEP cannot be 
excluded as N-Acetyl-L-Leucine is an inhibitor of these transporters in vitro. Sulfasalazine 
and rosuvastatin are included under prohibited medications, whereas substrates of MDR1 and 
BSEP and other substrates of BCRP may be used at the discretion of the investigator. 
 
5.9 
Treatment of Overdose 
No specific information on overdose of N-Acetyl-L-Leucine (IB1001) exists for humans. 
Based on the pharmacology, it is not expected that overdose would produce a clinically relevant 
reaction. The patient should be appropriately monitored.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 43 of 161 
Version 7.0, 10 Oct 2022 
6 
PARAMETERS AND METHODS OF ASSESSMENT 
The primary and secondary parameters used during the study are described below.  
Section 3 describes the Overall Design and Plan of Study for “naïve” and “non-naïve” patients. 
See Appendix 3A for “naïve” patients’ schedule of events and Appendix 3B for “non-naïve” 
patients’ schedule of events. 
Section 7 contains more detailed information on which study assessments and procedures will 
be conducted for each study phase and visit. 
6.1 Efficacy Parameters 
6.1.1 Measurement of Clinical Impression of Change in Severity  
The primary endpoint is defined as the clinical impression of change in severity (CI-CS) 
comparing end of treatment with N-Acetyl-L-Leucine (Visit 4) with baseline (Visit 2) minus 
the CI-CS comparing the end of washout (Visit 6) with the end of treatment with N-Acetyl-L-
Leucine (Visit 4) based on the primary anchor test. 
This primary endpoint will assess the efficacy of N-Acetyl-L-Leucine for the treatment of NPC, 
based on blinded raters’ CI-CS of patient’s change in performance over 6 weeks on either the 
9-hole peg test of the dominant hand (9HPT-D) or the 8-meter walk test (8MWT). A manual 
will be provided to each clinical site, which provides instructions for the administration of the 
CI-CS [Fields, 2020]. Similarly, a video-acquisition manual will be provided, which provides 
instructions for making standardized videos of the 8MWT and 9HPT-D anchor tests [Medpace, 
2019]. 
At Visit 1, the treating physician will evaluate each patient’s clinical symptoms and select 
either the 9HPT-D or 8MWT as the primary anchor around which the CI-CS assessment will 
be based. The primary evaluation of the CI-CS will be performed by two independent raters 
whose assessments will be based on videos of the anchor test taken at each visit. The raters will 
be blinded to the treatment phases to reduce detection and performance biases and for each pair 
of visits will make an assessment based on a 7-point Likert scale, e.g., -3 = ‘significantly 
worse’, 0 = ‘no change’ to +3 = ‘significantly improved’ (see Section 8.5.1 for further details 
on the primary efficacy analysis).  
6.1.1.1 Secondary Efficacy Endpoints That Directly Supplement the Analysis of the Primary 
Endpoint 
Supportive secondary endpoints will be evaluated that directly supplement the analysis of the 
primary endpoint as follows (see Section 8.5.2 for further details): 
• The individual components of the primary endpoint, that is the CI-CS from Visit 2 to 
Visit 4 and the CI-CS from Visit 4 to Visit 6. 
• Differences in the blinded rater’s Clinical Impression of Severity (CI-S) values from 
baseline to end of treatment and from end of treatment to end of washout. The two CI-S 
values at each of these periods (Visit 1 and Visit 2 for baseline, Visit 3 and Visit 4 for 
end of treatment and Visit 5 and Visit 6 for end of washout) will be averaged. 
• Sensitivity measurement of change in performance on either the 9HPT-D or the 8MWT 
on a 3-point scale. Using the CI-CS outcome for the primary anchor test based on the 
data for Visits 2 and Visit 4, any patient given a score of -1, -2, or -3 on the CI-CS will 
be classified as worsened (-1). Any patient classified as 0 on the CI-CS will be classified 
no change (0). Any patient given a score of +1, +2, +3 on the CI-CS will be classified 
as improved (+1). A similar classification will use the CI-CS comparing the end of 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 44 of 161 
Version 7.0, 10 Oct 2022 
treatment with N-Acetyl-L-Leucine with end of washout based on the data for Visits 4 
and Visit 6 and the difference between these scores calculated. 
• An evaluation of the CI-CS for the test (9HPT-D or 8MWT) that was not selected as 
the primary anchor test will also be undertaken. This will enable the separate analysis 
of CI-CS for both the 9HPT-D and the 8MWT.  
 
There will also be an investigation of the intra-rater correlation in relation to Videos from Visits 
1 and 2, Visits 3 and 4, and Visits 5 and 6 to help investigate the stability of the outcome 
evaluation and the disease itself. Pearson rank correlation coefficients will be calculated for 
each of these pairings for each of the two raters. 
Other secondary endpoints include the Spinocerebellar Ataxia Functional Index (SCAFI) and 
Scale for Assessment and Rating of Ataxia (SARA) scores, based on the changes from baseline 
(Visit 2) to the end of treatment with N-Acetyl-L-Leucine (Visit 4), as well as from the end of 
treatment with N-Acetyl-L-Leucine (Visit 4) to the end of post-treatment washout (Visit 6). 
See Section 8.5.2 for further details on the analysis of the secondary efficacy endpoints. 
6.1.2 Spinocerebellar Ataxia Functional Index (SCAFI) 
The SCAFI consists of a timed 8MWT to be carried out at maximum speed, the 9-hole peg test 
with both dominant and non-dominant hands (9HPT-D; 9HPT-ND) and the “PATA” test to 
measure speech performance. For the 8MWT and 9HPT tests, a lower score/time indicates a 
clinical improvement. A higher “PATA” test score indicates improvement in speech 
performance [Schmitz-Hübsch et al, 2008]. 
The SCAFI represents vital movement features (8MWT;9HPD-D/-ND for evaluation of the 
coordination of the upper extremities; PATA-test for evaluation of speech). After the 
assessment, raw scores are transformed into reciprocals and converted into subtest Z-scores. 
The final SCAFI is then generated as the arithmetic mean of all three Z-scores.  
Two subtests, the 9HPT-D and 8MWT, will be videoed in a standardized format at every visit, 
except Visit 0. 
A subset of the SCAFI, the 9HPT-D, serves as an inclusion criterion for the severity of ataxia 
at the beginning of the study prior to enrollment.  
The complete SCAFI will be performed at the time points designated on the schedule of events 
(Appendix 3A for “naïve” patients and Appendix 3B for “non-naïve” patients). 
The score will be assessed by the investigator or qualified member of the study team.  
6.1.2.1 Scale for the Assessment and Rating of Ataxia (SARA) 
The SARA [Schmitz-Hübsch et al, 2006; Subramony, 2007] is an eight-item clinical rating 
scale (range 0–40, where 0 is the best neurological status and 40 the worst). It is a reliable and 
valid clinical scale with a high internal consistency that measures the severity of ataxia and 
increases with ataxia disease stage. 
The SARA will serve as an inclusion criterion for the severity of ataxia at the beginning of the 
study.  
The complete SARA will be performed at the time points designated on the schedule of events 
(Appendix 3A for “naïve” patients and Appendix 3B for “non-naïve” patients).  
The score will be assessed by the investigator or qualified member of the study team.   


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 45 of 161 
Version 7.0, 10 Oct 2022 
6.1.3 Measurement of Health-related Quality of Life 
The EuroQol (EQ)-5D-5L is a self-administered questionnaire for evaluating quality of life 
(QoL) introduced in 2009 [EuroQol Group, 2017].  
The EQ-5D-5L is a multiple-choice questionnaire and a visual analogue scale that takes only 
few minutes to complete.  
The EQ-5D-5L is a standardized measure of health status and in order to provide a simple, 
generic measure of health for clinical and economic appraisal and consists of 2 parts - the EQ-
5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive 
system comprises the following 5 dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight 
problems, moderate problems, severe problems, and extreme problems. The EQ-5D-5L will be 
used in patients aged ≥ 18. 
The EQ-5D-Y is a child-friendly version of the EQ-5D, adapted to be appropriate for the 
measurement of health-related quality of life in young respondents [Wille et al, 2010]. It will 
be used in patients aged <18. If a patient turns 18 over the course of the Parent Study, they will 
continue to use the EQ-5D-Y for consistency. 
The EQ-5D-5L/EQ-5D-Y will be assessed at the time points designated on the schedule of 
events (Appendix 3A for “naïve” patients and Appendix 3B for “non-naïve” patients).  
6.1.4 Measurement of Overall Neurological Status 
The modified disability rating scale (mDRS) will be used to evaluate the overall neurological 
status in NPC. The original scale developed in 2006 featured four assessment domains: 
ambulation, manipulation, language and swallowing [Iturriaga et al, 2006] and was further 
extended in 2010 to also include seizures and ocular movements [Pineda et al, 2010]. This scale 
can be used to evaluate the severity of disease, as well as monitor NPC progression, and the 
effect of treatment, both symptomatic and disease-specific.  
The mDRS will be assessed at the time points designated on the schedule of events (Appendix 
3A for “naïve” patients and Appendix 3B for “non-naïve” patients). 
6.1.5 Measurement of Global Impression 
The Clinical Global Impression (CGI) Scale has been long been implemented in 
neurodegenerative disease trials to provide an index of clinical importance that cannot be 
obtained from quantitative assessment measures [Quinn et al, 2008]. The CGI-C has been 
widely validated and used successfully across a range of conditions, including neurological 
disorders such as Alzheimer’s disease [Schneider et al, 1997; Knopman et al, 1994], tardive 
dyskinesia [Solmi et al, 2018], and spinocerebellar ataxia [Monte et al, 2017], and other 
disorders such as radiologic findings in hypophosphatasia [Whyte et al, 2018]. It is currently 
being used in multiple clinical studies for NPC, including a Phase IIb/III clinical study of 2-
hydroxypropyl-β-cyclodextrin (VTS-270; ClinicalTrials.gov ID: NCT02534844) and a Phase 
II/III clinical study of arimoclomol (NCT02612129). 
The Clinical Global Impression of Severity (CGI-S) - physician asks the clinician one question:  
“Considering your total clinical experience with this particular population,  how ill is 
the patient at this time?” which is rated on the following seven-point scale: 1=normal, 
not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely 
ill; 7=among the most extremely ill the patient has been. 
The CGI-S - caregiver asks the caregiver one question:  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 46 of 161 
Version 7.0, 10 Oct 2022 
“Considering your total experience with this particular patient, how ill is the patient at 
this time?” which is rated on the following seven-point scale: 1=normal, not at all ill; 
2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 
7=among the most extremely ill the patient has been. 
The CGI-S - patient asks the patient (if able) one question:  
“Considering your total experience with this particular indication, how ill are you at 
this time?” which is rated on the following seven-point scale: 1=normal, not at all ill; 
2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 
7=among the most extremely ill I have ever been. 
The CGI-S will be assessed at the time points designated on the schedule of events (Appendix 
3A for “naïve” patients and Appendix 3B for “non-naïve” patients).  
The Clinical Global Impression of Change (CGI-C) - clinician asks the clinician one question: 
“Compared to the patient's condition (i) Visit 2 (prior to medication) versus (ii) Visit 4 
(end of medication) OR (i) Visit 4 (end of medication) versus (ii) Visit 6 (end of 
washout) OR (i) Early Termination Visit versus (ii) previous visit, this patient's 
condition is: 1=very much improved since the initiation of treatment; 2=much 
improved; 3=minimally improved; 4=no change from baseline (the initiation of 
treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation 
of treatment.” 
The Clinical Global Impression of Change (CGI-C) - caregiver asks the caregiver one question: 
“Compared to the patient’s condition (i) Visit 2 (prior to medication) versus (ii) Visit 4 
(end of medication) OR (i) Visit 4 (end of medication) versus (ii) Visit 6 (end of 
washout) OR (i) Early Termination Visit versus (ii) previous visit, how much has he/she 
changed: 1=very much improved since the initiation of treatment; 2=much improved; 
3=minimally improved; 4=no change from baseline (the initiation of treatment); 
5=minimally worse; 6=much worse; 7=very much worse since the initiation of 
treatment.” 
The Clinical Global Impression of Change (CGI-C) - patient asks the patient (if able) one 
question: 
“Compared to how you were (i) Visit 2 (prior to medication) versus (ii) Visit 4 (end of 
medication) OR (i) Visit 4 (end of medication) versus (ii) Visit 6 (end of washout) OR 
(i) Early Termination Visit versus (ii) previous visit, how much have you changed: 
1=very much improved since the initiation of treatment; 2=much improved; 
3=minimally improved; 4=no change from baseline (the initiation of treatment); 
5=minimally worse; 6=much worse; 7=very much worse since the initiation of 
treatment.” 
The CGI-C – clinician/caregiver/patient will be assessed at the time points designated on the 
schedule of events (Appendix 3A for “naïve” patients and Appendix 3B for “non-naïve” 
patients).  
6.1.6 NPC Clinical Severity Scale (NPC-CSS) 
The NPC clinical severity scale (NPC-CSS) [Yanjanin et al, 2010] was developed and validated 
in a cross-sectional study of current NPC patients and a longitudinal chart review of an 
historical cohort. The scale quantifies the major symptoms of NPC and characterizes the 
disease progression of NPC. The NPC-CSS measures clinical signs and symptoms in 9 major 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 47 of 161 
Version 7.0, 10 Oct 2022 
(ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, 
swallowing) and 8 minor (auditory brainstem response, behavior, gelastic cataplexy, 
hyperreflexia, incontinence, narcolepsy, psychiatric, respiratory problems) domains. A higher 
NPC-CSS score indicates a more severe clinical impairment and higher disease burden. An 
increase in the NPC-CSS score indicates a clinical worsening, while a decrease NPC-CSS score 
indicates a clinical improvement. A 0-point change in the NPC-CSS score represents a 
stabilization of disease progression, which is also a significant clinical improvement for rapidly 
progressive, neurogenerative diseases like NPC.  
NPC-CSS is a widely accepted clinical outcome measure for NPC trials that investigate long-
term treatment effect. Several clinical trials in patients with NPC have change in the NPC-CSS 
as primary endpoint, including a Phase IIb/III clinical trial of 2-hydroxypropyl-β-cyclodextrin 
(VTS-270; ClinicalTrials.gov ID: NCT02534844), a Phase II/III clinical trial of arimoclomol 
(NCT02612129), and an open-label Phase I/II clinical trial of lithium carbonate 
(NCT03201627). The ongoing Phase II/III trial of arimoclomol over 12 months has a modified 
version of the NPC-CSS as a primary endpoint, which includes 5 NPC-CSS domains: 
ambulation, speech, swallowing, cognition, and fine motor skills (EudraCT No. 2015-004438-
93). These domains were identified by Cortina-Borja et al. (2018) as the most important 
manifestations of the disease for patients with NPC. 
A recent consensus paper on clinical management guidelines for Niemann-Pick disease type C 
recommended that, bearing in mind the resources available to most physicians in practice, a 
modified version of the NPC-CSS that is widely used in clinical practice, and more user-
friendly, should be administered. This modified version excludes the hearing and auditory 
brainstem response domains [Geberhiwot et al, 2018]. Accordingly, all major and minor 
domains of the NPC-CSS [Yanjanin et al, 2010] will be assessed in this study, with the 
exception of the hearing and auditory brainstem response domains. The change in the full NPC-
CSS score, apart from hearing domains (i.e. hearing and auditory brainstem response), will be 
calculated.  
 
In addition, the 5-domain version of the NPC-CSS (limited to the 5 major domains ambulation, 
cognition, fine motor, speech, and swallowing) which has been demonstrated to be a reliable 
surrogate for the complete NPC-CSS scale will be assessed [Cortina-Borja et al, 2018; Mengel 
et al, 2020]. 
 
The NPC-CSS / 5-Domain NPC-CSS is included as an exploratory endpoint in the Parent 
Study, as it may not sensitive enough to detect short-term changes in disease severity.  
6.1.7 Remote Assessments 
Due to COVID-19, safety and efficacy parameters may be collected remotely in lieu of in-
person assessments (as feasible).  
 
6.2 Safety Parameters 
The Investigator is responsible for monitoring the safety of patients who have been enrolled 
in this study and for accurately documenting and reporting information as described in this 
section.  
In addition, the investigator will monitor the degree of stress to patients and the risk threshold 
throughout the trial.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 48 of 161 
Version 7.0, 10 Oct 2022 
6.2.1 Adverse Events 
Patients will be instructed to report to the Investigator any AE that they experience. 
Investigators will ask about the occurrence of AEs at each visit. Investigators are required to 
document all AEs occurring during the clinical study, commencing with the signing of the 
informed consent form (ICF) through the End of Study Visit (scheduled at 42 days post last 
IB1001 dose). Adverse event recording will continue for patients who discontinue study 
treatment but remain on-study, until their ET Visit has been completed. 
Adverse events will be recorded on designated eCRF pages. Each AE is to be characterized 
(i.e., verbatim term) and information provided regarding its seriousness, start and stop dates, 
intensity, outcome, and causal relationship with the study drug.  
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient 
during participation in an investigational study, in conjunction with the use of the drug or 
biologic, whether or not product-related. This includes any untoward signs or symptoms 
experienced by the patient from the time of signing of the informed consent until completion 
of the study. 
Adverse events may include, but are not limited to: 
• Subjective or objective symptoms spontaneously offered by the patient and/or observed 
by the Investigator or medical staff 
• Findings at physical examinations 
• Laboratory abnormalities of clinical significance 
Disease signs, symptoms, and/or laboratory abnormalities already existing prior to the use of 
the investigational product are not considered AEs after treatment unless they reoccur after the 
patient has recovered from the preexisting condition or, in the opinion of the Investigator, they 
represent a clinically significant exacerbation in intensity or frequency. Clinical significance is 
defined as any variation in signs, symptoms, or testing that has medical relevance and may 
result in an alteration in medical care. The Investigator will continue to monitor the patient 
until the assessment returns to Baseline or until the Investigator determines that follow-up is 
no longer medically necessary. 
 
An AE does not include:   
• Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, transfusion); the 
condition that leads to the procedure is an adverse event; Planned surgical measures 
permitted by the clinical study protocol and the condition(s) leading to these measures are 
not adverse events, if the condition(s) was (were) known before the start of study treatment. 
In the latter case, the condition should be reported as part of the subject’s medical history. 
• Pre-existing diseases or conditions present or detected prior to the start of study drug 
administration that do not worsen; 
• Situations where an untoward medical event has not occurred (e.g., hospitalization for 
elective surgery, social and/or convenience admissions). 
It is important that Investigators record accurate AE terms on eCRFs. Wherever possible, a 
specific disease or syndrome rather than individual associated signs and symptoms will be 
identified by the Investigator and recorded on the eCRF. However, if an observed or reported 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 49 of 161 
Version 7.0, 10 Oct 2022 
sign or symptom is not considered a component of a specific disease or syndrome by the 
Investigator, or is atypical, it should be recorded as a separate AE on the eCRF.  
6.2.1.1 Adverse Event Intensity 
The Adverse Event Intensity refers to the extent to which an AE affects the subject's daily 
activities. Severity will be categorized according to the following criteria:  
 
Mild: 
The AE does not interfere with the subject’s routine activities. 
Moderate: 
The AE interferes with the subject’s daily routine, but usual routine 
activities can still be carried out. 
Severe: 
The AE results in the inability to perform routine activities. 
 
The term "severity" is used to describe the intensity of an event. This is not the same as 
"serious". Seriousness, not severity, serves as the guide for defining regulatory reporting 
obligations. The highest severity grade attained should be reported, for AEs with divergent 
severities. 
 
6.2.1.2 Adverse Event Relatedness 
The Principal Investigator (Investigator) will make a judgment regarding whether or not, in 
his/her opinion, the AE was related to study drug. However, even if the Investigator feels there 
is no relationship to the study drug, the AE MUST be recorded on the adverse event eCRF. 
Below are guidelines for relationship assessment: 
Causality of Adverse Event:  
The Causality of Adverse Events refers to the relationship of the AE to study drug. Causality 
will be categorized according to the following criteria: 
Not 
related: 
Adverse events for which a reasonable explanation for an alternative cause 
is considered plausible, e.g., no study drug taken, plausible clinical 
alternative like accidental injury, expected progression of underlying or 
concomitant 
disease, 
pharmacologically 
incompatible 
temporal 
relationship, or intercurrent illness. 
Related: Adverse events for which a reasonably possible clinical and/or 
pharmacological relationship to study drug cannot be excluded, e.g., 
lacking plausible alternatives. 
 
6.2.2 
Serious Adverse Events 
Serious adverse events will be reportable from the time the patient signs the ICF through their 
last study visit (e.g. Visit 6 or Visit 12) or until the Investigator in collaboration with IntraBio 
Ltd determines that follow-up is no longer necessary. Serious adverse events that are suspected 
to be drug related will be reported even if they occur up to 30 days after the patient has taken 
the last dose of study drug. If a related SAE is ongoing at the end of the study or when a patient 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 50 of 161 
Version 7.0, 10 Oct 2022 
withdraws from the study, appropriate safety follow-up, including additional laboratory tests 
as required, will continue for 30 days. 
 
An SAE is any AE that results in any of the following outcomes: 
• Death 
• Life-threatening experience 
• Inpatient hospitalization or prolongation of existing hospitalization 
• Persistent or significant disability/incapacity 
• Congenital anomaly or Birth Defect 
• Important medical events that, based upon appropriate medical judgment, may 
jeopardize the patient and may require medical or surgical intervention to prevent 
one of the outcomes listed above. 
Life-threatening experience. Any adverse experience that places the patient, in the view of 
the reporter, at immediate risk of death from the adverse experience as it occurred, i.e., does 
not include an adverse experience that had it occurred in a more severe form, might have caused 
death. 
 
Required or prolonged inpatient hospitalization. The adverse experience resulted in an 
initial inpatient hospitalization or prolonged an existing hospitalization of the patient. If a 
patient is hospitalized as part of the clinical use of the product, a period of normal 
hospitalization will be outlined in the protocol or by the judgment of the Investigator. 
Hospitalizations longer than this period will be prolonged hospitalizations. 
 
Persistent or significant disability/incapacity. An adverse experience that resulted in a 
substantial disruption of a person’s ability to conduct normal life functions. 
 
Congenital Anomaly. The exposure of the patient to the drug or biologic during pregnancy 
that is judged to have resulted in the congenital anomaly/birth defect. 
 
Important medical events. Adverse experiences that may not result in death, be 
life-threatening, or require hospitalization may be considered a serious adverse experience 
when, based upon appropriate medical judgment, may jeopardize the patient or subject and 
may require medical or surgical intervention to prevent 1 of the outcomes listed above. 
Important medical events or interventions may be considered an SAE based upon medical 
judgment of the Investigator.  
6.2.2.1 Reporting Serious Adverse Events  
SAEs will be reported promptly once the Investigator determines that the event meets the 
protocol definition of an SAE. The Investigator or designate will fill out the SAE reporting 
form in the eCRF within 24 hours of his/her becoming aware of these events. In addition, 
for fatal and life-threatening events, the Sponsor’s Medical Monitor should be contacted 
immediately. Contact numbers for the Medical Monitor (including after-hours cover) will be 
provided to the site before any patients are screened and upon receipt should be kept in the 
Site’s study binder. 
The SAE Reporting Form of the eCRF will always be completed as thoroughly as possible with 
all available details of the event within the designated time frames. The Investigator will always 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 51 of 161 
Version 7.0, 10 Oct 2022 
provide an assessment of causality at the time of the initial report as described in Section 
6.2.1.2. 
If the Investigator does not have all information regarding an SAE, he/she will not wait to 
receive additional information before completing the form. The SAE reporting form will be 
updated when additional information is received within 24 hours of receipt of such 
information. 
The completion of the SAE Reporting Form in the eCRF is the preferred method for Reporting 
SAEs. Only if a technical failure prevents the ability to report an SAE in the eCRF, then the 
paper SAE Reporting Form provided by the Sponsor must be completed and emailed to 
PrimeVigilance (intrabio@primevigilance.com) and or faxed to +44 (0) 8000 669231. 
The fax and or email instructions can be found on the paper SAE Reporting Forms, which are 
filed in the Investigator Site File. 
6.2.2.2 Responsibilities of the Sponsor 
The Sponsor or their delegate, is responsible for fulfilling all obligations regarding notification 
of Regulatory Authorities, Independent Ethics Committees (IECs)/ Institutional Review Board 
(IRBs), and investigators according to applicable regulatory requirements (expedited and 
periodic reporting, e.g., serious unexpected suspected adverse reactions, Development Safety 
Update Report).  
6.2.3 
Pregnancy  
Every effort should be made to prevent pregnancy during the study treatment period. All 
patients of reproductive potential involved in the study are required to use highly effective 
methods of contraception during the study and for 28 days after the last IB1001 dose. Female 
patients will be instructed to notify the Investigator immediately if they discover they are 
pregnant. Pregnancy data during the study will be reported using the SAE reporting process 
(see Section 6.2.2). Since it will be necessary to collect detailed information on the course of 
any pregnancy occurring in a patient on study the Investigator will be provided with the 
pregnancy notification forms and specific guidance for completing these forms once the initial 
AE form documenting a pregnancy is received within 24 hours. 
Pregnant patients will discontinue study medication for the duration of the pregnancy. 
The pregnancy will be followed by the Investigator and the outcome of the pregnancy will be 
reported to the Pharmacovigilance group. 
At Visit 2, Visit 4, Visit 6, and then Early Termination Visit (if applicable), females of 
childbearing potential will have a urine dipstick pregnancy test (analyzed on site).  
6.2.4 Vital Signs 
Vital signs will be measured and recorded at the time points designated on the schedule of 
events (Appendix 3A for “naïve” patients and Appendix 3B for “non-naïve” patients). The 
following measurements must be performed: systolic/diastolic blood pressure and pulse. Vital 
signs will be measured after the subject has been in the supine position for at least 5 minutes. 
All measurements will be recorded on the vital signs eCRF. Abnormal test results may be 
repeated at the discretion of the Investigator and must be reported on the corresponding eCRF.  
Due to COVID-19, vital signs may not be able to be collected at the designated timepoints in 
the schedule of events (e.g. if visits are skipped and replaced by a remote visit or postponed). 
The Sponsor’s Medical Expert, Medical Monitor, and DSMB deem the risk posed by vital 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 52 of 161 
Version 7.0, 10 Oct 2022 
signs not being collected at the designated timepoints due to COVID-19 is acceptable in the 
context of remote visits where study staff will enquire regarding the health and wellbeing of 
the patient and assess for adverse events. This decision was based on the nature of the drug, 
the available non-clinical and clinical data for N-Acetyl-L-Leucine and N-Acetyl-DL-
Leucine (see Section 1), and the safety profile observed in this ongoing, open-label study 
(very well-tolerated) (and also in other ongoing trials with IB1001) to date.  
6.2.5 Electrocardiograms (ECGs) 
During the study, 12-lead ECGs will be performed approximately at the time points designated 
on the schedule of events (Appendix 3A for “naïve” patients and Appendix 3B for “non-naïve” 
patients). In addition, ECGs may be performed at other visits at the discretion of the 
Investigator if the findings from a previous ECG was clinically relevant. 
The patient must be in a supine position in a rested and calm state for at least 5 minutes 
before ECG assessment is conducted. If the patient is unable to be in the supine position, the 
patient should be in the most recumbent position possible. 
All ECGs should be performed in a standardized method prior to blood draws or other 
invasive procedures. 
Each ECG must include the following measurements:  
Corrected QT, and whether the ECG is Normal, Abnormal NCS (not clinically significant), or 
Abnormal CS (clinically significant) for the patient. 
The Principal Investigator or designated site physician will review and sign all ECGs. Results 
must be summarized in writing and classified as normal; Abnormal NCS (not clinically 
significant), or Abnormal CS (clinically significant) for the patient. Intervals of the ECG will 
be recorded in the eCRF. Once signed, the original ECG tracing will be retained with the 
patient’s source documents. At the request of the Sponsor, a copy of the original ECG will be 
made available.  
Due to COVID-19, ECGs may not be able to be collected at the designated timepoints in the 
schedule of events (e.g. if visits are skipped and replaced by remote visits or postponed) or if 
qualified study team members/ appropriate equipment are not available/accessible. The 
Sponsor’s Medical Expert, Medical Monitor, and DSMB deem the risk posed by ECGs not 
being collected at the designated timepoints is acceptable in the context of remote visits 
where study staff will enquire regarding the health and wellbeing of the patient and assess for 
adverse events. This decision was based on the nature of the drug, the available non-clinical 
and clinical data for N-Acetyl-L-Leucine and N-Acetyl-DL-Leucine (see Section 1), and the 
safety profile (no reports of cardiac issues, including QTc prolongation) observed in this 
ongoing, open-label study (and also in other ongoing trials with IB1001) to date. ECGs will 
be routinely collected at Visit 9 in the Extension Phase, allowing for further assessment of 
any cardiac effects.  
 
 
6.2.6 Physical Examinations 
Height and weight will be measured at the initial screening visit, Visit 1 (“naïve” patients) or 
Visit 0 (“non-naïve” patients). 
6.2.7 Additional Safety Assessments 
Not applicable. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 53 of 161 
Version 7.0, 10 Oct 2022 
6.3 Laboratory Parameters 
6.3.1 Safety Laboratory Assessments  
The tests listed in Table 6.1 will be conducted on samples collected and analyzed by standard 
laboratory procedures at the time points designated on the schedule of events (Appendix 3A 
for “naïve” patients and Appendix 3B for “non-naïve” patients). Tests that are not done must 
be reported as such on the eCRFs.  
Due to COVID-19, Safety Laboratory Assessments may not be collected at the designated 
timepoints in the schedule of events (e.g. if visits are skipped, performed remotely or 
postponed). The Sponsor’s Medical Expert, Medical Monitor, and DSMB deem that the risk 
posed by safety laboratory assessments not being collected at the designated timepoints due 
to COVID-19 is acceptable in the context of remote visits where study staff will enquire 
regarding the health and wellbeing of the patient and assess for adverse events. This decision 
was based on to the nature of the drug, the available non-clinical and clinical data for N-
Acetyl-L-Leucine and N-Acetyl-DL-Leucine (see Section 1), and the safety profile observed 
in this ongoing, open-label study (and also in other ongoing IB1001 trials to date).   
The total amount of blood taken per subject during the Parent Study will be approximately 
66 mL (42 mL blood for the safety analyses, 24 mL blood for the PK analyses).  
In the US, the safety laboratory assessments will be performed by Eurofins Central Laboratory 
US (2430 New Holland Pike, Lancaster, PA 17601, USA). Laboratory sampling and processing 
will be defined by Eurofins Central Laboratory US’s standard procedures.  
In Europe, the safety laboratory assessments will be performed by Eurofins Central Laboratory 
in the Netherlands (Bergschot 71, 4817 PA, Breda, The Netherlands). Laboratory sampling and 
processing will be defined by Eurofins Central Laboratory (based in the Netherlands) standard 
procedures.  
If abnormal laboratory values are signs of an AE (e.g., an infection) that has already been 
recorded, the respective abnormal laboratory value does not constitute a separate AE. 
Wherever reasonable the reporting Investigator will use the clinical term rather than the 
laboratory term (e.g., anemia versus low hemoglobin value). 
  
Blood Draw: Hematology  
- 
Hemoglobin 
- 
Erythrocytes 
- 
Hematocrit 
- 
Thrombocytes 
- 
Leukocytes 
 
Blood Draw: Clinical Chemistry  
- 
Sodium 
- 
Lactate dehydrogenase (LDH) 
- 
Potassium 
- 
Creatinine 
- 
Serum bilirubin level  
- 
Aspartate aminotransferase (AST)  
- 
Alanine aminotransferase (ALT)  
- 
Urea 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 54 of 161 
Version 7.0, 10 Oct 2022 
- 
Alkaline phosphatase (ALP) 
- 
Follicle-stimulating hormone (FSH; for postmenopausal women only) 
 
Urine Safety Laboratories  
- 
Leukocytes 
- 
Nitrite 
- 
Urobilinogen 
- 
Protein 
- 
pH 
- 
Occult blood (erythrocytes, leucocytes) 
- 
Specific gravity  
- 
Ketones 
- 
Bilirubin 
- 
Glucose 
 
As described in Section 6.2.3 females of childbearing potential will have a urine dipstick 
pregnancy test analyzed on site at Visit 2, Visit 4, Visit 6, and the Early Termination Visit 
(if applicable). 
6.3.2 Measurement of N-Acetyl-L-Leucine Concentration in Blood 
Blood samples for measurements of N-Acetyl-L-Leucine concentrations will be taken at the 
time points designated on the schedule of events (Appendix 3A for “naïve” patients and 
Appendix 3B for “non-naïve” patients). Sparse PK sampling will be carried out at the same 
times that blood is drawn for the safety blood laboratory tests for possible future modeling 
purposes. This sampling is exploratory/descriptive. 
For these PK analysis, Lithium-Heparin plasma samples will be drawn and frozen at -70ºC or 
below and shipped on dry ice for analysis at AZ-Biopharm, Berlin, Germany. Note, for each 
PK blood draw, it is important that the day and exact time of the last dose of N-Acetyl-L-
Leucine before the blood draw and the day and exact time of the blood draw are recorded. 
6.3.3 Measurement of N-Acetyl-D-Leucine Concentrations in Urine 
Urine samples will be collected for concentrations of N-Acetyl-D-Leucine at Visit 1, Visit 2, 
Visit 5, and Visit 6. 
Urine samples for measurement of N-Acetyl-D-Leucine will be frozen at -70ºC or below and 
shipped on dry ice for analysis at AZ-Biopharm, Berlin, Germany  
The urine sample provided at Visit 1 will be analyzed after it is received by AZ-Biopharm and 
results should be made available before start of the treatment phase to demonstrate that levels 
of N-Acetyl-D-Leucine are below the set threshold. 
The urine samples provided at Visit 2, Visit 5, and Visit 6 will be analyzed in batches and used 
for sensitivity analyses only. 
6.3.4 Additional Laboratory Samples for Research Purposes 
Retained samples from the Parent Study may be used for research purposes to provide more 
information on the disease NPC. 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 55 of 161 
Version 7.0, 10 Oct 2022 
6.3.5 Sample Processing 
IntraBio Ltd (or delegates) will provide a laboratory manual that will detail the logistics and 
handling of all samples taken during this study.  
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 56 of 161 
Version 7.0, 10 Oct 2022 
7 STUDY CONDUCT 
Per Section 3.1.2.5, due to COVID-19, changes to existing study procedures have been/ may 
continue to be necessary in order to safeguard participants due to the outbreak of COVID-19 
in the US and Europe, as well as their families and study teams.  
7.1 Observations by Visit 
At the initial screening visit, patients will be classified as “naïve” and “non-naïve” patients 
depending on their history and use of prohibited medications within the past 42 days. The 
schedule of events during the initial screening visit and throughout the baseline period (through 
Visit 1) will vary depending on patient’s classification as “naïve” or “non-naïve”. 
For all patients, Visit 2 (Baseline 2) should occur 14 days (+7 days) days after Visit 1 
(Baseline 1). 
Visits 2 through Visit 6 are the same for all patients and should occur within +7 days of the 
scheduled visit. All times should be recorded using the 24-hour clock (e.g., 23:20, not 
11:20 pm).  
7.1.1 Screening (Visit 0 or Visit 1) 
At the initial screening visit, after written informed consent has been obtained and while 
patients eligibility is being confirmed against the inclusion and exclusion criteria, patients (or 
their legal representative) will be asked to confirm whether the patient has used any of the 
prohibited medications within the past 42 days. This will determine whether the patient is 
classified as “naïve” or “non-naïve” and their respective baseline period before the treatment 
period. 
Patients who confirm that they have not used any prohibited mediations within the past 42 days 
will be classified as “naïve” patients (Section 7.1.1.1).  
Patients who confirm they have used, or are unable to confirm or deny if they have used, any 
prohibited medication within the past 42 days will be classified as “non-naïve” patients 
(Section 7.1.1.2).  
7.1.1.1 “Naïve” Patients Screening 
Screening Visit/Visit 1 (Baseline 1): Written informed consent will be obtained. All patients 
will be screened for inclusion and exclusion criteria. Only patients meeting all the inclusion 
and none of the exclusion criteria will be allocated to the trial. The Screening Visit will be 
treated as Visit 1: the first assessment of the baseline period. 9  
• Informed consent/informed consent form (ICF) signature and patient information 
• Patient demographics10 
• Patient weight and height measurements 
• 60-day drug history including documentation of prior therapies/medications, including 
prohibited medications, concomitant medications/therapies for treatment of study-
 
 
9 The Screening Visit will be confirmed as Visit 1 as soon as the patient’s eligibility is confirmed and the level of N-Acetyl-
D-Leucine detected in their urine sample is confirmed to be below the permitted threshold. Visit 1 will not be confirmed for 
patients classified as “naïve” but whose urine sample unexpectedly detect levels of N-Acetyl-D-Leucine above the permitted 
threshold. At the treating physician’s discretion, these patients will be given the option to undergo a minimum of 42 days 
washout before returning for a second screening visit. Should they agree, the patient will be reclassified and changed to 
“non-naïve”. 
10 Demographics for each patient will be collected in line with local regulations 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 57 of 161 
Version 7.0, 10 Oct 2022 
specific illness, including frequency of therapy (e.g., physiotherapy, speech therapy) 
(documented in hours per week) 
• Relevant medical history as well as medical history concerning the trial specific illness 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT)   11 
• Scale for Assessment and Rating of Ataxia (SARA)  
• Check for remaining inclusion/exclusion criteria (including confirmation that 
prohibited medications have not been used for the past 42 days) 
• Patient classified as “naïve”  
• Vital signs 
• Cognitive assessment according to standard procedures of the clinical site to assist with 
the Clinical Impression of Change in Severity (CI-CS) primary anchor test selection 
• Determine Clinical Impression of Change in Severity (CI-CS) primary anchor test 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients <18 years 
old  
• Modified Disability Rating Scale (mDRS)   
• Niemann-Pick Disease type C Clinical Severity Scale (NPC-CSS) 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient (if able) 
• 12-lead ECG 
• Urinalysis (done at central lab) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for safety laboratory tests, including FSH for menopausal women (done at 
central lab) 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
 
7.1.1.2 “Non-naïve” Patients: Baseline Period 
Screening Visit/Visit 0: Written informed consent will be obtained. All patients will be 
screened for inclusion and exclusion criteria. Patients who confirm they have used or are unable 
to confirm or deny if they have used, any prohibited medications within the past 42 days will, 
at the treating physician’s discretion, remain eligible for enrollment. The Screening Visit will 
be treated as Visit 0. 
• Informed consent/informed consent form (ICF) signature and patient information 
• Patient demographics  
• Patient weight and height measurements 
• 60-day drug history including documentation of prior therapies/medications, including 
prohibited medications, concomitant medications/therapies for treatment of trial-
specific illness, including frequency of therapy (e.g., physiotherapy, speech therapy) 
(documented in hours per week) 
 
 
11 The 9-hole Peg Test of the Dominant Hand (9HPT-D) and 8-meter Walk Test (8MWT) will be videotaped in a 
standardized manner at every visit., except Visit 0.  At Visit 1, these videos are made before the CI-CS primary anchor test is 
determined.  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 58 of 161 
Version 7.0, 10 Oct 2022 
• Relevant medical history as well as medical history concerning the trial specific illness 
• Vital signs 
• Spinocerebellar Ataxia Functional Index (SCAFI)  
• Scale for Assessment and Rating of Ataxia (SARA) 
• Check remaining inclusion/exclusion criteria  
• Patient classified as “non-naïve”  
• Documentation of adverse events  
 
Visit 1 (Baseline 1): Minimum of 42 days after Visit 0/washout from prohibited medication. 
All patients will be screened for inclusion and exclusion criteria. Only patients meeting the 
inclusion and none of the exclusion criteria will be allocated to the trial. This second visit will 
be treated as Visit 1: the first assessment of the baseline period. 12 
• Check of inclusion/exclusion criteria (including confirmation that prohibited 
medications have not been used within the past 42 days) 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication   
• Vital signs  
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording for Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 13 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Cognitive assessment according to standard procedures of the clinical site to assist with 
the Clinical Impression of Change in Severity (CI-CS) primary anchor test selection 
• Determine Clinical Impression of Change in Severity (CI-CS) primary anchor test 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Modified Disability Rating Scale (mDRS) 
• Niemann-Pick Disease type C Clinical Severity Scale (NPC-CSS) 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• 12-lead ECG  
• Urinalysis (done at central lab) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for safety laboratory tests, including FSH for menopausal women (done at 
central lab) 
• Blood draw for sparse PK (done at PK Lab) 
• Documentation of adverse events  
 
 
 
12 This screening visit will be confirmed as Visit 1 provided the patient’s eligibility is confirmed and the level of N-Acetyl-
D-Leucine detected their urine sample is below the permitted threshold. Non-naïve patients whose urine sample after Visit 1 
unexpectedly detect levels of N-Acetyl-D-Leucine above the permitted threshold will be marked as non-compliant and 
withdrawn from the study. 
13 The 9-hole Peg Test of the Dominant Hand (9HPT-D) and 8-meter Walk Test (8MWT) will be videotaped in a 
standardized manner at every visit, except Visit 0. At Visit 1, these videos are made before the CI-CS primary anchor test is 
determined.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 59 of 161 
Version 7.0, 10 Oct 2022 
7.1.2 Baseline Visit (Visit 2) 
Visit 2 (Baseline 2): Day 14 (+7 days) after Visit 1 (Baseline 1). The final day/ second 
assessment of the baseline period. The start of the treatment period. 
• Reconfirm patient eligibility, including confirmation that prohibited medications have 
not been used since Visit 1 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs  
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording for Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Modified Disability Rating Scale (mDRS)   
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site 
before first dose of study drug is taken) 
• Urine test for N-Acetyl-D-Leucine (test done at PK lab) 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
• Dispensing of trial drug + intake of study drug at site  
 
7.1.3 Treatment 1 (Visit 3) 
Visit 3 (Treatment 1) Day 28 (+7 days) of treatment period: First assessment of treatment 
period with N-Acetyl-L-Leucine. 
• Return of trial drug and compliance check (if feasible) 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged <18 
years 
• Modified Disability Rating Scale (mDRS)   
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• 12-lead ECG 
• Urinalysis (done at central lab) 
• Blood draw for safety laboratory tests (done at central lab) 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 60 of 161 
Version 7.0, 10 Oct 2022 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
• Dispensing of additional study drug if needed 
 
7.1.4 Treatment 2 (Visit 4) 
Visit 4 (Treatment 2): Day 42 (+7 days) of treatment period: the final day/second assessment 
of treatment period with N-Acetyl-L-Leucine. The start of washout period. 
• Return of trial drug and compliance check14 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged <18 
years 
• Modified Disability Rating Scale (mDRS)   
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Visit 2 to Visit 4 
• Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 2 to Visit 4 
• Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 2 to 
Visit 4 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
 
7.1.5 Washout 1 (Visit 5) 
Between Visit 4 – Visit 5: Wash-Out 
Visit 5 (Washout 1):  Day 28 (+7 days) of wash-out period: First assessment of wash-out 
period.  
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Modified Disability Rating Scale (mDRS) 
 
 
14 Or after Visit 4 if IMP is returned via courier 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 61 of 161 
Version 7.0, 10 Oct 2022 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• 12-lead ECG  
• Urinalysis (done at central lab) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
 
7.1.6 Washout Visit 2 (Visit 6) 
Visit 6 (Washout 2): Day 42 (+7 days) of washout period: the final day/second assessment of 
washout period. 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged <18 
years 
• Modified Disability Rating Scale (mDRS)   
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Visit 4 to Visit 6 
• Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 4 to Visit 6 
• Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 4 to 
Visit 6 
• Medication History: If the patient was classified as “naïve”, confirm if they have used 
N-Acetyl-Leucine (L, DL, D) at any time prior to Visit 1 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for laboratory safety tests (done at central lab) 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
• Investigator determines continued treatment with IB1001 in patient’s best interest (if 
applicable) 
• Informed consent/informed consent form (ICF) signature and patient information for 
Extension Phase (if applicable) 
• Check of inclusion/exclusion criteria for Extension Phase (if applicable) 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 62 of 161 
Version 7.0, 10 Oct 2022 
7.1.7 Early Termination Visit 
• Return of study drug and compliance check15 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged <18 
years 
• Modified Disability Rating Scale (mDRS)   
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Previous Visit 
to ET Visit  
• Clinical Global Impression of Change (CGI-C) by caregiver based on Previous Visit 
to ET Visit  
• Clinical Global Impression of Change (CGI-C) by patient if able based on Previous 
Visit to ET Visit 
• Medication History: If the patient was classified as “naïve”, confirm if they have used 
N-Acetyl-Leucine (L, DL, D) at any time prior to Visit 1 
• 12-lead ECG   
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for sparse PK (done at PK lab) 
• Documentation of adverse events  
 
 
15  Or after ET if IMP is returned via courier 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 63 of 161 
Version 7.0, 10 Oct 2022 
8 STATISTICAL METHODS 
8.1 General Analysis Plan 
8.1.1 Disposition of Patients 
The number of patients enrolled, plus the numbers contained within the Safety Analysis Set 
(SAF), the intention-to-treat analysis set (ITT), the modified intention-to-treat analysis set 
(mITT) and the Per Protocol Set (PPS) will be summarized overall and by country. The number 
of patients discontinuing treatment, together with the primary reason for discontinuation will 
be presented. 
 
Protocol Deviations 
Protocol deviations include but are not limited to: 
• Violation of key inclusion/exclusion criteria 
• Use of Prohibited Medications 
• Inadequate study medication compliance 
• Urgent/ contingency measures implemented due to COVID-19, including delayed or 
missed assessments due to postponed or skipped in-person visits 
 
Further detail will be provided in the Statistical Analysis Plan (SAP)  
8.1.2 Analysis Populations 
• The Safety Analysis Set (SAF) will consist of all patients who receive at least one dose 
of study drug (N-Acetyl-L-Leucine) 
• The intention-to-treat analysis set (ITT) will consist of all patients in the SAF with a 
video recording at either Visit 1 or Visit 2 (or both) 
• The modified intention-to-treat analysis set (mITT) will consist of all patients in the 
SAF with a video recording at either Visit 1 or Visit 2 (or both) and one video recording 
at either Visit 3 or Visit 4 (or both) 
• The Per Protocol Set (PPS) will consist of all patients with video recordings at baseline 
(Visit 1 or Visit 2), end of treatment (Visit 3 or Visit 4), and end of washout (Visit 5 or 
Visit 6) and without any major protocol deviations that could have influenced the 
validity of the data for the primary efficacy variable. 
8.2 General Considerations 
Statistical analysis will be performed using SAS; the version used will be specified in the SAP. 
All variables will be summarized using descriptive statistics. The number of patients, mean, 
standard deviation (SD), minimum, median, and maximum will be calculated for continuous 
and score variables. Frequency tables will be generated for categorical data. 
A one-sided significance level of 5% will be used throughout for all endpoints as a guide for 
evidence for activity. Conclusions regarding treatment efficacy will not solely rely on detecting 
statistical significance with equal emphasis placed on the magnitude and clinical relevance of 
treatment differences as judged by the point estimates. 
No correction for multiple comparisons will be included.  
8.3 Demographics, Baseline Characteristics and Concomitant Medications 
Demographic data and patient characteristics at baseline will be summarized descriptively. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 64 of 161 
Version 7.0, 10 Oct 2022 
Frequency and percentage of prior and concomitant medication use will be summarized by 
World Health Organization (WHO) Drug dictionary coded terms - Anatomic Therapeutic 
Chemical (ATC) classification and preferred term. 
8.4 Treatment Compliance 
Summary statistics for the number of N-Acetyl-L-Leucine doses taken, based on bottles of 
Study Drug dispensed and return bottle counts, will be calculated for each visit. Overall 
compliance in terms of the percentage of drug taken based on these data will be summarized 
descriptively together with the proportion of patients who take at least 80% of the prescribed 
medication. 
8.5 Efficacy Analyses 
The primary analyses of efficacy will be based on the mITT. Analyses of efficacy based on the 
PPS will also be undertaken to provide supplementary information.  
For each of the primary and secondary endpoints there will be separate analyses within key 
subgroups. The subgroups to be considered will be defined by: 
• Naïve versus non-naïve as determined at screening 
• Age (pediatric versus adult) 
• Age/weight/dosing group  
• Age of diagnosis: Early-infantile (<2 years), Late-infantile (2 to < 6 years), Juvenile 
(6 to < 15 years), Adolescent/Adult (≥ 15 years) 
• Disease severity based on SARA below/ above the median SARA score at Visit 1 
• Gender (male versus female) 
• Region (US versus Europe) 
• Primary Anchor Test (9HPT-D or 8MWT)   
• Patients on miglustat versus patients not on miglustat 
• Individual components of SARA scale: Gait Subtest 
• Composite of SARA Subtests 1-4 (Gait, Stance, Sitting, Speech) 
• Intra-patient variability between SARA score at Visit 1 (Baseline 1) versus Visit 2 
(Baseline 2) (below/above median). 
• Intra-patient variability between CI-S score Visit 1 (Baseline 1) versus Visit 2 
(Baseline 2) (below/above median). 
Additional subgroups can be added at the time of analysis on an exploratory basis. 
Separate trials are planned to be conducted with N-Acetyl-L-Leucine for NPC, GM2-
gangliosidosis, and ataxia-telangiectasia. There will however be a planned series of meta-
analyses that will bring together the data from the studies for the primary and selected 
secondary endpoints. Further details will be provided in an MASAP. 
8.5.1 Primary Efficacy Endpoint 
The primary endpoint for the study is based on blinded raters’ Clinical Impression of Change 
in Severity (CI-CS) comparing videos showing the patient’s change in performance over 42 
days (+7 days) on a pre-defined anchor clinical symptom scale: either the 9 Hole Peg Test of 
the Dominant Hand (9HPT-D) or the 8 Meter Walk Test (8MWT). A manual will be provided 
to each clinical site, which provides instructions for the administration of the CI-CS [Fields, 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 65 of 161 
Version 7.0, 10 Oct 2022 
2020]. Similarly, a video-acquisition manual will be provided, which provides instructions for 
making standardized videos of the 8MWT and 9HPT-D primary anchor tests [Medpace, 2019]. 
The comparison of the Visit 4 video with the Visit 2 video and the comparison of the Visit 6 
video with the Visit 4 video will provide the scores that contribute to the primary endpoint. 
Each of these comparisons will score change on a 7-point Likert scale (+3=significantly 
improved to -3= significantly worse).  
During the pre-treatment period, the treating physician will evaluate each patient’s clinical 
symptoms and select, at Visit 1, either the 9HPT-D or 8MWT as the primary anchor around 
which the CI-CS assessment will be scored. A cognitive assessment should be performed at 
Visit 1 according to standard procedures of the clinical site to assist with the selection of the 
anchoring functional test appropriate for each patient from both a cognitive and a motor 
perspective. 
The primary evaluation of the CI-CS will be performed by two independent raters whose 
assessments will be based on videos of the anchor test taken at each visit. These raters will be 
blinded to the treatment periods (baseline, treatment, or washout) to reduce detection and 
performance bias.  
The primary endpoint is defined as the CI-CS comparing end of treatment with N-Acetyl-L-
Leucine (Visit 4) with baseline (Visit 2) minus the CI-CS comparing the end of washout 
(Visit 6) with the end of treatment with N-Acetyl-L-Leucine (Visit 4) based on the primary 
anchor test.   
The CI-CS assessment will instruct the blinded rater to consider: ‘compared to the first video, 
how has the severity of their performance on the 9HPT-D or 8MWT changed (improved or 
worsened) in 6-weeks as observed in the second video?’ 
Each video pairing (CI-CS) will be read by the two independent raters, and the 
appropriate Likert scale score will be entered onto the eCRF. If there is a difference of 
one (1) point in the two primary blinded reviewers’ CI-CS scores for a specific video 
pairing, the two scores will be averaged. If there is difference greater than one (1) point 
between the two primary blinded reviewers’ CI-CS scores for a specific video pairing, an 
adjudication read will be triggered. In such cases, a third blinded reviewer will review the 
scores given from each of the two primary independent reviewers and determine which 
score is more accurate, that of reviewer A or reviewer B (adjudication by consensus). The 
adjudicator's decision will be the final score for that video assessment.  
The statistical analysis of this endpoint will utilize a single sample t-test comparing the mean 
value of the primary endpoint with zero. This endpoint allows the effect N-Acetyl-L-Leucine 
to be measured both in terms of improvement during treatment followed by any deterioration 
once treatment is removed. 
Summary statistics will in addition be calculated separately according to subgroups defined by 
the primary anchor test  
8.5.2 Secondary Efficacy Endpoints 
A key Secondary Endpoint that will be evaluated to directly supplement the analysis of the 
primary endpoint is based on the independent raters’ Clinical Impression of Severity (CI-S) of 
each video. 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 66 of 161 
Version 7.0, 10 Oct 2022 
The independent raters will be given 6 videos of the patient’s performance of the primary 
anchor test taken at Visit 1 to Visit 6. The videos will be labeled as Video A, B, C, D, E, F. 
The videos will be presented in a random order, and the independent raters will be blinded to 
the timepoint corresponding to each video. 
 
For each video, the independent raters will make their evaluation of the CI-S, which asks: 
“Considering your total clinical experience with this particular population, how ill is the 
patient at this time?”  
 
The CI-S is rated on a 7-point Likert scale ranging from + 3 (normal, not at all ill) to -3 (among 
the most extremely ill patients). For the CI-S, if there is one (1) point or more difference in the 
two blinded reviewers scores, the two scores will still be averaged.  
 
Supportive secondary endpoints will be evaluated that directly supplement the analysis of the 
primary endpoint as follows: 
 
• The CI-CS for end of treatment with N-Acetyl-L-Leucine (Visit 4) versus baseline 
(Visit 2) and end of washout (Visit 6) versus end of treatment with N-Acetyl-L-Leucine 
(Visit 4) will each be summarized descriptively. 
• Improvement in the primary and non-primary anchor test measures will be evaluated 
based on the change in the blinded raters’ Clinical Impression of Severity (CI-S) 
between baseline (average for Visit 1 and Visit 2) and end of treatment with N-Acetyl-
L-Leucine (average for Visit 3 and Visit 4) minus the change in CI-S between end of 
treatment with N-Acetyl-L-Leucine (average for Visit 3 and Visit 4) and end of washout 
(average for Visit 5 and Visit 6). Statistical testing for the primary anchor test CI-S 
endpoint will be as for the primary endpoint. There will be no formal statistical testing 
of the non-primary test. 
• Sensitivity measurement of change in performance on either the 9HPT-D or the 8MWT 
on a 3-point scale. Using the CI-CS outcome for the primary anchor test based on the 
data for Visits 2 and Visit 4, any patient given a score of <0 on the CI-CS will be 
classified as worsened (-1). Any patient classified as 0 on the CI-CS will be classified 
no change (0). Any patient given a score of >0 on the CI-CS will be classified as 
improved (+1). A similar classification will use the CI-CS comparing the end of 
treatment with N-Acetyl-L-Leucine with end of washout based on the data for Visits 4 
and Visit 6 and the difference between these scores calculated. The descriptive table 
will be similar to the primary endpoint. No statistical analysis will be performed. 
• An evaluation of the CI-CS for the test (9HPT-D or 8MWT) that was not selected as 
the primary anchor test (i.e., the non-primary anchor test) will also be undertaken. There 
will be no formal statistical testing of these endpoints, however.  
 
Bland-Altman plots in relation to videos from Visits 1 and 2, Visits 3 and 4, and Visits 5 and 6 
will be produced to help inform the stability of the outcome evaluation and the disease itself at 
baseline, end of treatment and end of washout. The scatter plot for videos from Visits 1 and 2 
will place the average CI-S outcome of the videos from Visits 1 and 2 on the x-axis and the 
difference between those on the y-axis. A y=0 line will be placed on the plot for reference 
purposes. Similar plots will be produced for videos from Visits 3 and 4 and videos from Visits 
5. and 6. Additional secondary endpoints will investigate other measures of symptoms and 
quality of life. Descriptive statistics will be provided for these measures at each visit and also 
changes from baseline (Visit 2) to the end of treatment with N-Acetyl-L-Leucine (Visit 4), as 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 67 of 161 
Version 7.0, 10 Oct 2022 
well as end of treatment with N-Acetyl-L-Leucine (Visit 4) to the end of post-treatment 
washout (Visit 6) for the following measures: 
 
 
• Spinocerebellar Ataxia Functional Index (SCAFI)16 
• Scale for Assessment and Rating of Ataxia (SARA) score 
• Quality of Life EQ-5D-5L for patients aged ≥18; EQ-5D-Y17 for patients aged <18 
years 
• Modified Disability Rating Scale (mDRS) 
• Treating Physician Clinical Global Impression of Severity (CGI-S) at every visit  
• Treating Physician Clinical Global Impression of Change (CGI-C) comparing end of 
treatment (Visit 4) to baseline (Visit 2), and end of washout (Visit 6) to end of treatment 
(Visit 4) 
• Caregiver Clinical Global Impression of Severity (CGI-S) at every visit  
• Caregiver Clinical Global Impression of Change (CGI-C) comparing end of treatment 
(Visit 4) to baseline (Visit 2), and end of washout (Visit 6) to end of treatment (Visit 4) 
• Patient Clinical Global Impression Scales Impression of Severity (CGI-S) at every visit 
if they are able 
• Patient Clinical Global Impression of Change (CGI-C) comparing end of treatment 
(Visit 4) to baseline (Visit 2), and end of washout (Visit 6) to end of treatment (Visit 4) 
if they are able 
The SARA total score, the SCAFI total score, the individual SCAFI subtests: 9 Hole Peg Test 
with the Dominant Hand (9HPT-D), 8 Meter Walk Test (8MWT), and PATA test, will be 
evaluated statistically based on a single sample t-test or a single sample Wilcoxon Signed Rank 
test. 
The individual SCAFI subtest: 9 Hole Peg Test with Nondominant hand (9HPT-ND), and the 
mDRS will be evaluated descriptively. 
The CGI-S measures, and caregiver and patient CGI-C measures will be summarized 
descriptively. The CGI-C measures will be analyzed as for the CI-CS primary endpoint. 
The measures of the two indices (-5L and -Y) of the EQ-5D descriptive system and measures 
of the two indices (-5L and -Y) of the EQ-5D visual analogue scale (VAS) will be evaluated 
descriptively. 
8.5.3 Exploratory Efficacy Endpoints 
Sparse PK sampling will be collected to characterize the PK of N-Acetyl-L-Leucine in patients 
with NPC.  
8.6 Missing Data 
The primary endpoint will utilize assessments based on single video recordings at the end 
baseline period (Visit 2), end of the treatment period (Visit 4), and end of the washout period 
(Visit 6). If the Visit 2 video is missing, the Visit 1 video will be used in its place. Similarly, 
if the Visit 4 and Visit 6 videos are missing, Visit 3 and Visit 5 videos will respectively be 
used in their place.  
 
 
16The 9 Hole Peg Test of the Dominant Hand (9HPT-D) and the 8 Meter Walk Test (8MWT), will be videoed for every 
patient at every visit except Visit 0 
17 European Sites Only 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 68 of 161 
Version 7.0, 10 Oct 2022 
Analyses based on the mITT analysis set will utilize a last observation carried forward (LOCF) 
approach for missing videos from Visit 5 and Visit 6. For the primary endpoint CI-CS, this 
implies that the CI-CS value for Visit 4 to Visit 6 will be assigned the value 0 (stable) if both 
videos from Visit 5 and Visit 6 are not available. 
A sensitivity analysis will be undertaken to assess the robustness of the primary analysis of the 
primary endpoint which are based on LOCF in the mITT analysis set as follows: 
If either video for Visit 3 or Visit 4 is available,  but either video from Visit 5 and Visit 6 are 
unavailable, impute the value -1 (worsening) instead of 0 for the CI-CS for Visit 4 to Visit 6, 
unless the missingness is due to a “technical reason” (e.g. due to machine failure).  
Additional methods to deal with missing data will be detailed in the SAP. Any changes from 
the SAP will be described and justified in the Clinical Study Report. 
8.7 Blinding 
The blinded independent raters will be given each of the 6 videos initially in a random order to 
make their evaluation of CI-S for each video. The blinded independent raters will then be 
provided with 3 pairs of video recordings blinded to information on the visits associated with 
these videos and their order and asked to provide a score for CI-CS for each pair. Further details 
regarding this blinding process will be detailed in the SAP. 
8.8 Safety Analyses 
The SAF will be the basis for all analyses of safety and tolerability.  
8.9 Interim Analyses 
There are no planned interim analyses.  
8.10 
Determination of Sample Size 
It is postulated that N-Acetyl-L-Leucine will show effectiveness in 30% of patients and this 
success rate is viewed as being clinically important. Assuming that this group of patients will 
have scores that are evenly distributed across the values 1 and 2 for the primary endpoint and 
further that the remaining 70% of patients will have scores that are evenly distributed between 
the values -1, 0, and 1. The resulting mean score is 0.45 and the standard deviation (SD) for 
the primary endpoint under these assumptions is then 1.02. With 30 patients reporting on the 
primary endpoint, the study will have 76% power to detect a treatment benefit in a 5% 
one-sided one-sample t-test. 
 
8.11 
COVID-19 Details 
This study is conducted during the COVID-19 outbreak. The following data capture decisions 
have been taken due to national, local, or site-specific restrictions imposed due to COVID-19, 
with the primary need to prioritize the safety of clinical study teams and patients, and to 
maintain the integrity of the study/data collection. 
 
- 
All protocol deviations relating to COVID-19 are collected 
- 
If in-person visits are not feasible, Visits 3 and / or 5 should be skipped and a remote 
visit conducted (i.e. phone, video conference) 
- 
If in-person visits are not feasible, Visits 4 and / or 6 can be postponed until the in-
person visit is feasible and should be performed in person.  
- 
For skipped in-person Visit 3/5 or postponed in-person Visit 4/6, remote visits should 
occur approximately -/+ 3 days from the original visit (as feasible). 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 69 of 161 
Version 7.0, 10 Oct 2022 
 
Currently, the complete impact of COVID-19 on the proposed statistical analyses is 
unknown. The statistical analysis plan already includes policies for handling missing data. 
Specific items/changes related to COVID-19 are being detailed in a separate document to the 
SAP (Addendum 1), which will be maintained throughout the study and adjusted as needed 
based on the duration and extent of the impact of the COVID-19 situation.  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 70 of 161 
Version 7.0, 10 Oct 2022 
9 DATA HANDLING AND RECORD KEEPING 
9.1 Data Collection 
Study data for all patients will be collected in a confidential fashion using an electronic Case 
Report Form (eCRF). Access to the eCRF is restricted to staff members not involved in any 
aspect of the blinded evaluations. All the information required by the protocol must be 
documented and any omissions explained. The Investigator must review all eCRF entries for 
completeness and accuracy. Source documents, including all demographic and medical 
information, eCRFs and informed consent form for each patient in the study must be 
maintained by the Investigator. All information in the eCRFs must be traceable to the original 
source documents. An audit trail of all changes to this database, including the date, reason for 
the data change and who made the change, will be maintained within the same database. The 
audit trail will be part of the archived data at the end of the study. Concomitant medication and 
AEs will be coded using standardized medical dictionaries. 
Responsible Monitor will review eCRFs entered by investigational staff for completeness and 
accuracy. Checks for data discrepancies in the eCRFs will be performed and the resulting 
queries will be notified to the investigational site. Designated Investigator site staff are required 
to respond to queries and make any necessary changes to the data.  
The complete data management process (data capture, data entry, data validation, checks on 
plausibility, query handling, data editing after entry, coding, data base closure, etc.) will be 
defined within a data handling plan/ data management plan. 
9.2 Data Correction 
Automatic and manual queries will be defined according to the data validation plan. These 
queries will be generated by the assigned Data Management Department and sent through the 
electronic data capture (EDC) system for clarification. Corrections will be entered directly into 
the system. This procedure will be repeated until all queries are resolved. 
9.2.1 Deviations from the Protocol 
Deviations from the protocol will be judged during the study and/or when an individual 
patient’s eCRF is completed (monitored) and documented in the protocol deviations log. 
Protocol deviations will be classified (major/minor protocol deviations) for statistical analysis. 
9.3 Data Quality Assurance 
If applicable, the Sponsor (IntraBio Ltd.) and/or their representative (i.e. Monitor engaged by 
the Sponsor) will conduct a site visit to verify the qualifications of each investigator, inspect 
the site facilities, and inform the Investigator of responsibilities and the procedures for ensuring 
adequate and correct documentation. 
9.3.1 Retention of Records 
All essential documents must be safely retained by the Investigator for at least 2 years following 
the date a marketing application is approved for the drug, for the indication for which it is being 
investigated; or if no application is filed or if the application is not approved for such indication 
for 15 years after the investigation is discontinued and the regulatory authorities are notified.   
9.4 Protection of personal data 
The completion of the Study involves the collection and processing of Personal Data. All 
processing of Personal Data at the clinic and by the Sponsor must be carried out in accordance 
with national legislation concerning the protection of Personal Data. Parties involved in the 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 71 of 161 
Version 7.0, 10 Oct 2022 
process will observe the requirements provided under Regulation (EU) 2016/679 concerning 
general personal data protection. 
The Investigator must ensure that the patient’s privacy is maintained. On the eCRF or other 
documents submitted to the Sponsor, patients will be identified by a patient ID number only. 
Documents that are not submitted to the Sponsor (e.g., signed informed consent form) should 
be kept in a strictly confidential file by the investigator. 
The Investigator shall permit direct access to patients’ records and source document for the 
purposes of monitoring, auditing, or inspection by the Sponsor, authorized representatives of 
the Sponsor, Regulatory Authorities and IECs and IRBs.  
As part of the required content of the informed consent, patients will be informed that their 
records may be reviewed by the Sponsor’s designee and by regulatory agencies.  Should access 
to medical record require a separate waiver or authorization, it is the Investigator’s 
responsibility to obtain such permission from the patient in writing before the patient is entered 
into the study. 
9.5 COVID-19 Protocol Deviations and Missing Data 
Protocol deviations related to COVID-19 are documented. These deviations in protocol-
specific procedures due to COVID-19 (changes in study visit schedules, remote and / or 
missed visits, or patient discontinuations) may lead to missing information.  
For each patient, the eCRF will capture specific information that (as much as possible) 
explains the basis of the missing data, including the relationship to COVID-19 for missing 
protocol-specified information (e.g., from missed study visits or study discontinuations due to 
COVID-19). This information will be summarized in the Parent Study clinical study report. 
!
!
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 72 of 161 
Version 7.0, 10 Oct 2022 
10 QUALITY CONTROL AND QUALITY ASSURANCE 
10.1 
Study Initiation Activities 
The investigator(s) are informed about study objectives and methods, the inclusion and 
exclusion criteria, the time-schedule, and study procedures at an investigators’ meeting (if 
applicable), and during the Site Initiation Visit by the Sponsor and the monitor. 
10.2 
Training of Site Staff 
The Principal Investigator (PI) is responsible for the conduct of the study at their study site, 
including delegation of specified study responsibilities and training of study staff. The PI shall 
ensure that the study is carried out in accordance with the protocol, ICH/GCP guidelines, and 
local regulations. 
The PI will maintain a record of all individuals involved in the study (medical, nursing and 
other staff). He or she will ensure that appropriate training relevant to the study is given to all 
of these staff, and that any new information of relevance to the performance of this study is 
forwarded to the staff involved. 
10.3 
Documentation and Filing 
10.3.1 List of Patients (patient identification log) 
The Investigator will keep a confidential list of names of all patient participating in the study, 
so that the patients’ records can be identified if necessary.  
In addition, the Investigator will keep a list of all patients screened on a screening log to 
document identification of patients who were consented and entered study screening. If 
someone is not eligible to participate in the study, a reason must be provided. 
10.3.2 Source Data 
Per ICH, source data are defined as all information in original records and certified copies of 
original records of clinical findings, observations, or other activities in a clinical study 
necessary for the reconstruction and evaluation of the study. Source data are contained in 
source documents which comprise clinical documentation, data, and records (e.g., hospital 
records, clinical and office charts, laboratory notes, memoranda, patients’ diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate copies, microfiches, photographic 
negatives, microfilm or magnetic media, x-rays, patient files, and records kept at the pharmacy, 
at the laboratories and at medico-technical departments involved in the clinical study). When 
a copy is used to replace an original document, the copy should fulfil the requirements for 
certified copies. 
10.3.3 Investigator Site File / Regulatory Binder 
Before site initiation, an Investigator Site File (ISF) will be provided to each site. The ISF will 
include essential documents as defined by the ICH GCP guideline and applicable local 
requirements that are required for study initiation at the investigational site. 
From that point onwards, the Investigator will be responsible for the update and maintenance 
of the ISF, which will be reviewed periodically by the monitor(s). These documents will be 
reviewed during an audit by the Sponsor or an inspection by the Regulatory Authorities. 
All study-related documents are to be archived and stored according to the local regulatory 
requirements and agreement with the study Sponsor. 
Details pertaining to the retention and archiving of study documents are found in Section 11.4. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 73 of 161 
Version 7.0, 10 Oct 2022 
10.4 
Alternative Site due to COVID-19 
Based on the exceptional circumstances of the COVID-19 pandemic and need to minimize 
risk (i.e. exposure to COVID-19) study visits may be conducted at alternative locations 
provided: 
• The PI determines it is justified based on the personal benefit-risk ratio for the 
individual trial participant; 
• The (i) patient and/or their family/ legal representative; (ii) PI / other applicable 
members of the study team; and, (iii) personnel at the alternative location (if 
applicable) consent to this alternative location  
• Conducting the study visit at the alternative location does not pose an unacceptable 
safety risk (as agreed by (i) patient and/or their family/ legal representative; (ii)PI / 
other applicable members of the study team; and, (iii) personnel at the alternative 
location (if applicable) 
• Traveling to/from this alternative location is permitted by national or local legislation 
and allowed by the alternative site and arrangements are made to provide adequate 
transportation (for applicable persons) 
• If a study assessment cannot be performed at the alternative location, this should be 
documented and captured in the eCRF.  
 
10.5 
Monitoring 
The monitor is responsible for checking the quality of data and ensuring that the investigative 
site is adhering to the study protocol. Additionally, the monitor ensures that the site is following 
the legal and ethical requirements as stated in local laws and the principles of GCP. 
The interval between monitoring visits will depend on the recruitment rate and the complexity 
of the study. 
Source data verification is an essential part of the monitoring process and the Investigator must 
grant direct access to the original patient’s source documents. 
The extent and nature of monitoring will be described in detail in the monitoring plan. 
Due to COVID-19, alternative monitoring measures may be required if on-site monitoring is 
not permitted and deviations to the study monitoring schedule are necessary. If it is not 
possible to follow the IntraBio recommended monitoring schedule of onsite visits due to 
national, local, or site-specific restrictions, possible temporary, alternative measures may be 
implemented to maintain proper oversight of the clinical trials [IntraBio Ltd 2020b]. All 
monitoring deviations related to COVID-19 should be well-documented to enable appropriate 
evaluation of the clinical trials. 
 
For all countries except Slovakia: Remote source data verification (SDV) will be allowed if 
it is permitted by the National Competent Authorities the site and Principal Investigator agree 
to this method of monitoring due to COVID-19 restrictions for onsite monitoring visits. To 
facilitate remote SDV, scans of source document worksheets, assessment forms, and other 
required documentation will be sent to the monitor. Monitors should be trained on remote 
SDV procedures. No protected health information should be scanned and sent to the 
monitors. If a site allows the monitors to have access to their electronic medical records, this 
should only be available to the monitor during the time of the remote visit. Site staff should 
be available to respond to monitors questions during the remote monitoring visit.  
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 74 of 161 
Version 7.0, 10 Oct 2022 
10.6 
Audits and Inspections 
The Sponsor’s or designated vendor’s Quality Assurance Department may visit the 
investigative site to audit the performance of the study, as well as all study documents. Audits 
may also be performed by contract auditors who will be instructed about the timing and extent 
of the audits. In the event of an audit at the investigational site, the monitor will usually 
accompany the auditor(s).  
Inspections by Regulatory Authority representatives and IECs/IRBs are possible at any time, 
even after the end of the study. The Investigator is to notify the Sponsor immediately of any 
such inspection. The Investigator and institution will permit study-related monitoring, audits, 
reviews by the IEC/IRB and/or Regulatory Authorities and will allow direct access to original 
source documents for monitoring, audits, and inspections. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 75 of 161 
Version 7.0, 10 Oct 2022 
11 ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS 
11.1 
Good Clinical Practice 
This research will be carried out in accordance with the protocol, US Code of Federal 
Regulations, GCP, 21 CFR Parts 50, 56, and 312, the ethical principles set forth in the 
Declaration of Helsinki, and the ICH harmonized tripartite guideline regarding GCP 
(E6 Consolidated Guidance). 
11.2 
Informed Consent 
A sample Informed consent form (ICF) will be provided to each site. No major deviations may 
be made from the sample ICF other than country- or region-specific formatting or 
requirements. The Sponsor and its advisors will review the draft ICF before it is finalized, and 
the final IRB/EC-approved documents must be provided to the Sponsor for regulatory 
purposes. 
 
As required, approved IRB/EC patient facing documents like the ICF will be made available 
in the patients/ parent/ legal guardian’s native language.  
The ICF must be signed by the patient or the patient’s legal guardian before his or her 
participation in the study. The Principal Investigator (PI) at each site will determine whether 
or not each patient has the capacity to give consent. When the patient is an adult (age 16 or 
older in the UK) and mentally impaired, and not able to give consent to confirm their 
willingness to participate in the study, a legal representative will be asked to decide on behalf 
of the patient if they will participate in the study.  
The PI will determine a participant’s capacity to consent according to the Mental Capacity 
Act (MCA). The PI will use a two-stage test of capacity to determine if a subject has the 
capacity to make a decision for themselves by considering:  
 
• Does the patient have an impairment of the mind or brain (temporary or 
permanent), or is there some sort of disturbance affecting the way their mind 
or brain works?   
• If so, does that impairment or disturbance mean that the patient is unable to 
make the decision in question at the time it needs to be made? 
 
If the PI determines the patient is mentally able to understand the study and give their informed 
consent verbally, but the patient is not able to give the signature by him/herself because of 
physical impairment, the signature of an impartial witness will be accepted after the patient has 
given verbal informed consent. 
The adult lacking capacity will also be informed as best as possible about the study according 
to, and at a level appropriate for, their capacity of understanding (as determined by the PI). 
No assent will be obtained from the impaired patient as standard, but the information 
discussed with the impaired adult patient will be documented in the patients records. 
A copy of the ICF must be provided to the patient or the patient's legal guardian. If applicable, 
it will be provided in a certified translation of the local language. The original signed ICF must 
remain in each patient’s study file and must be available for verification by study monitors at 
any time. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 76 of 161 
Version 7.0, 10 Oct 2022 
Due to COVID-19, reconsent for updated ICFs may be done remotely18. Approved updated 
patient information sheets and consent forms should be provided to trial participants by the 
investigator by e-mail, mail or courier before re-consent is obtained. The patient (or parent / 
legal representative) should be contacted by phone by the responsible site staff to discuss the 
updated ICF and answer all questions. After all questions have been answered and the patient 
(or parent/legal representative) has indicated their understanding of the ICF, oral consent 
should be obtained and documented. The patient (or parent/legal representative) will sign the 
ICF provided to them, and this will be returned to the site as soon as possible. A copy of the 
fully signed ICF will be provided to the patient (or parent/legal representative) as soon as 
possible.  
 
Both parties should sign and date the ICF and the wet-ink signed ICF should be filed in the 
investigator site file. The exact procedures by which remote ICF was obtained should be 
recorded in the patient source documents and / or on the applicable ICFs forms 
 
11.3 
Protocol Approval and Amendment 
Before the start of the study, the study protocol and/or other relevant documents will be 
approved by the IEC/IRB/Competent Authorities, in accordance with local regulatory 
requirements. The Sponsor must ensure that all ethical and regulatory requirements have been 
met before the first patient is enrolled in the study. 
This protocol is to be followed exactly. To alter the protocol, amendments must be written, 
receive approval from the appropriate personnel, and receive IRB/IEC/Competent Authority 
approval prior to implementation (if appropriate).  
In accordance with applicable regulatory body guidance’s issued in relation to COVID-19, 
changes to the protocol may need to be implemented without REC/IRB approval or before 
filing an amendment to the CTA/IND to minimize or eliminate immediate hazards or to 
protect the life and well-being of research participants (e.g., to limit exposure to COVID-19) 
and to maintain the integrity of the clinical trial. 
Any guidance issued by the Sponsor to clinical trial sites describing deviations in protocol-
specific procedures which may be necessary due to COVID-19 should be submitted to the 
applicable CA/REA/IRB for reference at the time they are issued.  All changes will be 
reported afterwards in a substantial amendment (SA) protocol application. 
 
11.4 
Archiving Study Records 
According to ICH guidelines, essential documents should be retained for a minimum of 2 years 
after the last approval of a marketing application in an ICH region and until there are no 
pending or contemplated marketing applications in an ICH region or at least 2 years have 
elapsed since the formal discontinuation of clinical development of the investigational product. 
 
 
18 Per EMA Guidance on the Management of Clinical Trials during the COVID-19 (CORONAVIRUS) 
Pandemic, Version 3, during the outbreak of COVID-19 “it should be avoided that trial participants visit trial 
sites for the sole purpose of obtaining re- consent.” 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 77 of 161 
Version 7.0, 10 Oct 2022 
However, these documents should be retained for a longer period if required by the applicable 
regulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the Investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be transferred to 
another location or party without written notification to the Sponsor. 
 
11.5 
Data Safety Monitoring Board 
The Data Safety Monitoring Board (DSMB), in conjunction with the study Medical Monitor 
and/or Sponsor, is responsible for the oversight of the safety. For this purpose, the DSMB will 
receive regular updates of safety.  
The DSMB will review all safety data on a regular basis. The exact content of review material 
and the frequency of review will be detailed in the DSMB charter.  
The DSMB will also be involved in risk-assessments of the impact of COVID-19, and 
reviewing any guidance issued by the Sponsor in regard to the global pandemic. They may 
give recommendations on the conduct of trial operations and protocol adjustments which may 
be required in light of COVID-19.   
11.6 
Premature Termination of the Study 
If Sponsor, an Investigator, or regulatory authorities discover conditions during the study 
that indicate that the study or related activities at a particular site should be terminated, this 
action may be taken after appropriate consultation between Sponsor and the Investigator. 
Conditions that may warrant study or site termination include but are not limited to: 
1. The incidence or severity of AEs in this or other studies indicates a potential health hazard 
to patients 
2. Patient recruitment is unsatisfactory 
3. Data recording is inaccurate or incomplete 
4. Investigator(s) do not adhere to the protocol or applicable regulatory guidelines in 
conducting the study 
5. GCP is not being maintained or adequately followed 
6. Administrative reasons 
7. Complications related to pandemics such as COVID-19 
8. Reasons unrelated to the study. 
Study or site termination and follow-up will be performed in compliance with the conditions 
set forth in 21 Code of Federal Regulations (CFR) Section 3.1.2 and/or other national and local 
regulations, as applicable, and in compliance with the principles set forth in International 
Conference on Harmonization (ICH) Good Clinical Practices (GCPs) and ethical principles 
established by the Declaration of Helsinki. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 78 of 161 
Version 7.0, 10 Oct 2022 
11.7 
Confidentiality 
All study findings and documents will be regarded as confidential. The Investigator and 
members of his/her research team must not disclose such information without prior written 
approval from the Sponsor. 
The anonymity of participating patients must be maintained. Patients will be identified on 
eCRFs and other documents submitted to IntraBio or affiliates by their patient number allocated 
in the trial, not by name. Documents not to be submitted to IntraBio or affiliates that identify 
the patient (e.g., the signed informed consent, patient identification list) must be maintained by 
the Investigator as part of the ISF in a secure and confidential manner.  
11.8 
Liability and Insurance 
In accordance with the relevant national regulations, the Sponsor will take out patient liability 
insurance for all patients who have given their consent to the clinical study. This cover is 
designed for the event that a fatality, physical injury, or damage to health occurs during the 
clinical study’s execution. 
11.9 
Publication Policy 
By signing the study protocol, the Investigator agrees with the use of results of the study for 
the purposes of national and international registration, publication and information for medical 
and pharmaceutical professionals. If necessary, the authorities will be notified of the 
investigator's name, address, qualifications and extent of involvement. 
It is understood that the Clinical Trial is part of the Multi-Center Clinical Trial and publication 
of results is expected. IntraBio will actively pursue publication of the results of the study in 
cooperation with the Principal Investigators (PIs), subject to the terms and conditions of the 
clinical trial agreement between IntraBio, the Investigator, and their respective clinical trial 
site. 
An Investigator shall not publish any data (poster, abstract, paper, etc.) without having 
consulted with the Sponsor in advance. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 79 of 161 
Version 7.0, 10 Oct 2022 
12 REFERENCE LIST 
Agencia Española de Medicamentos y Productos Sanitario (Spanish Agency of Medicines 
and Medical Devices; AEMPS) (2018). N-Acetyl-L-Leucine (IB1001): Meeting minutes 
(unofficial). Unpublished. 
Bremova, T., Malinová, V., Amraoui, Y., Mengel, E., Reinke, J., Kolníková, M., et al. (2015). 
Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology. 85(16), 1368-1375. 
Cortina-Borja, M., te Vruchte, D., Mengel, E., Amraoui, Y., Imrie, J., Jones, S. A., et al. (2018). 
Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease 
type C and for recruitment to clinical trials. Orphanet Journal of Rare Diseases, 13, 143. 
Churchill GC, Strupp M, Galione A, Platt FM. (2020). Unexpected differences in the 
pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical 
relevance. PLUS ONE. 15(2)  
Dutch Medicines Evaluation Board (MEB) (2018). Scientific Advice N-Acetyl-L-Leucine. 
Unpublished. 
EudraLex Volume 10. Ethical considerations for clinical trials on medicinal products 
conducted with minors: Recommendations of the expert group on clinical trials for the 
implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for 
human use. To be authorized under Regulation EU No 536/2014, once it becomes applicable. 
Available at: https://ec.europa.eu/health/documents/eudralex/vol-10_en#fragment1. Accessed: 
2019 August 05. 
EuroQol 
Group. 
EQ-5D 
Instruments 
| 
About 
EQ-5D. 
2017. 
Available 
at: 
https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/ Accessed: 2018 October 28. 
Fields, T. (2020). Clinical Impression of Change in Severity Administration and Scoring 
Manual. IntraBio Ltd Internal Document.  
Geberhiowt, T., Moro, A., Dardis, A., Ramaswami, U., Sirrs, S., et al. (2018). Consensus 
clinical management guidelines for Niemann-Pick disease type C. Journal of Rare Diseases, 
13(50), 1-19 
IntraBio Ltd. (2020a) Guidance on IB1001 Clinical Trials & COVID-19. Version 2.0 30 
March. Internal Document. 
IntraBio Ltd. (2020b) Guidance on IB1001 Clinical Trial Monitoring amid COVID-19 
Pandemic. Version 1.0 17 April. Internal Document 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 
2018.  
Available 
at: https://www.ispor.org/strategic-initiatives/value-assessment-
frameworks Accessed: 2018 Nov 24. 
Iturriaga, C., Pineda, M., Fernández-Valero, E. M., Vanier, M. T., Coll, M. J. (2006). Niemann-
Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci., 
249(1), 1–6. 
Kaya, E., Smith, D., Smith, C., Morris, L., Bremova-Ertl, T., et al. (2020a). Acetyl leucine 
slows disease progression in lysosomal storage disorders. Journal of Clinical Medicine. 
BioRxiv. Doi: https://doi.org/10.1101/2020.05.20.105973  
Kaya, E., Smith, D., Fletcher, C., Boland, B., Strupp, M., Platt, F. (2020b). Beneficial effects 
of Acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff Disease. J. Clin. Med. 2020, 9, 
1050; doi:10.3390/jcm9041050  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 80 of 161 
Version 7.0, 10 Oct 2022 
Knopman, D. S., Knapp M. J., Gracon, S. I., Davis, C. S. (1994). The Clinician Interview-
Based Impression (CIBI): A clinician’s global change rating scale in Alzheimer’s disease. 
Neurology, 44:2315-2321.  
Lord, S. E., Halligan, P. W., Wade, D. T. (1998). Visual Gait Analysis: the development of a 
clinical assessment and scale. Clinical Rehabilitation, 12(2), 107-119. 
Mann, M. (2018). Evaluation of Acetyl-leucine analogues in Niemann-Pick disease type C 
(NPC) and other Lysosomal Storage Diseases in vitro. Study Report from IntraBio Ltd 
Laboratories. 
MCL Medpace Laboratories. (2019). Video Acquisition Manual. IntraBio Ltd. Internal 
Document. 
Mengel, E., Patterson, M., Da Riol, R., Del Toro, M., Deodato, F., et al. Efficacy and safety of 
arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, 
placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metal Dis., 
2021; 44(6), 1463-1480.  
Monte, T.L., Reckziegel, E. R., Augustin, M. C., Silva, A. S. P., Locks-Coelho, L. D., 
Barsottini, O., et al. (2017). NESSCA Validation and Responsiveness of Several Rating Scales 
in Spinocerebellar Ataxia Type 2. Cerebellum, 16(4), 852-858. 
Patterson, M., Mengel, E., Wijburg, F., Muller, A., Schwierin, B., Drevon, H., et al. (2013). 
Disease and patient characteristics in NP-C patients: findings from an international disease 
registry. Orphanet J. Rare Dis., 8, 12. 
Patterson, M., Clayton, P., Gissen, P., Anheim, M., Bauer, P., et al. (2017). Recommendation 
for the detection and diagnosis of Niemann-Pick disease type C. An update. Neurology. 
Available from : https://doi.org/10.1212/CPJ.0000000000000399 
Picone, M. (2018). GM1 & GM2 Tanganil Health Initiative Report. Trend Community, 1-6. 
Pineda, M., Perez-Poyato, M.S., O’Callaghan, M., et al. (2010). Clinical experience with 
miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol 
Genet Metab., 99(4), 358–366. 
Platt, F. (2018). Evaluation of Acetyl-Leucine analogues in mouse models of Niemann-Pick 
disease type C (NPC) and Sandhoff disease. Study Report from Platt Laboratories. 
Quinn, T. J., Dawson, J., Walters, M. R., Lees, K. R. (2008). Variability in Modified Rankin 
Scoring Across a Large Cohort of International Observers. Stroke, 39, 2975-2979. 
Schmitz-Hübsch, T., du Montcel, S. T., Baliko, L., et al. (2006). Scale for the assessment and 
rating of ataxia: development of a new clinical scale. Neurology, 66(11), 1717–1720. 
Schmitz-Hübsch, T., Giunti, P., Stephenson, D., Globas, C., Baliko, L., Saccà, F., et al. (2008). 
SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. 
Neurology, 71, 486-492. 
Schneider L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., et al. (1997). 
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global 
Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc 
Disord., 11 Suppl 2, S22-32. 
Solmi, M., Pigato, G., Kane, J. M., Correll, C. U. (2018). Treatment of tardive dyskinesia with 
VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. 
Drug Des Devel Ther., 12: 1215-1238. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 81 of 161 
Version 7.0, 10 Oct 2022 
Strupp, M., Teufel, J., Habs, M., Feuerecker, R., Muth, C., van de Warrenburg, B. P., et al. 
(2013). Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J 
Neurol., 260, 2556–2561. 
Study No. V00251 IV 101 (704045) (2008). Pharmacokinetic study of 250mg, 1 g, 4 g L-
acetylleucine and 500 mg Tanganil® single dose after intravenous administration in 24 
healthy volunteers, Mediscis.  
Study No. V00251 IV 201 (2012). Double-blind placebo controlled study of 1 g, 2 g and 4 g 
V0251 efficacy and safety in vestibular neuritis. 
Study No. V00251 ST 101 (902022) (2010). Pharmacokinetic study of V0251 after oral (2 g, 
4 g and 8 g) and intravenous (1g, 2g, 4g) single increased doses in 18 healthy volunteers, 
Mediscis. 
Study No. V00251 ST 201 1A (2013). V0251 oral suspension efficacy and tolerance in 
vestibular neuritis. A randomised double-blind placebo controlled study. 
Subramony, S. H. (2007). SARA--a new clinical scale for the assessment and rating of ataxia. 
Nat Clin Pract Neurol., 3(3), 136–137. 
United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA) (2018). 
Scientific Advice Ref 1705/N-acetyl-L-leucine. Unpublished.  
United States Department of Health and Human Services (2018a). Meeting Minutes: PIND 
Application 134369 for N-Acetyl-L-Leucine (IB1001). Food and Drug Administration: 
Division of Gastroenterology and Inborn Errors. Unpublished.  
United States, Department of Health and Human Services (2018b). Meeting Request: Written 
Response PIND Application 138188 for N-Acetyl-L-Leucine (IB1001). Food and Drug 
Administration: Division of Neurology. Unpublished. 
Utz, J., Kim, S., King, K., Ziegler, R., Schema, L., Redtree, E., Whitley, C. (2017). Infantile 
gangliosidoses: Mapping a timeline of clinical changes. Mol. Genet. Metab., 121, 170–179. 
Vanier, M. (2010). Niemann-Pick disease type C. Orphanet J. Rare Dis., 5, 16. 
Wille, N., Badia, X., Bonsel, G., Burström, K., Cavrini, G., Devlin, N., et al. (2010). 
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res., 19(6), 
875-886. 
Wraith J.E., Baumgartner, M.R., Bembi, B., Covanis, A., Levade, T., Mengel, E., Pineda, M., 
Sedel, F., Topcu, M., Varnier, M.T., Widner, H., Wijburg, F.A., Patterson, M.C. (2009). 
Recommendation on the diagnosis and management of Niemann-Pick disease type C. Mol 
Genet Metab., 98, 152-165. 
Whyte, M. P., Fujita, K. P., Moseley, S., Thompson, D. D., McAlister, W. H. (2018). 
Validation of a Novel Scoring System for Changes in Skeletal Manifestations of 
Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression 
of Change Scale. J Bone Miner Res., 33(5), 868-874. 
Yanjanin, N.M., Vélez, J.I., Gropman, A., King, K., Bianconi, S.E., Conley, S.K., Brewer, 
C.C., et al. (2010). Linear Clinical Progression, Independent of Age of Onset, in Niemann-Pick 
Disease, type C. Am J Med Genet B Neuropsychiatr Genet, 153B(1), 132–140.


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 82 of 161 
Version 7.0, 10 Oct 2022 
13 APPENDICES 
13.1 
Appendix 1: Synopsis 
 
CLINICAL STUDY PROTOCOL SYNOPSIS 
 
 
SPONSOR: 
 
 
 
 
US LEGAL 
REPRESENTATIVE: 
 
 
 
EU LEGAL 
REPRESENTATIVE: 
 
IntraBio Ltd. 
Begbroke Science Park, Begbroke Hill 
Woodstock Road, Begbroke, Oxfordshire 
OX5 1PF, United Kingdom 
IntraBio Inc 
270 Devon Road 
Tenafly NJ 07670 
United States 
 
 
IntraBio Ireland Ltd 
10 Earlsfort Terrace, 
Dublin 2, 
D02 T380, Ireland 
 
 
STUDY NUMBER: 
IB1001-201 
 
 
EUDRACT NUMBER: 
IND NUMBER: 
 
 
2018-004331-71 
134369 
 
 
PRODUCT/COMPOUND: 
 
N-Acetyl-L-Leucine (IB1001) 
 
TITLE: 
 
Effects of N-Acetyl-L-Leucine on Niemann-Pick disease 
type C: A multinational, multicenter, open-label, rater-
blinded Phase II study. 
 
Short Title: A safety and efficacy study of N-Acetyl-L-
Leucine on Niemann-Pick type C. 
 
CLINICAL PHASE: 
 
Phase II 
 
 
(TARGET) INDICATION(S): 
 
Niemann-Pick disease type C  
 
 
STUDY SITES: 
 
 
US and Europe   
 
VERSION & DATE: 
 
Version 7.0, 10-OCT-2022 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 83 of 161 
Version 7.0, 10 Oct 2022 
 
Name of Sponsor/Company: 
IntraBio Ltd. 
Protocol Number: 
IB1001-201 
Phase of Development: 
Phase II 
Title of the Protocol: 
Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C: A multinational, multicenter, 
open-label, rater-blinded Phase II study. 
 
Short title: 
Short Title: A safety and efficacy study of N-Acetyl-L-Leucine on Niemann-Pick type C  
Purpose: 
The primary purpose of the study is to evaluate the safety and efficacy of N-Acetyl-L-Leucine 
(IB1001) in the treatment of Niemann-Pick disease type C (NPC) 
Study Rationale: 
The goal of this study is to demonstrate that N-Acetyl-L-Leucine is efficacious in improving 
symptoms, functioning, and quality of life against the defined endpoints in patients with NPC for 
the purpose of establishing the benefit/risk balance of the investigational medicinal product in the 
proposed clinical setting. 
 
N-Acetyl-L-Leucine is the L-enantiomer of N-Acetyl-DL-Leucine, a modified amino acid that has 
been available in France since 1957 under the trade name Tanganil® (Pierre Fabre Laboratories) as 
a treatment for acute vertigo and is available as a solution for injection and as a tablet. N-Acetyl-L-
Leucine is not currently authorized anywhere in the world for the treatment of any condition.  
 
The Sponsor’s (IntraBio Ltd.) development of Acetyl-Leucine for NPC began with the investigation 
of the commercially available racemic mixture, N-Acetyl-DL-Leucine (Tanganil®). Published case 
studies are available in the literature describing the effect of acute treatment with the racemate N-
Acetyl-DL-Leucine in patients with NPC disease [Bremova et al, 2015] as well as with Cerebellar 
Ataxias [Strupp et al, 2013; Schniepp et al., 2016]. An additional case series is available in the 
literature describing the disease modifying effect of long-term treatment with N-Acetyl-DL-Leucine 
[Cortina-Borja et al, 2018]. In all studies, the compound was well-tolerated with no discernible 
serious side effects.  
 
These preliminary findings have been corroborated by in vitro studies with fibroblasts from NPC 
patients and by in vivo studies in the Npc1-/- model for NPC disease to explain the pharmacological 
properties of N-Acetyl-D-Leucine in relation to the observed therapeutic effects [Mann, 2018; Platt, 
2018]. 
 
Recent in vitro and in vivo studies have demonstrated that the L-enantiomer is believed to mediate 
the therapeutic effect and have potential clinical benefits over the racemic mixture. IntraBio 
therefore intends to focus further development on N-Acetyl-L-Leucine without the presence of D-
Confidentiality Statement 
This clinical study protocol is the confidential information of IntraBio Ltd. and is 
intended solely for the guidance of the clinical investigation. This protocol may not be 
disclosed to parties not associated with the clinical investigation and may not be used for 
any purpose without the prior written consent of IntraBio Ltd. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 84 of 161 
Version 7.0, 10 Oct 2022 
enantiomer. The safety profiles of both N-Acetyl-DL-Leucine and N-Acetyl-L-Leucine have been 
characterized in both preclinical and clinical studies, and on the basis of compassionate use 
experience with N-Acetyl-DL-Leucine in NPC (as well as in patients with other lysosomal storage 
disorders, neurodegenerative and genetic diseases, and further indications) [Dr Michael Strupp, MD, 
Professor of Neurology LMU Munich, Personal Communication].  
 
Based on these findings, IntraBio is conducting a Phase II study investigating the efficacy and safety 
of N-Acetyl-L-Leucine for the treatment of NPC. Patients will only be included in the study if they 
meet the inclusion and exclusion criteria described in the study protocol approved by the relevant 
ethics committees and the regulatory authorities and informed consent is obtained. To further 
minimize risks, patients will receive the best available clinical care to manage the underlying 
conditions with careful monitoring of adverse events that may arise during the course of the clinical 
study. 
 
The confidentiality of all patients will be protected by pseudonymization and in accordance with 
guidelines and local laws. 
Primary Objective: 
The primary objective is to evaluate the efficacy of N-Acetyl-L-Leucine based on blinded raters’ 
Clinical Impression of Change in Severity (CI-CS) in the treatment of NPC. 
Secondary Objectives: 
o To assess the clinical efficacy of N-Acetyl-L-Leucine on symptoms of ataxia, 
functioning, and quality of life for patients with NPC; 
o To evaluate the safety and tolerability of N-Acetyl-L-Leucine at 4 g/day in adults and 
children with NPC, including patients aged ≥18 years in the United States and patients 
aged ≥13 years in Europe, and weight-tiered doses in children 6 to 12 years of age in 
Europe 
 
Exploratory Objectives: 
o To characterize the pharmacokinetics (PK) of N-Acetyl-L-Leucine in patients with 
NPC  
Primary Endpoint: 
The primary endpoint is defined as the Clinical Impression of Change in Severity (CI-CS) 
comparing end of treatment with N-Acetyl-L-Leucine (Visit 4) with baseline (Visit 2) minus the 
CI-CS comparing the end of washout (Visit 6) with the end of treatment with N-Acetyl-L-Leucine 
(Visit 4) based on the primary anchor test.  
 
This primary endpoint will assess the efficacy of N-Acetyl-L-Leucine for the treatment of NPC, 
based on blinded raters’ CI-CS of patient’s change in performance over 6 weeks on either the 9-hole 
peg test of the dominant hand (9HPT-D) or the 8-meter walk test (8MWT).  
 
At Visit 1, the treating physician will evaluate each patient’s clinical symptoms and select either the 
9HPT-D or 8MWT as the primary anchor around which the CI-CS assessment will be based. The 
primary evaluation of the CI-CS will be performed by two independent raters whose assessments 
will be based on videos of the anchor test taken at each visit. The raters will be blinded to the 
treatment phases to reduce detection and performance biases and for each pair of visits will make 
an assessment based on a 7-point Likert scale, e.g., -3 = ‘significantly worse’, 0 = ‘no change’ to +3 
= ‘significantly improved’.   
 
Secondary Endpoints: 
There will be several secondary endpoints that closely relate to the primary endpoint: 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 85 of 161 
Version 7.0, 10 Oct 2022 
• 
The CI-CS for end of treatment with N-Acetyl-L-Leucine (Visit 4) versus baseline (Visit 2) 
and end of washout (Visit 6) versus end of treatment with N-Acetyl-L-Leucine (Visit 4) will 
each be summarized descriptively. 
• 
Improvement in the primary and non-primary anchor test measures will be evaluated based 
on the change in the blinded raters’ Clinical Impression of Severity (CI-S) between baseline 
(average for Visit 1 and Visit 2) and end of treatment with N-Acetyl-L-Leucine (average 
for Visit 3 and Visit 4) minus the change in CI-S between end of treatment with N-Acetyl-
L-Leucine (average for Visit 3 and Visit 4) and end of washout (average for Visit 5 and 
Visit 6). Statistical testing for the primary anchor test CI-S endpoint will be as for the 
primary endpoint. There will be no formal statistical testing of the non-primary test. 
• 
Sensitivity measurement of change in performance on either the 9HPT-D or the 8MWT on 
a 3-point scale. Using the CI-CS outcome for the primary anchor test based on the data for 
Visits 2 and Visit 4, any patient given a score of -1, -2, or -3 on the CI-CS will be classified 
as worsened (>0). Any patient classified as 0 on the CI-CS will be classified no change (0). 
Any patient given a score of +1, +2, +3 on the CI-CS will be classified as improved (>0). 
The descriptive table will be similar to the primary endpoint. No statistical analysis will be 
performed  
• 
An evaluation of the CI-CS An evaluation of the CI-CS for the test (9HPT-D or 8MWT) 
that was not selected as the primary anchor test (i.e., the non-primary anchor test) will also 
be undertaken. There will be no formal statistical testing of these endpoints, however.  
 
The following assessments will be based on the absolute changes from baseline (Visit 2) to the 
end of treatment with N-Acetyl-L-Leucine (Visit 4), as well as end of treatment with N-Acetyl-L-
Leucine (Visit 4) to the end of post-treatment washout (Visit 6)19. 
  
• 
Spinocerebellar Ataxia Functional Index (SCAFI)20 
• 
Scale for Assessment and Rating of Ataxia (SARA) score 
• 
Quality of Life EQ-5D-5L for patients aged ≥18; EQ-5D-Y21 for children aged <18 years  
• 
Modified Disability Rating Scale (mDRS) 
• 
Treating Physician Clinical Global Impression of Severity (CGI-S) 
• 
Treating Physician Clinical Global Impression of Change (CGI-C) 22  
• 
Caregiver Clinical Global Impression of Severity (CGI-S) 
• 
Caregiver Clinical Global Impression of Change (CGI-C)4  
• 
Patient Clinical Global Impression of Severity (CGI-S) if they are able 
• 
Patient Clinical Global Impression of Change (CGI-C)4 if they are able 
 
Safety Parameters: 
Adverse events (AEs), safety laboratory tests including biochemistry, hematology, urinalysis 
including pregnancy test, vital signs, 12-lead electrocardiogram (ECG), and concomitant 
 
 
19 See the SAP for complete methods of dealing with missing data as well as how secondary endpoints will be 
investigated descriptively.  
20 Two subsets, the 9-hole peg test of the dominant hand (9HPT-D) and the 8-meter walk test (8MWT), will be 
videoed for every patient at every visit, except Visit 0. 
21 European Sites Only 
22 Based on the changes from baseline to the end of treatment with N-Acetyl-L-Leucine, as well as end of 
treatment with N-Acetyl-L-Leucine to the end of post-treatment washout. The two CI-S values at each of these 
periods (Visit 1 and Visit 2 for baseline, Visit 3 and Visit 4 for end of treatment and Visit 5 and Visit 6 for end of 
washout) will be averaged. 
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 86 of 161 
Version 7.0, 10 Oct 2022 
medications. Blood samples may be collected or retained for research purposes about the disease 
NPC. 
Note: in the Extension Phase, physical exams are also conducted. 
Pharmacokinetics (PK): Sparse PK sampling will be carried out at Visits 1, 2, 3, 4, 5 and 6 (at 
the same times that blood is drawn for the safety blood laboratory tests) for possible future 
modeling purposes. This sampling is exploratory/descriptive. 
Lithium-Heparin plasma samples will be drawn and frozen at -70ºC or below and shipped on dry 
ice for analysis at AZ-Biopharm, Berlin, Germany. Note, for each PK blood draw, it is important 
that the day and exact time of the last dose of N-Acetyl-L-Leucine before the blood draw and the 
day and exact time of the blood draw are recorded.  
Note: In the Extension Phase, full PK sampling will take place at baseline (Visit 7B) and after 1-
year treatment (Visit 9B). 
Urine samples will also be collected for concentrations of N-Acetyl-D-Leucine at Visit 1, Visit 2, 
Visit 5, and Visit 6. 
Urine samples for measurement of N-Acetyl-D-Leucine will be frozen at -70ºC or below and 
shipped on dry ice for analysis at AZ-Biopharm, Berlin, Germany.  
The urine sample provided at Visit 1 will be analyzed after it is received by AZ-Biopharm and 
results should be made available before start of the treatment phase to demonstrate that levels of N-
Acetyl-D-Leucine are below the set threshold. 
The urine samples provided at Visit 2, Visit 5, and Visit 6 will be analyzed in batches and used for 
sensitivity analyses only. 
Study Design and Methodology:  
This is a multinational, multicenter, open-label, rater-blinded Phase II study. In the Parent Study, 
patients will be assessed during three study periods: a baseline period, treatment period, and a 
washout period.  
As it is not uncommon for symptoms and functioning to fluctuate over a week, to help account for 
intra-patient variability, patients will be assessed twice during each period. 
At the initial screening visit, patients will be classified as either “naïve” or “non-naïve” patients 
depending on their use of prohibited medications within the past 42 days. The schedule of events 
during the initial screening visit and throughout the baseline period (through Visit 1) will vary 
depending on patient’s classification as either “naïve” or “non-naïve”. 
After Visit 2, all visits will be the same for all patients regardless of whether they were considered 
to be “naïve” or “non-naïve” at the time of enrollment.  
Screening/Baseline Period 
Study Schema 1: “Naïve” Patients 
“Naïve” patients are defined as patients who, at the initial screening visit, confirm (or whose legal 
representatives confirm on behalf of the patient) that they have not used any prohibited medications 
within the past 42 days. For these patients, the initial screening visit will be treated as Visit 1 
(Baseline 1). 
A urine sample will be taken at Visit 1 to detect N-Acetyl-D-Leucine. Provided the patient’s levels 
of N-Acetyl-D-Leucine are below the permitted threshold, the initial screening visit will be 
confirmed as Visit 1 (Baseline 1). Visit 2 (Baseline 2/Start of treatment period) will take place 
14 days (+7 days) after Visit 1 (Figure 1). 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 87 of 161 
Version 7.0, 10 Oct 2022 
 
Figure 1: Study Schema for “Naïve” Patients  
 
Reclassifying “Naïve” Patients to “Non-naïve” Patients 
Visit 1 will not be confirmed for “naïve” patients whose urine sample unexpectedly detected levels 
of N-Acetyl-D-Leucine above the permitted threshold. Provided the treating physician believes the 
patient will indeed comply with the pre-treatment washout and complete study the protocol23, these 
patients will be given the option to undergo a minimum of 42 days washout before returning for a 
second screening visit. Provided the patient (or legal representative on behalf of the patient) consent, 
the patient will be reclassified as “non-naïve” and will return for a repeat Visit 1 after the study run-
in washout period.   
 
Study Schema 2: “Non-naïve” Patients 
“Non-naïve” patients are defined as patients who confirm (or whose legal representatives on 
behalf of the patient confirm) they have used, or are unable to confirm or deny if they have used, 
any prohibited medication within the past 42 days24.  
Provided the treating physician believes the patient will comply with the pre-treatment washout 
and complete the study protocol, the “non-naïve” patient will be given the opportunity to undergo 
a minimum of 42 days washout before returning for a second screening visit. Provided the patient 
(or their legal representatives on behalf of the patient) consent, the initial screening visit will be 
treated and confirmed as Visit 0 (Figure 2). 
Visit 0 will commence study run-in period where patients undergo a washout from prohibited 
medications. Patients are eligible to return for a second screening visit after a minimum of 42 days 
washout. For patients (or their legal representatives on behalf of the patient) who confirm they have 
not used any prohibited medications for a minimum of 42 days, the second screening visit will be 
treated as Visit 1 (Baseline 1)25.  
A urine sample will be taken at Visit 1 to assess the level of N-Acetyl-D-Leucine. Provided the level 
of N-Acetyl-D-Leucine is below the permitted threshold, the second screening visit will be 
 
 
23 If the treating physician has reason to believe the patient will not comply with the pre-treatment washout or the 
complete study protocol, the patient will be notified they are ineligible for the study.  
24 As described, “non-naïve” patients can also be defined as patients who were initially classified as “naïve,” but 
whose initial urine sample unexpectedly detected levels of N-Acetyl-D-Leucine above the permitted threshold. 
Provided they are eligible, patients will be reclassified as “non-naïve” and return for a second screening visit after 
a minimum of 42 days washout.  
25 At Visit 1, patients who confirm (or whose legal representatives confirm) they have used, or are unable to 
confirm or deny if they have used, any prohibited medication within the past 42 days are ineligible to continue in 
the study.   
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 88 of 161 
Version 7.0, 10 Oct 2022 
confirmed as Visit 1 (Baseline 1). Visit 2 (Baseline 2/ Start of treatment period) will take place 
14 days (+7 days) after Visit 1.  
 
Figure 2: Study Schema for Non-Naïve Patients  
 
Treatment Period:  
During the treatment period, all patients will receive N-Acetyl-L-Leucine for 42 days (+7 days). 
Visit 3 (Treatment 1) will occur at Day 28 (+7 days) of the treatment period and Visit 4 
(Treatment 2) will occur after the full 42 days (+7 days) of treatment. 
 
Washout Period:  
A 6-week washout period will be performed following treatment with N-Acetyl-L-Leucine. Visit 5 
(Washout 1) will occur on Day 28 (+7 days) of the washout period and Visit 6 (Washout 2) will 
occur after the full 42 days (+7 days) of washout. 
 
Remote Visits: 
For any (i) skipped in-person Visit 3/5; (ii) postponed in person Visit 4/6: based on the availability 
of the patient/ the study team, within approximately  +/- 3 days of the originally scheduled 
visit, the study team/ PI should contact the patient (and as applicable, their parents/caregiver/legal 
representative) via phone/Skype26 to collect information in order to monitor adverse or serious 
adverse events, and provide study oversight (hereafter referred to as “remote visits”).  
 
Extension Phase:  
Patients who have participated in the study will be offered the opportunity to participate in a planned 
Extension Phase (EP) if the safety and tolerability during the 42 day (+7 day) treatment are 
considered to be acceptable by the Investigator for each specific patient, and the Investigator 
determines further treatment with IB1001 to be in the patient’s interest. Provided the patient (or their 
legal representative on their behalf) subsequently consent to participate, the Extension Phase is 
planned to allow patients to have further access to IB1001 for two, one-year treatment periods 
(Extension Phase Treatment Period I, Visit 8 + Visit 9, and Extension Phase Treatment Period II, 
Visits 11 and 12). The two, one-year EP treatment periods are separated by a washout period of 
approximately 42 days (+14 days) (Visit 10). 
 
 
 
26 As feasible; Skype is used as a generic term for videoconferencing, telemedicine but other software’s may be used. No video 
recordings should be made of these remote visits.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 89 of 161 
Version 7.0, 10 Oct 2022 
COVID-19: 
This study is ongoing during the COVID-19 outbreak. Coronavirus (COVID-19) outbreaks have 
been recorded in all countries with study sites and subjects participating in IntraBio’s clinical trials 
and have significantly impacted the IB1001-201clinical trial. 
 
The global pandemic has had a significant impact on the IB1001-201 clinical trial by impacting 
study subjects’ ability to attend study visits due to government-ordered lock downs, or the closure 
of state (domestic) and/or national borders. In addition, the issuance of site-specific policies 
limiting or halting the conduct of non-essential study visits, the conversion of study-sites into 
COVID-19 wards, and site staff not on duty or reassigned to other priorities at the hospitals have 
affected the feasibility of conducting study visits. Finally, considering NPC patients are already 
classified as a vulnerable patient population, patients may be self-isolating. 
 
Therefore, protocol deviations and changes to study visits have been /may be necessary in order to 
safeguard participants, their families, and study teams. These include: 
• 
Visit 3 and Visit 5 are “interim” visits of the treatment/washout phase (respectively), and 
the in-person visit may be skipped; 
• 
Visit 4 and Visit 6 are final visits of the treatment/washout phases and the in-person visit 
may be postponed, but cannot be skipped; 
• 
For any (i) skipped in-person Visit 3/5; (ii) postponed Visit 4/6: based on the availability 
of the patient/ the study team, within approximately +/- 3 days of the originally scheduled 
visit, a remote visit should be conducted; 
• 
If a visit is skipped or postponed, protocol-specific procedures may not take place at the 
designated timepoint in the schedule of events.  
 
Schedule of Events: 
An outline of the Parent Study design, defined by Visit, and per study schema, is shown below. 
For a detailed description of the study design and the tests procedures and assessments performed 
at each visit, refer to the Schedule of Events in Appendix 3A for “naïve” patients and 3B for “non-
naïve” patients. 
“NAÏVE” PATIENTS: SCREENING PERIOD 
Screening Visit/Visit 1 (Baseline 1): Written informed consent will be obtained. All patients will 
be screened for inclusion and exclusion criteria. Only patients meeting all the inclusion and none of 
the exclusion criteria will be allocated to the trial. The Screening Visit will be treated as Visit 1: the 
first assessment of the baseline period.27  
• 
Informed consent/informed consent form (ICF) signature and patient information 
• 
Patient demographics28 
• 
Patient weight and height measurements 
• 
60-day drug history including documentation of prior therapies/medications, including 
prohibited medications, and concomitant medications/therapies for treatment of trial-
specific illness  
 
 
27 The Screening Visit will be confirmed as Visit 1 as soon as the patient’s eligibility is confirmed and the level of 
N-Acetyl-D-Leucine detected in their urine sample is confirmed to be below the permitted threshold. Visit 1 will 
not be confirmed for patients classified as “naïve” but whose urine sample unexpectedly detect levels of N-Acetyl-
D-Leucine above the permitted threshold. At the treating physician’s discretion, these patients will be given the 
option to undergo a minimum of 42 days washout before returning for a second screening visit. Should they agree, 
the patient will be reclassified and changed to “non-naïve”. 
28 Demographics for each patient will be collected according to local laws 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 90 of 161 
Version 7.0, 10 Oct 2022 
• 
Relevant medical history as well as medical history concerning the trial specific illness, 
including frequency of physiotherapy and speech therapy (documented in hours per week) 
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 29 
• 
Scale for Assessment and Rating of Ataxia (SARA)  
• 
Check for remaining inclusion/exclusion criteria (including confirmation that prohibited 
medications have not been used for the past 42 days) 
• 
Patient classified as “naïve”  
• 
Vital signs 
• 
Cognitive assessment according to standard procedures of the clinical site to assist with the 
Clinical Impression of Change in Severity (CI-CS) Primary anchor test selection 
• 
Determine Clinical Impression of Change in Severity (CI-CS) Primary anchor test 
• 
Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients <18 years old  
• 
Modified Disability Rating Scale (mDRS) 
• 
Niemann-Pick Disease type C Clinical Severity Scale (NPC-CSS) 
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient (if able) 
• 
12-lead ECG 
• 
Urinalysis (done at central lab) 
• 
Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• 
Blood draw for safety laboratory tests, including follicle stimulating hormone (FSH) for 
menopausal women (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
 
“NON-NAÏVE” PATIENTS: SCREENING PERIOD 
Screening Visit/Visit 0: Written informed consent will be obtained. All patients will be screened 
for inclusion and exclusion criteria. Patients who confirm (or whose legal representatives on behalf 
of the patient confirm) they have used, or are unable to confirm or deny if they have used, any 
prohibited medications within the past 42 days will, at the treating physician’s discretion, remain 
eligible for enrollment. The Screening Visit will be treated as Visit 0. 
• 
Informed consent/ ICF signature and patient information 
• 
Patient demographics  
• 
Patient weight and height measurements 
• 
60-day drug history including documentation of prior therapies/medications, including 
prohibited medications, and concomitant medications/therapies for treatment of trial-
specific illness  
• 
Relevant medical history as well as medical history concerning the trial specific illness, 
including frequency of physiotherapy and speech therapy (documented in hours per week) 
• 
Vital signs 
• 
Spinocerebellar Ataxia Functional Index (SCAFI)  
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Check remaining inclusion/exclusion criteria  
• 
Patient classified as “non-naïve”  
• 
Documentation of adverse events  
 
 
29 The 9-hole peg test of the dominant hand (9HPT-D) and 8-meter walk test (8MWT) will be videotaped in a 
standardized manner at every visit, except Visit 0. At Visit 1, these videos are made before the CI-CS primary 
anchor test is determined.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 91 of 161 
Version 7.0, 10 Oct 2022 
 
Visit 1 (Baseline 1): Minimum of 42 days after Visit 0/washout from prohibited medication. All 
patients will be screened for inclusion and exclusion criteria. Only patients meeting the inclusion 
and none of the exclusion criteria will be allocated to the trial. This second screening visit will be 
treated as Visit 1: the first assessment of the baseline period. 30 
• 
Check of inclusion/exclusion criteria (including confirmation that prohibited medications 
have not been used for the past 42 days) 
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs  
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 31 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Cognitive assessment according to standard procedures of the clinical site to assist with the 
Clinical Impression of Change in Severity (CI-CS) primary anchor test selection 
• 
Determine Clinical Impression of Change in Severity (CI-CS) primary anchor test 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for patients aged <18 years  
• 
Modified Disability Rating Scale (mDRS) 
• 
Niemann-Pick Disease type C Clinical Severity Scale (NPC-CSS) 
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
12-lead EC 
• 
Urinalysis (done at central lab) 
• 
Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• 
Blood draw for safety laboratory tests, including FSH for menopausal women (done at 
central lab) 
• 
Blood draw for sparse PK (done at PK Lab) 
• 
Documentation of adverse events  
FOR ALL PATIENTS (“NAÏVE” AND “NON-NAÏVE”) 
Visit 2 (Baseline 2): Day 14 (+7 days) after Visit 1 (Baseline 1). The final day/ second assessment 
of the baseline period. The start of the treatment period. 
• 
Reconfirm patient eligibility, including confirmation that prohibited medications have not 
been used since Visit 1 
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs  
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for children aged <18 years 
• 
Modified Disability Rating Scale (mDRS) 
 
 
30 This screening visit will be confirmed as Visit 1 provided the patient’s eligibility is confirmed and the level of 
N-Acetyl-D-Leucine detected their urine sample is below the permitted threshold.  Non-naïve patients whose urine 
sample after Visit 1 unexpectedly detect levels of N-Acetyl-D-Leucine above the permitted threshold will be 
marked as non-compliant and withdrawn from the study. 
31 The 9-hole peg test of the dominant hand (9HPT-D) and 8-meter walk test (8MWT) will be videotaped in a 
standardized manner at every visit, except Visit 0. At Visit 1, these videos are made before the CI-CS primary 
anchor test is determined.  


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 92 of 161 
Version 7.0, 10 Oct 2022 
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
Urinalysis (done at central lab) 
• 
Urine by dipstick: pregnancy test for women of childbearing potential (done at site before 
first dose of study drug is taken) 
• 
Urine test for N-Acetyl-D-Leucine (test done at PK lab) 
• 
Blood draw for safety laboratory tests (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
• 
Dispensing of trial drug + intake of study drug at site  
 
Visit 3 (Treatment 1) Day 28 (+7 days) of treatment period: First assessment of treatment period 
with N-Acetyl-L-Leucine 
• 
Return of trial drug and compliance check (if feasible) 
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs 
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for children aged <18 years 
• 
Modified Disability Rating Scale (mDRS)   
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
12-lead ECG 
• 
Urinalysis (done at central lab) 
• 
Blood draw for safety laboratory tests (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
• 
Dispensing of study drug if needed 
 
Visit 4 (Treatment 2): Day 42 (+7 days) of treatment period: the final day/second assessment of 
treatment period with N-Acetyl-L-Leucine. The start of washout period. 
• 
Return of trial drug and compliance check32 
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs 
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for children aged <18 years  
• 
Modified Disability Rating Scale (mDRS) 
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
 
 
32 Or after Visit 4 if IMP is returned via courier 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 93 of 161 
Version 7.0, 10 Oct 2022 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
Clinical Global Impression of Change (CGI-C) by physician based on Visit 2 to Visit 4 
• 
Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 2 to Visit 4 
• 
Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 2 to Visit 4 
• 
Urinalysis (done at central lab) 
• 
Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• 
Blood draw for safety laboratory tests (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
 
Between Visit 4 – Visit 5: Wash-Out 
Visit 5 (Washout 1): Day 28 (+7 days) of wash-out period: First assessment of wash-out period.  
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs 
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for children aged <18 years 
• 
Modified Disability Rating Scale (mDRS)   
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
12-lead ECG  
• 
Urinalysis (done at central lab) 
• 
Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• 
Blood draw for safety laboratory tests (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
 
Visit 6 (Washout 2): Day 42 (+7 days) of washout period: the final day/second assessment of 
washout period. 
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs 
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for children aged <18 years 
• 
Modified Disability Rating Scale (mDRS)   
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
Clinical Global Impression of Change (CGI-C) by physician based on Visit 4 to Visit 6 
• 
Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 4 to Visit 6 
• 
Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 4 to Visit 6 
• 
Medication History: If the patient was classified as “naïve”, confirm if they have used N-
Acetyl-Leucine (L, DL, D) at any time prior to Visit 1 
• 
Urinalysis (done at central lab) 
• 
Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 94 of 161 
Version 7.0, 10 Oct 2022 
• 
Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• 
Blood draw for laboratory safety tests (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
• 
Investigator determines continued treatment with IB1001 in patient’s best interest (if 
applicable) 
• 
Informed consent/informed consent form (ICF) signature and patient information for 
Extension Phase (if applicable) 
• 
Check of inclusion/exclusion criteria for Extension Phase (if applicable) 
 
Early Termination Visit 
• 
Return of study drug and compliance check33 
• 
Documentation of frequency of therapy (hours per week) 
• 
Documentation of concomitant medication  
• 
Vital signs 
• 
Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• 
Scale for Assessment and Rating of Ataxia (SARA) 
• 
Quality of Life EQ-5D-5L for adults aged ≥18 years, EQ-5D-Y for children aged <18 years 
• 
Modified Disability Rating Scale (mDRS)   
• 
Clinical Global Impression of Severity (CGI-S) by physician 
• 
Clinical Global Impression of Severity (CGI-S) by caregiver 
• 
Clinical Global Impression of Severity (CGI-S) by patient if able 
• 
Clinical Global Impression of Change (CGI-C) by physician based on Previous Visit to ET 
Visit  
• 
Clinical Global Impression of Change (CGI-C) by caregiver based on Previous Visit to ET 
Visit  
• 
Clinical Global Impression of Change (CGI-C) by patient if able based on Previous Visit 
to ET Visit 
• 
Medication History: If the patient was classified as “naïve”, confirm if they have used N-
Acetyl-Leucine (L, DL, D) at any time prior to Visit 1 
• 
12-lead ECG   
• 
Urinalysis (done at central lab) 
• 
Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• 
Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• 
Blood draw for safety laboratory tests (done at central lab) 
• 
Blood draw for sparse PK (done at PK lab) 
• 
Documentation of adverse events  
 
Number of Patients: 
• 
To be enrolled: Approximately 39 patients  
 
• 
To be analyzed according to the modified Intention to Treat (mITT) analysis: 
Approximately 36 patients 
 
• 
To be analyzed according to the Per Protocol Analysis: Approximately 30 patients 
 
 
33 Or after ET if IMP is returned via courier 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 95 of 161 
Version 7.0, 10 Oct 2022 
Number of Sites: 
Approximately 9 sites 
Number of Participating Countries: 
Approximately 9 sites in the United States, United Kingdom, Germany, Spain, and Slovakia  
If necessary, additional countries may be included in the trial. 
 
Study Duration: 
The treatment and washout duration for the Parent Study for all patients, from the first day of dosing 
with the study drug (Visit 2) to the final follow-up visit after washout (Visit 6), is expected to be 
approximately 84 days.  
For “naïve” patients, there is a 14-day (+7 days) screening/ baseline period between Visit 1 and 
Visit 2. 
For “non-naïve” patients, there is a 42-day (+7 days) run-in period before Visit 1, and a 14-day (+7 
days) screening/ baseline period between Visit 1 and Visit 2.  
 
The total duration of the Parent Study may be impacted if Visit 4 and/or Visit 6 are postponed due 
to COVID-19. 
 
Study Population and Criteria for Inclusion/Exclusion: 
Inclusion Criteria: 
Individuals who meet all of the following criteria are eligible to participate in the study. 
1. Written informed consent signed by the patient and/or their legal representative/ parent/ 
impartial witness 
2. Male or female aged ≥6 years in Europe OR ≥18 years in the United States with a confirmed 
diagnosis of NPC at the time of signing informed consent. Confirmed diagnosis includes 
[Patterson et al. 2017]: 
a) Clinical features and positive biomarker screen and/or filipin test without genetic tests 
results (has not been performed) 
b) Clinical features and positive genetic test 
c) Clinical features and positive biomarker screen and/or filipin test but only one NPC 
mutation identified on genetic test 
d) Clinical features with positive biomarker screen and/or filipin test and positive genetic 
test. 
3. Females of childbearing potential, defined as a premenopausal female capable of becoming 
pregnant, will be included if they are either sexually inactive (sexually abstinent34 for 
14 days prior to the first dose and confirm to continue through 28 days after the last dose) 
or using one of the following highly effective contraceptives (i.e. results in <1% failure rate 
 
 
34 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatments. In this trial, abstinence is 
only acceptable if in line with the patient’s preferred and usual lifestyle. 
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception.  
As well, female condom and male condom should not be used together. 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 96 of 161 
Version 7.0, 10 Oct 2022 
when used consistently and correctly) 14 days prior to the first dose continuing through 
28 days after the last dose: 
a) intrauterine device (IUD); 
b) surgical sterilization of the partner (vasectomy for 6 months minimum); 
c) combined (estrogen or progestogen containing) hormonal contraception associated with 
the inhibition of ovulation (either oral, intravaginal, or transdermal); 
d) progestogen only hormonal contraception associated with the inhibition of ovulation 
(either oral, injectable, or implantable); 
e) intrauterine hormone releasing system (IUS);  
f) bilateral tubal occlusion. 
4. Females of non-childbearing potential must have undergone one of the following 
sterilization procedures at least 6 months prior to the first dose: 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 97 of 161 
Version 7.0, 10 Oct 2022 
a) hysteroscopic sterilization; 
b) bilateral tubal ligation or bilateral salpingectomy; 
c) hysterectomy; 
d) bilateral oophorectomy; 
OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle 
stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH 
analysis for postmenopausal women will be done at screening. FSH levels should be in the 
postmenopausal range as determined by the central laboratory. 
5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from 
sexual intercourse during the study until 90 days beyond the last dose of study medication 
and the female partner agrees to comply with inclusion criteria 3 or 4. For a vasectomized 
male who has had his vasectomy 6 months or more prior to study start, it is required that 
they use a condom during sexual intercourse. A male who has been vasectomized less than 
6 months prior to study start must follow the same restrictions as a non-vasectomized male. 
6. If male, patient agrees not to donate sperm from the first dose until 90 days after their last 
dose. 
7. Patients must fall within: 
a) A SARA score of 5 ≤ X ≤ 33 points (out of 40)  
AND 
b) Either: 
i. 
Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale   
OR  
ii. 
Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) 
(SCAFI subtest) in 20 ≤ X ≤150 seconds. 
8. Weight ≥15 kg at screening. 
9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of 
NPC, 
including 
those 
on 
the 
prohibited 
medication 
list. 
Non-prohibited 
medications/therapies (e.g. miglustat, concomitant speech therapy, and physiotherapy) are 
permitted provided: 
a) The Investigator does not believe the medication/therapy will interfere with the study 
protocol/results 
b) Patients have been on a stable dose/duration and type of therapy for at least 42 days 
before Visit 1 (Baseline 1)  
c) Patients are willing to maintain a stable dose/do not change their therapy throughout the 
duration of the study. 
10. An understanding of the implications of study participation, provided in the written patient 
information and informed consent by patients or their legal representative/parent, and 
demonstrates a willingness to comply with instructions and attend required study visits (for 
children this criterion will also be assessed in parents or appointed guardians).  
Exclusion Criteria: 
A patient will not be included in this study if one or more of the following criteria apply: 
1. Asymptomatic patients 
2. Patient has clinical features of NPC and a positive biomarker screen and/or filipin test, but 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 98 of 161 
Version 7.0, 10 Oct 2022 
a negative result on a previous genetic test for NPC 
3. Patients who have any of the following: 
a) Chronic diarrhea; 
b) Unexplained visual loss; 
c) Malignancies; 
d) Insulin-dependent diabetes mellitus. 
e) Known history of hypersensitivity to Acetyl-Leucine (DL-, L-, D-) or derivatives. 
f) History of known hypersensitivity to excipients of Ora-Blend® (namely sucrose, 
sorbitol, 
cellulose, 
carboxymethylcellulose, 
xanthan 
gum, 
carrageenan, 
dimethiconne, methylparaben, and potassium sorbate). 
4. Simultaneous participation in another clinical study or participation in any clinical study 
involving administration of an investigational medicinal product (IMP; ‘study drug’) within 
42 days prior to Visit 1. 
5. Patients with a physical or psychiatric condition which, at the investigator’s discretion, may 
put the patient at risk, may confound the study results, or may interfere with the patient’s 
participation in the clinical study.  
6. Known clinically-significant (at the discretion of the investigator) laboratories in 
hematology, coagulation, clinical chemistry, or urinalysis, including, but not limited to: 
a. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5x upper 
limit of normal (ULN); 
b. Total bilirubin >1.5x ULN, unless Gilbert’s syndrome is present in which case total 
bilirubin >2x ULN. 
7. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol. 
8. Current or planned pregnancy or women who are breastfeeding. 
9. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing 
aids) that, at the investigator’s discretion, interferes with their ability to perform study 
assessments. 
10. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting 
joints, muscles, ligaments, and/or nerves that by themselves affects patient’s mobility and, 
at the investigator’s discretion, interferes with their ability to perform study assessments. 
11. Patients unwilling and/or not able to undergo a 6-week washout period from any of the 
following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited 
medication through Visit 6. 
a) Aminopyridines (including sustained-release form); 
b) N-Acetyl-DL-Leucine (e.g. Tanganil®); 
c) N-Acetyl-L-Leucine (prohibited if not provided as IMP); 
d) Riluzole; 
e) Gabapentin; 
f) Varenicline; 
g) Chlorzoxazone; 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 99 of 161 
Version 7.0, 10 Oct 2022 
h) Sulfasalazine; 
i) Rosuvastatin. 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 100 of 161 
Version 7.0, 10 Oct 2022 
IMP, Dose and Mode of Administration: 
N-Acetyl-L-Leucine is a powder for oral suspension, being investigated for the treatment of NPC. 
The study drug contains no excipients. 
The study drug is formulated as 1000 mg Powder for suspension in 40 mL Ora-Blend® and oral 
administration. The suspension vehicle Ora-Blend® contains the following excipients: purified 
water, sucrose, glycerin, sorbitol, flavoring, microcrystalline cellulose, carboxymethylcellulose 
sodium, xanthan gum, carrageenan, calcium sulfate, trisodium phosphate, citric acid and sodium 
phosphate as buffers, dimethicone antifoam emulsion, preserved with methylparaben and 
potassium sorbate. 
The 40 mL of Ora-Blend® will be combined into the powder and must be shaken vigorously for 
2 minutes so that it fully mixes before being administered.  
During the treatment period of this study, the dosing of the study drug is as follows: 
o Adults and children aged ≥13 years in Europe and aged ≥18 years in the United States will 
take 4 g per day: 2 g in the morning, 1 g in the afternoon, and 1 g in the evening. 
o Children aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning 
and 1 g in the evening35. 
o Children aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 
1 g in the afternoon, and 1 g in the evening36. 
o Children aged 6-12 years weighing ≥35 kg will take 4 per day: 2 g in the morning, 1 g in 
the afternoon and 1 g in the evening (as per adults)37. 
The study drug should be taken 30 minutes before, or at least two hours after a meal. 
 
In the Extension Phase, patients will transition to taking IB1001 formulated as granules for oral 
suspension in a Sachet.  
 
Modifications to Scheduled Doses 
On visit days, patients should keep to their usual dosing schedule.  
If a patient misses a dose of study drug, the patient should wait and take the next dose according to 
the treatment schedule.  
Compliance will be assessed upon a review of the inventory of IB1001 bottles returned from 
patients.   
The patient’s total daily dose may be reduced by up to one-half of their assigned dose at the 
discretion of the investigator. 
In the event a patient turns 13 years old, or a patient aged 6-12 years old changes weight category 
over the course of the study, their daily dose will not change from the initial dosing regimen 
prescribed at Visit 2, the start of IMP.  
Study drug will be taken during the 42 days (+7 days) treatment period. After the 42 days (+7 days) 
treatment period, patients will enter a 42-day (+7 days) washout period, which includes efficacy and 
safety assessments.  
 
 
35 European Sites only 
36 European Sites only 
37 European Sites only 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 101 of 161 
Version 7.0, 10 Oct 2022 
Concomitant Medications and Therapies 
At Visit 0/Visit 1, all medication taken in the last 60 days prior to date of informed consent must be 
recorded. The current amount (in hours per week) of therapy (e.g., physiotherapy, speech therapy) 
needs to be recorded at the time of informed consent.  
Table 1 lists medications that are prohibited and must not have been used by the patient for at least 
42 days before Visit 1 (for both “naïve” and “non-naïve” patients). Medication not listed in this 
table will be permitted, at the discretion of the investigator, as long as there is no interference with 
the study objectives or patient’s safety. Doses of medications and therapies used for (the symptoms) 
NPC should remain as constant as possible (at the investigator’s discretion) throughout the trial.  
Table 1: 
Prohibited Medications 
Prohibited medication 
Washout prior to treatment 
Aminopyridines (including sustained-release form) 
42 days 
N-Acetyl-DL-Leucine (e.g. Tanganil®) or N-Acetyl-L-
Leucine (if not provided as study drug during the study) 42 days 
Riluzole 
42 days 
Gabapentin 
42 days 
Varenicline 
42 days 
Chlorzoxazone  
42 days 
Sulfasalazine 
42 days 
Rosuvastatin 
42 days 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 102 of 161 
Version 7.0, 10 Oct 2022 
Statistical Methods:  
Populations for Analysis 
• 
The Safety Analysis Set (SAF) will consist of all patients who receive at least one dose of 
study drug (N-Acetyl-L-Leucine) 
• 
The intention-to-treat analysis set (ITT) will consist of all patients in the Safety Analysis 
Set with a video recording at either Visit 1 or Visit 2 (or both) 
• 
The modified intention-to-treat analysis set (mITT) will consist of all patients in the SAF 
with a video recording at either Visit 1 or Visit 2 (or both) and one video recording at either 
Visit 3 or Visit 4 (or both). 
• 
The Per Protocol Set (PPS) will consist of all patients with video recordings at baseline 
(Visit 1 or Visit 2), end of treatment (Visit 3 or Visit 4), and end of washout (Visit 5 or 
Visit 6) and without any major protocol deviations that could have influenced the validity 
of the data for the primary efficacy variable. 
 
Statistical analysis will be performed using SAS; the version used will be specified in the SAP. 
All variables will be summarized using descriptive statistics. The number of patients, mean, standard 
deviation (SD), minimum, median, and maximum will be calculated for continuous and score 
variables. Frequency tables will be generated for categorical data. 
A one-sided significance level of 5% will be used throughout for all endpoints as a guide for 
evidence for activity. Conclusions regarding treatment efficacy will not solely rely on detecting 
statistical significance with equal emphasis placed on the magnitude and clinical relevance of 
treatment differences as judged by the point estimates. 
No correction for multiple comparisons will be included.  
 
Primary Endpoint  
The primary endpoint for the study is based on blinded raters’ Clinical Impression of Change in 
Severity (CI-CS) comparing videos showing the patient’s change in performance over 6 weeks on 
a pre-defined anchor clinical symptom scale: either the 9 Hole Peg Test of the Dominant Hand 
(9HPT-D) or the 8 Meter Walk Test (8MWT). 
The comparison of the Visit 4 video with the Visit 2 video and the comparison of the Visit 6 video 
with the Visit 4 video will provide the scores that contribute to the primary endpoint. Each of these 
comparisons will score change on a 7-point Likert scale (+3=significantly improved to -3= 
significantly worse).  
During the pre-treatment period, the treating physician will evaluate each patient’s clinical 
symptoms and select, at Visit 1, either the 9HPT-D or 8MWT as the primary anchor around which 
the CI-CS assessment will be scored. A cognitive assessment should be performed at Visit 1 
according to standard procedures of the clinical site to assist with the selection of the anchoring 
functional test appropriate for each patient from both a cognitive and a motor perspective. 
The primary evaluation of the CI-CS will be performed by two independent raters whose 
assessments will be based on videos of the anchor test taken at each visit. These raters will be blinded 
to the treatment periods (baseline, treatment, or washout) to reduce detection and performance bias.  
The primary endpoint is defined as the CI-CS comparing end of treatment with N-Acetyl-L-Leucine 
(Visit 4) with baseline (Visit 2) minus the CI-CS comparing the end of washout (Visit 6) with the 
end of treatment with N-Acetyl-L-Leucine (Visit 4) based on the primary anchor test.  
The CI-CS assessment will instruct the blinded rater to consider: ‘compared to the first video, how 
has the severity of their performance on the 9HPT-D or 8MWT changed (improved or worsened) in 
6-weeks as observed in the second video?’ 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 103 of 161 
Version 7.0, 10 Oct 2022 
Each video pairing (CI-CS) will be read by the two independent raters, and the appropriate 
Likert scale score will be entered onto the eCRF. If there is a difference of one (1) point in the 
two primary blinded reviewers’ CI-CS scores for a specific video pairing, the two scores will 
be averaged. If there is difference greater than one (1) point between the two primary blinded 
reviewers’ CI-CS scores for a specific video pairing, an adjudication read will be triggered. In 
such cases, a third blinded reviewer will review the scores given from each of the two primary 
independent reviewers and determine which score is more accurate, that of reviewer A or 
reviewer B (adjudication by consensus). The adjudicator's decision will be the final score for 
that video assessment.  
The statistical analysis of this endpoint will utilize a single sample t-test comparing the mean value 
of the primary endpoint with zero. This endpoint allows the effect N-Acetyl-L-Leucine to be 
measured both in terms of improvement during treatment followed by any deterioration once 
treatment is removed. 
Secondary Endpoints 
Supportive secondary endpoints will be evaluated that directly supplement the analysis of the 
primary endpoint as follows: 
 
• 
The CI-CS for end of treatment with N-Acetyl-L-Leucine (Visit 4) versus baseline (Visit 2) 
and end of washout (Visit 6) versus end of treatment with N-Acetyl-L-Leucine (Visit 4) will 
each be summarized descriptively. 
• 
Improvement in the primary and non-primary anchor test measure will be evaluated based 
on the change in the blinded raters’ Clinical Impression of Severity (CI-S) between baseline 
(average for Visit 1 and Visit 2) and end of treatment with N-Acetyl-L-Leucine (average 
for Visit 3 and Visit 4) minus the change in CI-S between end of treatment with N-Acetyl-
L-Leucine (average for Visit 3 and Visit 4) and end of washout (average for Visit 5 and 
Visit 6). The statistical analysis for the primary anchor test CI-S endpoint will be as for the 
analysis of the primary endpoint. There will be no formal statistical testing of the non-
primary anchor test for the CI-S endpoint. 
• 
Sensitivity measurement of change in performance on either the 9HPT-D or the 8MWT on 
a 3-point scale. Using the CI-CS outcome for the primary anchor test based on the data for 
Visits 2 and Visit 4, any patient given a score of -1, -2, or -3 on the CI-CS will be classified 
as worsened (<0). Any patient classified as 0 on the CI-CS will be classified no change (0). 
Any patient given a score of +1, +2, +3 on the CI-CS will be classified as improved (>0).  
• 
An evaluation of the CI-CS for the test (9HPT-D or 8MWT) that was not selected as the 
primary anchor test will also be undertaken. This will enable the separate analysis of CI-CS 
for both the 9HPT-D and the 8MWT.  
Each individual video (CI-S) will also be read by the two independent raters. For the CI-S, if there 
is one (1) point or more in the two blinded reviewers scores, the two scores will still be averaged.  
Additional secondary endpoints will investigate other measures of symptoms and quality of life. 
Descriptive statistics will be provided for these measures at each visit and also changes from 
baseline (Visit 2) to the end of treatment with N-Acetyl-L-Leucine (Visit 4), as well as end of 
treatment with N-Acetyl-L-Leucine (Visit 4) to the end of post-treatment washout (Visit 6) for the 
following measures: 
 
• 
Spinocerebellar Ataxia Functional Index (SCAFI)38 
• 
Scale for Assessment and Rating of Ataxia (SARA) score 
 
 
38The 9-hole Peg Test of the Dominant Hand (9HPT-D) and the 8-meter Walk Test (8MWT), will be videoed for 
every patient at every visit, except Visit 0. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 104 of 161 
Version 7.0, 10 Oct 2022 
• 
Quality of Life EQ-5D-5L for patients aged ≥18; EQ-5D-Y39 for children aged <18 years 
(visual analogue scale; descriptive system) 
• 
Modified Disability Rating Scale (mDRS) 
• 
Treating Physician Clinical Global Impression of Severity (CGI-S) at every visit  
• 
Treating Physician Clinical Global Impression of Change (CGI-C) comparing end of 
treatment (Visit 4) to baseline (Visit 2), and end of washout (Visit 6) to end of treatment 
(Visit 4) 
• 
Caregiver Clinical Global Impression of Severity (CGI-S) at every visit  
• 
Caregiver Clinical Global Impression of Change (CGI-C) comparing end of treatment 
(Visit 4) to baseline (Visit 2), and end of washout (Visit 6) to end of treatment (Visit 4) 
• 
Patient Clinical Global Impression Scales Impression of Severity (CGI-S) at every visit if 
they are able 
• 
Patient Clinical Global Impression of Change (CGI-C) comparing end of treatment (Visit 4) 
to baseline (Visit 2), and end of washout (Visit 6) to end of treatment (Visit 4) if they are 
able 
 
The SARA total score, the SCAFI total score, the individual SCAFI subtests: 9 Hole Peg Test with 
the Dominant Hand (9HPT-D), 8 Meter Walk Test (8MWT), and PATA test, will be evaluated 
statistically based on a single sample t-test or a single sample Wilcoxon Signed Rank test. 
 
The individual SCAFI subtest: 9 Hole Peg Test with Nondominant hand (9HPT-ND), and the mDRS 
will be evaluated descriptively. 
 
All CGI-S measures, and caregiver and patient CGI-C measures will be summarised descriptively. 
The physician’s CGI-C measures will be analysed as for the CI-CS primary endpoint. 
 
The measures of the two indices (-5L and -Y) of the EQ-5D descriptive system and measures of the 
two indices (-5L and -Y) of the EQ-5D visual analogue scale (VAS) will be evaluated descriptively. 
 
Exploratory Endpoints 
Sparse PK sampling will be collected to characterize the pharmacokinetics of N-Acetyl-L-Leucine 
in patients with NPC.  
 
Determination of Sample Size 
It is postulated that N-Acetyl-L-Leucine will show effectiveness in 30% of patients and this 
success rate is viewed as being clinically important. Assuming that this group of patients will have 
scores that are evenly distributed across the values 1 and 2 for the primary endpoint and further 
that the remaining 70% of patients will have scores that are evenly distributed between the values -
1, 0, and 1. The resulting mean score is 0.45 and the standard deviation (SD) for the primary 
endpoint under these assumptions is then 1.02. With 30 patients reporting on the primary endpoint, 
the study will have 76% power to detect a treatment benefit in a 5% one- sided one-sample t-test. 
 
Significance Level and Multiplicity 
A one-sided significance level of 5% will be used throughout for all endpoints as a guide for 
evidence for activity. Conclusions regarding treatment efficacy will not solely rely on detecting 
statistical significance with equal emphasis placed on the magnitude and clinical relevance of 
treatment differences as judged by the point estimates. 
No correction for multiple comparisons will be included.  
 
 
 
39 European sites only 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 105 of 161 
Version 7.0, 10 Oct 2022 
Missing Data 
The primary endpoint will utilise assessments based on single video recordings at the end baseline 
period (Visit 2), end of the treatment period (Visit 4), and end of the washout period (Visit 6). If the 
Visit 2 video is missing, the Visit 1 video will be used in its place. Similarly, if the Visit 4 and Visit 
6 videos are missing, Visit 3 and Visit 5 videos will respectively be used in their place.  
Analyses based on the mITT analysis set will utilise a last observation carried forward (LOCF) 
approach for missing at Visit 5 and Visit 6. For the primary endpoint CI-CS this implies that the CI-
CS value for Visit 4 to Visit 6 will be assigned the value 0 (stable) if both videos at Visit 5 and Visit 
6 are unavailable. 
Additional methods to deal with missing data will be detailed in the Statistical Analysis Plan 
(SAP). Any changes from the SAP will be described and justified in the Clinical Study Report. 
  
Subgroup Evaluation 
For each of the primary and additional secondary endpoints there will be separate analyses within 
key subgroups. These subgroups will be detailed in the SAP. 
 
Meta-analysis 
Separate trials will be conducted for NPC, GM2-gangliosidosis (Tay-Sachs and Sandhoff disease), 
and ataxia-telangiectasia. There will however be a series of meta-analyses that will bring together 
the data from the studies for the primary and secondary endpoints. Further details will be provided 
in a Meta-Analysis Statistical Analysis Plan (MASAP). 
 
Sparse PK sampling is exploratory/descriptive.  
 
COVID-19  
This study is conducted during the COVID-19 outbreak. Data capture decisions have been taken 
due to national, local, or site-specific restrictions imposed due to COVID-19, with the primary 
need to prioritize the safety of clinical study teams and patients, and to maintain the integrity of 
the study/data collection. 
 
The complete impact of COVID-19 on the proposed statistical analyses is unknown. The statistical 
analysis plan already contains policies for handling missing data, however. Specific items/changes 
related to COVID-19 are being detailed in a separate document to the SAP (for the Parent Study, 
Addendum 1), which will be maintained throughout the study continuation and adjusted as needed 
based on the duration and extent of the impact of the COVID-19 situation.  
 
Relevant safety related alerts/Withdrawal Criteria: 
The Data Safety Monitoring Board (DSMB), in conjunction with the study Medical Monitor and/or 
Sponsor, is responsible for the oversight of safety. For this purpose, the DSMB will receive regular 
updates of safety.  
The DSMB will review all safety data on a regular basis. The exact content of review material and 
the frequency of review will be detailed in the DSMB charter.  
The DSMB will also be involved in risk-assessments of the impact of COVID-19, and reviewing 
any guidance issued by the Sponsor in regard to the global pandemic.  The DSMB may be asked 
to give recommendations on the conduct of trial operations and protocol adjustments which may 
be required in light of COVID-19.   


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 106 of 161 
Version 7.0, 10 Oct 2022 
Patient Withdrawal 
Patients may withdraw from the study at any time at their own request without stating the reason(s) 
for withdrawal. If a patient withdraws early from the study after start of treatment an early 
termination (ET) visit should be arranged, preferably 7-14 days after the last dose of study drug. 
“Non-naïve” patients (including “naïve” patients reclassified as “non-naïve”) will be withdrawn 
from the study if their urine sample from Visit 1 (Baseline 1) detects levels of N-Acetyl-D-Leucine 
above the permitted threshold.  
The treating physician may decide that a patient should be withdrawn from the study or from the 
study drug. Reasons for withdrawal from the study or the study drug may include, but are not limited 
to, the following: 
• 
Development of any adverse event (AE), serious AE (SAE), laboratory abnormality, 
condition, intercurrent illness, injury, medical condition, or use of a medication that is likely 
to interfere with patient safety, the overall assessment, or the study procedures, such that 
continued participation in the study would not be in the best interest of the patient. 
• 
Consent withdrawal. 
• 
The patient becomes pregnant or plans to become pregnant. 
• 
Significant patient noncompliance, defined as an unwillingness to complete the procedures 
defined in the Schedule of Assessments. 
• 
Patient lost to follow-up (i.e., staff unable to contact patient after several attempts). 
• 
Investigator, Medical Monitor, and/or Sponsor decision for any other reason not listed 
above that may invalidate the results of the study or jeopardizes the health and/or safety of 
a patient. 
• 
Complications related to pandemics such as COVID-19. 
Patients who discontinue study drug prior to completing the full treatment period, should be asked 
to complete the remaining study visits as far as possible and complete safety assessments at a 
minimum. If unwilling to complete the remaining study visits, regardless of the reason for 
withdrawal, best efforts should be made to have the patient take part in early termination (ET) 
procedures, preferably 7-14 days following the last dose of the study drug, unless the patient is lost 
to follow-up or has withdrawn his/her consent to further study participation.  
References 
Bremova, T., Malinová, V., Amraoui, Y., Mengel, E., Reinke, J., Kolníková, M., et al. (2015). 
Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology, 85(16), 1368-1375. 
Cortina-Borja, M., te Vruchte, D., Mengel, E., Amraoui, Y., Imrie, J., Jones, S. A., et al. (2018). 
Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease 
type C and for recruitment to clinical trials. Orphanet Journal of Rare Diseases. 13:143. 
Mann, M. 2018. Evaluation of Acetyl-leucine analogues in Niemann-Pick disease type C (NPC) 
and other Lysosomal Storage Diseases in vitro. Study Report from IntraBio Ltd Laboratories, 
Oct. 
Patterson, M., Clayton, P., Gissen, P., Anheim, M., Bauer, P., et al. (2017). Recommendation 
for the detection and diagnosis of Niemann-Pick disease type C. An update. Neurology. 
Available from : https://doi.org/10.1212/CPJ.0000000000000399 
Platt, F. 2018. Evaluation of Acetyl-Leucine analogues in mouse models of Niemann-Pick 
disease type C (NPC) and Sandhoff disease. Study Report from Platt Laboratories, Oct. 
Schniepp, R., Strupp, M., Wuehr, M., Jahn, K., Dieterich, M., Brandt, T., et al. (2016). Acetyl-
DL-leucine improves gait variability in patients with cerebellar ataxia-a case series. Cerebellum 
Ataxias, 3, 8. 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 107 of 161 
Version 7.0, 10 Oct 2022 
Strupp, M., Teufel, J., Habs, M., Feuerecker, R., Muth, C., van de Warrenburg, B., et al. 
(2013). Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series. J. 
Neurol., 260, 2556-2561. 
 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 108 of 161 
Version 7.0, 10 Oct 2022 
13.2 
Appendix 2: List of Institutions Involved in the Study 
 
Sponsor 
 
 
 
 
 
 
 
Sponsor’s Medical Expert 
IntraBio Ltd. 
Begbroke Science Park, Begbroke Hill 
Yarnton, Oxford OX5 1PF, UK 
Tel: +44 (0) 1865 271858 
Fax: +44 (0) 2079 006607 
Professor Mallory Factor, Director 
mfactor@intrabio.com 
 
Professor Michael Strupp, MD, FRCP, FANA, FEAN 
Professor of Neurology 
Department of Neurology and German Center for 
Vertigo and Balance Disorders 
University Hospital, Munich Campus Großhadern  
Marchioninistr. 15 
81377 Munich Germany 
Tel: +49-89-4400-73678 
Fax: +49-89-4400-76673 
Michael.strupp@med.uni-muenchen.de 
 
 
 
Data Management 
 
 
 
 
 
 
Electronic Case Report Form 
(eCRF) 
LINK Medical Research 
Gjerdrumsvej 19 N-0484 Oslo  
Norway 
Tel: + 4740982493 
Priya Kulkarni 
Priya.Kulkarni@linkmedical.eu 
 
PCG Solutions  
S:t Persgatan 6 
SE – 753 20 Uppsala, Sweden  
Tel: +46 (0)704453157 
Johannes Molin 
johannes.molin@viedoc.com 
 
Medical Monitor 
 
 
 
 
PV Consultancy Ltd.  
113 Saint Georges Square Mews 
London, SW1V 3RZ, UK 
Tel: +44 (0) 7484 546479 
Dr Glyn Belcher, MA, MB, BChir, PhD, FFPM 
glynbelcher@pvconsult.co.uk 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 109 of 161 
Version 7.0, 10 Oct 2022 
Biostatistician 
 
RK Statistics 
Brook House, Mesne Lane 
Bakewell, DE45 1AL, UK 
Tel: +44 (0)1629 810093 
Dr Richard Kay, PhD 
richard.kay@rkstatistics.com 
 
Adverse Event Reporting 
PrimeVigilance 
Oreskoviceva 20A, 10 000 Zagreb, Croatia 
Tel: +385 (0) 1 4628 523 
Kristina Cmrlec 
Kristina.Cmrlec@primevigilance.com 
 
Central Laboratory  
 
 
 
Eurofins Central Laboratory US  
2430 New Holland Pike, Lancaster, PA 17601, USA 
Tel: +1 717 556 7350 
Fax: +1 717 556 3888  
clinicaltrials@eurofins.com 
 
Eurofins Central Laboratory, Netherlands 
Bergschot 71, 4817 PA, Breda, The Netherlands 
Tel: +31 (0)76 572 72 72 
Fax:  +31 (0)76 573 77 78 
clinicaltrials@eurofins.com 
 
 
PK laboratory 
 
 
 
 
 
 
 
PK Modeling 
 
 
 
 
 
 
 
IMP Manufacturing 
 
 
 
 
 
 
 
Analytisches Zentrum Biopharm Berlin GmbH 
Bitterfelder Strasse 19 
12681 Berlin Germany 
Tel: +49 30 936520  
Fax: +49 (30) 93 65 2200 
Dr Martin Reinsch 
m.reinsch@az-biopharm.de 
 
ThinkQ2 
Oberneuhofstrasse 5 
6340 Baar Switzerland 
Tel: +41 79 870 1999 
Dr Thomas Wagner 
thomas.wagner@thinkq2.com 
 
 
Patheon UK Limited,  
151 Milton Park, Abingdon 
Oxfordshire OX14 4SD, United Kingdom  
Tel: +441235 433028 
Stewart Raven 
stewart.raven@patheon.com 
 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 110 of 161 
Version 7.0, 10 Oct 2022 
 
 
 
 
 
 
 
 
 
 
IMP Packaging, Labeling, 
Distribution 
 
 
Patheon France S.A.S. 
40 Boulevard de Champaret 
CS 11006 
Bourgoin Jallieu, 38 300, France 
Tel: +33 4 7493 8700 
Fax: +33 4 7493 8781 
Name Didier Rumeau 
Email: didier.rumeau@thermofisher.com 
 
 
Fisher Clinical Services UK Ltd,  
Langhurstwood Road, Horsham 
West Sussex, RH12 4QD, United Kingdom 
Tel: +441403 224311 
Name: Karen Witten 
Email: Karen.Witten@thermofisher.com 
 
 
Fisher Clinical Services GmbH,  
Im Woerth 3,  
79576 Weil am Rhein, Germany 
Tel: +41 61 485 23 00 
Name: Karen Witten 
Email: Karen.Witten@thermofisher.com 
 
 
Videotaping 
Medpace Core Laboratories 
5375 Medpace Way 
Cincinnati, OH  45227 
United States 
Victoria Baker 
v.baker@medpace.com 
+1.513.579.9911 


IntraBio Ltd. 
Study Code: IB1001-201 
EUDRACT NUMBER: 2018-004331-71 
IND NUMBER: 134369 
 
CONFIDENTIAL 
 
Page 111 of 161 
Version 7.0, 10 Oct 2022 
13.3 Appendix 3: Schedule of Events 
 


 
CONFIDENTIAL 
 
Page 112 of 161 
Version 7.0, 10 Oct 2022 
Period 
Baseline Period 
Treatment Period 
Wash-Out Period 
Early Term. 
Duration of the whole period 
1 Day 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening/Bsl 1 
Baseline 2 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -14 
Day 1, Start IMP 
Day 28 
Day 42 
Day 70 
Day 84 
XX 
Visit Window allowed 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+ 7days  
na 
Appendix 3A – Schedule of Events for “Naïve” Patients 
Patient information and informed consent 
process  
X 
 
 
 
 
X19 
 
Inclusion / exclusion criteria 
X 
X 
 
 
 
X19 
 
Patient weight and height measurements 
X 
 
 
 
 
 
 
Confirmation prohibited medications have 
not been used in the past 42 days 
X 
X3,4 
 
 
 
 
 
Classify patient as “Naïve” or “Non-naïve” 
X 
 
 
 
 
 
 
Patient demographics (in accordance with 
local regulations) 
X 
 
 
 
 
 
 
Relevant medical history 
X 
 
 
 
 
 
 
60-Day drug history 
X 
 
 
 
 
 
 
Documentation of therapy 
X 
X 
X 
X 
X 
X 
X 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
12-lead electrocardiogram (ECG)5 
X 
 
X 
 
X 
 
X 
Urine test for N-Acetyl-D-Leucine6 
X7 
X 
 
 
X 
X 
X 
Blood safety laboratory tests8 
X 
X 
X 
X 
X 
X 
X 
Follicle stimulating hormone serum 8, 9 
X 
 
 
 
 
 
 
Urinalysis 8 
X 
X 
X 
X 
X 
X 
X 
Urine by dipstick for pregnancy test10 
 
X 
 
X 
 
X 
X 


 
CONFIDENTIAL 
 
Page 113 of 161 
Version 7.0, 10 Oct 2022 
Period 
Baseline Period 
Treatment Period 
Wash-Out Period 
Early Term. 
Duration of the whole period 
1 Day 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening/Bsl 1 
Baseline 2 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -14 
Day 1, Start IMP 
Day 28 
Day 42 
Day 70 
Day 84 
XX 
Visit Window allowed 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+ 7days  
na 
 
Blood sample for sparse PK 6 
X 
X 
X 
X 
X 
X 
X 
Quality of Life EQ-5D-5L for patients aged 
≥18; EQ-5D-Y11 for children aged <18 years 
X 
X 
X 
X 
X 
X 
X 
Scale for Ataxia Rating (SARA) 
X 
X 
X 
X 
X 
X 
X 
Modified Disabling Rating Score (mDRS) 
X 
X 
X 
X 
X 
X 
X 
Niemann-Pick Disease type C Clinical 
Severity Scale (NPC-CSS) 
X 
 
 
 
 
 
 
Scale for Spinocerebellar Ataxia Functional 
Index (SCAFI)12  
X 
X 
X 
X 
X 
X 
X 
Cognitive assessment according to standard 
procedures of the clinical site 
X 
 
 
 
 
 
 
Determination of CI-CS Primary Anchor 
Test (9HPT-D or 8MWT) 
X 
 
 
 
 
 
 
Clinical Global Impression of Severity 
(CGI-S) by Physician 
X 
X 
X 
X 
X 
X 
X 
Clinical Global Impression of Severity 
(CGI-S) by Caregiver 
X 
X 
X 
X 
X 
X 
X 
Clinical Global Impression of Severity 
(CGI-S) by Patient13 
X 
X 
X 
X 
X 
X 
X 
Clinical Global Impression of Change  
(CGI-C) by Physician 
 
 
 
X 
 
X 
X 
Clinical Global Impression of Change  
(CGI-C) by Caregiver 
 
 
 
X 
 
X 
X 
Clinical Global Impression of Change 
(CGI-C) by Patient13 
 
 
 
X 
 
X 
X 


 
CONFIDENTIAL 
 
Page 114 of 161 
Version 7.0, 10 Oct 2022 
Period 
Baseline Period 
Treatment Period 
Wash-Out Period 
Early Term. 
Duration of the whole period 
1 Day 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening/Bsl 1 
Baseline 2 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -14 
Day 1, Start IMP 
Day 28 
Day 42 
Day 70 
Day 84 
XX 
Visit Window allowed 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+ 7days  
na 
1 If the patient’s eligibility is confirmed and their urine screen for N-Acetyl-D-Leucine is below the permitted threshold. The next visit, Visit 2, should be planned 14 days (+7 days) from Visit 1.  
2 All assessments must be done pre-dose 
3 At Visit 2, confirm no prohibited medications since Visit 1  
4 If the patient (or caregiver) states the patient has been using prohibited medication at Visit 2, they will be classified as non-compliant and withdrawn from the study 
5 If feasible, repeat assessments performed at treating physician’s discretion if clinically significant results at Visit 3 
6 To be analyzed at PK lab 
7 If the patient’s urine sample unexpectedly detects levels of N-Acetyl-D-Leucine above the permitted threshold, they will (provided eligible) switch to “non-naïve” 
8 To be analyzed at the central lab 
9 Only for post-menopausal women of non-child bearing potential with amenorrhea for at least 1 year prior to the first dose (and have not undergone sterilization procedures at least 6 months prior to the first dose) 
10 Only for women of childbearing potential; done at site  
11 In Europe only 
12 Two subtests, the 9-hole Peg Test of the Dominant Hand (9HPT-D) and 8-meter Walk Test (8MWT) will be videoed in a standardized format at every visit (except Visits 0). 
13 If the patient is able to provide the CGI-S/C 
14 Any concomitant medication needs to be recorded, used or not used for (symptoms of) NPC since the last 60 days prior to date of informed consent, up to End of Study / ET 
15 If needed 
16 Patient should not have used any of the prohibited concomitant medication 42 days prior to first dose of study drug, and have had a urine screen for N-Acetyl-D-Leucine below the permitted threshold prior to first dose 
of study drug. 
17 If feasible 
18 Or after the Visit if IMP is returned via courier 
19 If Investigator determines continued treatment with IB1001 in patient’s best interest, and patient would like to participate in the optional Extension Phase, task performed for continuation into the Extension Phase 
General note: due to COVID-19, deviations from the schedule of visits and assessments may be necessary, i.e. visits may be skipped, postponed, or performed remotely. See Section 3.1.2 for 
details
Medication History: Confirm if N-Acetyl-
Leucine ever used for “naïve” patients 
 
 
 
 
 
X 
X 
Documentation of concomitant medication14 
X 
X 
X 
X 
X 
X 
X 
Documentation of AEs 
X 
X 
X 
X 
X 
X 
X 
Dispensing of study drug 
 
X 
X15 
 
 
 
 
Intake of study drug at site 
 
X16 
 
 
 
 
 
Return of study drug 
 
 
X 
X 
 
 
X 
Study drug compliance check 
 
 
X17 
X18 
 
 
X18 


 
CONFIDENTIAL 
 
Page 115 of 161 
Version 7.0, 10 Oct 2022 
 
Study Run-In 
Baseline Period  
Treatment Period 
Wash-Out Period 
Early Term. 
Screening 
visit 
Pre-
treatment 
Washout 
Duration of the whole period 
1 Day 
6 Weeks 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 0 
 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening 
 
Baseline 1 
Baseline 2/ 
Start IMP 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -56 
 
Day -14 
Day 1 
Day 28 
Day 42 
Day 70 
Day 84 
na 
Visit Window allowed 
na 
 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+7 days 
na 
Appendix 3B: Schedule of Events for “Non-naïve” Patients 
Patient information and informed 
consent process  
X 
 
 
 
 
 
 
 
 
Inclusion / exclusion criteria 
X 
 
X 
X 
 
 
 
X19 
 
Patient weight and height 
measurements 
X 
 
 
 
 
 
 
X19 
 
Confirmation prohibited 
medications have not been used in 
the past 42 days at Visit 1/since 
Visit 1 for Visit 2 
 
 
X 
X3 
 
 
 
 
 
Confirmation prohibited 
medications have been used within 
past 42 days4 
X 
 
 
 
 
 
 
 
 
Classify patient as “Naïve” or 
“Non-naïve” 
X 
 
 
 
 
 
 
 
 
Patient demographics (in 
accordance with local regulations) 
X 
 
 
 
 
 
 
 
 
Relevant medical history 
X 
 
 
 
 
 
 
 
 
60-Day drug history 
X 
 
 
 
 
 
 
 
 
Documentation of therapy 
X 
 
X 
X 
X 
X 
X 
X 
X 
Vital signs 
X 
 
X 
X 
X 
X 
X 
X 
X 
12-lead electrocardiogram (ECG)5 
 
 
X 
 
X 
 
X 
 
X 


 
CONFIDENTIAL 
 
Page 116 of 161 
Version 7.0, 10 Oct 2022 
 
Study Run-In 
Baseline Period  
Treatment Period 
Wash-Out Period 
Early Term. 
Screening 
visit 
Pre-
treatment 
Washout 
Duration of the whole period 
1 Day 
6 Weeks 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 0 
 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening 
 
Baseline 1 
Baseline 2/ 
Start IMP 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -56 
 
Day -14 
Day 1 
Day 28 
Day 42 
Day 70 
Day 84 
na 
Visit Window allowed 
na 
 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+7 days 
na 
 
Urine Test for N-Acetyl-D-
Leucine6 
 
 
X7 
X 
 
 
X 
X 
X 
Blood safety laboratory tests8  
 
 
X 
X 
X 
X 
X 
X 
X 
Follicle stimulating hormone 
serum9 
 
 
X 
 
 
 
 
 
 
Urinalysis8 
 
 
X 
X 
X 
X 
X 
X 
X 
Urine by dipstick for pregnancy 
test10 
 
 
 
X 
 
X 
 
X 
X 
Blood sample for sparse PK6 
 
 
X 
X 
X 
X 
X 
X 
X 
Quality of Life EQ-5D-5L for 
patients aged ≥18 years; EQ-5D-Y11 
for children aged <18 years  
 
 
X 
X 
X 
X 
X 
X 
X 
Scale for Ataxia Rating (SARA) 
X 
 
X 
X 
X 
X 
X 
X 
X 
Modified Disabling Rating Score 
(mDRS) 
 
 
X 
X 
X 
X 
X 
X 
X 
Niemann-Pick Disease type C 
Clinical Severity Scale (NPC-CSS) 
 
 
X 
 
 
 
 
 
 
Scale for Spinocerebellar Ataxia 
Functional Index (SCAFI)12 
X 
 
X 
X 
X 
X 
X 
X 
X 
Cognitive assessment according to 
standard procedures of the clinical 
site 
 
 
X 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
Page 117 of 161 
Version 7.0, 10 Oct 2022 
 
Study Run-In 
Baseline Period  
Treatment Period 
Wash-Out Period 
Early Term. 
Screening 
visit 
Pre-
treatment 
Washout 
Duration of the whole period 
1 Day 
6 Weeks 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 0 
 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening 
 
Baseline 1 
Baseline 2/ 
Start IMP 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -56 
 
Day -14 
Day 1 
Day 28 
Day 42 
Day 70 
Day 84 
na 
Visit Window allowed 
na 
 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+7 days 
na 
 
 
 
Determination of CI-CS Primary 
Anchor Test (9HPT-D or 8MWT) 
 
 
X 
 
 
 
 
 
 
Clinical Global Impression of 
Severity (CGI-S) by Physician 
 
 
X 
X 
X 
X 
X 
X 
X 
Clinical Global Impression of 
Severity (CGI-S) by Caregiver 
 
 
X 
X 
X 
X 
X 
X 
X 
Clinical Global Impression of 
Severity (CGI-S) by Patient13 
 
 
X 
X 
X 
X 
X 
X 
X 
Clinical Global Impression of 
Change (CGI-C) by Physician 
 
 
 
 
 
X 
 
X 
X 
Clinical Global Impression of 
Change (CGI-C) by Caregiver 
 
 
 
 
 
X 
 
X 
X 
Clinical Global Impression of 
Change (CGI-C) by Patient13 
 
 
 
 
 
X 
 
X 
X 
Documentation of concomitant 
medication14 
X 
 
X 
X 
X 
X 
X 
X 
X 
Documentation of AEs 
X 
 
X 
X 
X 
X 
X 
X 
X 
Dispensing of study drug 
 
 
 
X 
X15 
 
 
 
 
Intake of study drug at site 
 
 
 
X16 
 
 
 
 
 
Return of study drug 
 
 
 
 
X 
X 
 
 
X 
Study drug compliance check 
 
 
 
 
X17 
X18 
 
 
X18 


 
CONFIDENTIAL 
 
Page 118 of 161 
Version 7.0, 10 Oct 2022 
 
Study Run-In 
Baseline Period  
Treatment Period 
Wash-Out Period 
Early Term. 
Screening 
visit 
Pre-
treatment 
Washout 
Duration of the whole period 
1 Day 
6 Weeks 
2 Weeks 
6 Weeks 
6 Weeks 
1 Day 
Visit number 
Visit 0 
 
Visit 11 
Visit 22 
Visit 3 
Visit 4 
Visit 5 
Visit 6 / EOS 
ET 
Name of the Visit 
Screening 
 
Baseline 1 
Baseline 2/ 
Start IMP 
Treatment 1 
Treatment 2 
Washout 1 
Washout 2 
ET 
Timeline (Days) 
Day -56 
 
Day -14 
Day 1 
Day 28 
Day 42 
Day 70 
Day 84 
na 
Visit Window allowed 
na 
 
na 
+7 days 
+7 days 
+7 days 
+7 days 
+7 days 
na 
1 If the patient’s eligibility is confirmed and their urine screen for N-Acetyl-D-Leucine is below the permitted threshold. The next visit, Visit 2, should be planned 14 days (+7) days from Visit 1.  
2 All assessments must be done pre-dose 
3 At Visit 2, confirm no prohibited medications since Visit 1  
4 If the patient (or caregiver) states the patient has been using prohibited medication at Visit 1 or Visit 2, they will be classified as non-compliant and withdrawn from the study 
5 If feasible, repeat assessments performed at treating physician’s discretion if clinically significant results at Visit 3 
6 Analyzed at PK lab 
7 Patients whose Visit 1 urine sample detects limits of N-Acetyl-D-Leucine above the permitted threshold are classified as non-compliant and withdrawn from the study 
8 Analyzed at central lab 
9 Only for post-menopausal women of non-child bearing potential with amenorrhea for at least 1 year prior to the first dose (and have not undergone sterilization procedures at least 6 months 
prior to the first dose) 
10 Only for women of childbearing potential; done at site 
11 In Europe only 
12 At Visit 1 through Visit 6 (not Visit 0), two subtests, the 9-hole Peg Test of the Dominant Hand (9HPT-D) and 8-meter Walk Test (8MWT) will be videoed in a standardized format at every 
visit. From Visit 2, the selected anchor test (9HPT-D or 8MWT) is to be performed first, before the remaining SCAFI subsets.  
13 If the patient is able to provide the CGI-S/C 
14 Any concomitant medication needs to be recorded, used or not used for (symptoms of) NPC since the last 60 days prior screening, up to End of Study / ET 
15 If needed 
16 Patient should not have used any of the prohibited concomitant medication 42 days prior to first dose of study drug, and have had a urine screen for N-Acetyl-D-Leucine below the permitted 
threshold prior to first dose of study drug. 
17 If feasible 
18 Or after the Visit if IMP is returned via courier 
19 If Investigator determines continued treatment with IB1001 in patient’s best interest, and patient would like to participate in the optional Extension Phase, task performed for continuation into 
the Extension Phase 
General note: due to COVID-19, deviations from the schedule of visits and assessments may be necessary, i.e. visits may be skipped, postponed, or performed remotely. See Section 3.1.2 for 
details


 
 
CONFIDENTIAL 
 
Page 119 of 161 
Version 7.0, 10 Oct 2022 
13.4 Appendix 4: Rationale for the Clinical Impression of Change in Severity 
(CI-CS)  
Detailed rational for the development, administration, and scoring of the primary 
Clinical Impression of Change in Severity (CI-CS) endpoint is located in the 
supplementary document “Clinical Impression of Change in Severity.  Administration 
and Scoring Manual” [Fields, 2020]. 
 
 


 
 
CONFIDENTIAL 
 
Page 120 of 161 
Version 7.0, 10 Oct 2022 
13.5 Appendix 5: Protocol Amendment History 
 
The Protocol Amendment Summary of Changes is located in the supplementary 
document, “IB1001-201 Protocol Summary of Changes Version 2.0, 10-OCT-2022”. 
An overview of the Protocol Version history is located directly before the Table of 
Contents (TOC). 


 
 
CONFIDENTIAL 
 
Page 121 of 161 
Version 7.0, 10 Oct 2022 
13.6 Appendix 6: Extension Phase 
 
 


 
 
CONFIDENTIAL 
 
Page 122 of 161 
Version 7.0, 10 Oct 2022 
1 
Introduction – Extension Phase 
This Extension Phase allows patients who have completed Visit 6 of the Parent Study 
of IB1001-201 to, at the discretion of the Principal Investigator (PI), continue treatment 
with N-Acetyl-L-Leucine (IB1001) if the PI determines it is in their best interest. The 
overall design is presented in Section 3.1.240. 
 
The Extension Phase will be conducted at clinical sites that participated in the Parent 
Study, and in countries that have regulatory and ethics/institutional review board 
approval for the Extension Phase. The primary eligibility criteria for a patient to enter 
the Extension Phase is the participation and completion of the IB1001-201 study with 
IB1001.  
 
The Extension Phase will assess patients after one-year of treatment with IB1001, 
followed by a 42-day (+14 day) washout. After the 42-day Extension Phase washout 
(Visit 10), at the discretion of the Principal Investigator (PI), patients will be able to 
continue treatment with N-Acetyl-L-Leucine (IB1001) for an additional 1-year if the PI 
determines it is in their best interest. 
 
The Extension Phase will collect information on the long-term safety, tolerability, 
pharmacokinetics (PK), and efficacy of IB1001 as a treatment for NPC for the purpose 
of further assessing the risk/ benefit balance of the investigational medicinal product in 
the proposed clinical setting.  
 
1.1 
Risk/Benefit Considerations 
NPC is a rare, serious, and life-threatening indication that predominantly affects the 
pediatric population. Treatment of NPC is so-far limited to symptomatic management 
and miglustat (Zavesca™) (which is not approved in the US). Therefore, there is a 
strong need for the development of novel and more effective therapies to treat this 
disease.  
 
The active ingredient in IB1001 is N-Acetyl-L-Leucine, an acetylated derivate of a 
ubiquitously present amino acid occurring in human food. N-Acetyl-L-Leucine is also 
an endogenously generated metabolite of L-Leucine.  
 
Appropriate patient selection is one factor in considering the balance of risks of adverse 
events (AEs) against potential clinical benefit. Patients will only be considered for the 
Extension Phase, if they have completed the Parent Study and the PI determined 
continued treatment with N-Acetyl-L-Leucine to be in the patient’s best interest.  
 
Based upon the very good safety profile of N-Acetyl-L-Leucine (and N-Acetyl-DL-
Leucine) observed in animals at dose levels up to the limit dose (p.o. 2000 mg/kg/day) 
as well as knowledge of safe use of N-Acetyl-DL-Leucine in children as young as 9 
months of age [Picone, 2018], inclusion of children aged 6 years and over who took 
part in the Parent Study is judged to be safe. Women of childbearing potential and 
partners of women of childbearing potential will continue to be required to adhere to 
 
 
40 Sections referenced in Appendix 6 refer to the Appendix 6 Sections, unless otherwise indicated by 
“..of the Parent Study”  


 
 
CONFIDENTIAL 
 
Page 123 of 161 
Version 7.0, 10 Oct 2022 
strict precautions to prevent pregnancy. Women who are pregnant, breast-feeding, or 
planning to become pregnant will be excluded from the study. In addition, a negative 
pregnancy test will be a prerequisite for the inclusion of women of child bearing 
potential and urine pregnancy tests will be carried out at each visit of the Extension 
Phase.  
 
Levels of risk and burden on participants 
 
N-Acetyl-L-Leucine is being developed for the treatment of adults and children with 
NPC, a rare and ultimately fatal disorder that predominantly affects pediatric patients 
[Vanier, 2010; Utz et al, 2017]. As described in Section 1.1 of the Parent Study, 
published case series and long-term use of N-Acetyl-DL-Leucine in patients with NPC 
suggest the prospect of a direct benefit to the participating patients over standard of 
care.  
 
To ensure the feasibility of this trial, NPC clinical experts [Dr Marc Patterson, MD, 
Mayo Clinic, Professor Pediatric Neurology] and the heads of multinational NPC 
patient organizations [Dr William Evans, Chairman Nieman-Pick UK; Joslyn Crowe, 
Executive Director, National Niemann-Pick Disease Foundation, Inc.] were consulted 
and involved in its design.  
 
The degree of burden to participants in the Extension Phase is defined by the description 
of assessments in Section 7.  
 
The behavioral tests for evidence of efficacy are routinely used in the evaluation of 
NPC and are relatively fast to perform, with the individual subtests of the SCAFI rarely 
taking more than 2 minutes for patients with NPC to complete [Bremova et al, 2015]. 
The Scale for Assessment and Rating of Ataxia (SARA) takes about 15 minutes and 
the Niemann-Pick type C Clinical Severity Scale (NPC-CSS) takes about 45 minutes 
to complete [Dr Marc Patterson, MD, Mayo Clinic, Professor Pediatric Neurology]. 
The use of these tests was determined together with representatives of the patient 
community and parents of patients with NPC and Tay-Sachs disease, as being clinically 
meaningful for the patients and families and reflective of the ability to perform acts of 
everyday life safety and securely, while at the same time not being exhausting [Dr 
William Evans, Chairman Nieman-Pick UK, Personal Communication; Daniel Lewi, 
President, Cure Action for Tay-Sachs Foundation, Personal Communication]. 
 
To minimize patient fatigue, visits with PK sampling may be conducted over two days, 
with the blood draws for PK taken on the day after the behavioral tests. Topical 
anesthesia may be applied before blood sampling. The total amount of blood taken per 
subject during the Extension Phase is provided in Section 6.5.5. Patients will be ≥15 kg 
and the total blood volume taken in accordance with the maximum allowable research-
related blood sample volumes provided in the incoming EU ethical considerations for 
clinical trials on medicinal products conducted with minors [EudraLex Volume 10, 
2017].  
 
The impact of the interventions will be assessed by patient-reported outcomes 
(measurement of global impression, see Section 6.1.5 of the Parent Study), where 
feasible, and quality of life assessments (EQ-5D-5L and EQ-5D-Y, see Section 6.1.3 of 
the Parent Study).  


 
 
CONFIDENTIAL 
 
Page 124 of 161 
Version 7.0, 10 Oct 2022 
 
The investigator will monitor the degree of stress to patients and the risk threshold 
throughout the trial. Patients will be instructed to report any AEs that they experience 
to the Investigator and the Investigator will ask about the occurrence of AEs at each 
visit. As described in Section 11.6 of the Parent Study, if the Investigator (or the 
Sponsor or Medical Monitor) becomes aware of conditions or events that suggest a 
possible hazard to patients if the study continues, the clinical study may be terminated 
after appropriate consultation between the involved parties. 
 
In addition, as described in Section 11.5 of the Parent Study, the Data Safety Monitoring 
Board (DSMB), in conjunction with the study Medical Monitor and/or Sponsor, will 
monitor the level of risk on a regular basis throughout the study. The DSMB is a 
multidisciplinary group consisting of clinicians with pediatric experience and a 
biostatistician. The DSMB has been set up to safeguard the interests of study 
participants by providing an independent review of patient safety data to monitor that 
no undue harm is occurring to patients due to their participation. The DSMB may 
recommend changes in the conduct of the studies to IntraBio, if needed, to ensure the 
safety of patients in the study and the proper conduct of the studies. The DSMB may 
also recommend suspending recruitment or terminate the study early because of undue 
safety risks to patients or any issues concerning the rights of patients. For this purpose, 
the DSMB will receive regular updates of safety and review all safety data on a regular 
basis.  
 
Based upon the nature of the drug, the available non-clinical and clinical data for N-
Acetyl-L-Leucine and N-Acetyl-DL-Leucine, the current lack of effective treatments 
for NPC, and in the context of a marketed racemate, this clinical trial is concluded to 
pose acceptable levels of risk and burden on participants.  
 
Extension Phase Treatment Period II  
Protocol Amendment 6.0 introduced an additional year of dosing upon completion of 
the extension-phase washout Visit 10. Extension Phase Treatment Period II will provide 
additional information on long-term safety and tolerability of IB1001 while allowing 
patients to have further access to IB1001 for an additional one-year period. Based on 
the nature of the drug and previous non-clinical and clinical findings (as detailed in 
Section 1 of the Parent Study) and the safety profile observed in this ongoing study (and 
in other ongoing IB1001 clinical trials) to date, the risk of allowing patients who have 
completed the first year of extension-phase dosing, and who agree to continue in the 
study, is considered acceptable.  
 


 
 
CONFIDENTIAL 
 
Page 125 of 161 
Version 7.0, 10 Oct 2022 
2 
STUDY OBJECTIVES – EXTENSION PHASE 
 
All endpoints in the extension phase are considered secondary to those in the Parent 
Study. 
2.1 
Primary Objective 
The primary objective in the Extension Phase is to evaluate the efficacy of N-Acetyl-
L-Leucine based on the 5-Domain Niemann-Pick type C Clinical Severity Scale (NPC-
CSS). 
2.2 
Secondary Objectives 
The secondary objectives are: 
• To evaluate the long-term safety and tolerability of N-Acetyl-L-Leucine at 
4 g/day in patients aged ≥13 years, and weight-tiered doses in patients 6 to 
12 years of age, with NPC 
• To characterize the pharmacokinetics (PK) of N-Acetyl-L-Leucine in patients 
with NPC 
2.3 
Exploratory Objectives 
The exploratory objectives are: 
• To assess the clinical efficacy of long-term treatment with N-Acetyl-L-Leucine 
on symptoms, functioning, and quality of life for patients with NPC 
• To assess the effects of a 42-day (+14 days) washout from N-Acetyl-L-Leucine 
after one-year treatment on symptoms, functioning, and quality of life for 
patients with NPC 
 


 
 
CONFIDENTIAL 
 
Page 126 of 161 
Version 7.0, 10 Oct 2022 
3 
OVERALL DESIGN AND PLAN OF THE EXTENSION PHASE 
3.1 
Overview 
3.1.1 Trial Design/Patient Population 
This Extension Phase will enroll patients who have completed Visit 6 of the parent 
study phase of IB1001-201. Patients will be offered the opportunity to participate in 
this Extension Phase if the safety and tolerability during the 42-day (+7 days) treatment 
period of the parent study are considered to be acceptable by their Principal Investigator 
(PI) and the PI determines further treatment with IB1001 to be in the patient’s best 
interest.  
Recruitment into the Extension Phase will continue until all patients who participated 
in the parent study, and who are willing and eligible to participate in the Extension 
Phase, are enrolled.  
Section 4 contains more detailed information on the eligibility criteria for the Extension 
Phase.  
3.1.2 Study Design 
Patients will be assessed approximately 6 times over a 116-week period: at the start of 
the Extension Phase, after 6 months of treatment, 1 year of treatment, after a 42-day 
(+14 day) post-extension-phase treatment washout, after 6 months of resuming 
treatment, and after 1 year of resuming treatment. 
Section 7 contains detailed information on the study assessments and procedures that 
will be conducted at each study phase and visit.  
3.1.2.1 Baseline Visit of the Extension Phase 
Preferably, the first visit of the Extension Phase (Visit 7 Part A and Part B; Baseline 
Visit) should be conducted 1 day (+6 days) after Visit 6, the end of the parent study.  
 
The assessments comprising Visit 7 may be conducted over a two-day period (“Part A” 
and “Part B”)41. If Visit 7, Part B is scheduled 1 day (+6 days) after Visit 6 (Washout 2 
of the parent study), the assessments conducted at Visit 6 should count as Visit 7, Part 
A (i.e. the assessments do not need to be repeated). 
 
If Visit 7B cannot be scheduled 1 day (+6 days) after Visit 6, the assessments included 
in Visit 7, Part A and Visit 7, Part B may be performed over two consecutive days, i.e. 
Visit 7B occurs +1 day after Visit 7A. 
 
During Visit 7, Part B, after all efficacy assessments have been performed, the patient 
will take the first Extension-Phase dose of N-Acetyl-L-Leucine on site.  
 
3.1.2.2 Extension Phase Treatment Period I 
From Visit 7B onward, all patients will receive treatment with N-Acetyl-L-Leucine for 
365 days (+/-14 days).  
 
 
41 If Visit 7 is conducted within +7 days of Visit 6, the assessments performed at “Part A” do not need 
to be duplicated and Visit 7 will be conducted over one day only.  


 
 
CONFIDENTIAL 
 
Page 127 of 161 
Version 7.0, 10 Oct 2022 
Visit 8 will occur at Day 180 (+/-14 days). 
Visit 9, Part A will occur at Day 365 (+/-14 days). 
Visit 9, Part B should occur on the day after Visit 9, Part A 
3.1.2.3 Extension Phase Washout Period 
After Visit 9, all patients will enter a 42-day (+14 days) washout phase.  
Visit 10 will occur at Day 407 (+ 14 days) 
3.1.2.4 Extension Phase Treatment Period II 
From Visit 10 onward, all patients will receive treatment with N-Acetyl-L-Leucine 
for 365 days (+/-14 days). 
Visit 11 will occur at Day 587 (+/-14 days). 
Visit 12 will occur at Day 767 (+/-14 days). 
3.1.3 Centers 
The trial will be conducted in clinical trial centers that participated in parent study and 
continue to meet the requirements for performing the planned trial-related 
investigations. The Extension Phase will only be conducted in countries/study centers 
where regulatory and Independent Ethics Committee/Institutional Review Board 
approval has been granted for the Extension Phase. 
3.1.4 Study Duration 
The treatment and washout duration for all patients, from the first day of dosing with 
the study drug during the Extension Phase (Visit 7) to the final follow-up visit (Visit 
12), is expected to be approximately 767 days.  
3.2 
Discussion of Study Design 
3.2.1 Choice of the Primary Endpoint 
The primary endpoint in this Extension Phase is success measured on the 5-domain 
Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS) from the Extension 
Phase baseline (Visit 7) to the end of treatment in the Extension Phase (Visit 9).  
3.2.2 Choice of the Secondary Endpoints  
Full PK sampling will be conducted during the Extension Phase.  
3.2.3 Choice of the Exploratory Endpoints  
All endpoints in the Extension Phase are considered secondary to those in the Parent 
Study. 
In the parent study, the Niemann-Pick type C Clinical Severity Scale (NPC-CSS) was 
not included as an endpoint, as this measure was considered not sensitive enough to 
detect changes after 6 weeks of treatment (see Section 3.2.3 of the Parent Study). 
Given the extended duration of treatment in the Extension Phase, the NPC-CSS will be 
introduced as an endpoint, where the graduation of changes is expected to detect 
clinically relevant changes in functioning / benefit after one year of treatment.   


 
 
CONFIDENTIAL 
 
Page 128 of 161 
Version 7.0, 10 Oct 2022 
The NPC-CSS was designed to be a measure to characterize and quantify disease 
progression and is applicable to assess the long-term treatment effects of an 
interventional therapy [Yanjanin et al, 2010].  
Exploratory endpoints in this Extension Phase may also be based on the following 
timepoints: 
- 
The beginning of the Extension Phase (Visit 7) to the end of the Extension Phase 
washout period (Visit 10) 
- 
The end of the Extension Phase treatment period I (Visit 9) to the end of the 
Extension Phase washout period (Visit 10). 
- 
The end of the Extension Phase washout (Visit 10) to the end of the Extension 
Phase treatment period II (Visit 12) 
- 
The beginning of the Parent study (Visit 1) to the end of the Extension Phase 
treatment period II (Visit 12)42 
The exploratory endpoints are defined in Section 8.5.2. 
 
3.2.4 Dose/ Duration of Treatment 
The purpose of the Extension Phase is to give patients who participated in the Parent 
Study, and whose investigators believe may benefit from continued treatment with 
IB1001, the opportunity to further access N-Acetyl-L-Leucine once the parent study 
has been completed. During the Extension Phase, long-term safety and efficacy data 
will be recorded. In order to be eligible for the Extension Phase, the investigator must 
also be of the opinion that this is in the patient’s best interest.  
 
As discussed in Section 1.1, on the basis of the chemical nature of N-Acetyl-L-Leucine, 
available non-clinical and clinical evidence, and post marketing experience with the 
racemate (including compassionate use in NPC), it is considered justifiable from a 
safety point-of-view to dose for an additional year. This will provide patients continued 
access to drug while other patients complete the Parent Study and the results from the 
symptomatic study with a 6-week treatment period are generated (including the blinded 
rater review) and analyzed.  
 
3.3 
End of Study Definition 
A patient is considered to have completed the Extension Phase if he/she has completed 
all routine visits of the Extension Phase including the last visit (Visit 12). 
The end of the study (Parent Study + Extension Phase) is defined as the date of the last 
visit of the last patient in Study IB1001-201 globally. 
 
 
42 Additional exploratory analysis may be conducted to analyze change in outcome assessments over the patients’ entire duration 
of participation in the IB1001-201 clinical trial. Procedures will be defined in the statistical analysis plan (SAP).  


 
 
CONFIDENTIAL 
 
Page 129 of 161 
Version 7.0, 10 Oct 2022 
4 
STUDY POPULATION – EXTENSION PHASE 
The study population comprises patients with NPC who have completed Visit 6 of the 
parent study of IB1001-201. To be eligible, patients must satisfy the following entry 
criteria:   
4.1 
Inclusion Criteria 
1. Completed Visit 6 of the IB1001-201 Parent Study  
2. The Principal Investigator determines further treatment with IB1001 to be in 
patient’s best interest  
3. Written informed consent signed by the patient and/or their legal 
representative/parent/ impartial witness for participation in the Extension 
Phase  
4. Patients are willing to continue to remain without the following prohibited 
medication from Visit 6 throughout the duration the Extension Phase: 
a) Aminopyridines (including sustained-release form); 
b) N-Acetyl-DL-Leucine (e.g. Tanganil®); 
c) N-Acetyl-L-Leucine (prohibited if not provided as investigational 
medicinal product [IMP]); 
d) Riluzole; 
e) Gabapentin; 
f) Varenicline; 
g) Chlorzoxazone; 
h) Sulfasalazine; 
i) Rosuvastatin. 
 
4.2 
Patient Withdrawal  
Patients may withdraw from the study at any time at their own request, without stating 
the reason(s) for withdrawal. The policies/procedures for patient withdrawal are defined 
in Parent Study in Section 4.3. 
 
4.3 
Patient Identification  
Patients will be defined by their unique, seven-digit identification number assigned at 
screening of the Parent Study (see Section 4.4 of the Parent Study).  


 
 
CONFIDENTIAL 
 
Page 130 of 161 
Version 7.0, 10 Oct 2022 
5 
STUDY DRUG – EXTENSION STUDY 
5.1 
Identity 
Product: N-Acetyl-L-Leucine (internal development name: IB1001) 
Chemical name: 2(S)-(acetylamino)-4-methylpentanoic acid 
Generic name: N-Acetyl-L-Leucine 
Trade name: to be determined 
Two IMPs of equal strength and comparable dosage forms may be used during the 
Extension Phase:  
1. The original IMP approved for use in the Parent Study (“Powder for oral 
suspension”, packed in 60 mL glass bottles, see Section 5.1.1) or; 
2. The commercial formulation developed for use in the Extension Phase 
(“Granules for oral suspension in sachet”, see Section 5.1.2) 
Information on both IMPs is provided below.  
5.1.1 N-Acetyl-L-Leucine, 1000 mg powder for oral suspension in 60 mL 
glass bottles (without further excipients) 
Strength: 1000 mg per 60 mL glass bottle 
Manufacturer:  
Manufacture of dosage form, QC testing, Stability studies: 
‐ 
Patheon UK Limited,  
151 Milton Park, Abingdon, Oxfordshire OX14 4SD, United Kingdom  
 
Secondary packaging, Labelling, IMP release, Clinical distribution  
‐ 
Fisher Clinical Services UK Ltd,  
Langhurstwood Road, Horsham, West Sussex, RH12 4QD, United Kingdom 
‐ 
Fisher Clinical Services GmbH,  
Im Woerth 3, 79576 Weil am Rhein, Germany 
 
Description: 
The product is formulated as 1000 mg powder for oral suspension, to be suspended in 
40 mL Ora-Blend®.  
The suspension vehicle Ora-Blend® contains the following excipients: 
- 
purified water 
- 
sucrose 
- 
glycerin  
- 
sorbitol  
- 
flavoring 
- 
microcrystalline cellulose 
- 
carboxymethylcellulose sodium 
- 
xanthan gum 
- 
carrageenan 
- 
calcium sulfate 


 
 
CONFIDENTIAL 
 
Page 131 of 161 
Version 7.0, 10 Oct 2022 
- 
trisodium phosphate 
- 
citric acid and sodium phosphate as buffers 
- 
dimethicone antifoam emulsion 
- 
preserved with methylparaben and potassium sorbate 
 
Preparation before administration: 
The 40mL of Ora-Blend® will be combined into the powder and must be shaken 
vigorously for 2 minutes so that it fully mixes before being administered.  
 
5.1.2 N-Acetyl-L-Leucine, 1000 mg Granules for oral suspension in sachet 
Strength: 1000 mg per sachet 
Manufacturer:  
Manufacture of dosage form, QC testing, Stability studies: 
‐ 
Patheon UK Limited,  
151 Milton Park, Abingdon, Oxfordshire OX14 4SD, United Kingdom  
‐ 
Patheon France S.A.S. 
40 Boulevard de Champaret, Bourgoin Jallieu, 38 300, France 
 
Secondary packaging, Labelling, IMP release, Clinical distribution  
‐ 
Fisher Clinical Services UK Ltd,  
Langhurstwood Road, Horsham, West Sussex, RH12 4QD, United Kingdom 
‐ 
Fisher Clinical Services GmbH,  
Im Woerth 3, 79576 Weil am Rhein, Germany 
 
Description: 
The product is formulated as 1000 mg granules for oral suspension in sachet. 
The granules for oral suspension contain the following excipients:   
- 
Isomalt  
- 
Hypromellose  
- 
Strawberry Flavour  
Strawberry flavour contains natural flavouring substances, flavouring preparations, and 
carrier additives. 
 
Preparation before administration:  
One sachet should be suspended (poured) into 40 mL water (i.e., approximately 
quarter of a glass of water). The granules should be fully suspended (fully mixed) 
before being consumed (swallowed as a drink).  
 
5.2 
Administration 
All patients are to receive N-Acetyl-L-Leucine (IB1001). 


 
 
CONFIDENTIAL 
 
Page 132 of 161 
Version 7.0, 10 Oct 2022 
See Section 5.1.1 and Section 5.1.2 for instructions regarding preparation before 
administration for the powder for oral suspension and the granules for oral suspension, 
respectively.  
The study drug should be taken 30 minutes before, or at least two hours after a meal. 
During the treatment period of this Extension Phase, the dosing of the study drug is as 
follows: 
• Patients aged ≥13 years will take 4 g per day: 2 g in the morning, 1 g in the 
afternoon, and 1 g in the evening. 
• Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the 
morning and 1 g in the evening. 
• Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the 
morning, 1 g in the afternoon, and 1 g in the evening. 
• Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the 
morning, 1 g in the afternoon, and 1 g in the evening (as per patients aged ≥13). 
Study drug will be taken during the two 365-day (+/- 14 days) treatment periods. The 
patient’s dose for the extension treatment phase will be determined based on their age 
and weight at Visit 7. In the event a patient turns 13 years old or a patient aged 6-12 
years old changes weight categories between Visit 7 and Visit 8 of the Extension Phase, 
their daily dose will be adjusted accordingly at Visit 8. In the event a patient turns 
13 years old or a patient aged 6-12 years old changes weight categories between Visit 8 
and Visit 10, or Visit 10 and Visit 11 of the Extension Phase, their daily dose will be 
adjusted accordingly at Visit 10 or Visit 11. 
5.3 
Modification of Dose Schedule and Transition to Sachet Formulation 
5.3.1 Modification of Dose  
On visit days, patients should keep to their usual dosing schedule, except for Visit 9B, 
which is a PK day. 
If a patient misses a dose of study drug, the patient should wait and take the next dose 
according to the treatment schedule.  
Compliance will be assessed upon a review of the inventory of IB1001 bottles/sachets 
returned by patients.   
The patient’s total daily dose may be reduced by up to one-half of their assigned dose 
at the discretion of the investigator. 
At Visit 8, Visit 10, or Visit 11, the patient’s daily dose may be modified if a patient 
aged 6-12 years turned 13 or if a patient aged 6-12 years changed weight category since 
the previous visit (see Section 5.2).  
During the Extension Phase treatment period I, study drug will be taken for 365 days 
(+/- 14 days). After the 365-day (+/- 14 days) extension phase treatment period I, 
patients will enter a 42-day (+14 days) extension phase washout period, which includes 
efficacy and safety assessments. During the Extension Phase treatment period II 
(starting at the end of the extension phase washout), study drug will then be taken for 
an additional 365 days (+/- 14 days). 
See Section 5.9 for information on the treatment of overdose.  


 
 
CONFIDENTIAL 
 
Page 133 of 161 
Version 7.0, 10 Oct 2022 
5.3.2 Transition from IB1001 in Bottles to Sachet Formulation 
It is planned that all patients will receive the sachet formulation for the duration of the 
Extension Phase treatment period (see Section 5.1.2).  
Patients may receive IB1001 in bottles at the beginning of the Extension Phase 
treatment period depending on the availability of the sachet supply (see 
Section 5.1.1). In this event, patients will transition to the sachet formulation at the 
instruction of the Investigator during the Extension Phase. To receive the sachet 
formulation, patients should visit the study site for an unscheduled visit to be trained 
on how to administer the sachet formulation.  At this visit, all used, partially used, or 
unused kits (IB1001 bottles and Ora-Blend® bottles) should be returned to the study 
site43. 
Due to the outbreak of COVID-19, there is a great need to minimize immediate risks 
and prioritize the safeguarding of patients, their families, and clinical study teams by 
minimizing all potential exposure to COVID-19. 
 
Accordingly, if necessary, instead of attending the study site for this unscheduled 
visit, patients may be trained remotely on how to prepare the sachet formulation. In 
this event, the addendum to the informed consent regarding the sachet formulation 
may also be performed remotely.  
 
5.4 
Packaging, Labeling and Storage 
The IB1001 bottle and sachet formulations will be packaged by Fisher Clinical Services 
UK Ltd (Langhurstwood Road, Horsham, West Sussex, RH12 4QD, United Kingdom) 
or by Fisher Clinical Services GmbH (Im Woerth 3, 79576 Weil am Rhein, Germany), 
according to all local legal requirements. Study drug will be labelled in accordance with 
applicable regulatory requirements.  
All study drug supplies must be stored in accordance with the manufacturer’s 
instructions. Until dispensed to the patients, the study drug will be stored in a securely 
locked area, accessible to authorized personnel only.  
Packaging and labelling of IMP will comply with Good Manufacturing Practice (GMP), 
Good Clinical Practice (GCP) rules, EU GMP Annex 13, and country-specific 
regulatory requirements. Packaging and labeling of the IMP will be available in the 
local language. 
 
5.4.1 N-Acetyl-L-Leucine, 1000 mg powder for oral suspension in 60 mL 
glass bottles (without further excipients) 
IB1001 and Ora-Blend® will be supplied in kits. Each kit contains 28 bottles of N-
Acetyl-L-Leucine (each bottle containing 1000 mg N-Acetyl-L-Leucine for a total of 
total 28,000 mg per kit), packed with 3 bottles of Ora-Blend® (each bottle containing 
473 mL, for a total of 1,419 mL per kit). 
 
 
 
43 Or after the Visit if IMP is returned via courier 


 
 
CONFIDENTIAL 
 
Page 134 of 161 
Version 7.0, 10 Oct 2022 
5.4.2 N-Acetyl-L-Leucine, 1000 mg granules for oral suspension in sachet 
IB1001 will be supplied in cartons of either “1-month” or “3-month” supplies44.  
 
The “one-month” carton will contain 124 sachets of N-Acetyl-L-Leucine (each sachet 
containing 1000 mg N-Acetyl-L-Leucine for a total of total 124,000 mg per carton). 
 
The “three-month” carton will contain 370 sachets of N-Acetyl-L-Leucine (each sachet 
containing 1000 mg N-Acetyl-L-Leucine for a total of total 370,000 mg per carton).  
 
5.5 
Blinding and Breaking the Blind 
This study is not blinded. Videos collected from each study visit (except Visit 0 or 
unscheduled visits) and associated pairs of videos will be assessed in a blinded way by 
the independent raters.  
5.6 
Drug Accountability 
The Investigator is responsible for maintaining accurate study drug accountability 
records throughout the study. Study drug accountability will be performed at Visit 8 
and Visit 9 and, if applicable, at the Extension Phase early termination visit. Unused or 
returned drug will be destroyed at the site. Alternatively, the study drug may be returned 
to Fisher Clinical Services UK Ltd (Langhurstwood Road, Horsham, West Sussex, 
RH12 4QD, United Kingdom), Fisher Clinical Services Germany (Im Wörth 3, 79576 
Weil am Rhein, Germany), or Fisher Clinical Services US (7554 Schantz Rd, 
Allentown, PA 18106, USA) if the study drug cannot be destroyed at the site. The 
Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for maintaining up to date inventory and site accountability logs. Each 
dispensing of study drug to a patient will be documented in the medical records and 
patient-level accountability logs. 
5.7 
Investigational Medicinal Product (IMP; ‘study drug’) Compliance 
At Visit 8 and Visit 1145 patients should return all used IB1001 materials (IB1001 
bottles, sachets, Ora-Blend® bottles). 
At Visit 9, Visit 12, or Early Termination (if applicable), patients should return all study 
materials (i.e. used and unused IB1001 bottles and sachets and used and unused Ora-
Blend® bottles [if applicable]) to the trial site for compliance checks.  
Compliance will be assessed upon a review of the inventory of IB1001 bottles/sachets 
returned from patients.   
5.8 
Concomitant Medications and Therapies 
All medication taken after Visit 6 will continue to be recorded as concomitant 
medications. The current amount (in hours per week) of therapy (e.g. physiotherapy, 
speech therapy) needs to continue to be recorded. 
Table 5.1 lists medications that are prohibited. Medication not listed in this table may 
be permitted, at the discretion of the investigator, as long as there is no interference 
 
 
44 Labels based on assumption of a total daily dose of 4 g/day.  
45 If an unscheduled visit occurs during the extension phase treatment period, where patients switch from taking the IB1001 
bottles to the IB1001 sachets, all used, partially used, or unused IB1001 kits (IB1001 bottles + Ora-Blend bottles) must be 
returned at this visit, or after the visit if the IMP is returned via courier.  


 
 
CONFIDENTIAL 
 
Page 135 of 161 
Version 7.0, 10 Oct 2022 
with the study objectives or patient safety. Doses of medications and therapies used for 
(the symptoms of) NPC should remain as constant as possible (at the investigator’s 
discretion) throughout the trial.  
Table 5.1: 
Prohibited Medications 
Aminopyridines (including sustained-release form) 
N-Acetyl-DL-Leucine (e.g. Tanganil®) or N-Acetyl-L-Leucine (if not provided as 
study drug during the study) 
Riluzole 
Gabapentin 
Varenicline 
Chlorzoxazone  
Sulfasalazine 
Rosuvastatin 
 
Any medication the patient takes other than the study drug is considered a concomitant 
medication. All concomitant medications must be recorded in the electronic case report 
form (eCRF). The following information must be recorded in the eCRF for each 
concomitant medication: generic name, route of administration, start date, stop date, 
dosage, and indication. Any changes in the dosage or regimen of a concomitant 
medication must be recorded in the eCRF.  
A patient found using a new concomitant medication, or a patient who changes their 
previous regimen/dose, may continue with the study/study drug if the Investigator does 
not believe the medication/therapy will interfere with the patient’s safety.  
Note: Drug interactions with substrates of transporters MDR1, BCRP, or BSEP cannot 
be excluded as N-Acetyl-L-Leucine is an inhibitor of these transporters in vitro. 
Sulfasalazine and rosuvastatin are included under prohibited medications, whereas 
substrates of MDR1 and BSEP and other substrates of BCRP may be used at the 
discretion of the investigator. 
 
5.9 
Treatment of Overdose 
No specific information on overdose of N-Acetyl-L-Leucine (IB1001) exists for 
humans. Based on the pharmacology, it is not expected that overdose would produce a 
clinically relevant reaction. The patient should be appropriately monitored.  


 
 
CONFIDENTIAL 
 
Page 136 of 161 
Version 7.0, 10 Oct 2022 
6 
PARAMETERS AND METHODS OF ASSESSMENT – EXTENSION 
PHASE 
All analyses of the extension phase are considered secondary to ones of the parent 
study. For the most part, the same clinical outcome assessments used during the Parent 
Study (described in Section 6 of the Parent Study) will be used during the Extension 
Phase. These outcome assessments will be used in the Extension Phase to continue to 
monitor the long-term effects of IB1001. The section below describes how existing 
efficacy parameters have been updated for use in the Extension Phase, as well as 
additional efficacy parameters that have been added. Assessments in the Extension 
Phase will be performed at the times indicated in the Extension Phase schedule of 
events (see Table 6.1).  
 
6.1 
Updated Efficacy Parameters 
6.1.1 Measurement of Global Impression 
The clinical global impression of severity (CGI-S) and change (CGI-C) will continue 
to be measured, with the questions for the physicians, caregivers, and patients modified 
to accommodate the Extension Phase visits.  
 
Physician, Caregivers, and Patients (if able) will be asked to assess the CGI-S at each 
visit (Visit 7, Visit 8, Visit 9, Visit 10, Visit 11, Visit 12 and at the Extension Phase 
Early Termination visit, if applicable). The question is identical to that described in the 
Parent Study Section 6.1.5. 
 
Physician, Caregivers, and Patients (if able) will be asked to assess the CGI-C at Visit 8, 
Visit 9, Visit 10, Visit 11, Visit 12, and the Extension Phase Early Termination Visit (if 
applicable).   
 
The Clinical Global Impression of Change (CGI-C) - clinician asks the clinician 
one question: 
“Compared to the patient's condition at:  
(i) Visit 7 (extension phase baseline) versus (ii) Visit 8 (interim extension phase 
treatment visit) OR versus Visit 9 (end of extension phase treatment); 
OR 
(i) Visit 9 (end of extension phase treatment) versus (ii) Visit 10 (end of extension phase 
washout); 
OR 
(i) Visit 10 (end of extension phase washout) versus (ii) Visit 11 (interim extension 
phase treatment visit) OR versus Visit 12 (end of extension phase treatment period II); 
OR 
(i) Early Termination Visit versus (ii) the previous visit, 
this patient’s condition is: 1=very much improved since the initiation of treatment; 
2=much improved; 3=minimally improved; 4=no change from baseline (the initiation 
of treatment); 5=minimally worse; 6= much worse; 7=very much worse.” 


 
 
CONFIDENTIAL 
 
Page 137 of 161 
Version 7.0, 10 Oct 2022 
 
The Clinical Global Impression of Change (CGI-C) - caregiver asks the caregiver 
one question: 
“Compared to the patient's condition at:  
(i) Visit 7 (extension phase baseline) versus (ii) Visit 8 (interim extension phase 
treatment visit) OR versus Visit 9 (end of extension phase treatment); 
OR 
(i) Visit 9 (end of extension phase treatment) versus (ii) Visit 10 (end of extension phase 
washout); 
OR 
(i) Visit 10 (end of extension phase washout) versus (ii) Visit 11 (interim extension 
phase treatment visit) OR versus Visit 12 (end of extension phase treatment period II); 
OR 
(i) Early Termination Visit versus (ii) the previous visit, 
how much has he/she changed: 1=very much improved; 2=much improved; 
3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very 
much worse.” 
 
The Clinical Global Impression of Change (CGI-C) - patient asks the patient (if 
able) one question: 
“Compared to your condition at:  
(i) Visit 7 (extension phase baseline) versus (ii) Visit 8 (interim extension phase 
treatment visit) OR versus Visit 9 (end of extension phase treatment); 
OR 
(i) Visit 9 (end of extension phase treatment) versus (ii) Visit 10 (end of extension phase 
washout); 
OR 
(i) Visit 10 (end of extension phase washout) versus (ii) Visit 11 (interim extension 
phase treatment visit) OR versus Visit 12 (end of Extension Phase Treatment Period 
II); 
OR 
(i) Early Termination Visit versus (ii) the previous visit, 
how much have you changed? 1=very much improved; 2=much improved; 
3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very 
much worse.” 
6.1.2 Clinical Impression of Change in Severity 
Videos of the primary and non-primary anchor tests are collected throughout the 
extension phase for the Clinical Impression of Change in Severity (CI-CS). These 
videos may be analyzed in order to inform the development and validation of the CI-
CS endpoint.  


 
 
CONFIDENTIAL 
 
Page 138 of 161 
Version 7.0, 10 Oct 2022 
 
 
6.2 
New Efficacy Parameters Introduced for the Extension Phase 
6.2.1  NPC Clinical Severity Scale (NPC-CSS) 
The NPC clinical severity scale (NPC-CSS) [Yanjanin et al, 2010] was developed and 
validated in a cross-sectional study of current NPC patients and a longitudinal chart 
review of an historical cohort. The scale quantifies the major symptoms of NPC and 
characterizes the disease progression of NPC. The NPC-CSS measures clinical signs 
and symptoms in 9 major (ambulation, cognition, eye movement, fine motor, hearing, 
memory, seizures, speech, swallowing) and 8 minor (auditory brainstem response, 
behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, 
respiratory problems) domains. A higher NPC-CSS score indicates a clinical 
worsening, while a lower NPC-CSS score indicates a clinical improvement. A 0-point 
change in the NPC-CSS score represents a stabilization of disease progression, which 
is also a significant clinical improvement for rapidly progressive, neurogenerative 
diseases like NPC.  
NPC-CSS is a widely accepted clinical outcome measure for NPC trials that investigate 
long-term treatment effect. Several clinical trials in patients with NPC have change in 
NPC-CSS as primary endpoint, including a Phase IIb/III clinical trial of 2-
hydroxypropyl-β-cyclodextrin (VTS-270; ClinicalTrials.gov ID: NCT02534844), a 
Phase II/III clinical trial of arimoclomol (NCT02612129), and an open-label Phase I/II 
clinical trial of lithium carbonate (NCT03201627).  
A recent consensus paper on clinical management guidelines for Niemann-Pick disease 
type C recommended that, bearing in mind the resources available to most physicians 
in practice, a modified version of the NPC-CSS that is widely used in clinical practice, 
and more user-friendly, should be administered. This modified version excludes the 
hearing and auditory brainstem response domains [Geberhiwot et al, 2018]. 
Accordingly, all major and minor domains of the NPC-CSS [Yanjanin et al, 2010] will 
be assessed in this study, with the exception of the hearing and auditory brainstem 
response domains. The change in the full NPC-CSS score, apart from hearing domains 
(i.e. hearing and auditory brainstem response), will be calculated.  
It is also planned that a stratified version of the NPC-CSS scale, limited to the 
assessment of 5 NPC-CSS domains (Ambulation, Cognition, Fine motor, Speech, and 
Swallowing) will also be evaluated (this is a primary endpoint in the arimoclomol trial; 
NCT02612129) as the primary objective in the extension phase.  
If an NPC-CSS score is available from Visit 1 of the Parent Study, additional analysis 
will be performed comparing the NPC-CSS at Visit 1, Visit 7, Visit 9, and Visit 10. 
Finally, while providing informed consent for participation Extension Phase, patients 
(or their legal representative on their behalf) will be asked if they agree to provide 
relevant medical history, including outcomes of NPC-CSS assessments conducted prior 
to their enrollment and participation in the Parent Study. Provided the patient (or legal 
representative on their behalf) consents, the available retrospective data may be used to 
conduct additional analyses which assess the slope of disease progression before 


 
 
CONFIDENTIAL 
 
Page 139 of 161 
Version 7.0, 10 Oct 2022 
enrollment in the trial and after the initiation of treatment with IB1001. The same 
investigator should perform the NPC-CSS at all extension phase Visits (Visit 7 – Visit 
12).46 
6.2.2  Annual Severity Increment Score (ASIS) 
The Annual Severity Increment Score (ASIS) [Cortina-Borja et al, 2018] is a metric 
that measures the annual increment in clinical severity for individual NPC patients. The 
ASIS score is based on the assessments performed in the NPC-CSS assessment; no 
additional tests are required. The ASIS score is obtained by dividing the total NPC-CSS 
severity score of a patient by the age of the patient, providing a measure of the rate of 
disease progression in individual patients.  
Cortina-Borja et al (2018) demonstrated in 38 patients from two independent 
international clinical cohorts that the ASIS was stable over several years. They also 
applied the ASIS score to quantify the slowing of the rate of disease progression in 10 
NPC patients receiving long-term treatment with Acetyl-DL-Leucine. The study 
demonstrated that the ASIS is a reliable predictor of progression of clinical severity and 
a valuable tool to quantify the effect of an experimental therapy for NPC disease 
progression. 
The ASIS scale is included to quantify the potential effects of IB1001 as a 
neuroprotective/disease-modifying treatment for NPC.  
6.3 
Exploratory Endpoints for the Washout Phase 
Exploratory endpoints are defined in Section 8.5.2. 
6.4 
Safety Parameters 
The Investigator is responsible for monitoring the safety of patients who have been 
enrolled in this study and for accurately documenting and reporting information as 
described in this section.  
6.4.1 Adverse Events 
See Section 6.2.1 of the Parent Study.   
6.4.2 Serious Adverse Events 
See Section 6.2.2 of the Parent Study.  
6.4.3 Pregnancy  
The policies for pregnancy are identical to the Parent Study (see Section 6.2.3 of the 
Parent Study) except that at all visits of the Extension Phase (Visits 7 through Visit 10 
and the Extension Phase Early Termination Visit [if applicable]), females of 
childbearing potential will have a urine dipstick pregnancy test (analyzed on site).  
 
 
46 In addition, the same investigator should perform the SARA assessment at all extension phase Visits 
(Visit 7 – Visit 12) 


 
 
CONFIDENTIAL 
 
Page 140 of 161 
Version 7.0, 10 Oct 2022 
6.4.4 Vital Signs 
Vital signs will be measured and recorded at the time points designated on the 
Extension Phase schedule of events (see Table 6.1), in accordance with the procedures 
and policies described in Section 6.2.4 of the Parent Study. 
6.4.5 Electrocardiograms (ECGs) 
During the Extension Phase, one 12-lead ECG will be performed at the time point 
designated on the Extension Phase schedule of events (Table 6.1), following the 
procedures and policies provided in Section 6.2.5 of the Parent Study.  
In addition, ECGs may be performed at other visits at the discretion of the Investigator.  
6.4.6 Physical Examinations 
A complete physical examination that is limited to the following body systems: general 
appearance (including skin), head and neck, eyes and ears, nose and throat, pulmonary, 
cardiovascular, gastrointestinal, muscular skeletal, lymphatic, neurological, will be 
performed at the time points designated on the Extension Phase schedule of events 
(Table 6.1). 
 
If a new, significant abnormal or worsened abnormal pre-existing condition is detected, 
the condition needs to be recorded as an AE.  
 
Weight will be measured at the time points designated on the Extension Phase schedule 
of events (Table 6.1). 
6.4.7 Medical History 
While providing informed consent for participation Extension Phase, patients (or their 
legal representative on their behalf) will be asked if they agree to provide relevant 
medical history, including outcomes of NPC-CSS assessments conducted prior to their 
enrollment and participation in the Parent Study. Provided the patient (or legal 
representative on their behalf) consents, the available retrospective data may be used to 
conduct additional analyses which assess the slope of disease progression before 
enrollment in the trial and after the initiation of treatment with IB1001.  
 
6.5 
Laboratory Parameters 
6.5.1 Safety Laboratory Assessments 
Samples will be collected and analyzed by standard laboratory procedures at the time 
points designated on the schedule of events – Extension Phase (see Table 6.1), in 
accordance with the procedures and policies described in Section 6.3.1 of the Parent 
Study.  
The total amount of blood taken per patient during the study (Parent Study + Extension 
Phase) is provided in Section 6.5.5.  
6.5.2 Measurement of N-Acetyl-L-Leucine Concentration in Blood on FULL 
PK days 
Blood samples for the quantification of N-Acetyl-L-Leucine in plasma will be obtained 
according to the Extension Phase schedule of events (Table 6.1). 


 
 
CONFIDENTIAL 
 
Page 141 of 161 
Version 7.0, 10 Oct 2022 
At Visit 7B, the first sample will be taken before first dosing of N-Acetyl-L-Leucine in 
the Extension Phase; subsequent samples will be taken at 30 minutes (+/- 5 minutes), 
60 minutes (+/- 5 minutes), 90 minutes (+/- 10 minutes), 120 minutes (+/- 10 minutes), 
150 (+/- 15 minutes), 180 minutes (+/- 15 minutes), 240 minutes (+/- 15 minutes), and 
360 minutes (+/- 15 minutes) after the first extension phase IMP dose is taken. 
At Visit 9B, the first sample will be taken directly before last IMP intake of the 
treatment period; subsequent samples will be taken at 30 minutes (+/- 5 minutes), 
60 minutes (+/- 5 minutes), 90 minutes (+/- 10 minutes), 120 minutes (+/- 10 minutes), 
150 minutes (+/- 15 minutes), 180 minutes (+/- 15 minutes), 240 minutes (+/- 15 
minutes), and 360 minutes (+/- 15 minutes) after the last extension phase IMP dose is 
taken.  
At Visit 7B and Visit 9B, it is important that the day and exact time of the dose of N-
Acetyl-L-Leucine that is taken after the first pre-dose PK blood draw, and before the 
subsequent first post-dose blood draw at 30 minutes (+/- 5 minutes) is recorded.  
At Visit 7B and Visit 9B, for each PK blood draw, it is important that the day and exact 
time of each blood draw is recorded. 
On Visit 7B and Visit 9B, when full PK sampling is conducted, the drug should be 
taken in accordance with the protocol (that is, taken 30 minutes before or at least two 
hours after a meal). In addition, on Visit 7B and Visit 9B, the days PK sampling is 
conducted, all meal times should be recorded until the last PK draw has been made. For 
Visit 7, the next dose of N-Acetyl-L-Leucine should be taken after the last PK draw has 
been made at the earliest. Note, for Visit 9B, no further doses will be given after the PK 
draws until the end of Visit 10 (Visit 9B marks the end of the Extension Phase treatment 
period I). Shipment instructions for N-Acetyl-L-Leucine PK blood samples will be 
provided in the laboratory manual.  
The total amount of blood taken per patient during the Extension Phase (that is, in 
addition to the Parent Study) is provided in Section 6.5.5. 
6.5.3 Measurement of N-Acetyl-D-Leucine Concentration in Urine 
Urine tests for N-Acetyl-D-Leucine will be done pre-dose at Visit 7A47, and pre-dose 
at Visit 10. Data will be analyzed in batches and used for sensitivity analyses only.  
6.5.4 Additional Laboratory Samples for Research Purposes 
Retained samples from the Parent Study or Extension Phase may be used for research 
purposes to provide more information on the disease NPC. 
 
Blood samples will be obtained for possible research purposes to provide more 
information on the disease NPC according to the Extension Phase schedule of events 
(Table 6.1).   
 
6.5.5 Total Blood Volume 
The total amount of blood taken per subject during the Extension Phase will be 
approximately 119 mL (35 mL for safety analysis, and 72 mL for the PK analysis, 12 
mL for research purposes). If a safety laboratory analysis is performed at Visit 7, Part 
 
 
47 If Visit 7 is scheduled within +7 days of Visit 6, the urine test for N-Acetyl-D-Leucine taken at Visit 6 may be 
used as the pre-dose urine test. 


 
 
CONFIDENTIAL 
 
Page 142 of 161 
Version 7.0, 10 Oct 2022 
A, an additional 7 mL will be taken, and the total amount of blood taken per subject 
during the Extension Phase will be approximately 126 mL.  
The total of blood taken during the total study, Parent study + Extension phase, will be 
approximately 192 mL (66 mL from the Parent study + 126 mL from the Extension 
Phase). 


 
 
CONFIDENTIAL 
 
Page 143 of 161 
Version 7.0, 10 Oct 2022 
7 
STUDY CONDUCT – EXTENSION PHASE 
7.1 
Observations by Visit 
7.1.1 Visit 7: Extension Phase Baseline Visit 
Visit 7: The assessments comprising Visit 7 may be conducted over a two-day period 
(“Part A” and “Part B”)48. If Visit 7, Part B is scheduled 1 day (+6 days) after Visit 6 
(Washout 2), the assessments defined as Part A will use the results obtained at Visit 6. 
At Visit 6 of the Parent Study, the PI should determine continued treatment with IB1001 
to be in the patient’s best interest, and, provided the patient/caregiver would like to 
continue participation in the Extension Phase, the PI should obtain informed 
consent/informed consent form (ICF) signature and patient information (see Section 
7.1.6 of the Parent Study). 
 
Visit 7, Part A: Part A of the Extension Phase baseline assessment. 
If Visit 7, Part B is scheduled 1 day (+6 days) after Visit 6, the results obtained for 
assessments at Visit 6 can be carried over to Visit 7, Part A (i.e. assessments performed 
at Visit 6 don’t need to be repeated). If Visit 7, Part B cannot be scheduled within 1 day 
(+6 days) after Visit 6, Visit 7 Part A assessments must be carried out and Visit 7 may 
be conducted over 2 days.  
 
• Addendum to the informed consent/informed consent form (ICF) signature and 
patient information for Extension Phase (if applicable) 
• Check of inclusion/exclusion criteria for Extension Phase (if applicable) 
• Vital signs 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of 
Clinical Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 
8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients 
aged <18 years  
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at 
site) 
• Urine test for N-Acetyl-D-Leucine 
• Blood draw for laboratory safety tests (done at central lab) 
• Blood draw for research purposes 
• Documentation of adverse events. 
 
 
 
48 If Visit 7 is conducted within +7 days of Visit 6, the assessments performed at “Visit 7 Part A” do 
not need to be duplicated.  


 
 
CONFIDENTIAL 
 
Page 144 of 161 
Version 7.0, 10 Oct 2022 
 
Visit 7, Part B:  Part B of the Extension Phase baseline assessment. Scheduled either 1 
day (+6 days) after Visit 6, or +1 Day after Visit 7, Part A. Start of IMP during the 
Extension Phase.  
• Physical examination  
• Weight 
• Niemann-Pick Disease Type C Clinical Severity Scale (NPC-CSS) 
• Pre-dose blood draw for PK (taken directly before the first dose of N-Acetyl-L-
Leucine in the Extension Phase) (done at PK lab) 
• Dispensing of study drug + intake of study drug at site  
• Blood draws for PK taken at the defined post-dose timepoints (done at PK lab) 
• Documentation of adverse events.  
 
7.1.2 Visit 8: Day 180 (+/- 14 days): First assessment of the Extension Phase 
treatment period I with N-Acetyl-L-Leucine 
• Return of trial drug and compliance check 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Physical examination 
• Weight 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Niemann-Pick disease type C Clinical Severity Scale 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Visit 7 
• Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 7 
• Clinical Global Impression of Change (CGI-C) by patient if able based Visit 7 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Blood draw for safety laboratory tests (done at central lab) 
• Documentation of adverse events  
• Dispensing of additional study drug.  
7.1.3 Visit 9:  Day 365 (+/- 14 days): Final assessments of the Extension 
Phase treatment period I with N-Acetyl-L-Leucine 
The assessments comprising Visit 9 may be conducted over a two-day period (“Part 
A” and “Part B”). 


 
 
CONFIDENTIAL 
 
Page 145 of 161 
Version 7.0, 10 Oct 2022 
7.1.3.1 Visit 9, Part A:  Day 365 (+/- 14 days) of the treatment period 
• Spinocerebellar Ataxia Functional Index (SCAFI) + including Video-Recording of 
Clinical Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 
8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Niemann-Pick Disease Type C Clinical Severity Scale (NPC-CSS) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Visit 7 
• Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 7 
• Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 7 
• 12-lead ECG 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Documentation of adverse events.  
 
7.1.3.2 Visit 9, Part B 
The final treatment visit in the Extension Phase.  +1 Day after Visit 9, Part A.  
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Physical examination 
• Weight 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for research purposes 
• Pre-dose blood draw for PK (taken directly before the last dose of N-Acetyl-L-
Leucine in the Extension Phase) (done at PK lab) 
• Last intake of study drug at site  
• Blood draws for PK taken at the defined post-dose timepoints (done at PK lab) 
• Return of trial drug and compliance check 
• Documentation of adverse events.  
 
7.1.4 Visit 10: Extension Phase Washout Visit  
The final day/first assessment of Extension Phase washout period. 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Physical examination 
• Weight 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Niemann-Pick Disease Type C Clinical Severity Scale (NPC-CSS) 


 
 
CONFIDENTIAL 
 
Page 146 of 161 
Version 7.0, 10 Oct 2022 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on previous visit 
• Clinical Global Impression of Change (CGI-C) by caregiver based on previous visit 
• Clinical Global Impression of Change (CGI-C) by patient if able based on previous 
visit 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for safety laboratory tests (done at central lab) 
• Documentation of adverse events  
• Addendum to the informed consent/informed consent form (ICF) signature and 
patient information for Extension Phase treatment period II (if applicable) 
• Dispensing of study drug + intake of study drug at site.  
 
7.1.5 Visit 11: Day 587 (+/- 14 days): Interim Extension Phase visit treatment 
period II 
• Return of trial drug and compliance check 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Physical examination 
• Weight 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Visit 10 
• Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 10 
• Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 10 
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Blood draw for safety laboratory tests (done at central lab) 
• Documentation of adverse events  
• Dispensing of additional study drug.  
7.1.6 Visit 12 Day 767: Final assessments of the Extension Phase treatment 
period II with N-Acetyl-L-Leucine 
• Return of trial drug and compliance check 


 
 
CONFIDENTIAL 
 
Page 147 of 161 
Version 7.0, 10 Oct 2022 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Physical examination 
• Weight 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on Visit 10 
• Clinical Global Impression of Change (CGI-C) by caregiver based on Visit 10 
• Clinical Global Impression of Change (CGI-C) by patient if able based on Visit 10  
• Urinalysis (done at central lab) 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for research purposes 
• Documentation of adverse events.  
 
 
 
7.1.7 Extension Phase Early Termination (ET) 
• Return of trial drug and compliance check 
• Documentation of frequency of therapy (hours per week) 
• Documentation of concomitant medication  
• Vital signs 
• Physical examination 
• Weight 
• Spinocerebellar Ataxia Functional Index (SCAFI) + Video-Recording of Clinical 
Impression of Change in Severity (CI-CS) Anchor Tests (9HPT-D and 8MWT) 
• Scale for Assessment and Rating of Ataxia (SARA) 
• Niemann-Pick Disease Type C Clinical Severity Scale (NPC-CSS) 
• Quality of Life EQ-5D-5L for patients aged ≥18 years, EQ-5D-Y for patients aged 
<18 years 
• Clinical Global Impression of Severity (CGI-S) by physician 
• Clinical Global Impression of Severity (CGI-S) by caregiver 
• Clinical Global Impression of Severity (CGI-S) by patient if able 
• Clinical Global Impression of Change (CGI-C) by physician based on previous visit 
• Clinical Global Impression of Change (CGI-C) by caregiver based on previous visit 
• Clinical Global Impression of Change (CGI-C) by patient if able based on previous 
visit 
• 12-lead ECG 
• Urinalysis (done at central lab) 


 
 
CONFIDENTIAL 
 
Page 148 of 161 
Version 7.0, 10 Oct 2022 
• Urine by dipstick: pregnancy test for women of childbearing potential (done at site) 
• Urine test for N-Acetyl-D-Leucine (done at PK lab) 
• Blood draw for safety laboratory tests (done at central lab) 
• Blood draw for research purposes 
• Documentation of adverse events.  
 


 
 
CONFIDENTIAL 
 
Page 149 of 161 
Version 7.0, 10 Oct 2022 
8 
STATISTICAL METHODS – EXTENSION PHASE 
8.1 
General Analysis Plan 
8.1.1 Disposition of Patients 
The number of patients enrolled, plus the numbers contained within the Extension 
Phase Safety Analysis Set (SAFe), intention-to-treat (ITTe), modified intention-to-treat 
analysis set (mITTe), and the Per Protocol Set (PPSe) will be summarized overall and 
by country. The number of patients discontinuing treatment, together with the primary 
reason for discontinuation will be presented. 
 
Protocol Deviations 
Protocol deviations include but are not limited to: 
• Violation of key inclusion /exclusion criteria  
• Use of Prohibited Medications 
Further detail will be provided in the Statistical Analysis Plan (SAP)  
8.1.2 Analysis Populations 
• The Safety Analysis Set Extension Phase (SAFe) will consist of all patients who 
receive at least one dose of study drug (N-Acetyl-L-Leucine) in the Extension 
Phase  
• The intention-to-treat Extension Phase (ITTe) population will consist of all 
patients who receive at least one dose of study drug (N-Acetyl-L-Leucine) in 
the Extension Phase and with NPC-CSS scores at baseline (Visit 7) 
• The extension phase modified intention to treat analysis set (mITTe) will consist 
of all patients with NPC-CSS scores at baseline (Visit 7) and end of treatment 
period I (Visit 9). 
• The Per Protocol Set Extension Phase (PPSe) will consist of all patients with 
NPC-CSS scores at baseline (Visit 7) and end of treatment period I (Visit 9) 
without any major protocol deviations that could have influenced the validity of 
the data for the primary efficacy variable 
8.2 
General Considerations 
Statistical analysis will be performed using SAS; the version used will be specified in 
the SAP. 
All variables will be summarized using descriptive statistics. The number of patients, 
mean, standard deviation (SD), minimum, median, and maximum will be calculated for 
continuous and score variables. Frequency tables will be generated for categorical data. 
90% confidence intervals, together with a one-sided significance level of 0.05 where 
appropriate, will be used for all endpoints as a guide for evidence for activity. 
Conclusions regarding treatment efficacy will not solely rely on detecting statistical 
significance with equal emphasis placed on the magnitude and clinical relevance of 
treatment differences as judged by the point estimates and confidence intervals. 
No correction for multiple comparisons will be included.  
8.3 
Demographics, Baseline Characteristics and Concomitant Medications 
Demographic data and patient characteristics at baseline will be summarized 
descriptively. 


 
 
CONFIDENTIAL 
 
Page 150 of 161 
Version 7.0, 10 Oct 2022 
Frequency and percentage of prior and concomitant medication use will be summarized 
by World Health Organization (WHO) Drug dictionary coded terms - Anatomic 
Therapeutic Chemical (ATC) classification and preferred term. 
8.4 
Treatment Compliance 
Summary statistics for the number of N-Acetyl-L-Leucine doses taken, based on bottles 
or sachets of Study Drug dispensed and return bottle or sachet counts, will be 
calculated. Overall compliance in terms of the percentage of drug taken based on these 
data will be summarized descriptively together with the proportion of patients who take 
at least 80% of the prescribed medication. 
8.5 
Efficacy Analyses 
The primary analyses of efficacy will be based on the mITTe analyses of efficacy based 
on the PPSe will also be undertaken to provide supplementary information.  
For the primary endpoint there will be separate analyses within key subgroups. The 
subgroups to be considered will be defined by: 
• Naïve versus non-naïve: trial classification as determined at screening 
• Patients on miglustat versus patients not on miglustat  
• Age (pediatric versus adult) 
• Age/weight/dosing group  
• Age of diagnosis: Early-infantile (<2 years), Late-infantile (2 to < 6 years), 
Juvenile (6 to < 15 years), Adolescent/Adult (≥ 15 years) 
• Disease severity based on NPC-CSS below/ above the median NPC-CSS 
score at Visit 7 
• Gender (male versus female) 
• Primary Anchor Test (9HPT-D or 8MWT)   
• Composite of SARA Subtests 1-4 (Gait, Stance, Sitting, Speech)  
• Composite of Modified NPC-CSS score: Ambulation, Cognition, Fine motor, 
Speech and Swallowing 
• Stratification based on Annual Severity Increment Score (ASIS) 
Additional subgroups can be added at the time of analysis on an exploratory basis. 
Separate Extension Phases are planned to be conducted with N-Acetyl-L-Leucine for 
NPC, GM2-gangliosidosis, and ataxia-telangiectasia. There will however be a planned 
series of meta-analyses that will bring together the data from the studies for the primary 
and selected exploratory endpoints. Further details will be provided in a meta-analysis 
statistical analysis plan (MASAP). 
8.5.1 Primary Efficacy Endpoint 
The primary endpoint is based on the modified 5-domain NPC-CSS score with 
success defined as no change or a decrease in the 5-domain NPC-CSS score from 
Visit 7 to Visit 9.  
 
It is postulated that under standard of care, 90% of patients would worsen (higher score) 
in terms of their performance in 5-domain NPCS-CSS scale over a 12-month period, 
while conversely only 10% would show similar performance or some improvement. 
Statistical evaluation of the primary binary endpoint (success/failure on the 5-Domain 


 
 
CONFIDENTIAL 
 
Page 151 of 161 
Version 7.0, 10 Oct 2022 
NPC-CSS scale) will compare the proportion of success with 10% in a one-sided 
Fishers Exact test at the one-sided 5% significance level. 
 
8.5.2 Exploratory Efficacy Endpoints  
Additional exploratory endpoints will investigate other measures of symptoms and 
quality of life. Descriptive statistics will be provided for these measures at each visit 
and also changes from Extension Phase baseline (Visit 7) to the end of Extension Phase 
treatment period I with N-Acetyl-L-Leucine (Visit 9) for the following measures: 
 
• Spinocerebellar Ataxia Functional Index (SCAFI)49 score 
• Scale for Assessment and Rating of Ataxia (SARA) score 
• Niemann-Pick Disease Type C Clinical Severity Scale (NPC-CSS) 
• Quality of Life EQ-5D-5L for patients aged ≥18; EQ-5D-Y50 for patients aged 
<18 years 
• Treating Physician Clinical Global Impression of Severity (CGI-S)  
• Treating Physician Clinical Global Impression of Change (CGI-C) comparing 
end of treatment (Visit 9) to Extension Phase baseline (Visit 7) 
• Caregiver Clinical Global Impression of Severity (CGI-S)  
• Caregiver Clinical Global Impression of Change (CGI-C) comparing end of 
treatment (Visit 9) to Extension Phase baseline (Visit 7) 
• Patient Clinical Global Impression Scales Impression of Severity (CGI-S) if 
they are able 
• Patient Clinical Global Impression of Change (CGI-C) comparing end of 
treatment (Visit 9) to Extension Phase baseline (Visit 7) if they are able 
• Annual Severity Increment Score (ASIS) 
 
Videos of the primary and non-primary anchor tests are collected throughout the 
extension phase for the CI-CS. These videos may be analyzed in order to inform the 
development and validation of the CI-CS.  
 
8.5.2.1 Exploratory Efficacy Endpoints related to the Washout Phase 
Exploratory endpoints in the Extension Phase may also be based on changes over the 
following time periods: 
- 
The beginning of the Extension Phase (Visit 7) to the end of the Extension Phase 
washout period (Visit 10) 
- 
The end of the Extension Phase treatment period I (Visit 9) to the end of the 
Extension Phase washout period (Visit 10). 
- 
The end of Extension Phase period I washout (Visit 10) to the end of Extension 
Phase treatment period II (Visit 12) 
- 
The beginning of the Parent study (Visit 1) to the end of the Extension Phase 
treatment period II (Visit 12) 
 
 
 
49The 9 Hole Peg Test of the Dominant Hand (9HPT-D) and the 8 Meter Walk Test (8MWT) will be videoed for 
every patient at every visit except Visit 0 of the parent study. 
50 European Sites Only 


 
 
CONFIDENTIAL 
 
Page 152 of 161 
Version 7.0, 10 Oct 2022 
Finally, exploratory endpoints will be based on the changes on the Niemann-Pick 
Disease type C Clinical Severity Scale (NPC-CSS) and the five-domain NPC-CSS 
scale. An exploratory evaluation of the NPC-CSS will be based on the changes from 
Extension Phase baseline (Visit 7) to the end of the Extension Phase washout period 
(Visit 10). 
 
If a NPC-CSS score is available from Visit 1 of the Parent Study, additional analysis 
will be performed comparing the NPC-CSS at Visit 1, Visit 7, Visit 9, Visit 10, Visit 
11, and Visit 12. 
 
While providing informed consent for participation Extension Phase, patients (or their 
legal representative on their behalf) will be asked if they agree to provide relevant 
medical history, including outcomes of NPC-CSS assessments conducted prior to their 
enrollment and participation in the Parent Study. Provided the patient (or legal 
representative on their behalf) consents, the available retrospective data may be used to 
conduct additional analyses which assess the slope of disease progression before 
enrollment in the trial and after the initiation of treatment with IB1001.  
 
All exploratory endpoints relating to the washout phase, or the Extension Phase 
Treatment period II, will be evaluated based on descriptive statistics. 
 
8.6 
Missing Data 
Analyses based on the mITTe analysis set will utilize a last observation carried 
forward (LOCF) approach for a missing video at Visit 9.  
For the primary endpoint 5-Domain NPC-CSS endpoint  this implies that the  score of 
Visit 8 will be used instead. Other endpoints will not be imputed, and missing data 
will be reported as is. No sensitivity analyses will be applied.  
 
For all other endpoints there will be no imputation for missing data and data will be 
reported and evaluated as observed.  
8.7 
Blinding 
This study is not blinded. Videos of the primary and non-primary anchor tests are 
collected throughout the extension phase for the CI-CS may be analyzed in order to 
inform the development and validation of the CI-CS. The blinded independent raters 
will be given each of the 3 videos initially in a random order to make their evaluation 
of CI-S for each video. The blinded independent raters will then be provided with 3 
pairs of video recordings blinded to information on the visits associated with these 
videos and their order and asked to provide a score for CI-CS for each pair. Further 
details regarding this blinding process will be detailed in the SAP. 
8.8 
Safety Analyses 
The SAFe will be the basis for all analyses of safety and tolerability.  
8.9 
Interim Analyses 
There will be an analysis of the primary and other endpoints relating to the Extension 
Phase once all patients have completed Visit 10. 


 
 
CONFIDENTIAL 
 
Page 153 of 161 
Version 7.0, 10 Oct 2022 
8.10 Determination of Sample Size 
Sample size is determined by the number of patients that move into this Extension 
Phase from the parent study. The expectation is that between 60% and 70% of patients 
will rollover into the extension period. With 20 out of 32 patients (62.5%) rolling over, 
the study will have 80% power to detect an improvement in the success rate to 31% 
compared to the null hypothesis value of 10%. 


 
 
CONFIDENTIAL 
 
Page 154 of 161 
Version 7.0, 10 Oct 2022 
9 
DATA HANDLING AND RECORD KEEPING – EXTENSION PHASE 
See Section 9 of Parent Study.  


 
 
CONFIDENTIAL 
 
Page 155 of 161 
Version 7.0, 10 Oct 2022 
10 QUALITY CONTROL AND QUALITY ASSURANCE – EXTENSION 
PHASE 
See Section 10 of the Parent Study.  


 
 
CONFIDENTIAL 
 
Page 156 of 161 
Version 7.0, 10 Oct 2022 
11 ETHICAL, LEGAL AND ADMINISTRATIVE ASPECTS – EXTENSION 
PHASE 
See Section 11 of the Parent Study.  


 
 
CONFIDENTIAL 
 
Page 157 of 161 
Version 7.0, 10 Oct 2022 
12 LIST OF REFERENCES – EXTENSION PHASE 
Bremova, T., Malinová, V., Amraoui, Y., Mengel, E., Reinke, J., Kolníková, M., et al. 
(2015). Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology, 85(16), 
1368-1375. 
Cortina-Borja, M., te Vruchte, D., Mengel, E., Amraoui, Y., Imrie, J., Jones, S. A., et 
al. (2018). Annual severity increment score as a tool for stratifying patients with 
Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet Journal 
of Rare Diseases, 13, 143. 
EudraLex Volume 10. (2017). Ethical considerations for clinical trials on medicinal 
products conducted with minors: Recommendations of the expert group on clinical 
trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on 
medicinal products for human use. To be authorized under Regulation EU No 
536/2014, 
once 
it 
becomes 
applicable. 
Available 
at: 
https://ec.europa.eu/health/documents/eudralex/vol-10_en#fragment1. Accessed: 2019 
August 05. 
Fields, T. (2020). Clinical Impression of Change in Severity Administration and 
Scoring Manual. IntraBio Ltd Internal Document. 
Geberhiowt, T., Moro, A., Dardis, A., Ramaswami, U., Sirrs, S., et al. (2018). 
Consensus clinical management guidelines for Niemann-Pick disease type C. Journal 
of Rare Diseases, 13(50), 1-19.  
Kaya, E., Smith, D., Smith, C., Morris, L., Bremova-Ertl, T., et al. (2020). Acetyl 
leucine slows disease progression in lysosomal storage disorders. Journal of Clinical 
Medicine. BioRxiv. doi: https://doi.org/10.1101/2020.05.20.105973  
MCL Medpace Laboratories. (2019). Video Acquisition Manual. IntraBio Ltd. Internal 
Document. 
Picone, M. (2018). GM1 & GM2 Tanganil Health Initiative Report. Trend Community, 
1-6. 
Utz, J., Kim, S., King, K., Ziegler, R., Schema, L., Redtree, E., Whitley, C. (2017). 
Infantile gangliosidoses: Mapping a timeline of clinical changes. Mol. Genet., Metab., 
121, 170–179. 
Vanier, M. (2010). Niemann-Pick disease type C. Orphanet J. Rare Dis., 5, 16. 
Yanjanin, N.M., Vélez, J.I., Gropman, A., King, K., Bianconi, S.E., Conley, S.K., 
Brewer, C.C., et al. (2010). Linear Clinical Progression, Independent of Age of Onset, 
in Niemann-Pick Disease, type C. Am J Med Genet B Neuropsychiatr Genet., 
153B(1), 132–14


 
 
CONFIDENTIAL 
 
Page 158 of 161 
Version 7.0, 10 Oct 2022 
Table 6.1 – Schedule of Events for the Extension Phase 


 
 
CONFIDENTIAL 
 
Page 159 of 161 
Version 7.0, 10 Oct 2022 
Period in the Extension Phase (EP) 
EP Baseline Period 
EP Treatment Period I 
EP Wash-Out Period 
EP Treatment Period II 
EP Early Term. 
Duration of the whole period 
1 Day 
1 Day 
1 Year 
6 Weeks 
1 Year 
1 Day 
Visit number 
Visit 7Ai 
Visit 7B 
Visit 8 
Visit 9A 
Visit 9B 
Visit 10  
Visit 11 
Visit 12 / EOS 
ET 
Name of the Visit 
EP Screening/Bsl 
EP Baseline  
EP Treatment 1 
EP Treatment 2 
EP Treatment 2 
EP Washout 1 
EP Treatment 4 
EP Treatment 5 
EP ET 
Timeline (Days) 
Day -1 
Day 1, Start IMP 
Day 180 
Day 365 
Day 366  
Day 407 
Day 587 
Day 767 
XX 
Visit Window allowed 
na 
+6 dayii 
+/- 14 days 
+/- 14 days 
na 
+14 days 
+/- 14 days 
+/- 14 days 
na 
 
 
Patient information and informed 
consent process  
X 
 
 
 
 
X 
 
 
 
Inclusion / exclusion criteria 
X 
 
 
 
 
 
 
 
 
Patient Weight  
 
X 
X 
 
X 
X 
X 
X 
X 
Physical Examination 
 
X 
X 
 
X 
X 
X 
X 
X 
Documentation of concomitant 
medication 
X 
 
X 
 
X 
X 
X 
X 
X 
Documentation of frequency of 
therapy (hours per week) 
X 
 
X 
 
X 
X 
X 
X 
X 
Vital signs 
X 
 
X 
 
X 
X 
X 
X 
X 
12-lead electrocardiogram (ECG) 
 
 
 
X 
 
 
 
 
X 
Blood safety laboratory testsiii 
X 
 
X 
 
X 
X 
X 
X 
X 
Blood samples for research purposes 
X 
 
 
 
X 
 
 
X 
X 
PK Blood Samplingiv 
 
X 
 
 
X 
 
 
 
 
Urinalysis 
X 
 
X 
X 
 
X 
X 
X 
X 
Urine by dipstick for pregnancy testv  
X 
 
X 
X 
 
X 
X 
X 
X 
Urine test for N-Acetyl-D-Leucine 
X 
 
 
 
 
X 
 
 
X 
Quality of Life EQ-5D-5L for 
patients aged ≥18; EQ-5D-Y for 
children aged <18 yearsvi 
X 
 
X 
X 
 
X 
X 
X 
X 
Scale for Ataxia Rating (SARA) 
X 
 
X 
X 
 
X 
X 
X 
X 
Scale for Spinocerebellar Ataxia 
Functional Index (SCAFI) 
 
X 
 
X 
X 
 
X 
X 
X 
X 
Video-Recording Primary Anchor 
Tests (8MWT + 9HPT-D) 
Xvii 
 
X 
X 
 
X 
X 
X 
X 


 
 
CONFIDENTIAL 
 
Page 160 of 161 
Version 7.0, 10 Oct 2022 
Period in the Extension Phase (EP) 
EP Baseline Period 
EP Treatment Period I 
EP Wash-Out Period 
EP Treatment Period II 
EP Early Term. 
Duration of the whole period 
1 Day 
1 Day 
1 Year 
6 Weeks 
1 Year 
1 Day 
Visit number 
Visit 7Ai 
Visit 7B 
Visit 8 
Visit 9A 
Visit 9B 
Visit 10  
Visit 11 
Visit 12 / EOS 
ET 
Name of the Visit 
EP Screening/Bsl 
EP Baseline  
EP Treatment 1 
EP Treatment 2 
EP Treatment 2 
EP Washout 1 
EP Treatment 4 
EP Treatment 5 
EP ET 
Timeline (Days) 
Day -1 
Day 1, Start IMP 
Day 180 
Day 365 
Day 366  
Day 407 
Day 587 
Day 767 
XX 
Visit Window allowed 
na 
+6 dayii 
+/- 14 days 
+/- 14 days 
na 
+14 days 
+/- 14 days 
+/- 14 days 
na 
Abbreviations: EP = Extension Phase; na = not applicable.  
i Visit 7A may be taken from Visit 6, provided Visit 7B is scheduled within 1 day (+6 days) of Visit 6 
ii if Visit 7B cannot be scheduled 1 day (+6 days) after Visit 6, Visit 7A and Visit 7B should be conducted over a two-day period on two consecutive days, i.e. Visit 7B occurs 
+1 day after Visit 7A 
iii Analyzed at central lab 
iv Analyzed at PK lab 
v Only for women of childbearing potential; done at site 
vi If a patient turns 18 over the course of the study, they should continue to use the EQ-5D-Y 
Niemann-Pick Disease type C 
Clinical Severity Scaleviii 
X 
X 
X 
X 
 
X 
X 
X 
X 
Clinical Global Impression of 
Severity (CGI-S) by Physician 
X 
X 
X 
X 
 
X 
X 
X 
X 
Clinical Global Impression of 
Severity (CGI-S) by Caregiver 
X 
 
X 
X 
 
X 
X 
X 
X 
Clinical Global Impression of 
Severity (CGI-S) by Patient 
X 
 
X 
X 
 
X 
X 
X 
X 
Clinical Global Impression of 
Change (CGI-C) by Physician 
 
 
X 
X 
 
X 
X 
X 
X 
Clinical Global Impression of 
Change  
(CGI-C) by Caregiver 
 
 
X 
X 
 
X 
X 
X 
X 
Clinical Global Impression of 
Change 
(CGI-C) by Patient 
 
 
X 
X 
 
X 
X 
X 
X 
Documentation of AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Dispensing of study drug 
 
X 
X 
 
 
X 
X 
 
 
Intake of study drug at site 
 
X 
 
 
X 
 
 
 
 
Return of study drugix 
 
 
X 
 
X 
 
X 
X 
Xx 
Study drug compliance check 
 
 
X 
 
X 
 
X 
X 
X 


 
 
CONFIDENTIAL 
 
Page 161 of 161 
Version 7.0, 10 Oct 2022 
Period in the Extension Phase (EP) 
EP Baseline Period 
EP Treatment Period I 
EP Wash-Out Period 
EP Treatment Period II 
EP Early Term. 
Duration of the whole period 
1 Day 
1 Day 
1 Year 
6 Weeks 
1 Year 
1 Day 
Visit number 
Visit 7Ai 
Visit 7B 
Visit 8 
Visit 9A 
Visit 9B 
Visit 10  
Visit 11 
Visit 12 / EOS 
ET 
Name of the Visit 
EP Screening/Bsl 
EP Baseline  
EP Treatment 1 
EP Treatment 2 
EP Treatment 2 
EP Washout 1 
EP Treatment 4 
EP Treatment 5 
EP ET 
Timeline (Days) 
Day -1 
Day 1, Start IMP 
Day 180 
Day 365 
Day 366  
Day 407 
Day 587 
Day 767 
XX 
Visit Window allowed 
na 
+6 dayii 
+/- 14 days 
+/- 14 days 
na 
+14 days 
+/- 14 days 
+/- 14 days 
na 
vii If Visit 7A is based on Visit 6 assessments, the video recordings from Visit 6 should be used  
viii All major and minor domains should be assessed, with the exception of the hearing and auditory brainstem response domains  
ix Or after visit if IMP is returned via courier 
x If applicable 
General note: due to COVID-19, deviations from the schedule of visits and assessments may be necessary. Any changes to the schedule of visits/assessments should be 
discussed between the PI and Sponsor. 
 

SAP_001.pdf: 
 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 1 of 67 
  
STATISTICAL ANALYSIS PLAN 
 
 
 
 
(Short) study title:  
Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C: A 
multinational, multicenter, open-label, rater-blinded Phase II study  
Name of the sponsor:  
IntraBio Ltd.  
Protocol identification:  
IB1001-201, version 7.0 (10Oct2022), US version 7.1 (11Oct2022) 
Version and date of SAP:  Final 4.0, 26 January 2023 
 
 
 
 
 
                                          
 
 
 
 
 
Confidentiality statement 
This document is confidential. The information within this document may not be reproduced or otherwise 
disseminated without approval of IntraBio Ltd. 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 2 of 67 
 
VERSION HISTORY 
 
Version Date 
 History list  
0.1 
16 January 2019 
Draft version for sponsor review. 
0.2 
21 May 2019 
2nd Draft version for sponsor review. 
0.3 
18 July 2019 
Pre-final version for sponsor review. 
1.0 
24 July 2019 
Final version. 
1.1 
18 March 2020 
Draft version for sponsor review: new protocol version, 
including extension phase and some textual adaptions 
and clarifications. 
1.2 
16 April 2020 
Pre-final version for sponsor review, including a section 
on Covid-19. 
2.0 
20 May 2020 
Final version: separate Covid-19 document, addition of 
ITT analysis population, textual adaptations and 
clarifications. 
2.1 
23 September 2021 Update for extension phase for review, including 
changes in the analysis for the parent phase as 
considered change from SAP when performing the 
interim analysis for the Parent study phase. 
 
3.0 
13 October 2021 
Final version for signature. 
3.1 
22 December 2022 Update after update protocol for extension phase, for 
review. 
4.0 
26 January 2023 
Final version for signature. 
 
 
 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 3 of 67 
APPROVAL PAGE 
 
I hereby declare that I have read and reviewed this document. To the best of my knowledge, 
the content accurately states the intended analyses and output to be provided. This document 
is intended for an agreement on analysis and reporting details between the sponsor and 
Certara Inc. 
 
(Lead) Statistician: 
C. Baljé-Volkers, M.Sc. 
Certara Inc. (via Clin-Q B.V.) 
 
 
 
__________________________________                      ________________________ 
Signature 
Date 
 
Sponsor representative: 
Prof. M. Factor, Director 
IntraBio Ltd. 
 
 
 
__________________________________                      ________________________ 
Signature 
Date 
 
Sponsor Biostatistician: 
Dr Richard Kay, PhD 
RK Statistics 
 
 
 
__________________________________                      ________________________ 
Signature 
Date 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 4 of 67 
TABLE OF CONTENTS 
Version history ........................................................................................................................... 2 
Approval page ............................................................................................................................ 3 
Table of contents ........................................................................................................................ 4 
List of Abbreviations ................................................................................................................. 8 
1 
General ........................................................................................................................... 10 
2 
Study Information ........................................................................................................... 10 
2.1 
Study Objectives ................................................................................................. 10 
2.1.1 
Parent Study ................................................................................................. 10 
2.1.2 
Extension Phase ........................................................................................... 10 
2.2 
Design of the Study ............................................................................................ 11 
2.2.1 
Parent Study ................................................................................................. 11 
2.2.2 
Extension Phase ........................................................................................... 12 
2.3 
Study medication ................................................................................................ 13 
2.3.1 
Parent Study ................................................................................................. 13 
2.3.2 
Extension Phase ........................................................................................... 13 
2.4 
Sample size ......................................................................................................... 14 
2.4.1 
Parent Study ................................................................................................. 14 
2.4.2 
Extension Phase ........................................................................................... 14 
2.5 
Study flow chart .................................................................................................. 15 
2.5.1 
Parent Study ................................................................................................. 15 
2.5.2 
Extension phase ........................................................................................... 23 
3 
Subjects for Analysis ...................................................................................................... 26 
3.1 
Parent Study: Analysis populations .................................................................... 26 
3.1.1 
Intention-to-Treat (ITT) population ............................................................ 26 
3.1.2 
Modified Intention-to-Treat (mITT) population ......................................... 26 
3.1.3 
Per Protocol Set (PPS) ................................................................................. 26 
3.1.4 
Safety Analysis Set (SAF) ........................................................................... 26 
3.2 
Extension Phase: Analysis populations .............................................................. 26 
3.2.1 
Modified Intention-to-Treat Extension Phase (mITTe) population ............ 26 
3.2.2 
Safety Analysis Set Extension Phase (SAFe) .............................................. 26 
3.3 
Protocol deviations ............................................................................................. 26 
3.4 
Blinded Data Review Meeting ........................................................................... 27 
4 
Study endpoints .............................................................................................................. 27 
4.1 
Parent Study ........................................................................................................ 27 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 5 of 67 
4.1.1 
Primary endpoint ......................................................................................... 27 
4.1.2 
Key secondary efficacy endpoints ............................................................... 27 
4.1.3 
Additional secondary efficacy endpoints .................................................... 28 
4.1.4 
Exploratory endpoints ................................................................................. 29 
4.1.5 
Safety endpoints .......................................................................................... 29 
4.2 
Extension Phase .................................................................................................. 29 
4.2.1 
Primary endpoint ......................................................................................... 29 
4.2.2 
Secondary efficacy endpoints ...................................................................... 29 
4.2.3 
Exploratory endpoints ................................................................................. 29 
4.2.4 
Additional exploratory endpoints ................................................................ 30 
4.2.5 
Safety endpoints .......................................................................................... 30 
5 
Parent Study: Statistical Analysis ................................................................................... 31 
5.1 
General considerations ....................................................................................... 31 
5.2 
Adjudication of endpoint data ............................................................................ 31 
5.3 
Missing data ........................................................................................................ 32 
5.4 
Interim analysis ................................................................................................... 34 
5.5 
Baseline characteristics ....................................................................................... 34 
5.5.1 
Inclusion/exclusion criteria ......................................................................... 34 
5.5.2 
Demographics .............................................................................................. 34 
5.5.3 
Baseline characteristics ............................................................................... 34 
5.5.4 
Disposition ................................................................................................... 35 
5.5.5 
Medical history ............................................................................................ 35 
5.5.6 
Pregnancy data ............................................................................................. 35 
5.5.7 
Other screening data .................................................................................... 35 
5.6 
Statistical analysis efficacy endpoints ................................................................ 36 
5.6.1 
Primary endpoint ......................................................................................... 36 
5.6.2 
Key secondary endpoints ............................................................................. 37 
5.6.3 
Additional secondary endpoints .................................................................. 38 
5.6.4 
Other additional statistical analyses ............................................................ 39 
5.7 
Safety and tolerability evaluation ....................................................................... 40 
5.7.1 
Adverse events ............................................................................................. 40 
5.7.2 
Clinical laboratory ....................................................................................... 41 
5.7.3 
Vital Signs ................................................................................................... 42 
5.7.4 
Electrocardiography (ECG) ......................................................................... 42 
5.7.5 
Prior and concomitant medication/therapies ............................................... 42 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 6 of 67 
5.8 
Scheduled visits, dosing, and treatment compliance .......................................... 42 
5.8.1 
Visit dates .................................................................................................... 42 
5.8.2 
Dosing and treatment compliance ............................................................... 42 
6 
Extension Phase: Statistical Analysis ............................................................................. 43 
6.1 
General considerations ....................................................................................... 43 
6.2 
Adjudication of endpoint data ............................................................................ 44 
6.3 
Missing data ........................................................................................................ 44 
6.4 
Interim analysis ................................................................................................... 44 
6.5 
Baseline characteristics ....................................................................................... 45 
6.5.1 
Inclusion/exclusion criteria ......................................................................... 45 
6.5.2 
Demographics .............................................................................................. 45 
6.5.3 
Baseline characteristics ............................................................................... 45 
6.5.4 
Disposition ................................................................................................... 45 
6.5.5 
Medical history ............................................................................................ 46 
6.5.6 
Pregnancy data ............................................................................................. 46 
6.5.7 
Other screening data .................................................................................... 46 
6.6 
Statistical analysis efficacy endpoints ................................................................ 46 
6.6.1 
Primary endpoint ......................................................................................... 47 
6.6.2 
Secondary endpoints .................................................................................... 48 
6.6.3 
Exploratory endpoints ................................................................................. 48 
6.6.4 
Additional exploratory endpoints ................................................................ 49 
6.6.5 
Other additional statistical analyses ............................................................ 49 
6.7 
Safety and tolerability evaluation ....................................................................... 49 
6.8 
Scheduled visits, dosing, and treatment compliance .......................................... 50 
7 
Changes to protocol and other relevant remarks ............................................................ 50 
8 
COVID-19 details ........................................................................................................... 51 
9 
Data receipt ..................................................................................................................... 52 
10 
Technical details ............................................................................................................. 52 
10.1 
Programming conventions .................................................................................. 52 
10.2 
Coding ................................................................................................................ 56 
10.3 
Analysis software ............................................................................................... 56 
10.4 
Presentation of tables, listings, graphs ................................................................ 56 
11 
Tables, listings, graphs – parent study ............................................................................ 57 
11.1 
General ................................................................................................................ 57 
11.2 
In-text tables and graphs ..................................................................................... 57 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 7 of 67 
11.3 
End-of-text tables and graphs ............................................................................. 57 
11.4 
Listings ............................................................................................................... 62 
12 
Tables, listings, graphs – extension phase ...................................................................... 64 
12.1 
General ................................................................................................................ 64 
12.2 
In-text tables and graphs ..................................................................................... 64 
12.3 
End-of-text tables and graphs ............................................................................. 64 
12.4 
Listings ............................................................................................................... 66 
 
 
 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 8 of 67 
LIST OF ABBREVIATIONS 
_avg 
Average 
_recipr 
Reciprocal 
8MWT 
8-Meter Walking Test 
9HPT-D 
9 Hole Peg Test of the Dominant Hand 
9HPT-ND 
9 Hole Peg Test of the Non-Dominant Hand 
ADaM 
Analysis Data Model 
AE 
Adverse Event 
ALT 
Alanine Aminotransferase 
AST 
Aspartate Transaminase 
ATC 
Anatomic Therapeutic Chemical 
BDRM 
Blinded Data Review Meeting 
BL 
Baseline 
CFB 
Change from Baseline 
CGI-C 
Clinical Global Impression of Change 
CGI-I 
Clinical Global Impression of Improvement 
CGI-S 
Clinical Global Impression of Severity 
CI 
Confidence Interval 
CI-CS 
Clinical Impression of Change in Severity 
CI-S 
Clinical Impression of Severity 
COVID-19 
Coronavirus Disease 2019 
CRF 
Case Report Form 
EMA 
European Medicines Agency 
EU 
European Union 
FDA 
Food and Drug Administration 
FSH 
Follicle Stimulating Hormone 
GCP 
Good Clinical Practice  
ICH 
International Council on Harmonisation 
LoA 
Limits of Agreement 
LOCF 
Last Observation Carried Forward 
M(C)AR 
Missing (Completely) at Random 
MedDRA 
Medical Dictionary for Regulatory Activities 
mDRS 
Modified Disability Rating Scale 
mITT 
Modified Intention-to-Treat  
NPC 
Niemann-Pick disease type C 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 9 of 67 
PI 
Principal Investigator 
PK 
Pharmacokinetics 
PM 
Project Manager 
PPS 
Per Protocol Set 
PT 
Preferred Term 
RBC 
Red Blood Cell Count 
SAF 
Safety Analysis Set 
SAP 
Statistical Analysis Plan 
SAS 
Statistical Analysis System 
SARA 
Scale for the Assessment and Rating of Ataxia 
SCAFI 
Spinocerebellar Ataxia Functional Index 
SD 
Standard Deviation 
SDTM 
Study Data Tabulation Model 
SOC 
System Organ Class 
TEAE 
Treatment Emergent Adverse Event 
US 
United States 
VAS 
Visual Analogue Scale 
WBC 
White Blood Cell Count 
WHO 
World Health Organization 
 
 
 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 10 of 67 
1 
GENERAL 
This Statistical Analysis Plan (SAP) describes in detail the methods and presentation of the 
data analyses which will be conducted by Certara Inc. for study IB1001-201. This plan is 
written in agreement with protocol version 7.0, dated 10 October 2022 / US version 7.1 dated 
11 October 2022, and annotated Case Report Form (CRF) version 9.6, dated 22 June 2020, 
and the relevant Good Clinical Practice International Council on Harmonisation (GCP-ICH) 
guidelines. Furthermore, sponsor requirements for reporting will be considered. Additional 
changes or updates of those documents or requirements may result in a new version of the 
reporting/statistical analysis plan. This plan is to be finalized preferably prior to enrolment of 
the first patient in the study, but at least before first programming/data analysis. 
 
2 
STUDY INFORMATION 
2.1 
Study Objectives 
2.1.1 Parent Study 
Primary Objective 
The primary objective is to evaluate the efficacy of N-Acetyl-L-Leucine based on blinded 
raters’ clinical impression of change in severity (CI-CS) in the treatment of Niemann-Pick 
disease type C (NPC). 
 
Secondary Objectives 
The secondary objectives are: 
• To assess the clinical efficacy of N-Acetyl-L-Leucine on symptoms of ataxia, 
functioning, and quality of life for patients with NPC. 
• To evaluate the safety and tolerability of N-Acetyl-L-Leucine at 4 g/day in patients with 
NPC, including patients aged ≥18 years in the United States and patients aged ≥13 years 
in Europe, and weight-tiered doses in patients 6 to 12 years of age in Europe. 
 
Exploratory Objectives 
The exploratory objective is: 
• To characterize the pharmacokinetics (PK) of N-Acetyl-L-Leucine in patients with 
NPC. 
2.1.2 Extension Phase 
Primary Objective 
The primary objective in the Extension Phase is to evaluate the efficacy of N-Acetyl-L-
Leucine based on the 5-Domain Niemann-Pick type C Clinical Severity Scale (NPC-CSS). 
Secondary Objectives 
The secondary objectives are: 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 11 of 67 
• To evaluate the long-term safety and tolerability of N-Acetyl-L-Leucine at 4 g/day in 
patients aged ≥13 years, and weight-tiered doses in patients 6 to 12 years of age, with 
NPC 
• To characterize the pharmacokinetics (PK) of N-Acetyl-L-Leucine in patients with 
NPC. 
Exploratory Objectives 
The exploratory objectives are: 
• To assess the clinical efficacy of long-term treatment with N-Acetyl-L-Leucine on 
symptoms, functioning, and quality of life for patients with NPC 
• To assess the effects of a 42-day (+14 days) washout from N-Acetyl-L-Leucine after 
one-year treatment on symptoms, functioning, and quality of life for patients with NPC. 
 
2.2 
Design of the Study 
2.2.1 Parent Study 
This is a multinational, multicenter, open-label, rater-blinded Phase II study investigating the 
efficacy and safety of N-Acetyl-L-Leucine for the treatment of NPC. Approximately 39 male 
and female patients aged ≥6 years in Europe or ≥18 years in the United States with a 
confirmed diagnosis of NPC are planned to be enrolled. 
 
The visit schedule differs between “naïve” (patients not previously exposed to prohibited 
medications within the 6 weeks (42 days) before the initial screening visit) and “non-naïve” 
patients: see figures 1 and 2 below. 
 
Figure 1: Study Scheme for Naïve Patients 
 
 
 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 12 of 67 
Figure 2: Study Scheme for Non-naïve Patients 
  
2.2.2 Extension Phase  
The (full) Extension phase is considered the study period starting with the Extension phase 
baseline (Visit 7) until Visit 12. In some instances, however, it may be beneficial to make the 
following split:  
• Extension phase I is considered the study period starting with the Extension phase 
Visit 7 until Visit 10.  
• Extension phase II is considered the study period starting with the Extension phase 
Visit 10 until Visit 12. 
 
The Extension phase will enroll patients who have completed Visit 6 of the Parent study 
phase.  
 
During the Extension phase, patients will be assessed 6 times over a 25.5-month period. 
 
Baseline Visit of the Extension Phase  
Visit 7 (Part A and B) is the baseline of the extension phase. The assessments (Part A and 
Part B) comprising Visit 7 may be conducted over a two-day period (“Part A” and “Part B”). 
If Visit 7B is scheduled 1 day (+6 days) after Visit 6 (Washout 2 of the Parent study), the 
assessments conducted at Visit 6 should count as Visit 7A (i.e. the assessments do not need to 
be repeated). 
 
If Visit 7B cannot be scheduled 1 day (+6 days) after Visit 6, the assessments included in 
Visit 7A and Visit 7B should be performed over two consecutive days, i.e. Visit 7B occurs 
+1 day after Visit 7A. 
 
In general Visit 7A will be the same as Visit 6 in the Parent phase, or within one week 
following Visit 6. But a non-seamless transition of several weeks or months is possible. The 
same subject numbers will be used throughout the Parent and the Extension study phase. 
 
Extension Phase Treatment Period I 
From Visit 7B onward, all patients will receive treatment with N-Acetyl-L-Leucine for 
365 days (+/-14 days).  
Visit 8 will occur at approximately Day 180 (+/-14 days). 
Visit 9 (Part A and B) will occur at approximately Day 365 (+/-14 days). 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 13 of 67 
The assessments comprising Visit 9 may be conducted over a two-day period (“Part A” and 
“Part B”). 
 
Extension Phase Washout Period 
After Visit 9B, all patients will enter a 42-day (+14 days) washout phase.  
Visit 10 will occur at Day 407 (+ 14 days).   
 
Extension Phase Treatment Period II 
From Visit 10 onward, all patients will receive treatment with N-Acetyl-L-Leucine for 365 
days (+/-14 days). 
Visit 11 will occur at Day 587 (+/-14 days). 
Visit 12 will occur at Day 767 (+/-14 days). 
 
 
 
2.3 
Study medication 
2.3.1 Parent Study 
All patients are to receive N-Acetyl-L-Leucine (IB1001) in this single-arm study. The study 
drug will be taken during a 6-week (42 days + 7 days) treatment period. The patient’s dose 
for the Parent Study will be determined based on their age and weight at Visit 1. During the 
treatment phase of this study, the dosing of the study drug is as follows: 
 
• Patients aged ≥13 years in Europe and aged ≥18 years in the United States will take 
4 g per day: 2 g in the morning, 1 g in the afternoon, and 1 g in the evening. 
• Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the 
morning and 1 g in the evening. 
• Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the 
morning, 1 g in the afternoon, and 1 g in the evening. 
• Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g 
in the afternoon and 1 g in the evening (as per patients aged ≥13) 
2.3.2 Extension Phase 
All patients are to receive N-acetyl-L-leucine (IB1001) during the extension phase. The study 
drug will be taken for two 365-day (+/- 14 days) treatment periods (Extension phases I and II). 
The patient’s dose for the Extension phase I will be determined based on their age and weight 
at Visit 7, following the same tiered doses as for the Parent study (see Section 2.3.1). The 
patient’s dose for the Extension phase I will be determined based on their age and weight at 


 
 
  Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 14 of 67 
Visit 7, following the same tiered doses as for the Parent study (see Section 2.3.1). The patient’s 
dose for the Extension phase II will be determined based on their age and weight at Visit 10, 
following the same tiered doses as for the Parent study (see Section 2.3.1).  
In the event a patient turns 13 years old, or a patient aged 6-12 years old changes weight 
categories between Visit 7 and Visit 8 or Visit 10 and Visit 11 of the Extension Phase, their 
daily dose will be adjusted accordingly at Visit 8 or Visit 11 (respectively). 
2.4 
 Sample size 
2.4.1 Parent Study 
Under the original protocol, it was postulated that N-Acetyl-L-Leucine will show 
effectiveness in 30% of patients and this success rate is viewed as being clinically important. 
Assuming that this group of patients will have scores that are evenly distributed across the 
values 1 and 2 for the primary endpoint and further that the remaining 70% of patients will 
have scores that are evenly distributed between the values -1, 0, and 1, the resulting mean 
score is 0.45 and the standard deviation for the primary endpoint is 1.02. With 30 patients 
reporting on the primary endpoint, the study will have 76% power to detect a treatment 
benefit in a 5% one-sided one-sample t-test. 
 
Recruitment will continue until approximately 30 patients complete dosing. The following 
numbers of patients are foreseen: 
 
• To be enrolled: Approximately 39 patients  
• To be analyzed according to the modified Intention to Treat analysis (mITT): 
Approximately 36 patients 
• To be analyzed according to the Per Protocol Set (PPS): Approximately 30 patients 
2.4.2 Extension Phase 
The sample size is determined by the number of patients that move into this Extension Phase 
from the Parent Study. The expectation is that between 60% and 70% of patients will rollover 
into the extension period. With 20 out of 32 patients (62.5%) rolling over, the study will have 
80% power to detect an improvement in the success rate to 31% compared to the null 
hypothesis value of 10%. 
Patients who completed Visit 10 of the Extension phase and are willing to continue for an 
additional year will continue in the Extension Phase until Visit 12. 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 15 of 67 
2.5 
Study flow chart 
2.5.1 Parent Study 
Schedule of Events for “Naïve” Patients 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 16 of 67 
 
 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 17 of 67 
 
General note: due to COVID-19, deviations from the schedule of visits and assessments may be necessary, i.e. visits may be skipped, postponed, or performed remotely. 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 18 of 67 
Schedule of Events for “Non-naïve” Patients 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 19 of 67 
 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 20 of 67 
 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 21 of 67 
 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 22 of 67 
 
General note: due to COVID-19, deviations from the schedule of visits and assessments may be necessary, i.e. visits may be skipped, postponed, or performed remotely. 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 23 of 67 
2.5.2 Extension phase 
 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 24 of 67 
 
 
 
 
 


 
 
                          Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201 
                                                                         
                                         US version 7.1 (11Oct2022)   
 
 
                                         Final SAP 4.0, 26Jan2023 
Confidential 
 
Page 25 of 67 
 
 
 
General note: due to COVID-19, deviations from the schedule of visits and assessments may be necessary, i.e. visits may be skipped, postponed, or performed remotely. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 26 of 67 
 
3 
SUBJECTS FOR ANALYSIS 
3.1 
Parent Study: Analysis populations  
3.1.1 Intention-to-Treat (ITT) population 
The ITT population will consist of all patients who receive at least one dose of study drug (N-
Acetyl-L-Leucine) and with one video recording at either Visit 1 or Visit 2 (or both). 
3.1.2 Modified Intention-to-Treat (mITT) population 
The mITT population will consist of all patients who receive at least one dose of study drug 
(N-Acetyl-L-Leucine) and with one video recording at either Visit 1 or Visit 2 (or both) and 
one video recording at either Visit 3 or Visit 4 (or both). 
3.1.3 Per Protocol Set (PPS) 
The PPS will consist of all patients with at least one video recording at baseline (either Visit 1 
or Visit 2), end of treatment (either Visit 3 or Visit 4), and end of washout (either Visit 5 or 
Visit 6) and without any major protocol deviations that can influence the validity of the data 
for the primary efficacy variable.  
3.1.4 Safety Analysis Set (SAF) 
The Safety Analysis Set (SAF) will consist of all patients who receive at least one dose of 
study drug (N-Acetyl-L-Leucine). 
 
3.2 
Extension Phase: Analysis populations 
The Extension Phase will only include patients who completed Visit 6 of the Parent Study 
and fulfill the inclusion criteria of the Extension Phase. Patients who completed Visit 10 of 
the Extension phase and are willing to continue for an additional year will continue in the 
Extension Phase until Visit 12. 
3.2.1 Modified Intention-to-Treat Extension Phase (mITTe) population 
The mITTe population will consist of all patients who receive at least one dose of study drug 
(N-Acetyl-L-Leucine) in the Extension Phase and with NPC-CSS scores at Visit 7. This 
analysis population will be used for efficacy analyses throughout the Extension phase until 
Visit 12.  
3.2.2 Safety Analysis Set Extension Phase (SAFe) 
The SAFe will consist of all patients who receive at least one dose of study drug (N-Acetyl-
L-Leucine) in the Extension Phase. This analysis population will be used for all safety 
analyses throughout the Extension phase until Visit 12.  
3.3 
Protocol deviations 
Major protocol deviators will be identified to the extent possible by individuals responsible 
for data collection/compliance, and its analysis and interpretation. Any subjects or data values 
excluded from the PPS analysis will be identified, along with their reason for exclusion. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 27 of 67 
 
3.4 
Blinded Data Review Meeting 
There will be a BDRM meeting held for the Parent study. No BDRM will be necessary for 
the Extension phase since no Per Protocol analysis population will be defined then. 
 
The patients will be classified during the Blinded Data Review Meeting (BDRM) to the 
analysis populations based upon the protocol deviations. Invitees to this meeting are the 
Sponsor’s Medical Expert, the Sponsor’s representative, the Sponsor’s Project Manager 
(PM), the Medical Monitor, the Sponsor statistician, and the Certara statistician, but more 
roles can be invited if considered necessary. Input to this meeting will be supplied by the 
involved Data Management provider or the responsible PM at least one week in advance of 
the meeting: a blinded list of all protocol deviations (including missing and likely erroneous 
data), with specific detailing and description regarding the deviation, preferably in Excel. 
 
Possible compliance issues and unforeseen or reclassification of categories for missingness of 
the primary endpoint data will be part of the discussions held at the meeting.  
 
Where possible, this meeting will be held in a blinded manner, that is blind to study outcome 
data (also for open studies). The goal of this meeting is to reach consensus on minor and 
major protocol deviations. In case of a major deviation impacting the primary or secondary 
endpoints, the specific patient will be excluded from the PPS population, either completely or 
from a specific time point onwards. The meeting must be held prior to database lock.  
 
The decisions taken during this meeting and the reasons for those decisions will be 
documented by the PM (or a delegate as agreed) and sent for review to all parties involved as 
soon as possible after the meeting, but before database lock. If all parties involved agree, then 
the document is finalized, signed and stored in the TMF before database lock. 
 
4 
STUDY ENDPOINTS  
4.1 
Parent Study 
4.1.1 Primary endpoint 
The primary efficacy endpoint is based on the blinded raters’ Clinical Impression of Change 
in Severity (CI-CS) score on either the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or 
the 8 Meter Walk Test (8MWT). The primary endpoint is defined as the CI-CS comparing the 
end of treatment (Visit 4) with baseline (Visit 2) minus the CI-CS comparing the end of 
washout (Visit 6) with the end of treatment (Visit 4). 
4.1.2 Key secondary efficacy endpoints  
Supportive secondary endpoints that directly supplement the analysis of the primary endpoint 
will be evaluated as follows: 
 
• The individual components of the primary endpoint, that is the CI-CS from Visit 2 to 
Visit 4 and the CI-CS from Visit 4 to Visit 6. 
• Difference in the blinded rater’s Clinical Impression of Severity (CI-S) values from 
baseline (average of Visit 1 and Visit 2) to end of treatment (average of Visit 3 and 
Visit 4) and from end of treatment (average of Visit 3 and Visit 4) to end of washout 
(average of Visit 5 and Visit 6). 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 28 of 67 
 
• Measurement of change in performance of the CI-CS score of either the 9HPT-D or 
the 8MWT reclassified to a 3-point scale.  
• An evaluation of the CI-CS for the test (9HPT-D or 8MWT) that was not selected as 
the primary anchor test. 
4.1.3 Additional secondary efficacy endpoints 
For all additional secondary endpoints, the change from Visit 2 to Visit 4 and the change 
from Visit 4 to Visit 6 will be evaluated. 
Measurement of Ataxia and Functioning 
• Spinocerebellar Ataxia Functional Index (SCAFI). 
The SCAFI is composed of the 8MWT, the 9HPT, and the PATA rate, a measure of 
speech performance. 
• Scale for Assessment and Rating of Ataxia (SARA) score. 
SARA has 8 items that are related to gait, stance, sitting, speech, finger-chase test, 
nose-finger test, fast alternating movements and heel-shin test. 
 
Measurement of Health-related Quality of Life 
• Quality of Life EQ-5D-5L for patients aged ≥18; EQ-5D-Y for children aged 6-17 
years (two parts: the EQ visual analogue scale (EQ-VAS) and the EQ descriptive 
system). 
 
Measurement of Overall Neurological status 
• Modified Disability Rating Scale (mDRS) 
The scores of the six components (ambulation, language, manipulation, swallowing, 
seizures, and ocular movement) of this scale add up to a composite value. 
 
Measurement of Global Impression 
• Clinical Global Impression of Severity by the treating physician (CGI-S-physician) at 
every visit. 
• Clinical Global Impression of Change by the treating physician (CGI-C-physician) 
comparing end of treatment (Visit 4) to baseline (Visit 2), and end of washout (Visit 
6) to end of treatment (Visit 4). 
• Clinical Global Impression of Severity by the caregiver (CGI-S-caregiver) at every 
visit. 
• Clinical Global Impression of Change by the caregiver (CGI-C-caregiver) comparing 
Visit 4 to Visit 2 and Visit 6 to Visit 4. 
• Clinical Global Impression of Severity by the patient (CGI-S-patient) at every visit if 
they are able. 
• Clinical Global Impression of Change by the patient (CGI-C-patient) comparing Visit 
4 to Visit 2 and Visit 6 to Visit 4 if they are able. 
 
The CGI-S scales are on a 7-point scale ranging from ‘normal, not ill at all’ to ‘among the 
most ill patients’. The CGI-C scales are also on a 7-point scale ranging from ‘very much 
improved’ to ‘very much worse’. 
 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 29 of 67 
 
4.1.4 Exploratory endpoints  
Sparse PK sampling will be collected for biochemical analysis so to characterize the 
pharmacokinetics of N-Acetyl-L-Leucine in patients with NPC.  
(Note that analysis and reporting of pharmacokinetics is outside the scope of this analysis 
plan. PK data handling, analysis and reporting will be done by an external company that 
specializes in PK analysis and reporting. The PK report will be added to Appendix 16.1 of the 
CSR as a separate document.) 
4.1.5 Safety endpoints 
The safety parameters to be evaluated are: 
• Adverse Events 
• Laboratory safety measurements: haematology, clinical chemistry, urinalysis 
• Vital signs 
• Electrocardiography (ECG) 
 
4.2 
Extension Phase 
With respect to the parent study, all endpoints for the Extension phase are considered 
secondary to the endpoints of the Parent study phase. 
4.2.1 Primary endpoint  
The primary endpoint is based on the modified 5-domain NPC-CSS score with success 
defined as no change or a decrease in the 5-domain NPC-CSS score from Visit 7 to Visit 9.  
4.2.2 Secondary efficacy endpoints  
Supportive secondary endpoints for the Extension Phase that directly supplement the analysis 
of the primary endpoint for the Extension Phase will be evaluated as follows: 
• Full PK sampling at Visit 7 and Visit 9 to characterize the pharmacokinetics of N-
Acetyl-L-Leucine in patients with NPC.  
(Note that analysis and reporting of pharmacokinetics is outside the scope of this 
analysis plan. PK data handling, analysis and reporting will be done by an external 
company that specializes in PK analysis and reporting. The PK report will be added to 
Appendix 16.1 of the CSR as a separate document.)  
 
4.2.3 Exploratory endpoints  
Exploratory endpoints will investigate other measures of symptoms and quality of life from 
Visit 7 to Visit 9 for the following measures: 
Measurement of Ataxia and Functioning 
• Spinocerebellar Ataxia Functional Index (SCAFI). 
The SCAFI is composed of the 8MWT, the 9HPT, and the PATA rate, a measure of 
speech performance. 
• Scale for Assessment and Rating of Ataxia (SARA) score. 
SARA has 8 items that are related to gait, stance, sitting, speech, finger-chase test, 
nose-finger test, fast alternating movements and heel-shin test. 
 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 30 of 67 
 
Measurement of Health-related Quality of Life 
• Quality of Life EQ-5D-5L for patients aged ≥18; EQ-5D-Y for children aged 6-17 
years (two parts: the EQ visual analogue scale (EQ-VAS) and the EQ descriptive 
system). 
 
Measurement of Global Impression 
• Clinical Global Impression of Severity by the treating physician (CGI-S-physician).  
• Clinical Global Impression of Change by the treating physician (CGI-C-physician). 
• Clinical Global Impression of Severity by the caregiver (CGI-S-caregiver). 
• Clinical Global Impression of Change by the caregiver (CGI-C-caregiver). 
• Clinical Global Impression of Severity by the patient (CGI-S-patient) if they are able. 
• Clinical Global Impression of Change by the patient (CGI-C-patient) if they are able. 
 
The CGI-S scales are on a 7-point scale ranging from ‘normal, not ill at all’ to ‘among the 
most ill patients’. The CGI-C scales are also on a 7-point scale ranging from ‘very much 
improved’ to ‘very much worse’. 
 
Measurement of Disease Progression 
• NPC-CSS (Niemann-Pick disease type C clinical severity scale). 
• ASIS (Annual Severity Increment Score).  
 
Videos of the primary and non-primary anchor tests are collected throughout the extension 
phase for the CI-CS. These videos may be analyzed in order to inform the development and 
validation of the CI-CS.  
4.2.4 Additional exploratory endpoints  
For all additional exploratory endpoints, the change from Visit 7 to Visit 10, Visit 9 to Visit 
10 and Visit 10 to Visit 12 may also be evaluated. In addition, the change from Visit 1 to 
Visit 12 may also be investigated. 
• SCAFI 
• 9-HPT of dominant hand 
• 8MWT 
• SARA 
• Health-related Quality of Life (EQ-5D-5L/Y) 
• CGI-S by physician 
• CGI-S by caregiver 
• CGI-S by patient if able 
• CGI-C by physician 
• CGI-C by caregiver 
• CGI-C by patient if able 
• NPC-CSS 
• Modified (5-domain) NPC-CSS 
4.2.5 Safety endpoints 
The safety parameters to be evaluated are: 
• Adverse Events 
• Laboratory safety measurements: haematology, clinical chemistry, urinalysis 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 31 of 67 
 
• Vital signs 
• ECGs 
• Physical Examination 
 
5 
PARENT STUDY: STATISTICAL ANALYSIS  
5.1 
General considerations 
The parent study is considered the study period between screening (Visit 0 or Visit 1) through 
Visit 6. 
 
Raw data (in listings) will be presented in the same precision as received. Appropriate 
rounding will be performed for the following summary statistics, where applicable: mean, 
standard deviation (SD) and two-sided 90% confidence limits will be presented with at least 
one more decimal than the original data; minimum and maximum values will be presented 
with the same precision as the original data. In frequency tables, percentages will be 
presented with 1 decimal unless otherwise stated.  
 
P-values will be presented with 3 decimals, and those smaller than 0.001 will be replaced by 
<0.001. One-sided p-values smaller than 0.05 will be considered statistically significant for 
the primary endpoint and indicative for other endpoints. No adjustment for multiple 
comparisons will be applied. Conclusions regarding treatment efficacy will not solely rely on 
detecting statistical significance but equal emphasis will be placed on the magnitude and 
clinical relevance of treatment differences as judged by the point estimates. All evaluations 
other than the primary endpoint will be considered exploratory in nature. 
 
Descriptive statistics presented in general summary tables will be the number of non-missing 
observations (n), mean, SD, minimum, median and maximum for quantitative data. For 
categorical data, frequency counts and percentages will be determined. 
 
In general, baseline is defined as the value measured prior to first study treatment 
administration (at Visit 2), unless otherwise specified. In case no value at Visit 2 is available, 
the value measured at Visit 1 will be used. A footnote may be added to those tables/listings 
presenting baseline value, with an explanation how this value was assessed.  
 
If available in the database, data for screening failures will not be presented in summary 
tables, except for disposition, medical history and end-of-study displays. Data for screening 
failures will be listed as available. 
 
A treatment emergent adverse event (TEAE) is defined as an adverse event that appears 
during or after study treatment and was absent before.  
5.2 
Adjudication of endpoint data 
Each individual video (CI-S) or video pairing (CI-CS) will be read by two independent 
reviewers. For the CI-S assessments of the primary and non-primary anchor test, the 
independent raters will be given 6 videos of the patient’s performance taken at Visit 1 to Visit 
6. For the CI-CS assessments of the primary and non-primary anchor test, the raters will be 
given three pairs of videos and asked to score the CI-CS for each video pair. The video pairs 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 32 of 67 
 
will be labeled Video A to Video B, Video B to Video C, and Video C to Video A1. The 
videos will be presented in a random order, and the independent raters will be blinded to the 
timepoint corresponding to each video. The appropriate Likert scale score will be provided to 
each of the videos and pairs of videos. 
 
For the CI-CS assessment, pairs of videos will be evaluated with the Likert scale defined 
as: 
• Significantly Improved (Score = +3) 
• Much Improved (Score = +2) 
• Minimally Improved (Score = +1) 
• No Observable Change (Score = 0) 
• Minimally Worse (Score = -1) 
• Much Worse (Score = -2) 
• Significantly Worse (Score = -3) 
 
If there is a scoring difference between the two blinded raters for a CI-CS assessment, the 
following rules will apply: 
• If the difference between the blinded raters is 1, the two scores will be averaged, and 
the unrounded average value will be used for further analysis.  
• If there is a scoring difference of >1 between the two blinded raters for a CI-CS 
assessment, then a third blinded rater will review the scores and will determine which 
score is more accurate (adjudication by consensus). The adjudicator's decision will be 
the final score for that video assessment and used for further analysis. 
For the CI-S assessment, individual videos will be evaluated with the Likert scale defined 
as: 
• Normal, not at all ill (Score = +3) 
• Borderline ill (Score = +2) 
• Mildly ill (Score = +1) 
• Moderately ill (Score = 0) 
• Markedly ill (Score = -1) 
• Severely ill (Score = -2) 
• Among the most extremely ill patients (Score = -3) 
 
If there is any scoring difference between the two blinded raters for a CI-S assessment, the  
two scores will be averaged, and the unrounded average value will be used for further  
analysis.  
 
Note that in averaging situations for the CI-CS and CI-S assessments, the scores may not fit  
the Likert scales as mentioned above. In case of average scoring present in the database,  
presentations will be on score only, without the additional description. 
 
5.3 
 Missing data 
Patients that withdraw from the study are replaced at the discretion of the sponsor. Data from 
withdrawal patients will be included in the analysis until their last assessment. 
 
 
1 MCL Medpace Laboratories. (2019). Video Review Charter. IntraBio Ltd. Internal Document. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 33 of 67 
 
For handling missing data of the statistical analyses applied to the primary and key secondary 
endpoints, refer to the respective analysis sections.  
 
For other endpoints being presented with descriptive statistics only, such as 
baseline/screening data, safety presentations, additional secondary endpoints and (additional) 
exploratory endpoints, no imputation will be performed, unless otherwise specified (in the 
respective analysis section or in Section 10.1). All these analyses will be performed on data 
available at the visit considered. In summary tables, the number of patients without missing 
data will be presented (per visit, if applicable) unless otherwise specified. In calculations of 
percentages, subjects with missing data will not be considered in numerator or denominator 
unless otherwise specified.  
 
Using the most conservative approach, missing/incomplete information related to AEs will be 
handled as listed below, to indicate an AE as being treatment emergent or presented having a 
certain intensity/causality. Note that the imputed dates or intensity/causality will not appear 
in data listings, but only in descriptive statistics tables (where applicable). 
 
• In case of (partially) missing onset dates, the AE will be handled as follows: 
o If full start date is available, and on or after first dosing date, the AE is 
considered treatment emergent. 
o In case full stop date is available and prior to first dosing date, the AE is 
considered prior. 
o If the day part of the start date is missing: 
§ The AE is considered treatment emergent if the month and year of the 
start date are the same or after the month and the year of the first 
dosing date. 
o If the day and month part of the start date are missing: 
§ The AE is considered treatment emergent if the year of the start date is 
the same or after the year of the first dosing date. 
o In case the start date is completely missing:  
§ If stop date is fully available and on or after the first dosing date, the 
AE is considered treatment emergent. 
§ If the stop date is partially missing, but the month and year (or year 
alone in case of missing month) are after the month and year (or year 
alone) of the first dosing date, the AE is considered treatment 
emergent. 
o In case full start date and full stop date are missing, the AE is considered 
treatment emergent. 
 
• In case intensity is missing for a certain TEAE, this will be regarded as severe.  
• In case causality is missing for a certain TEAE, this will be regarded as related.  
• In case seriousness is missing for a certain AE, this is discussed and addressed prior to 
database lock and unblinding in agreement with the sponsor and data management 
provider.  
 
Regarding prior/concomitant medication, a similar approach will be followed for partially 
missing dates, as will be done for AEs as described above. If a comedication is started and 
stopped prior to the first date of study treatment (i.e. first dosing date), this is considered 
prior. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 34 of 67 
 
 
Based on the BDRM, certain values can be decided to be excluded from analyses. These 
values will be listed, but not included in descriptive statistics, plots or statistical analyses. 
This may be outlier data that are a result of unambiguous measurement errors.  
5.4 
Interim analysis 
Per-patient data listings and summary tables/plots will be provided for the several DSMB 
meetings and as specified in the DSMB Charter. 
 
A limited draft analysis prior to database lock of the Parent Study is scheduled as indicated 
by an NTF created by IntraBio. 
 
There will be an analysis of the primary, secondary, and exploratory endpoints relating to the 
Parent phase once Visit 6 has been completed, and an interim CSR will be written.  
5.5 
Baseline characteristics 
5.5.1 Inclusion/exclusion criteria 
An individual patient listing of the deviations from inclusion and exclusion criteria will be 
presented. 
 
5.5.2 Demographics 
Demographic data at baseline will be summarized for all patients and by the 4 
age/weight/dosing groups in tabulations.  
Appropriate descriptive statistics for age, height, weight, BMI, ethnic group and sex will be 
given. The summary will be created for each analysis population separately. Additionally, 
demographic data will be listed.  
 
5.5.3 Baseline characteristics 
The following relevant patient baseline characteristics will be listed and summarized overall 
(frequency and percentage) and are considered key subgroups. The subgroups differentiated 
on a median value will use the median value as determined for the specific analysis 
population. 
• Naïve versus non-naïve as determined at screening 
• Age (paediatric versus adult) 
• Age/weight/dosing group  
• Region (US versus EU) 
• Selected Primary Anchor Test (9HPT-D or 8MWT)  
• Patients on miglustat vs Patients not on miglustat at baseline visit (Visit 1 and/or 
Visit 2) 
• Composite of SARA Subtests 1- 4 (Gait, Stance, Sitting, Speech): classification 
based on below (≤)/above the median value at Visit 1. 
• Intra-Patient variability between SARA score at Visit 1 (Baseline 1) vs Visit 2 
(Baseline 2): classification based on below (≤)/above the median value of the 
difference between the two visits. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 35 of 67 
 
• Intra-Patient variability between CI-S score (for primary anchor only) Visit 1 
(Baseline 1) vs Visit 2 (Baseline 2): classification based on below (≤)/above the 
median value of the difference between the two visits. 
• Age of diagnosis: Early-infantile (<2 years), Late-infantile (2 to < 6 years), Juvenile 
(6 to < 15 years), Adolescent/Adult (≥ 15 years) 
• Disease severity: classification based on below (≤)/ above the median SARA score at 
Visit 1. 
 
5.5.4 Disposition 
A summary table will be created, stating the number of patients per site, including site 
number, location/country, and investigator. 
 
To present disposition, a summary of all included, randomised, treated and completed 
patients will be created. Number/percentage screened will be included as well (if available in 
the database). Additionally, in the same summary, the number/percentage of patients in the 
SAF, mITT and PPS will be presented. Furthermore, the frequency and percentage per reason 
for non-completion will be added. 
 
Additionally, a listing displaying all disposition information (including reasons for 
withdrawal and reasons for exclusion from the analysis population, if available electronically) 
on a per patient level will be created. This listing will include follow-up time for each patient, 
calculated from date of first dose until end of study for the parent phase.  
 
5.5.5 Medical history 
Medical history will be tabulated per System Organ Class (SOC) and Preferred term (PT) 
according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology list 
and presented as number/percentage of patients in each SOC and PT for the SAF. SOC and 
PT will be presented in descending order of frequency of occurrence based on SOC and PT. 
These data will also be listed on a per patient level. 
 
NPC specific history will be summarized as appropriate, presenting confirmed diagnosis 
(yes/no) and time since diagnosis. For calculation of time since diagnosis, see Section 10.1.  
 
NPC specific history data as collected will also be listed on a per patient level. 
5.5.6 Pregnancy data 
Pregnancy test result data will be listed for females of childbearing potential only, on a per 
visit basis. 
5.5.7 Other screening data 
Other data collected at screening and/or baseline only, if available, will be listed. These 
screening/baseline data will be presented using all subjects included in the study, if 
applicable.  


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 36 of 67 
 
5.6 
Statistical analysis efficacy endpoints 
The primary analysis population is the mITT for the primary and all secondary endpoints. 
Analyses of these endpoints based on the PPS will also be undertaken to provide 
supplementary information on efficacy. The ITT population will be used only for baseline 
summary tables. 
 
Analyses of the primary endpoint based on the mITT population will utilise a last observation 
carried forward (LOCF) approach for missing/unreadable videos at Visit 5 and Visit 6. For 
the primary endpoint CI-CS, this implies that the CI-CS value for Visit 4 to Visit 6 will be 
assigned the value 0 (stable) if both videos at Visit 5 and Visit 6 are unavailable. 
 
Also, for the key secondary endpoint, Change in Severity Score based on Averaged Clinical 
Impression of Severity (CI-S), it is assumed that if both videos are missing/unreadable for the 
baseline (Videos from Visit 1 or 2), treatment (Videos from Visit 3 or 4), or washout (Videos 
from Visit 5 or 6) period, the average change from one period to another will be assigned the 
value 0 (stable).  
 
A sensitivity analysis for missing data will be performed for the statistical analyses to 
compare patient’s outcome on the primary outcome measure and their compliance throughout 
the study. The robustness of the primary analyses in the mITT analysis set will be assessed as 
follows:  
 
• If either video for Visit 3 or Visit 4 is available but both videos for Visit 5 and Visit 6 
are not available, then the value -1 (worsening) will be used instead of 0 for the CI-CS 
for Visit 4 to Visit 6 unless the missingness is due to a technical reason (MCAR, e.g. 
due to machine failure).  
 
For each of the primary and secondary endpoints there will be separate descriptive statistical 
displays within the key subgroups as listed in Section 5.5.3 without any statistical analysis. 
For the subgroup presentations, only the mITT population will be used. Spaghetti plots will 
not be created for the subgroup analyses; these will be presented in forest plots (one for each 
endpoint, excluding the SARA -, SAFI - and mDRS subscores and excluding the EQ-5D-
5L/Y), presenting the mean or (pseudo-)median with a 90% two-sided CI, using a stem at 
mean or median difference of 0, where applicable. Upon discretion of the programmer, the 
forest plots may be presented as two plots: one for Visit 4 versus Visit 2 and one for Visit 6 
versus Visit 4.  
Considering the number of subgroups, the forest plots may become unclear and 
indecipherable. When that occurs, a split will be made into two forest plots for the endpoints: 
one for the first 7 subgroups, and one for the remaining. 
 
All individual primary and secondary endpoint data will be listed as well. 
 
5.6.1 Primary endpoint 
The primary efficacy endpoint is based on the blinded raters’ Clinical Impression of Change 
in Severity (CI-CS) score over 6 weeks determined by comparing videos showing the 
patient’s performance on a pre-defined anchor clinical symptom scale: either the 9 Hole Peg 
Test of the Dominant Hand (9HPT-D) or the 8 Meter Walk Test (8MWT).  


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 37 of 67 
 
 
For each patient, there will be two CI-CS scores. These two scores indicate the level of 
change in severity observed in Visit 4 (end of treatment) compared to Visit 2 (baseline) and 
the level of change in severity observed in Visit 6 (end of washout) compared to Visit 4 (end 
of treatment). Both CI-CS scores are measured on a 7-point Likert-point scale (-3 = 
significantly worse to +3 = significantly improved, see Section 5.2 for the precise definition) 
and the primary endpoint is defined as the difference between both CI-CS scores.  
 
The primary endpoint will be summarized using descriptive statistics, including a frequency 
table, and frequency percentages will be presented graphically using a bar chart.  
The primary statistical analysis will be performed using a one-sample t-test comparing the 
CI-CS difference score to zero. Statistical output will present the number of patients included 
in the analysis, both CI-CS scores, the mean of the difference, the corresponding two-sided 
90% confidence interval, and a one-sided p-value. 
 
The assumption of normality will be visually checked and if the assumption does not hold, a 
Wilcoxon signed-rank test will be performed instead of the t-test using the difference score. 
Statistical output will then present the number of patients included in the analysis, both CI-
CS scores, the (pseudo-) median of the difference using the Hodges-Lehmann estimator, the 
corresponding two-sided 90% confidence interval, and a one-sided p-value. 
 
5.6.2 Key secondary endpoints 
All key secondary endpoints will be presented using the mITT and PPS populations. 
 
Clinical Impression of Change in Severity 
The CI-CS scores on the pre-defined anchor test for Visit 4 versus Visit 2, and the CI-CS 
score on the pre-defined anchor test for Visit 6 versus Visit 4 will be evaluated separately. 
These key secondary endpoints will be summarized using descriptive statistics and frequency 
tables, and percentages will be shown graphically using a bar chart. No sensitivity analysis 
will be applied. 
 
Change in severity score based on Averaged Clinical Impression of Severity (CI-S) 
CI-S scores are measured on a 7-point Likert-point scale (-3 = among the most extremely ill 
patients to +3 = normal, not at all ill; see Section 5.2 for the precise definition) and the 
primary endpoint is defined as the difference between both CI-CS scores.  
Improvement in the pre-defined anchor test measure will be evaluated based on the change in 
the blinded raters’ CI-S scores between the baseline period (average for Visit 1 and Visit 2) 
and end of treatment period (average for Visit 3 and Visit 4) minus the change in CI-S 
between end of treatment period (average for Visit 3 and Visit 4) and end of washout period 
(average for Visit 5 and Visit 6). Note that if a CI-S score is missing at one visit for a period, 
but available at the other visit in the same period, that one value will be used instead of the 
average. The presentations and statistical analyses will be similar to the primary endpoint, 
excluding the sensitivity analysis which is only to be used for the primary endpoint. Data 
received for non-anchor CI-S scores will only be listed. 
 
Clinical Impression of Change in Severity reclassified on a 3-point scale 
Using the CI-CS outcome on the pre-defined anchor test based on the data for Visits 2 and 
Visit 4, any patient given a score <0 on the CI-CS will be classified as worsened (-1). Any 
patient classified as 0 on the CI-CS will be classified no change (0). Any patient given a score 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 38 of 67 
 
>0 on the CI-CS will be classified as improved (+1). Similarly, the CI-CS comparing Visit 4 
and Visit 6 will be reclassified and the differences between these two scores on a 3-point 
scale will be calculated. 
The descriptive table and graphical presentations will be similar to the primary endpoint. No 
statistical analysis will be performed, and no sensitivity analysis will be applied. 
 
Clinical Impression of Change in Severity (CI-CS) score non-primary anchor test  
Descriptive statistics and frequency tables of the CI-CS scores for the test (9HPT-D or 
8MWT) that was not selected as the primary anchor test will be presented for Visit 4 versus 
Visit 2, and separately, for Visit 6 versus Visit 4. No plots will be created, and no sensitivity 
analysis will be applied. 
 
5.6.3 Additional secondary endpoints 
All additional secondary endpoints will be presented using the mITT and PPS populations, 
and all individual data will be listed as well. No sensitivity analysis will be applied. 
 
Measurement of Ataxia and Functioning 
• SARA total score 
• SCAFI total score 
o 9HPT-D 
o 9HPT-ND 
o 8MWT 
o PATA test 
 
Descriptive statistics will be used to summarize the endpoints above at each visit.  
 
The subscores of the SARA score (gait, stance, sitting, speech disturbance, finger chase, 
nose-finger test, fast alternating hand movements, heel-shin slide) will also be summarized 
for each visit using descriptive statistics. Stacked bar charts will be provided per visit, based 
on the subscores of the total SARA score.  
 
Spaghetti plots of individual patient SARA total scores and the SCAFI total scores versus 
time will be made as well as a mean or median display versus time, depending upon the 
distribution, and corresponding two-sided 90% CI at each visit. 
 
The average SCAFI subscores (8MW_avg, 9HPT-D_avg, 9HPT-ND_avg and PATA_avg) as 
determined according to Section 10.1, following the scoring manual, will also be summarized 
with descriptive statistics. 
 
The changes in SARA total score, SCAFI total score, the SCAFI subscores (8MW_avg, 
9HPT-D_avg, and PATA_avg) between Visit 2 and Visit 4, as well as the changes between 
Visit 4 and Visit 6 will be analysed using a one-sample t-test or a Wilcoxon Signed Rank test 
depending on the distribution of the data. The SCAFI subscore 9HPT-ND_avg will only be 
descriptively summarized in tabular format. 
 
Measurement of Health-related Quality of Life 
The results of EQ-5D-5L as well as the EQ-5D-Y will be combined into a 5-digit number 
presenting the health status of the subject. Frequency tables will be presented per visit for the 
5 domains, as well as for the 5-digit number of the EQ-5D-5L and the EQ-5D-Y separately.  


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 39 of 67 
 
In addition, EQ-5D-5L and EQ-5D-Y domain percentages will be presented in separate bar 
charts per visit, with all visits combined into one plot (if possible). 
 
The EQ-VAS score will be summarized by visit using descriptive statistics for patients aged 
< and ≥18 years combined. Spaghetti plots of individual patient EQ-VAS scores versus time 
will be made as well as a mean or median display versus time, depending upon the 
distribution, and corresponding two-sided 90% CI at each visit. 
 
Measurement of Overall Neurological Status 
The mDRS composite score and individual components (ambulation, language, manipulation, 
swallowing, seizures, and ocular movement) will be summarized using descriptive statistics 
at each visit. As graphical display, a stacked bar chart of the 6 mDRS subscores at each visit 
will be created. Spaghetti plots of individual patient mDRS composite scores versus time will 
be made as well as a mean or median display versus time, depending upon the distribution, 
and corresponding two-sided 90% CI at each visit. 
 
Furthermore, changes in the mDRS composite score between Visit 2 and Visit 4 as well as 
between Visit 4 and Visit 6 will be descriptively presented in a summary table.  
 
Measurement of Global Impression 
The three CGI-S scores (scored by treating physician, caregiver, and patient) will be 
summarized using descriptive statistics and frequency tables for each visit. 
Bar charts will be presented for the three CGI-S scores, spaghetti plots of individual CGI-S 
scores versus time will be made as well as a mean or median display versus time, depending 
upon the distribution, and corresponding two-sided 90% CI at each visit. 
 
Descriptive statistics and frequency tables will also be used to summarize the three CGI-C 
scores (treating physician, caregiver and patient) between Visit 2 and Visit 4, and between 
Visit 4 and Visit 6, and corresponding bar charts will be created. 
 
The CGI-C scores for Visit 4 versus Visit 2, and for Visit 6 versus Visit 4 will be evaluated 
using descriptive statistics. Similarly, the CGI-C from Visit 2 to Visit 4 minus the CGI-C 
from Visit 4 to Visit 6 will be presented descriptively. In addition, the CGI-C measures for 
treating physician will be analyzed similar to the primary endpoint: the CGI-C from Visit 2 to 
Visit 4 minus the CGI-C from Visit 4 to Visit 6 will be compared to a difference of zero 
using a one-sample t-test or Wilcoxon signed-rank test. 
 
Note that CGI-C is referred to as CGI-I in the eCRF. 
 
It is important to realize that the CGI-S and CGI-C scores per visit for each patient as 
provided by the caregiver may be based on varying caregivers and hence additional variation 
is introduced. No correction for this variation can be done and a footnote will be added to the 
table to describe this situation. 
 
5.6.4 Other additional statistical analyses 
The following analysis will provide an estimate of intra-patient variability and provides 
information on the stability of the outcome evaluation. Note that, considering the high degree 
of variability within and between these patients, this is only a simple approach as results may 
be influenced by e.g. rater variability, disease progression or treatment effect. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 40 of 67 
 
The analysis will be done for the mITT population only, and only for the CI-S outcome of the 
videos. No sensitivity analysis will be applied, and no separate analysis will be performed for 
subgroups. 
The Intraclass Correlation Coefficient (ICC) will be used as an index of reliability to measure 
agreement between pairs of observations for Visit 1 and 2, Visit 3 and 4, and Visit 5 and 6 
respectively, presenting the proportion of the total variance in the observations that is due to 
the differences between pairs. The ICC takes on values between 0 (meaning no agreement) to 
1 (perfect agreement), with and ICC >0.80 representing high reliability. No imputation for 
missing visits will be done, and the ICC can only be determined for subjects having data for 
both visits in the pairs. The ICC value and the corresponding 95% confidence interval will be 
presented in a tabular format, and for additional clarity the number of available pairs will be 
added as well. 
 
5.7 
Safety and tolerability evaluation 
5.7.1 Adverse events 
A treatment emergent adverse event (TEAE) is defined as an adverse event (AE) that appears 
during or after study treatment and was absent before. 
 
An AE overview table will be created displaying the number and percentage of subjects 
experiencing a treatment-emergent adverse event (TEAE) and the number of TEAEs for: any 
TEAE, any mild/moderate/severe TEAE, any related/unrelated TEAE, any serious AE, and 
any TEAE leading to study discontinuation. 
 
Furthermore, all TEAEs will be tabulated by System Organ Class (SOC) and Preferred Terms 
(PTs) within each SOC according to the MedDRA terminology list, using frequency counts 
(number of subjects with at least one event, and number of events) and percentage of subjects 
with the event.  
 
TEAEs will also be tabulated by severity (mild/moderate/severe) and by relationship to study 
medication (related/unrelated). Similar tables will be created for TEAEs leading to premature 
discontinuation, SAEs and deaths, if applicable. These summary tables will be presented by 
decreasing frequency of occurrence based on SOC and PT. 
 
In addition, similar TEAE tables (overall, by severity and by relationship, premature 
discontinuation, SAEs, and deaths) by SOC and PT will be presented per treatment cycle, and 
frequencies and percentages will be determined for the active treatment cycle and the 
washout cycle. The treatment cycle is the period between start of first treatment at Visit 2 and 
24 hours after last dose at Visit 4. The washout cycle starts 24 hours after last dose at Visit 4 
until and including Visit 6. 
  
The summary tables will be accompanied by individual subject listings of all AEs including 
information on AE number, actual AE description, date/time of start and end of AE (or 
ongoing), PT (MedDRA), SOC (MedDRA), severity, relationship, pre-dose (yes/no), 
seriousness, action taken, outcome and other information collected in the CRF for adverse 
events. Pre-dose AEs are not considered to be treatment-emergent, except in case of 
worsening during/after study treatment (to be collected as separate AE in the database). AEs 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 41 of 67 
 
starting prior to administration of the study drug will only be listed. In this listing, a clear 
distinction will be made between prior and treatment emergent events. 
 
To address the study delays due to Covid-19 in reference to AE occurrences, AE incidence 
rates will also be determined per study cycle (treatment cycle and washout cycle). Incidence 
rate of adverse events is defined as the number of adverse event cases per patient-year(s). The 
calculation of the incidence rate is the number of cases (i.e. patient with an AE) divided by 
the sum of the follow-up time of all patient at risk (which will be all subjects receiving 
treatment). This calculation is accomplished as follows: 
- 
Denominator: ∑pi × ti, where pi = patient i and ti= treatment duration of 
patient i in years (total # days divided by 365.25), where treatment 
duration is determined based on first and last (dose) date. 
- 
Numerator: the total number of cases (note: a single patient can be counted 
more than once if the AE occurs on separate occasions) 
- 
Incidence rate=numerator/denominator 
 
The use of this measure implies the assumption that the incidence rate is constant over 
different periods of time. Since the calculation is done per cycle, the denominator (patient-
years) is also determined per cycle, based on the patients available within that cycle. 
 
Separate listings will be created for SAEs and deaths, if applicable. The SAF population is 
used for the AE presentations. 
5.7.2 Clinical laboratory 
The following laboratory safety data are collected for this study: 
Haematology 
Chemistry 
Urinalysis 
Hemoglobin 
Sodium 
Leukocytes 
Erythrocytes 
LDH (Lactate dehydrogenase) 
Nitrite 
Hematocrit 
Potassium 
Urobilinogen 
Thrombocytes 
Creatinine  
Protein 
Leukocytes 
Serum bilirubin level 
pH 
 
AST (Aspartate aminotransferase) 
Occult blood (erythrocytes, 
leucocytes) 
 
ALT (Alanine aminotransferase) 
Specific gravity 
 
Urea 
Ketones 
 
ALP (Alkaline phosphatase) 
Bilirubin 
 
FSH (Follicle-stimulating hormone) 
(for postmenopausal women only) 
Glucose 
 
Laboratory safety data for haematology, biochemistry and urinalysis will be summarized 
using descriptive statistics and listed per visit, using protocol visits. Change from baseline 
will be calculated and presented as well for quantitative data, using the same summary 
statistics. If applicable, laboratory safety data collected as additional/unscheduled 
assessments (i.e. apart from those per protocol) will only be listed and will not be used in 
summary statistics. 
Baseline is defined as the Visit 2 measurement. In case the Visit 2 measurement is missing, 
the Visit 1 measurement will be used.  
 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 42 of 67 
 
For laboratory safety data, all recorded and determined laboratory safety data will be listed, 
including information on the reference ranges, if available. In addition, information regarding 
age at screening and sex will be added to the listing. 
 
All safety laboratory parameters will be presented in the tables and listings in the same 
standard units as supplied, which will be SI units.  
 
Lastly, for clinical laboratory parameters, a listing will be created presenting all data that are 
out of reference range on a per-patient level, including any available unscheduled 
measurements. Note that clinical significance for out-of-range values is not collected per 
eCRF and can therefore not be presented. Information regarding age at screening and sex will 
be added to this listing. The SAF population is used for the presentations. 
5.7.3 Vital Signs 
Vital sign data consist of measurements for pulse rate and systolic/diastolic blood pressure 
(sitting). Vital signs will be summarized and listed per visit (protocol visits). Change from 
baseline will be calculated and presented as well, using the same summary statistics. Visit 2 
is considered the baseline visit for vital signs; in case Visit 2 is missing, the Visit 1 
measurement will be used as baseline instead. If applicable, vital sign measurements 
collected as additional/unscheduled assessments (i.e. apart from those per protocol) will only 
be listed and will not be used in summary statistics. The SAF population is used for the 
presentations. 
5.7.4 Electrocardiography (ECG) 
ECG outcome results (corrected QT interval and normal/abnormal result) will be presented 
descriptively per protocol visit. If applicable, ECG measurements collected as 
additional/unscheduled assessments (i.e. apart from those per protocol) will only be listed and 
will not be used in summary statistics. The SAF population is used for the presentations. 
5.7.5 Prior and concomitant medication/therapies 
The use of prior and concomitant medication/therapies will be listed for all subjects: included 
will be the preferred term, World Health Organization (WHO) coding information and the 
Anatomic Therapeutic Chemical (ATC) class code), dose, route of administration, start and 
stop date, frequency and reason for administration, as well as information if given for an AE. 
Differentiation will be made between prior and concomitant medication/therapies, by creating 
two separate listings. A frequency table per ATC class code and WHO drug code will be 
created if considered relevant, separately for prior and concomitant medication/therapies. The 
SAF population is used for the presentation. 
5.8 
Scheduled visits, dosing, and treatment compliance 
5.8.1 Visit dates  
A listing with actual visit dates (and times, if applicable) per patient will be presented.  
 
5.8.2 Dosing and treatment compliance 
Relevant dosing information (first dosing date, last dosing date), scheduled and actual dosing 
dates/times and treatment compliance information will be determined and listed for each 
patient. Summary statistics for the number of N-Acetyl-L-Leucine doses taken during the 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 43 of 67 
 
Parent study phase, based on bottles/sachets of dispensed and returned unused bottle/sachets 
counts, will be calculated. Compliance is defined as 100% * (total number of IB1001 bottles 
and/ or sachets dispensed – total number of IB1001 unused bottles and/ or sachets returned), 
divided by the number of bottles which should have been used. Note that the number of bottles 
and/ or sachets the patients should have used depends on the dosage they should take (see 
Section 2.3 for reference) and the duration of the treatment period. Considering the fact that 
the patient’s total daily dose may be reduced by up to half of their assigned dose at the 
discretion of the investigator, the actual dose will be used to determine the correct compliance 
calculation, if collected in the eCRF. The proportion of patients who take at least 80% of the 
prescribed medication will also be shown. Total dosing period is defined as the duration (in 
days) between first dose date and last dose date.  
 
6 
EXTENSION PHASE: STATISTICAL ANALYSIS  
6.1 
General considerations 
The Extension phase is considered the study period starting with the Extension phase baseline 
(Visit 7) until Visit 12. In principle, data presentations will be created for the full Extension 
phase. Only where applicable and relevant, a separation will be made as follows:  
• Extension phase I:  Extension phase Visit 7 until Visit 10 
• Extension phase II: Extension phase Visit 10 until Visit 12. 
 
All evaluations will be exploratory in nature, and all endpoints for the Extension Phase are 
considered secondary to the endpoints of the Parent Study. Statistical analysis will only be 
applied for some of the endpoints as defined for Extension phase I, no statistical analyses will 
be done for the endpoints in Extension phase II. 
Summary presentations and listings will be presented and only reported data will be 
presented (i.e. no imputation or LOCF will be done) for data collected during Extension 
phase II. If not otherwise defined, data will we presented as missing where applicable. 
Raw data (in listings) will be presented in the same precision as received. Appropriate 
rounding will be performed for the following summary statistics, where applicable: mean, 
standard deviation (SD) and two-sided 90% confidence limits will be presented with at least 
one more decimal than the original data; minimum and maximum values will be presented 
with the same precision as the original data. In frequency tables, percentages will be 
presented with 1 decimal unless otherwise stated.  
 
P-values will be presented with 3 decimals, and those smaller than 0.001 will be replaced by 
<0.001. One-sided p-values smaller than 0.05 will be considered statistically significant for 
the primary endpoint and indicative for other endpoints. No adjustment for multiple 
comparisons will be applied. Conclusions regarding treatment efficacy will not solely rely on 
detecting statistical significance but equal emphasis will be placed on the magnitude and 
clinical relevance of treatment differences as judged by the point estimates.  
 
Descriptive statistics presented in general summary tables will be the number of non-missing 
observations (n), mean, SD, minimum, median and maximum for quantitative data. For 
categorical data, frequency counts and percentages will be determined. 
 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 44 of 67 
 
For the full Extension Phase, the measurement at Visit 7 is considered the baseline. In case of 
missing Visit 7A data for safety measurements (e.g. for safety lab), and Visit 7B has occurred 
within 1 (+6) days of Visit 6, the Visit 6 data from the Parent Study should be used instead 
(data are not being re-entered in the database): see also Section 2.2.2 for clarification. No 
screen failures will be present in the data. 
 
No screen failures will be present in the data. 
 
For the full Extension Phase, a treatment emergent adverse event (TEAE) is defined as an 
adverse event (AE) that appears during or after the start of study treatment in the Extension 
Phase at Visit 7B and was absent before. As a consequence, AEs occurring during the 
washout phase between Visit 9 and Visit 10 will also be considered treatment emergent. 
6.2 
Adjudication of endpoint data 
Videos of the primary and non-primary anchor tests are collected throughout the extension 
phase for the CI-CS. These videos may be analyzed in order to inform the development and 
validation of the CI-CS but will not be reported in the CSR (and hence not listed or 
tabulated). Data received will be included as-is in the CDISC files. In case of analysis, the 
following process applies: For the CI-CS assessments of both the primary and non-primary 
anchor tests, after a patient completes Visit 10 of the Extension phase, the independent raters 
will be given 3 video pairs of from Visit 7 to Visit 9, Visit 9 to Visit 10, and Visit 7 to Visit 
10. After a patient completes Visit 12 of the Extension phase, the independent raters will be 
given a video pair from Visit 10 to Visit 12 (the raters may also assess additional video pairs, 
i.e. Visit 1 to Visit 12, on an exploratory basis). The videos will be presented in a random 
order, and the independent raters will be blinded to the timepoint corresponding to each 
video. The appropriate Likert scale score will be provided to each of the videos and pairs of 
videos. For further details regarding scoring and adjudication, which will be similar to that of 
the Parent study, see Section 5.2.  
 
6.3 
 Missing data 
Data from withdrawal patients will be included in the analysis until their last assessment. 
 
For handling missing data in the Extension Phase, similar approaches as described in Section 
5.3 will be followed, with the alteration that “first dose date” is the first dosing of the 
Extension Phase. For AE and concomitant medication this indicates that events started during 
the Parent Study and continuing during the Extension Phase will be considered prior for the 
Extension Phase. 
6.4 
Interim analysis 
Per patient data listings and summary tables/plots will be provided for several DSMB 
meetings as specified in the DSMB Charter created for the Parent study. 
 
The final CSR will be written upon the completion of the full Extension phase, and no 
interim analysis is performed during the Extension phase. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 45 of 67 
 
6.5 
Baseline characteristics 
6.5.1 Inclusion/exclusion criteria 
An individual patient listing of the deviations from inclusion criteria will be presented. No 
exclusion criteria are collected for the Extension Phase, and no separate inclusion is done for 
Extension phase II. 
 
6.5.2 Demographics 
Demographic data at baseline will be summarized for all patients and by the 4 
age/weight/dosing groups (using Visit 7 information) in tabulations, even if there is a change 
in dose between Visit 7 and 8, or between Visit 8 and 10, or Visit 10 and 11 (see Section 
2.3.2).  
Appropriate descriptive statistics2 for age, height, weight, BMI, ethnic group and sex will be 
given. The summary will be created for each analysis population separately. Additionally, 
demographic data will be listed.  
 
6.5.3 Baseline characteristics 
The following relevant patient baseline characteristics will be listed and summarized overall 
(frequency and percentage) and are considered key subgroups, and will only be used for 
presentations of the primary endpoint in Extension phase I analyses: 
• Naïve versus non-naïve, as determined at screening during the parent study 
• Age (paediatric versus adult) at Visit 7 
• Gender (male versus female) 
• Age/weight/dosing group as applicable at Visit 7 
• Selected Primary Anchor Test (9HPT-D or 8MWT) as defined during the parent 
study 
• Patients on miglustat vs Patients not on miglustat at Visit 7  
• Composite of SARA Subtests 1- 4 (Gait, Stance, Sitting, Speech): classification 
based on below (≤)/above the median value at Visit 7 
• Composite of modified (5 domain) NPC-CSS score: classification based on below 
(≤)/above the median value at Visit 7 
• ASIS: classification based on below (≤)/above the median value at Visit 7 
• Age of diagnosis: Early-infantile (<2 years), Late-infantile (2 to < 6 years), Juvenile 
(6 to < 15 years), Adolescent/Adult (≥ 15 years) 
• Disease severity: classification based on NPC-CSS below (≤)/ above the median 
score at Visit 7. 
 
6.5.4 Disposition 
A summary table will be created, stating the number of patients per site, including site 
number, location/country, and investigator. 
 
2 Only present descriptive statistics and listings for those demographics data that are collected during the 
Extension Phase. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 46 of 67 
 
 
To present disposition, a summary of all included, treated, and completed patients will be 
created for the Extension phase I and II separately, and for the full Extension phase. 
Additionally, in the same summary, the number/percentage of patients in the SAFe and 
mITTe will be presented. Furthermore, the frequency and percentage per reason for non-
completion will be added. 
 
A listing displaying all disposition information (including reasons for withdrawal and reasons 
for exclusion from the analysis population, if available electronically) on a per patient level 
will be created. This listing will include follow-up time for each patient, calculated from date 
of first dose during the Extension Phase until end of Extension phase or withdrawal date. 
 
6.5.5 Medical history 
Note that only for patients not having a seamless transition from the Parent study to the 
Extension phase, additional medical history data may be collected during the intermediate 
time. Medical history3 will be tabulated per System Organ Class (SOC) and Preferred term 
(PT) according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology 
list and presented as number/percentage of patients in each SOC and PT for the SAFe. SOC 
and PT will be presented in descending order of frequency of occurrence based on SOC and 
PT. These data will also be listed on a per patient level.  
6.5.6 Pregnancy data 
Pregnancy test result data will be listed for females of childbearing potential only, on a per 
visit basis. 
6.5.7 Other screening data 
Other data collected at screening and/or baseline only, if available, will be listed. These 
screening/baseline data will be presented using all subjects included in the extension phase, if 
applicable.  
6.6 
Statistical analysis efficacy endpoints 
The analysis population for all efficacy endpoints is the mITTe.  
 
Analyses of the primary and key secondary endpoints based on the mITTe population will 
utilise a last observation carried forward (LOCF) approach for missing NPC-CSS scores at 
Visit 9. For the primary endpoint 5-Domain NPC-CSS this implies that the measurement of 
Visit 8 will be used instead. Other endpoints will not be imputed, and missing data will be 
reported as is. No sensitivity analyses will be applied.  
 
For the primary endpoint for the Extension Phase there will be separate descriptive statistical 
displays within the key subgroups as listed in Section 6.5.3, without any statistical analysis. 
For the subgroup presentations, only the mITTe population will be used. No plots will be 
created. All individual primary endpoint data will be listed as well. 
 
 
3 Only collected medical history between the Parent phase and Extension phase, as the medical history for the 
Parent phase will already be presented in the interim CSR. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 47 of 67 
 
All efficacy endpoints for Extension phase Visit 10 to Visit 12 are considered exploratory, 
and therefore described under section 6.6.3. 
 
6.6.1 Primary endpoint 
The Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS) measures disease 
progression4 via clinical signs and symptoms in 9 major (ambulation, cognition, eye 
movement, fine motor, hearing, memory, seizures, speech, swallowing) and 8 minor/modifier 
(auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, 
narcolepsy, psychiatric, respiratory problems) domains. A higher NPC-CSS score indicates a 
clinical worsening, while a lower NPC-CSS score indicates a clinical improvement. A 0-point 
change in the NPC-CSS score represents a stabilization of disease progression, which is also 
considered a significant clinical improvement. In the current study, a 15-domain version of 
the NPC-CSS has been used which omits the ‘hearing’ major domain, and the ‘auditory brain 
stem’ minor domain from the full 17-domain scale. A modified (5 domain) NPC-CSS score is 
limited to the assessment of the following 5 major domains: ambulation, cognition, fine 
motor, speech, and swallowing.  
 
The primary endpoint in this Extension Phase is success measured on the 5-domain NPC-
CSS score from the Extension Phase baseline (Visit 7) to the end of treatment in the 
Extension Phase (Visit 9).  Success is defined as no change or a decrease in the 5-domain 
NPC-CSS score from Visit 7 to Visit 9.  
The primary endpoint will be summarized using a frequency table. The primary statistical 
analysis of comparing the proportion success with the null proportion of 0.10 will be done 
using a one-sided Fisher’s Exact Test, expecting an increase in the success rate. The 
statistical result (one-sided p-value and exact 90% confidence interval5) will be added to the 
frequency table. This analysis is considered to be exploratory. 
 
The modified (5 domain) NPC-CSS score will also be presented descriptively including 
change from baseline values (Visit 9 versus Visit 7). This modified score will range between 
0 and 25. If collected, data at Visit 1 of the parent study will also be included. 
 
In addition, a spaghetti plot presenting the total modified (5-domain) NPC-CSS scores of 
each patient through time will be created. 
 
 
4 Cortina-Borja et al. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment 
to clinical trials. Orphanet Journal of Rare Diseases (2018) 13:143.  
 
Orphazyme (2019) Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C 
(NPC) [Press Release]. 30 January 2019. 
Patterson, M., Mengel, E., Bembi, B., Del Toro, M., Deodato, F., et al. Efficacy and Safety of Arimoclomol in Patients with Niemann–Pick 
Disease Type C: Results from a Double-Blind, Randomized, Placebo-Controlled Trial of a Novel Treatment. Poster presented at: 16th 
Annual WORLDSymposium; 2020 Feb 10-13; Orlando, FL 
Yanjanin M. et al. Linear Clinical Progression, Independent of Age of Onset, in Niemann-Pick Disease, type C. Am J Med Genet B 
Neuropsychiatr Genet. 2010 January 5; 153B(1): 132–140. 
 
Mengel et al. Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study. Orphanet J Rare Dis 
(2020) 15:328 
 
5 The exact CI and the p-value using the Fisher’s Exact test can contradict each other, especially in small sample sizes. Therefore, the exact 
CI will include a mid-p adjustment. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 48 of 67 
 
6.6.2 Secondary endpoints  
As PK is handled by an external company, there are no analyses for secondary endpoints to 
add here. 
6.6.3 Exploratory endpoints  
All exploratory endpoints for the Extension Phase will be presented using the mITTe 
population, and all individual data will be listed as well. For all exploratory efficacy 
endpoints, the change from Visit 7 to Visit 9 will be evaluated. Except for 15-domain NPC-
CSS and modified (5-domain) NPC-CSS, no statistical analysis other than descriptive 
statistics will be done. No plots will be created. 
Measurement of Ataxia and Functioning 
• SARA total score 
• SCAFI total score 
o 9HPT-D 
o 9HPT-ND 
o 8MWT 
o PATA test 
 
Descriptive statistics will be used to summarize the endpoints above at each visit.  
 
The subscores of the SARA score (gait, stance, sitting, speech disturbance, finger chase, 
nose-finger test, fast alternating hand movements, heel-shin slide) will not be summarized 
separately, and only listed.  
 
The average SCAFI subscores (8MW_avg, 9HPT-D_avg, 9HPT-ND_avg and PATA_avg) as 
determined according to Section 10.1, following the scoring manual, will also be summarized 
with descriptive statistics. 
 
The changes in SARA total score, SCAFI total score, and the SCAFI subscores (8MW_avg, 
9HPT-D_avg, 9HPT-ND_avg and PATA_avg) between Visit 7 and Visit 9 will be 
descriptively summarized in tabular format as well. 
 
Measurement of Health-related Quality of Life 
The results of EQ-5D-5L as well as the EQ-5D-Y will be combined into a 5-digit number 
presenting the health status of the subject. Frequency tables will be presented per visit for the 
5 domains, as well as for the 5-digit number of the EQ-5D-5L and the EQ-5D-Y separately.  
 
Note that if a patient turns 18 before Visit 7, this patient can have results on EQ-5D-Y in the 
Parent Study, and results on EQ-5D-5L in the Extension phase Visit 7 to 10. For this reason, 
separate QoL presentations will be created for Extension phase I, using Visit 7 measurements 
as baselines. The EQ-VAS score will be summarized by visit using descriptive statistics in a 
combined manner for patients aged < and ≥18 years (using Visit 7 age values).  
 
Measurement of Global Impression 
The three CGI-S scores (scored by treating physician, caregiver, and patient) will be 
summarized using descriptive statistics and frequency tables for each visit.  
 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 49 of 67 
 
Descriptive statistics and frequency tables will also be used to summarize the three CGI-C 
scores (treating physician, caregiver, and patient) between Visit 7 and Visit 9. 
 
Note that CGI-C is mentioned as CGI-I in the eCRF. 
 
It is important to realize that the CGI-S and CGI-C scores per visit for each patient as 
provided by the caregiver may be based on varying caregivers and hence additional variation 
is introduced. No correction for this variation can be done and a footnote will be added to the 
table to describe this situation. 
 
Measurement of Disease Progression 
Descriptive statistics will be provided for (15 domain) NPC-CSS total sum score, including 
Visit 1 of the parent study if collected. Change from baseline (Visit 9 versus Visit 7) will be 
presented descriptively as well. The sum of the major domains (ranging from 0-40), the sum 
of the modifier domains (ranging from 0-14), and each domain subscore at each visit will not 
be presented descriptively, and only included in listings. 
 
The ASIS score is obtained by dividing the total NPC-CSS severity score of a patient by the 
age of the patient (at Visit 9), providing a measure of the rate of disease progression in 
individual patients. Descriptive statistics for ASIS will be provided, including the change in 
ASIS score from Visit 7 to Visit 9. 
6.6.4 Additional exploratory endpoints  
For all additional exploratory endpoints as described in Section 4.2.4, descriptive 
presentations will be made and the change from Visit 7 to Visit 10, Visit 9 to Visit 10, Visit 
10 to Visit 12, and Visit 1 to Visit 12 will be evaluated descriptively. No plots will be 
created, and no statistical analysis done. 
These presentations include the endpoints as mentioned above in sections 6.6.1, 6.6.2, and 
6.6.3 that will be presented as exploratory using only descriptive statistics for the Extension 
phase on data collected after Visit 10. For EQ-5D-5L as well as the EQ-5D-Y, a different 
questionnaire could be used between Visits 10 and 12 if a patient turns 18 before Visit 10, 
and for this reason separate QoL presentations will be created for Extension phase II, using 
Visit 10 measurements as baselines. The EQ-VAS score will be summarized by visit using 
descriptive statistics in a combined manner for patients aged < and ≥18 years (using Visit 10 
age values).  
For presentations on efficacy data collected after Visit 10, no imputations or LOCF is 
considered necessary.  
6.6.5 Other additional statistical analyses 
No other additional statistical analyses are foreseen. 
6.7 
Safety and tolerability evaluation 
The safety and tolerability evaluation for the extension study is similar to what is described 
for the Parent study (see Section 5.7), with the remark that the evaluation is limited to the 
Extension phase only and Visit 7 is considered the baseline. For the AE presentation per 
treatment cycle, the cycles for Extension phase are as follows:  


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 50 of 67 
 
- 
Treatment cycle Extension phase I: the period between start of first 
treatment at Visit 7 and 24 hours after last dose at Visit 9.  
- 
Washout cycle Extension phase I: starts 24 hours after last dose at Visit 9 
until and includes Visit 10.  
- 
Treatment cycle Extension phase II: the period between start of first 
treatment at Visit 10 and 24 hours after last dose at Visit 12.  
- 
No washout cycle is defined for Extension phase II. 
Note that for those patients that do not transition seamlessly to the Extension phase, 
additional prior medication/adverse events may be collected at the start of the Extension 
phase, and these will be presented separately from the prior medication/adverse events of the 
Parent phase. 
Physical examination, which is collected twice during the Extension phase, will be presented 
as follows: general physical examination data will be tabulated and listed per visit. The 
summary table will include number/percentage of patients with normal or abnormal 
observations and NCS/CS frequencies/percentages for abnormal observations per visit. 
6.8 
Scheduled visits, dosing, and treatment compliance 
The presentation for the Extension study phase is similar to what is described for the Parent 
study (see Section 5.8), with the remark that the evaluation is limited to the Extension phase 
only and Visit 7 is considered the baseline. Compliance calculations are done for Extension 
phase I and II separately, with Visit 7 or Visit 10 as reference/first dose date. 
7 
CHANGES TO PROTOCOL AND OTHER RELEVANT REMARKS  
The SAP is based on two protocol versions: a US version and a general version. The 
difference between the two is a difference in inclusion criteria, which will impact the CDISC 
datasets as well as the documentation (including annotated CRF) thereof. 
 
Instead of Bland-Altman analyses of outcome scores at Visit 1 vs Visit 2, Visit 3 vs Visit 4, 
and Visit 5 vs Visit 6 as described in the protocol for the Parent study, an ICC method for 
agreement between the visits will be used instead to assess the stability of the outcome, as 
described in section 5.6.4. This is because no per-rater information is available in the dataset 
to be received, only an averaged or agreed value. 
 
Regarding CI-S, the protocol is stating that for each assessment, the videos will be labeled as 
Video A, B, C, D, E, F. This is however not present in the DTA and test data from Medpace 
and is therefore removed from the SAP. 
 
For Quality-of-Life measures, since the scoring is done for children with the -Y and for adults 
with the -5L, tabulations and analyses will be done separately for the corresponding age 
groups. The proposed statistical analysis on the VAS in the protocol has also been replaced 
with descriptive statistics. 
 
NPC-CSS has been added to the protocol during the addition of the Extension study, to be 
collected at Visits 1, 7, 8, 9 and 10. As a consequence, only for a limited number of patients 
has this value been collected during screening (Visit 1) of the parent study. Considering these 
measurements are only of importance for the Extension phase, presentation of Visit 1 NPC-
CSS will not be done for the Parent study but will be included in the CDISC datasets and 
analyses for the Extension phase. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 51 of 67 
 
 
For the parent study, sparse PK sampling will be collected for biochemical analysis to 
characterize the pharmacokinetics of N-Acetyl-L-Leucine in patients with NPC. For the 
extension study, full PK profiles will be collected at Visit 7 and Visit 9. Creation of 
descriptive displays and reporting of these data is outside the scope of this statistical analysis 
plan. PK concentration data and PK parameters will be included in CDISC domains, after receipt. 
For the Parent phase a listing of PK concentration data will be created for inclusion in the Parent 
phase interim CSR, since the full PK report will only be available after the end of the Extension 
phase. Furthermore, urine tests for N-Acetyl-D-Leucine are handled by the same lab but will be 
included in the clinical database and will therefore be part of the CDISC datasets. 
 
Regarding the sensitivity analysis (imputation of value -1) for missing data in the primary and 
secondary analyses: this is only applied to the primary analysis.  
Regarding the LOCF/assumption of value 0 for missing data: this is only applied to the 
primary and one key secondary endpoint as stated in this SAP. 
 
The investigation of the intra-rater correlation cannot be performed, since the Medpace data 
do not differentiate the data per rater but rather provide an average or agreed value. 
Therefore, this analysis has been removed from the SAP. 
 
Considering the primary endpoint of the Extension phase is a different one then the primary 
endpoint of the Parent Study, the trial is called successful only when the primary endpoint of the 
Parent Study is positive. All analyses of the Extension phase on data collected until Visit 10 are 
considered secondary to ones of the Parent Study. All presentations in the Extension phase on 
data collected after Visit 10 are exploratory and descriptive. 
 
Baseline characteristics/subgroups are defined slightly different in this SAP as compared to 
the protocol, but only to provide more clarity on the precise subgroups. The protocol used for 
the adaptations for the extension phase, also has adjustments for the subgroups for the parent 
phase (SARA gait subtest and gender). However, the parent phase SAP was based on an 
earlier version of the protocol and does not include these subgroups. Therefore, these 
subgroups are not added to the SAP. 
 
The protocol has an ITTe analysis population and an PPSe analysis population defined. Since 
neither of these analysis populations are not used for any efficacy analysis in the extension 
phase, they are removed from the SAP. Consequently, there is no need for a BDRM to decide 
on minor/major protocol deviations for the extension phase. 
 
For some patients, repeat visits were scheduled if measurements could not be fully handled 
during the agreed visit. Repeat visits will be listed for BDRM, and during BDRM or Clean 
File meeting it will be decided how the repeat data will be handled for analysis. Decisions 
will be documented prior to Database lock. 
8 
COVID-19 DETAILS 
This study is conducted during the COVID-19 outbreak. The following data capture decisions 
have been taken due to national, local, or site-specific restrictions imposed due to COVID-19, 
with the primary need to prioritize the safety of clinical study teams and patients, and to 
maintain the integrity of the study/data collection. 
 
- 
All protocol deviations relating to COVID-19 are collected. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 52 of 67 
 
- 
If Visit 2 is performed 8 weeks (56 days) or more after Visit 1, some Visit 1 
assessments must be repeated.  
- 
Visits 3 and 5 can be converted to remote visits (i.e. phone, video conference). 
- 
Visits 4 and 6 can be postponed until the in-person visit is feasible and should be 
performed in person. Where applicable, remote data collection should be collected on 
the date of the original visit. The postponed Visits 4 and 6 will collect all data per 
protocol. 
 
Currently, the impact of COVID-19 on the proposed statistical analyses is unknown. The 
statistical analysis already allows some flexibility for handling missing data, however, 
specific items/changes related to COVID-19 are being detailed in a separate document 
(Addendum 1), which will be maintained as a living document throughout the study 
continuation of the Parent phase and adjusted based on the duration and extent of the impact 
of the COVID-19 situation.  
 
Note that no COVID-19 specific measures are taken for the Extension Phase. 
9 
DATA RECEIPT 
All clinical eCRF data received from the Data Management provider per transfer agreement 
will be mapped to SDTM files. The information regarding minor/major violations will be 
received as excel file (a so-called “protocol deviations log”) and will be transferred to SDTM 
as well. The blinded results on the video-recordings (blinded rater’s CI-CS and CI-S) will be 
received from Medpace as provider following the transfer agreement and will be mapped to 
SDTM. The received data will include relevant categorizations on missing data. 
 
The SDTM files will be recoded to ADaM format, where necessary. Listings will be 
programmed on the SDTM and ADaM datasets, statistical analyses, tables, and figures will 
be programmed on ADaM datasets.  
 
For all received data, a split will be made between data for the Parent Study and the data for 
the Extension Phase, to allow submission of the CDISC data and documentation for the 
Parent Study.  
10 TECHNICAL DETAILS 
10.1 Programming conventions 
Programming conventions apply to both the Parent Study as well as the Extension Phase, 
unless otherwise specified. 
 
Demographics 
BMI will be calculated in SAS as follows: weight/height2, with weight in kg and height in 
meter (unit kg/m2). Durations will be programmed as stated in the respective analysis 
sections. Where applicable, weight and height measurements will be converted to units cm 
and kg, using the following conversion factors: from inch to cm: multiply by 2.54, from lb to 
kg: multiply by 0.45359237. Variables with values representing a missing observation (such 
as -99, 99, 888 or 999) will be recoded to missing in SAS. 
 
NPC Diagnosis 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 53 of 67 
 
Time since diagnosis will be calculated as the difference in days between first dose date and 
the date of diagnosis +1. Date of diagnosis will be taken as the earliest date from the 
following two records: the (earliest) date of Medical History with MHDECOD= “Niemann-
Pick Disease’ and the date of genetic confirmation of disease as recorded in the Primary 
Genetic Diagnosis of NPC data. 
If considered more feasible, the duration may be presented in weeks (calculated time divided 
by 7), months (calculated time divided by 365.25/12) or years (calculated time divided by 
365.25) instead of days. For historical data however, it is likely that partial dates are 
available. If date of diagnosis is (partially) missing, the following will be applied: 
• If only day is missing, the first day of the month will be used. 
• If day and month are both missing, 1 January of the same year will be used. 
If full date is missing, no imputation will be done. 
 
Age calculation 
Age at diagnosis will be based on the date of diagnosis (see above for determination) and the 
birth date as collected in the database. For a partial missing date of diagnosis, the rules as 
stated above will be applied. For partially missing birthdate: depending upon the level of 
precision of the collected birth date: if only month and year is available, then imputation of 
day 15 is used for calculation of age. If only birth year is available, 15 June of that year will 
be used as birthdate. 
 
Age is not collected during the Extension Phase, therefore whenever age is necessary for any 
calculations or presentations at Visit 7, 8 or 9, it should be calculated using the respective 
visit date combined with the date of birth as collected at Visit 1. The same imputation rule as 
stated above (for calculation of age at diagnosis) will be applied. 
 
Blinded data 
The blinded results on the video-recordings (blinded rater’s CI-CS and CI-S) will be received 
from Medpace according to the agreed transfer specifications. Recoding needs to be done 
using the visit schedule provided with the blinded results, since the visit review order is 
randomly assigned. The LOCF for video comparison is already available in the Medpace 
data. 
 
SCAFI 
For 8MWT, assistance of another person or using the wall as support is not allowed. 
However, timed 8MWT trials for participants who used “unallowable support” (another 
person or the wall) are entered in the database, considering these measurements are also 
necessary due to their relation to the primary and a number of secondary endpoints of the 
study based on videos of the test. Therefore, for the SCAFI analysis, the data for these 
patients that used either the wall or person support during the 8MWT should be made 
missing. 
 
Furthermore, patients for 9HPT, the following clinical rules apply: 
• if proband cannot complete trial in 5 minutes (i.e. 300 seconds) with dominant hand, 
move on to the trials with non-dominant hand 
• if proband cannot complete one trial in 5 minutes (i.e. 300 seconds) with non-
dominant hand, discontinue 9HPT 
As a consequence, if in the database values >300 are entered for Trial 1 and/or 2, the 
approach for handling these data in regards to SCAFI will be: 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 54 of 67 
 
• In the case Trial 1 has a value <300 and Trial 2 has a value of >300 seconds, only the 
trial 1 with value <300 will be used for further analysis. 
• In the case Trial 1 has a value of >300 seconds and Trial 2 has a value of <300 
seconds, the data will count as missing and unable to perform due to physical 
limitations (as per the discontinuation rules defined above, Trial 2 should not have 
been conducted) 
• In other instances, where only one trial is performed with a value >300 seconds, or 
two trials are performed with both values >300 seconds, the data will be considered 
missing due to physical limitations and replaced with a missing value for further 
analysis. 
 
After the adjustments made for 8MWT and 9HPT as above, SCAFI total score will be 
calculated as follows: 
The mean of the trial1 and trial2 scores are determined for each subtest/hand, and referred to 
as: 
8MW_avg, 9HPT-D_avg, 9HPT-ND_avg and PATA_avg. In case a subtest is only 
performed once, this value is taken as the mean. Then, the 8MW and 9HPT performance 
times are converted to the same dimension as the PATA rate, as follows: 8MW_recipr = 
1/8MW_avg, 9HPT_recipr = (1/9HPT-D_avg + 1/9HPT-ND_avg)/2. Note that 8MW and 
9HPT performance times cannot be 0. 
Then each is converted into a Z-score using the following algorithms: 
• 8MW_zscore = (8MW_recipr - BL(mean 8MW_recipr)) / BL(SD 8MW_recipr) 
• 9HPT_zscore = (9HPT_recipr - BL(mean 9HPT_recipr)) / BL(SD 9HPT_recipr) 
• PATA_zscore = (PATA_avg - BL(mean PATA_avg)) / BL(SD PATA_avg) 
where BL means baseline value and SD means standard deviation. The mean 8MW_recipr 
and SD 8MW_recipr are determined using the SAF analysis population. 
 
In case of missing values, the following applies:  
• The cases with either 8MW, 9HPT (in one or both hands) or PATA tests not 
performed at all (“unable to perform due to physical limitations” or “not performed 
for other reason”) are excluded from the calculation of baseline means. 
• Only when an 8MW score, 9HPT score or PATA score is missing due to “unable to 
perform due to physical limitations”, then a substitution will be applied as follows: 
• When 8MW tests were not performed, then 8MW_recipr will be substituted by 
1/1800 s. 
• When 9HPT tests were not performed: if only data for one hand is missing, then 
9HPT_avg=3000 s for that specific hand; when data for both hands are missing, then 
9HPT_recipr=1/3000 s. 
• When PATA tests were not performed, then PATA_avg is substituted with 0. 
 
For agreement on “unable to perform due to physical limitations” or “not performed for other 
reason”, the sponsor will be contacted. The missings created for 8MWT and 9HPT as stated 
above are considered “unable to perform due to physical limitations”. 
 
According to the “SCAFI rating manual”, the SCAFI total score is to be determined as the 
arithmetic mean of the 3 Z-scores. However, following explanation of IntraBio and Dr. Tanja 
Schmitz-Huebsch, the SCAFI score needs to be calculated as the mean of the non-missing Z-
scores. The SCAFI score can only be determined if at least one test is actually performed, i.e. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 55 of 67 
 
in case all tests were imputed because of missing values, no SCAFI score will be determined. 
This contradicts the “SCAFI rating manual”.  
 
SARA 
The overall SARA score is reported as provided in the eCRF. For presentation of the 
subscore results, the individual results as provided in the eCRF will be used, where for the 
subscores finger chase, nose-finger test, fast alternating hand movements, heel-shin slide this 
is the average value for the two sides (left and right) as determined per eCRF. 
 
mDRS 
The mDRS composite score (only relevant for the Parent Study) is calculated as a sum of the 
separate subscores divided by 24. If one of the subscores is missing, the mDRS composite 
score is missing as well. As compared to the official questionnaire, the eCRF allows values of 
0 (‘normal’) for the subscores. 
 
Modified NPC-CSS and ASIS 
The modified (15 domain) NPC-CSS total score is calculated as the sum of the 8 major and 
the 7 modifier scores, and ranges from 0-54. This is referred to as the (15 domain) NPC-CSS 
sum/total score. The modified (5 domain) NPC-CSS consists of the domains for Ambulation, 
Cognition, Fine motor, Speech and Swallowing. The ASIS score is obtained by dividing the 
total (15 domain) NPC-CSS severity score of a patient by the age of the patient at Visit 9, 
providing a measure of the rate of disease progression in individual patients. The modified 
(15 domain) NPC-CSS total score, the modified (5 domain) NPC-CSS score and the ASIS 
score are all only relevant for the Extension Phase. 
If one of the NPC-CSS subscores is missing, the total sum scores will be missing as well and 
so will the ASIS score. 
 
Durations, determination of baseline values and handling of missing data will be programmed 
as stated in the respective analysis sections. 
Laboratory 
Laboratory safety data measurements that are denoted as smaller/larger than a certain value 
(e.g. < x.x), will be imputed with this value (e.g. x.x) for calculations of descriptive statistics. 
Listings will show the value as collected, and a footnote will be added to the summary tables 
for explanation. 
Comments 
The following data are either not collected or only collected as free text fields in the 
eCRF/database, or lack relevant information in the database, and it is therefore necessary that 
these details are added in the programming code manually. The decisions to drive this manual 
coding may be documented and finalized during the BDRM but can already be 
maintained/discussed during the course of the trial for efficiency. 
• The reason for video unavailability is recorded as free text field, and it needs to be 
deducted if any of these reasons consider a “technical issue”. The sponsor will 
provide input. 
• PATA score missing due to “unable to perform due to physical limitations” is not 
available as such in the database but needs to be deducted from a free comment field. 
The sponsor will provide input. 
•  Age is not collected during the Extension Phase and full birthdate is not provided in 
the Parent study; therefore, sponsor will provide details which patients turned 13 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 56 of 67 
 
between Visit 7 and 8, and between Visit 10 and 11. Note that this may deviate from 
the age calculations performed for other presentations. 
• SCAFI comments as stated above on SCAFI calculations. The sponsor will provide 
input to which comments relate to “unable to perform due to physical limitations” and 
which relate to “not performed for other reason”. 
• Information to match the supplied bottles and/or sachets of study drug with the 
returned bottles and/or sachets, to be able to differentiate bottles/sachets used for the 
Parent phase and the Extension phase to allow appropriate compliance calculations. 
Other 
Durations, determination of baseline values and handling of missing data will be programmed 
as stated in the respective analysis sections. 
 
Any other programming conventions that are not foreseen in preparation of this SAP, will be 
handled when encountered and documented separately. 
10.2 Coding 
Coding of adverse events, concomitant medication and medical history will be performed by 
the Data Management provider. Adverse events and medical history are coded with the 
MedDRA coding system, version 23.0 including COVID-19 items as released on 19 April 
2020. Concomitant medication is coded according to the WHO drug code and the ATC class 
code, using WHO ATC/DDD Index 2019. Coding will be supplied as part of the data 
transfer. 
10.3 Analysis software 
The statistical analysis and reporting will be done using SAS® for WindowsTM version 9.4. 
SAS tabular output (tables and listings) will be saved in RTF format. SAS graphs will be 
saved in PNG format. Both will be imported into PDF and/or Word® and supplied to the 
Medical Writer for use in the clinical study report. When the sponsor wants to receive the 
output before the study report, then a PDF document is supplied. 
 
Furthermore, a number of excels will be provided to the client when providing the output. For 
the Parent phase this may concern the CI-CS Visit 2 to Visit 6 for each patient and the CI-S 
primary anchor data for each patient at each visit from the Parent Study, and the excels for 
creation of Forest plots of the Parent Study.  
 
10.4 Presentation of tables, listings, graphs 
All output will be generated as SAS tables, graphs and listings.  
 
All tables and listings will be created such that they fit landscape pages. The tables for the 
end-of-text and listings for the appendix will be created using SAS, following the 
specifications according to the TLF template document that will be created separately.  
 
For graphs, output will be as created as PNG plot. Graphs are preferably created using black, 
grey, and white color only, to facilitate black-and-white printing. Different line patterns and 
symbols will be used to differentiate between classification or treatment levels. If certain 
plots can only be visually improved by using colours, then this will be done using colors as 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 57 of 67 
 
distinct as possible. Graphs will be created such (i.e. taking into account line thickness and 
font size) that they can be presented as two (2) per page in the clinical study report. 
 
11 TABLES, LISTINGS, GRAPHS – PARENT STUDY 
11.1 General 
A detailed list of tables, graphs and listings is presented, if applicable, per report section in 
Sections 11.2, 11.3 and 11.4. 
Template tables and listings as well as example plots (as received from client or extracted 
from a relevant paper, if available) will be used as a reference for creation of all output, and a 
separate document will be created for this. Table/graph/listing numbering will be followed, 
however, if the data give cause for combining or splitting tables or listings, the numbering 
may be adapted as necessary. In case there are no data available for a certain table/listing, an 
empty table will be created and ‘No data available’ will be stated. 
 
11.2 In-text tables and graphs 
Not applicable. Will be designed or extracted by the Medical Writer during creation of the 
Clinical Study Report, based on the tables and graphs created for Section 14 of the CSR.  
 
11.3 End-of-text tables and graphs 
Following ICH E3 guidelines, all tables and graphs mentioned here will be presented in 
Section 14 of the CSR, and tables will be prepared in the order and with section number as 
stated.  
 
Table/graph 
number 
Contents of table/graph 
14.1 Demographic Data Summary figures and tables 
14.1.1-14.1.4 
Demographics (ITT, mITT, PPS and SAF population) 
14.1.5-14.1.7 
Baseline characteristics (ITT, mITT and PPS population) 
14.1.7 
Disposition 
14.1.8 
Medical history 
14.1.9 
NPC specific history 
14.1.10 
Compliance 
14.2 Efficacy Data Summary figures and Tables 
14.2.1 
Result of t-test or Wilcoxon test on the primary endpoint (mITT and PPS), 
including sensitivity analysis (only mITT).  
14.2.2 
Frequency table of the CI-CS score Visit 4 vs Visit 2 minus the CI-CS score 
Visit 6 vs Visit 4, combined with the frequency table of the CI-CS score Visit 
4 vs Visit 2 and separately, the CI-CS score Visit 6 vs Visit 4 (mITT and PPS 
population) 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 58 of 67 
 
14.2.3 
Descriptive statistics of the CI-CS score Visit 4 vs Visit 2 minus the CI-CS 
score Visit 6 vs Visit 4, combined with the descriptive statistics of the CI-CS 
score Visit 4 vs Visit 2 and separately, the CI-CS score Visit 6 vs Visit 4  
(mITT and PPS population). 
14.2.4 
Bar chart of CI-CS score Visit 4 vs Visit 2 minus CI-CS score Visit 6 vs Visit 
4 (mITT and PPS population) 
14.2.5 
Frequency table of the CI-CS score Visit 4 vs Visit 2 minus the CI-CS score 
Visit 6 vs Visit 4 according to subgroups, combined with the frequency table 
of the CI-CS score Visit 4 vs Visit 2 and separately, the CI-CS score Visit 6 
vs Visit 4 according to subgroups (mITT population) 
14.2.6 
Descriptive statistics of the CI-CS score Visit 4 vs Visit 2 minus the CI-CS 
score Visit 6 vs Visit 4 according to subgroups, combined with the descriptive 
statistics of the CI-CS score Visit 4 vs Visit 2 and separately, the CI-CS score 
Visit 6 vs Visit 4 according to subgroups (mITT population) 
14.2.7 
Bar chart of CI-CS score Visit 4 vs Visit 2 and separately, CI-CS score Visit 
6 vs Visit 4 (mITT and PPS population) 
14.2.8 
Pearson rank correlation coefficients (mITT population) 
14.2.9 
Bland-Altman plots (mITT population) 
14.2.10 
Result of t-test or Wilcoxon test on the key secondary endpoint ‘Change in 
severity score based on averaged CI-S’ (mITT and PPS population), 
14.2.11 
Frequency table of the change in severity score based on averaged CI-S 
scores between baseline and treatment minus the change between treatment 
and washout (mITT and PPS population) 
14.2.12 
Descriptive statistics of the change in severity score based on averaged CI-S 
scores between baseline and treatment minus the change between treatment 
and washout (mITT and PPS population) 
14.2.13 
Bar chart of change in severity score based on averaged CI-S scores between 
baseline and treatment minus the change between treatment and washout 
(mITT and PPS population) 
14.2.14 
Frequency table of the change in severity score based on averaged CI-S 
scores between baseline and treatment minus the change between treatment 
and washout according to subgroups (mITT population) 
14.2.15 
Descriptive statistics of change in severity score based on averaged CI-S 
scores between baseline and treatment minus the change between treatment 
and washout according to subgroups (mITT population) 
14.2.16 
Result of Wilcoxon test on the key secondary endpoint ‘CI-CS score 
reclassified’ (mITT and PPS) 
14.2.17 
Frequency table of the CI-CS score reclassified on a 3-point scale Visit 4 vs 
Visit 2 and separately, the reclassified CI-CS score Visit 6 vs Visit 4 (mITT 
and PPS population) 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 59 of 67 
 
14.2.18 
Descriptive statistics of the CI-CS score reclassified on a 3-point scale Visit 4 
vs Visit 2 and separately, the reclassified CI-CS score Visit 6 vs Visit 4 
(mITT and PPS population) 
14.2.19 
Bar chart of CI-CS score reclassified on a 3-point scale Visit 4 vs Visit 2 and 
separately, CI-CS score Visit 6 vs Visit 4 (mITT and PPS population) 
14.2.20 
Frequency table of the CI-CS score reclassified on a 3-point scale Visit 4 vs 
Visit 2 and separately, the reclassified CI-CS score Visit 6 vs Visit 4 
according to subgroups (mITT population) 
14.2.21 
Descriptive statistics of the CI-CS score reclassified on a 3-point scale Visit 4 
vs Visit 2 and separately, the reclassified CI-CS score Visit 6 vs Visit 4 
according to subgroups (mITT population) 
14.2.22 
Frequency table of the CI-CS score for the non-primary anchor test Visit 4 vs 
Visit 2 and separately, the CI-CS score Visit 6 vs Visit 4 (mITT and PPS 
population) 
14.2.23 
Descriptive statistics of the CI-CS score for the non-primary anchor test Visit 
4 vs Visit 2 and separately, the CI-CS score Visit 6 vs Visit 4 (mITT and PPS 
population) 
14.2.24 
Frequency table of the CI-CS score for the non-primary anchor test Visit 4 vs 
Visit 2 and separately, the CI-CS score Visit 6 vs Visit 4 according to 
subgroups (mITT population)  
14.2.25 
Descriptive statistics of the CI-CS score for the non-primary anchor test Visit 
4 vs Visit 2 and separately, the CI-CS score Visit 6 vs Visit 4 according to 
subgroups (mITT population) 
14.2.26 
Result of t-test or Wilcoxon test on the change in SARA total score between 
Visit 2 and Visit 4, as well as Visit 4 and Visit 6 (mITT and PPS population) 
14.2.27 
Descriptive statistics of the SARA total score and 8 subscores at each visit 
(mITT and PPS population) 
14.2.28 
Mean or median plot versus time of the SARA total score (mITT and PPS 
population) 
14.2.29 
Stacked bar chart of the 8 SARA subscores at each visit (mITT and PPS 
population) 
14.2.30 
Spaghetti plot of SARA total score at each visit (mITT and PPS population) 
14.2.31 
Descriptive statistics of the SARA total score and 8 subscores at each visit 
according to subgroups (mITT population) 
14.2.32 
Result of t-test or Wilcoxon test on the change in SCAFI total score, and 
subscores 8MW_avg, 9HPT-D_avg and PATA_avg between Visit 2 and Visit 
4, as well as Visit 4 and Visit 6 (mITT and PPS population) 
14.2.33 
Descriptive statistics of the SCAFI total score and subscores 8MW_avg, 
9HPT-D_avg, 9HPT-ND_avg and PATA_avg at each visit (mITT and PPS 
population) 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 60 of 67 
 
14.2.34 
Mean or median plot of SCAFI total score versus time (mITT and PPS 
population) 
14.2.35 
Spaghetti plot of SCAFI total score versus time (mITT and PPS population) 
14.2.36 
Descriptive statistics of the SCAFI total score and subscores 8MW_avg, 
9HPT-D_avg, 9HPT-ND_avg and PATA_avg at each visit according to 
subgroups (mITT population) 
14.2.37 
Frequency table of the EQ-5D-5L and EQ-5D-Y health status and 5 
subdomains at each visit (mITT and PPS population) 
14.2.38 
Frequency table of the EQ-5D-5L and EQ-5D-Y health status and 5 
subdomains at each visit according to subgroups (mITT population) 
14.2.39 
Descriptive statistics of the EQ-VAS for -5L and -Y combined at each visit 
(mITT and PPS population) 
14.2.40 
Mean or median plot of EQ-VAS versus time for -5L and -Y combined 
(mITT and PPS population) 
14.2.41 
Spaghetti plot of EQ-VAS versus time for -5L and -Y combined (mITT and 
PPS population) 
14.2.42 
Descriptive statistics of the EQ-VAS for -5L and -Y combined at each visit 
according to subgroups (mITT population) 
14.2.43 
Descriptive statistics on the change in mDRS composite score between Visit 
2 and Visit 4, as well as Visit 4 and Visit 6 (mITT and PPS population) 
14.2.44 
Descriptive statistics of the mDRS composite score and 6 components at each 
visit (mITT and PPS population) 
14.2.45 
Mean or median plot versus time of the mDRS composite score (mITT and 
PPS population) 
14.2.46 
Spaghetti plot of the mDRS composite score versus time (mITT and PPS 
population) 
14.2.47 
Descriptive statistics of the mDRS composite score and 6 components at each 
visit according to subgroups (mITT population) 
14.2.48 
Frequency table of the 3 CGI-S scores (treating physician, caregiver and 
patient) at each visit (mITT and PPS population) 
14.2.49 
Descriptive statistics of the 3 CGI-S scores (treating physician, caregiver and 
patient) at each visit (mITT and PPS population) 
14.2.50 
Bar charts of the 3 CGI-S scores (treating physician, caregiver and patient) at 
each visit (mITT and PPS population) 
14.2.51 
Mean or median plot versus time of the 3 CGI-S scores (treating physician, 
caregiver and patient) (mITT and PPS population) 
14.2.52 
Spaghetti plot of the 3 CGI-S scores (treating physician, caregiver and 
patient) versus time (mITT and PPS population) 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 61 of 67 
 
14.2.53 
Frequency table of the 3 CGI-S scores (treating physician, caregiver and 
patient) at each visit according to subgroups (mITT population) 
14.2.54 
Descriptive statistics of the 3 CGI-S scores (treating physician, caregiver and 
patient) at each visit according to subgroups (mITT population) 
14.2.55 
Frequency table of the 3 CGI-C scores (treating physician, caregiver and 
patient) between Visit 2 vs Visit 4, and between Visit 4 and Visit 6 (mITT 
and PPS population) 
14.2.56 
Descriptive statistics of the 3 CGI-C scores (treating physician, caregiver and 
patient) between Visit 2 vs Visit 4, between Visit 4 and Visit 6, and Visit 4 vs 
Visit 2 minus the CI-CS score Visit 6 vs Visit 4 (mITT and PPS population). 
14.2.57 
Result of t-test or Wilcoxon test on the change of CGI-C score for treating 
physician Visit 4 vs Visit 2 minus Visit 6 vs Visit 4 (mITT and PPS 
population) 
14.2.58 
Result of t-test or Wilcoxon test on the change of CGI-C score for treating 
physician between Visit 2 and Visit 4, as well as Visit 4 and Visit 6 (mITT 
and PPS population) 
14.2.59 
Bar charts of the 3 CGI-C scores (treating physician, caregiver and patient) 
between Visit 2 vs Visit 4, and between Visit 4 and Visit 6 (mITT and PPS 
population) 
14.2.60 
Frequency table of the 3 CGI-C scores (treating physician, caregiver and 
patient) between Visit 2 vs Visit 4, and between Visit 4 and Visit 6 according 
to subgroups (mITT population) 
14.2.61 
Descriptive statistics of the 3 CGI-C scores (treating physician, caregiver and 
patient) between Visit 2 vs Visit 4, and between Visit 4 and Visit 6 according 
to subgroups (mITT population) 
14.2.62 
Forest plots 
14.3 Safety Data Summary figures and tables – 14.3.1 Displays of Adverse Events 
14.3.1.1 
Overview adverse events 
14.3.1.2 
Treatment emergent adverse events 
14.3.1.3  
Treatment emergent adverse events by severity grade 
14.3.1.4 
Treatment emergent adverse events by relationship 
14.3.1.5 
Treatment emergent adverse events leading to premature discontinuation 
14.3.1.6 
Treatment emergent adverse events by treatment cycle 
14.3.1.7  
Treatment emergent adverse events by severity grade by treatment cycle 
14.3.1.8 
Treatment emergent adverse events by relationship by treatment cycle 
14.3.1.9 
Treatment emergent adverse events leading to premature discontinuation by 
treatment cycle 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 62 of 67 
 
14.3 Safety Data Summary figures and tables – 14.3.2 Listings of Deaths, Other Serious and 
Significant Adverse Events 
14.3.2.1 
SAEs 
14.3.2.2 
Deaths 
14.3 Safety Data Summary figures and tables – 14.3.4 Abnormal Laboratory Value Listing (each 
patient) 
14.3.4.1 
Out of range clinical laboratory 
14.3.4.2 
Clinical laboratory – haematology 
14.3.4.3 
Clinical laboratory – clinical chemistry 
14.3.4.4 
Clinical laboratory – urinalysis 
14.3.5 
Vital signs 
14.3.6 
ECG 
14.3.7 
Prior and concomitant medication and therapies  
 
11.4 Listings 
Following ICH E3 guidelines, all listings mentioned here will be presented in Section 16.2 of 
the CSR, and listings will be prepared in the order and with section number as stated.  
 
Individual listings will be prepared of the data collected in the database, following SDTM 
data format. No combining of data other than mentioned in this paragraph will be performed. 
The key variables in the listings (except for a few displaying screening data) will be patient 
number, and age/weight/dosing group. If applicable, visit number will be listed additionally. 
Furthermore, a listing containing study visit dates will be presented. 
 
Listing number 
Contents of listing 
16.2.1 Discontinued patients 
16.2.1.1 
Inclusion/exclusion criteria – deviations 
16.2.1.2 
Patient disposition 
16.2.2 Protocol deviations 
16.2.2 
Protocol deviations 
16.2.3 Demographic and baseline data 
16.2.3.1 
Demographics 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 63 of 67 
 
16.2.3.2 
Baseline characteristics 
16.2.3.3 
Medical history 
16.2.3.4 
NPC specific history 
16.2.4 Compliance and/or treatment data 
16.2.4.1 
Drug administration 
16.2.4.2 
Drug accountability 
16.2.4.3 
Study visits 
16.2.5 Individual efficacy response data 
16.2.5.1 
Individual CI-S and CI-CS scores 
16.2.5.2 
Individual scores on ataxia and functioning - SARA test 
16.2.5.3 
Individual scores on ataxia and functioning - SCAFI test 
16.2.5.4 
Individual health related quality of life – EQ-5D-5L, EQ-5D-Y and the 
respective EQ-VAS 
16.2.5.5 
Individual overall neurological status – mDRS test 
16.2.5.6 
Individual global impression scores – CGI-S (treating physician, caregiver, 
and patient) 
16.2.5.7 
Individual change in global impression scores – CGI-C (treating physician, 
caregiver, and patient) 
16.2.6 Adverse event listings 
16.2.6.1 
Adverse events 
16.2.6.2 
AEs leading to discontinuation from the study 
16.2.6.3 
Vital signs 
16.2.6.4 
ECG 
16.2.6.5 
Prior and concomitant medication and therapies 
16.2.7 Listing of individual laboratory measurements by patient 
16.2.7.1 
Laboratory safety data – haematology 
16.2.7.2 
Laboratory safety data – clinical chemistry 
16.2.7.3 
Laboratory safety/pregnancy data – urinalysis 
16.2.7.4 
Listing of urine test for N-Acetyl-D-Leucine 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 64 of 67 
 
16.2.7.5 
Listing of PK concentration data 
16.2.7.6 
General comments 
 
12 TABLES, LISTINGS, GRAPHS – EXTENSION PHASE 
12.1 General 
A detailed list of tables, graphs and listings is presented, if applicable, per report section in 
Sections 12.2, 12.3 and 12.4. 
Template tables and listings as well as example plots (as received from client, a previous 
study, or extracted from a relevant paper, if available) will be used as a reference for creation 
of all output, and a separate document will be created for this. Table/graph/listing numbering 
will be followed, however, if the data give cause for combining or splitting tables or listings, 
the numbering may be adapted as necessary. In case there are no data available for a certain 
table/listing, an empty table will be created and ‘No data available’ will be stated. 
 
12.2 In-text tables and graphs 
Not applicable. Will be designed or extracted by the Medical Writer during creation of the 
Clinical Study Report, based on the tables and graphs created for Section 14 of the CSR.  
 
12.3 End-of-text tables and graphs 
Following ICH E3 guidelines, all tables and graphs mentioned here will be presented in 
Section 14 of the CSR, and tables will be prepared in the order and with section number as 
stated.  
 
Table/graph 
number 
Contents of table/graph 
14.1 Demographic Data Summary figures and tables 
14.1.11-14.1.13 
Demographics (mITTe and SAFe) 
14.1.14-14.1.15 
Baseline characteristics (mITTe) 
14.1.16 
Disposition 
14.1.17 
Medical history 
14.1.18 
NPC specific history 
14.1.19 
Compliance 
14.2 Efficacy Data Summary figures and Tables 
14.2.63 
Frequency table, p-value, and CI on the primary endpoint (5 domain) NPC-
CSS success rate (mITTe)  
14.2.64 
Frequency table on the primary endpoint (5 domain) NPC-CSS success rate 
(mITTe), according to subgroups. 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 65 of 67 
 
14.2.65 
Descriptive statistics on 5 domain NPC-CSS sum score, including change 
values between visits (mITTe). 
14.2.66 
Descriptive statistics on 5 domain NPC-CSS sum score, including change 
values between visits (mITTe) according to subgroups. 
14.2.67 
Spaghetti plot of the (5 domain) NPC-CSS sum score through time. 
14.2.68 
Descriptive statistics of the SARA total score at each visit, including change 
values between visits (mITTe) 
14.2.69 
Descriptive statistics of the SCAFI total score and subscores 8MW_avg, 
9HPT-D_avg, 9HPT-ND_avg and PATA_avg at each visit, including change 
values between visits (mITTe) 
14.2.70 
Frequency table of the EQ-5D-5L and EQ-5D-Y health status and 5 
subdomains at each visit (mITTe) 
14.2.71 
Descriptive statistics of the EQ-VAS for -5L and -Y combined at each visit 
(mITTe) 
14.2.72 
Descriptive statistics of the (15 domain) NPC-CSS sum score at each visit, 
including change from baseline (mITTe) 
14.2.73 
Descriptive statistics of the ASIS score at each visit, including change from 
baseline (mITTe), if available 
14.2.74 
Frequency table of the 3 CGI-S scores (treating physician, caregiver and 
patient) at each visit (mITTe) 
14.2.75 
Descriptive statistics of the 3 CGI-S scores (treating physician, caregiver and 
patient) at each visit (mITTe) 
14.2.76 
Frequency table of the 3 CGI-C scores (treating physician, caregiver, and 
patient) at each visit (mITTe) 
14.2.77 
Descriptive statistics of the 3 CGI-C scores (treating physician, caregiver, and 
patient) at each visit (mITTe) 
14.3 Safety Data Summary figures and tables – 14.3.1 Displays of Adverse Events 
14.3.1.10 
Overview adverse events 
14.3.1.11 
Treatment emergent adverse events 
14.3.1.12 
Treatment emergent adverse events by severity grade 
14.3.1.13 
Treatment emergent adverse events by relationship 
14.3.1.14 
Treatment emergent adverse events leading to premature discontinuation 
14.3.1.15 
Treatment emergent adverse events by treatment cycle 
14.3.1.16 
Treatment emergent adverse events by severity grade by treatment cycle 
14.3.1.17 
Treatment emergent adverse events by relationship by treatment cycle 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 66 of 67 
 
 
 
12.4 Listings 
Following ICH E3 guidelines, all listings mentioned here will be presented in Section 16.2 of 
the CSR, and listings will be prepared in the order and with section number as stated.  
 
Individual listings will be prepared of the data collected in the database, following SDTM 
data format. No combining of data other than mentioned in this paragraph will be performed. 
The key variables in the listings (except for a few displaying screening data) will be patient 
number, and age/weight/dosing group. If applicable, visit number will be listed additionally. 
Furthermore, a listing containing study visit dates will be presented. 
 
14.3.1.18 
Treatment emergent adverse events leading to premature discontinuation by 
treatment cycle 
14.3 Safety Data Summary figures and tables – 14.3.2 Listings of Deaths, Other Serious and 
Significant Adverse Events 
14.3.2.3 
SAEs 
14.3.2.4 
Deaths 
14.3 Safety Data Summary figures and tables – 14.3.4 Abnormal Laboratory Value Listing (each 
patient) 
14.3.4.8 
Out of range clinical laboratory 
14.3.4.9 
Clinical laboratory – haematology 
14.3.4.10 
Clinical laboratory – clinical chemistry 
14.3.4.11 
Clinical laboratory – urinalysis 
14.3.8 
Vital signs 
14.3.9 
ECG 
14.3.10 
Prior and concomitant medication and therapies  
14.3.11 
Physical examination 
16.2.3 Demographic and baseline data 
16.2.3.5 
Demographics 
16.2.3.6 
Baseline characteristics 
16.2.3.7 
Medical history 
16.2.3.8 
NPC specific history 
16.2.4 Compliance and/or treatment data 


 
 
Protocol ID: Version 7.0 (10Oct2022) /  
Clinical Study Reference: IB1001-201                                                                        US version 7.1 (11Oct2022)
 
 
  Final SAP 4.0, 26Jan2023 
Page 67 of 67 
 
 
 
16.2.4.4 
Drug administration 
16.2.4.5 
Drug accountability 
16.2.4.6 
Study visits 
16.2.5 Individual efficacy response data 
16.2.5.8 
Individual (15 domain) NPC-CSS scores, (5 domain) NPC-CSS scores, the 
respective underlying questions, and the ASIS scores. 
16.2.5.9 
Individual scores on ataxia and functioning - SARA test 
16.2.5.10 
Individual scores on ataxia and functioning - SCAFI test 
16.2.5.11 
Individual health related quality of life – EQ-5D-5L, EQ-5D-Y and the 
respective EQ-VAS 
16.2.5.12 
Individual global impression scores – CGI-S (treating physician, caregiver, 
and patient) 
16.2.5.13 
Individual change in global impression scores – CGI-C (treating physician, 
caregiver, and patient) 
16.2.6 Adverse event listings 
16.2.6.6 
Adverse events 
16.2.6.7 
AEs leading to discontinuation from the study 
16.2.6.8 
Vital signs 
16.2.6.9 
ECG 
16.2.6.10 
Prior and concomitant medication and therapies 
16.2.6.11 
Physical examination 
16.2.7 Listing of individual laboratory measurements by patient 
16.2.7.7 
Laboratory safety data – haematology 
16.2.7.8 
Laboratory safety data – clinical chemistry 
16.2.7.9 
Laboratory safety/pregnancy data – urinalysis 
16.2.7.10 
Listing of urine test for N-Acetyl-D-Leucine 
16.2.7.11 
Listing of PK concentration data 
16.2.7.12 
General comments